CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF

Info

Publication number: 20080261994
Type: Application
Filed: Jan 18, 2008
Publication Date: Oct 23, 2008
Applicant:
Inventors: Takashi INABA (Osaka), Julia Hass (Boulder, CO), Makoto Shiozaki (Osaka), Nicole M. Littmann (Erie, CO), Katsutaka Yasue (Osaka), Steven W. Andrews (Longmont, CO), Atushi Sakai (Osaka), Andrew M. Fryer (Erie, CO), Takafumi Matsuo (Osaka), Ellen R. Laird (Longmont, CO), Akira Suma (Osaka), Yuichi Shinozaki (Osaka), Yoshikazu Hori (Osaka), Hiroto Imai (Osaka), Tamotsu Negoro (Osaka)
Application Number: 12/016,755

Abstract

The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

Description

Description

This Application claims benefit of priority of U.S. provisional Application No. 60/529,116, filed Dec. 15, 2003, the contents of which are hereby incorporated by reference.

The present invention relates to a novel cyclopropane compound. In further detail, the present invention relates to a cyclopropane compound or a pharmaceutically acceptable salt thereof having an aggrecanase inhibitory activity or matrix metalloproteinase (MMP) inhibitory activity, a pharmaceutical composition which comprises this compound and a pharmaceutical use thereof.

Aggrecan is a main proteoglycan in cartilage, and decomposition of its core protein by protease is one of the early signs of a joint disorder associated with arthrodial cartilage destruction, such as rheumatoid arthritis and osteoarthritis. This process of decomposition leading to the cartilage destruction begins with the disappearance of aggrecan on the surface of cartilage, and progresses to the decomposition of collagen type II fiber. MMPs (Matrix metalloproteinases) that cleave Asn 341-Phe 342 and aggrecanase that cleaves Glu 373-Ala 374 are known as enzymes involved in this decomposition of aggrecan, and both are metal-proteases having zinc in the catalytic active center. The latter was determined to be ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) in 1999. ADAMTS 1 to 20 have been identified so far, and ADAMTS 4 and 5 correspond to aggrecanase-1 and aggrecanase-2, respectively. Conventionally, MMP have been considered to mainly cause cartilage destruction, but many reports have documented that the aggrecan fragments found in the joint of osteoarthritis (OA) patients are predominantly the fragments cleaved by aggrecanases. Thus, aggrecanase is also considered to be a significant vicious factor for these disease states.

At present, conservative treatments and surgical treatments are available for treating OA. The conservative therapy includes body weight control, exercise therapy, physical therapy, drug therapy (administration of anti-inflammatory drug), hyperthermia, and the like. It is a general practice to inject hyaluronic acid into the joint in the course of these treatments to smoothen movement of the joint.

When improvement of conditions by the conservative treatments such as drug therapy, physical therapy, etc., is not achieved, a surgical treatment is performed. When the joint is highly deformed and causes a strong pain, an arthroplasty for embedding an artificial joint is performed as the final option. However, artificial joints have a life of only about 15 to 20 years, after which the QOL (Quality of Life) of the patient deteriorates.

At present, no drug that suppresses enzyme involved in cartilage destruction is available for OA treatment. When no improvement is made by a conservative treatment, cartilage destruction progresses and a surgical treatment will be required. Therefore, prevention of cartilage destruction before reaching the stage requiring a surgical treatment is important. A drug that inhibits aggrecanases involved in the destruction of cartilage is acknowledged to be an anti-OA drug having a sufficient cartilage destruction inhibitory activity. Without a surgical treatment, and moreover, such drug is expected to improve the QOL of patients.

Aggrecanase inhibitors have been developed as shown in the reports by DuPont (WO99/0900), Pfizer (JP-A-2001-114765) and the like, in which poor oral availability is a concern.

In addition, the MMP inhibitors under development include a compound that causes systemic connective tissue toxicity due to nonselective collagenase inhibition. It is proposed that the cause thereof is suppression of turnover of normal connective tissue collagen due to inhibition of collagenase-1 (MMP-1). It is clear, therefore, that the conventional products are not entirely satisfactory from the aspects of effective inhibition and occurrence of side effects.

The compound of the present invention possesses improved oral availability and shows strong aggrecanase inhibitory activity. While the compound is free of an MMP-1 inhibitory activity, it also has selective inhibitory activity of MMP-13, involved in joint destruction. Therefore, the compound is expected to suppress progress of joint diseases without causing side effects.

In addition, expressed in glioma, aggrecanase is suggested to be also involved in metastasis or tissue infiltration of tumor cells, like MMP, and in view of the current development of MMP inhibitor as an antimetastatic drug, the compound of the present invention having an inhibitory activity on both aggrecanase and MMP is expected to be a highly effective antitumor agent.

In bone metabolism, MMP suppresses decomposition of bone matrix and has a major part in bone resorption. In respiratory diseases, protease plays a key role in the course of destruction and remodeling of lung structure. MMP that uses an extracellular matrix (ECM), which is an architectural component of the protease, as a substrate is considered to be an important factor. Therefore, the compound of the present invention having MMP inhibitory activity is expected to be applicable to the bone resorption disorders and lung diseases, in which MMP is involved.

Various reports on compounds aiming at therapy of disorders such as OA, rheumatoid arthritis and the like by inhibition of aggrecanase have been published recently.

For example, JP-A-2002-284686 discloses a sulfonamide derivative having MMP-13 inhibitory activity and aggrecanase inhibitory activity. However, this publication does not include the compound having a structure, such as the structure of the compound of the present invention, or a disclosure suggestive thereof JP-A-2001-114765 discloses a hydroxamic acid derivative represented by the following formula:

wherein X is carbon atom or nitrogen atom; R¹and R²are each independently hydrogen atom, hydroxy or methyl, and at least one of R¹and R²is methyl; R³and R⁴are each independently hydrogen atom, hydroxy or methyl, or R³and R⁴may be taken together to form carbonyl group; R⁵and R⁶are each independently hydrogen atom, halogen, cyano, methyl or ethyl; with the proviso that when X is carbon atom, R⁷and R⁸are both hydrogen atom and at least one of R¹, R², R³and R⁴is hydroxy; when X is carbon atom and R⁵is para-halo, at least one of R⁶, R³and R⁴is not hydrogen atom; when X is nitrogen atom, R⁸is not present and R⁷is hydrogen atom or the group of the formula:

wherein Y is —CH₂—NH₂or —NH—CH₃; when X is nitrogen atom and R⁷is H, R³and R⁴may be taken together to form carbonyl group, which has aggrecanase inhibitory activity. However, the compound of this publication has a piperidine ring or piperazine ring having substituent(s) as a skeletal structure. This publication does not include the compound having a cyclopropane structure, such as the structure of the compound of the present invention, or a disclosure suggestive thereof.

WO03/053915 discloses a cyclopropane derivative represented by the formula:

wherein M is —(C(R³⁰)(R⁴⁰))m- wherein m is 1 to 6; T is R²¹-substituted alkyl group, cycloalkyl group, heterocycloalkyl group, cycloalkenyl, heterocycloalkenyl, aryl group, heteroaryl group, —OR³, —C(O)R⁴, —C(O)OR³, —C(O)NR²⁴R²⁵, —C(O)NR²⁴OR³, —C(O)SR³, —NR²⁴R²⁵, —NR²⁵C(O)R⁴, —NR²⁵C(O)OR³, —NR²⁵C(O)NR²⁴R²⁵, —NR²⁵C(O)NR²⁴OR³, —SR³, —S(O)_xNR²⁴R²⁵, —S(O)_xNR²⁵OR³, etc.; V is alkyl group, R²¹-substituted alkyl group, cycloalkyl group, heterocycloalkyl group, cycloalkenyl, heterocycloalkenyl, aryl group, heteroaryl group, —OR³, —C(O)R⁴, —(CR²³R²⁴)_n1C(O)OR³, —C(O)NR²⁴R²⁵, —(CR²³R²⁴)_n1C(O)NR²⁵OR³, —C(O)SR³, —NR²⁴R²⁵, —NR²⁵C(O)R⁴, —NR²⁵C(O)OR³, —NR²⁵C(O)NR²⁴R²⁵, —NR²⁵C(O)NR²⁴R³, —SR³, —S(O)xNR²⁴R²⁵, —S(O)xNR²⁵OR³, etc.; W is a covalent bond, —(C(R³)(R⁴))_n2—, —O—, —S—, etc.; X is alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, —C≡C—, etc.; U is a covalent bond, —(C(R³)(R⁴))_p—, —Y—(C(R³)(R⁴))q-, —(C(R³)(R⁴))t-Y-, -Y-, etc.; Y is —O—, —S(O)x-, etc.; n is 0 to 2; R¹is alkyl group, R²¹-substituted alkyl group, cycloalkyl group, heterocycloalkyl group, cycloalkenyl, heterocycloalkenyl, aryl group, heteroaryl group, etc.; R², R⁴and R⁵are each independently hydrogen atom, halo, alkyl group, etc.; R³is hydrogen atom, alkyl group, R²²-substituted alkyl group, etc.; R²³is hydrogen atom, hydroxyl, halo, etc., R²⁴is hydrogen atom or alkyl; R²⁵is hydrogen atom, hydroxyl, alkyl group, etc.; R³⁰is hydrogen atom, etc.; R⁴⁰is hydrogen atom, etc.; with the proviso that at least one of V and T is —C(O)N(R³) (OR⁴), —C(O)OR³or —C(O)NR²⁴R²⁵. However, the compound of the formula disclosed in this publication is structurally different from the compound of the present invention. This publication does not include a compound having a structure of the compound of the present invention, or a disclosure suggestive thereof.

DISCLOSURE OF INVENTION

The present invention provides a compound having superior aggrecanase inhibitory activity and MMP inhibitory activity (particularly, MMP-13 inhibitory activity), and useful as a prophylactic or therapeutic agent for osteoarthritis, a prophylactic or therapeutic agent for rheumatoid arthritis, a prophylactic or therapeutic agent for a disorder such as joint injury, reactive arthritis, bone resorption disorder, cancer, asthma, allergic reaction, chronic pulmonary emphysema, fibroid lung, acute respiratory distress (ARDS), lung infection, interstitial pneumonia, etc. compound.

Some embodiments of the present invention provide an aggrecanase inhibitor, an MMP inhibitor, a prophylactic or therapeutic agent for osteoarthritis and a prophylactic or therapeutic agent for rheumatoid arthritis.

The present inventors have conducted intensive studies to obtain the above objects and found a cyclopropane compound represented by the following formula (1) has superior aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as an aggrecanase inhibitor, an MMP inhibitor, a prophylactic or therapeutic agent for osteoarthritis and a prophylactic or therapeutic agent for rheumatoid arthritis, based on which findings the present invention has been completed.

Accordingly, the present invention relates the compounds [1] to [34] shown below and pharmaceutical use thereof.

[1] A cyclopropane compound of formula (1):

wherein
R¹is selected from
(1) a substituted C_1-6alkyl group
and
(2) —(CH₂)_m—X—(CH₂)_n-A¹,
wherein

m and n are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X is a linker selected from the following group A, group A:

(a) a single bond,
(b) a C_1-6alkylene group,
(c) a C_2-6alkenylene group,
(d) a C_2-6alkynylene group,

(e) —O—, (f) —N(R⁵)—, (g) —S(O)_m1—, (h) —CO—, (i) —COO—, (i) —OCO—, (k) —CON(R⁵)—, (l) —N(R⁵)CO—, (m) —SO₂N(R⁵)—, (n) —N(R⁵)SO₂—, (O)—N(R⁵)CON(R⁶)—, (p) —N(R⁵)SO₂N(R⁶)—, (q) —OCON(R⁵)—, (r) —N(R⁵)COO—

and
(s) —S(O)_m1—(CH₂)_n1—CO—;

wherein

- R⁵and R⁶are the same or different and each is selected from a hydrogen atom, a C_1-6alkyl group optionally substituted by halogen atoms or hydroxyl groups, a C_3-14hydrocarbon ring group and a heterocyclic group,
- m1 is selected from 0 and an integer ranging from 1 to 2 and
- n1 is selected from an integer ranging from 1 to 2, and

A¹is selected from a substituted C_3-14hydrocarbon ring group and a substituted heterocyclic group;

R²and R³are the same or different and each is selected from

—(CH₂)_p—X₁—(CH₂)_q-A², (1)

wherein

p and q are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X₁is a linker selected from the above-mentioned group A and

A²is selected from an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group,

and

—(CH₂)_m8—X₈—(CH₂)_n8—R²⁷, (2)

wherein

m8 and n8 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X₈is a linker selected from the above-mentioned group A and

R²⁷is a substituent selected from the following group B, group B:

(a) a hydrogen atom,
(b) a halogen atom,
(c) a hydroxyl group,
(d) a nitro group,
(e) a cyano group,
(f) a carboxyl group,
(g) an amino group,
(h) an amido group,
(i) a C_2-6acyl group,
(j) a halogenated C_1-6alkyl group,
(k) a C_1-6alkyl group optionally substituted by hydroxyl groups,
(l) a C_2-6alkenyl group optionally substituted by halogen atoms,
(m) a C_2-6alkynyl group,
(n) a C_1-6alkoxy group optionally substituted by hydroxyl groups,
(o) a C_1-6alkoxy-C_1-6alkyl group,
(p) a C_1-6alkoxy-carbonyl group,
(q) a C_1-6alkyl-aminocarbonyl group optionally substituted by halogen atoms,
(r) a mono(C_1-6alkyl)amino group,
(s) a di(C_1-6alkyl)amino group,
(t) a C_1-6alkyl-carbonylamino group optionally substituted by halogen atoms,
(u) a C_1-6alkylsulfonyl group
and
(v) a C_1-6alkylsulfonylamino group;
or A²and R²⁷may be taken together to form an optionally substituted fused ring group,
or R²and R³may be taken together with a carbon atom bonded thereto to form the following ring

wherein m13 is selected from an integer ranging from 1 to 6, provided that R²and R³are not hydrogen atoms at the same time;
R⁴is selected from

(1) —CO₂R⁹, (2) —C(O)NHOR⁹, (3) —C(O)NH—SO₂—R⁹, (4) —C(O)NHR⁹, (5) —SH, (6) —CH₂CO₂R⁹, (7) —C(O)R⁹, (8) —N(OH)COR⁹, (9) —SN₂H₂R⁹, (10) —SONHR⁹, (11) —CH₂CO₂H, (12) —PO(OH)₂, (13) —PO(OH)NHR⁹, (14) —CH₂SH, (15) —CH₂OH,

(16) —(CH₂)_r1—PO(OH)—(CH₂)_r2—R⁹,

(17) —NHR⁹ (18) —NH—NHR⁹

and
(19) —(CH₂)_r1—R⁵⁰
wherein

r1 and r2 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

R⁹is selected from

- (1) a hydrogen atom,
- (2) an optionally substituted C_1-10alkyl group,
- (3) an optionally substituted C_6-14aryl-C_1-6alkyl group

and

- (4) (CH₂)_m9—X₉—(CH₂)_n9—R²⁸

wherein

- m9 and n9 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
- X₉is a linker selected from the above-mentioned group A and
- R²⁸is a substituent selected from the following group C,
  group C:
  (a) a hydrogen atom,
  (b) a halogen atom,
  (c) a hydroxyl group,
  (d) a nitro group,
  (e) a cyano group,
  (f) a carboxyl group,
  (g) an amino group,
  (h) an amido group,
  (i) a C_2-6acyl group,
  (j) a halogenated C_1-6alkyl group,
  (k) a C_1-6alkyl group optionally substituted by hydroxyl groups,
  (l) a C_2-6alkenyl group optionally substituted by halogen atoms,
  (m) a C_2-6alkynyl group,
  (n) a C_1-6alkoxy group optionally substituted by hydroxyl groups,
  (o) a C_1-6alkoxy-C_1-6alkyl group,
  (p) a C_1-6alkoxy-carbonyl group,
  (q) a C_1-6alkyl-aminocarbonyl group optionally substituted by halogen atoms,
  (r) a mono(C_1-6alkyl)amino group,
  (s) a di(C_1-6alkyl)amino group,
  (t) a C_1-6alkyl-carbonylamino group optionally substituted by halogen atoms,
  (u) a C_1-6alkylsulfonyl group,
  (v) a C_1-6alkylsulfonylamino group,
  (w) a C_3-14hydrocarbon ring group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B and
  (x) a heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B, and

R⁵⁰is selected from an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group;

or R⁹of —C(O)NHR⁹, A²and the cyclopropane ring may be taken together to form an optionally further substituted fused ring;
R²⁰and R²¹are the same or different and each is selected from

—(CH₂)_m10—X₁₀—(CH₂)_n10-A³, (1)

wherein

m10 and n10 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X₁₀is a linker selected from the above-mentioned group A and

A³is selected from an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group,

and

—(CH₂)_m12—X₁₂—(CH₂)_n12—R³⁰, (2)

wherein

m12 and n12 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X₁₂is a linker selected from the above-mentioned group A and

R³⁰is a substituent selected from the above-mentioned group B;

or A², R³⁰and the cyclopropane ring may be taken together to form a optionally further substituted fused ring, or R⁹of —CO₂R⁹, R²⁰and the cyclopropane ring may be taken together to form an optionally further substituted fused ring, or R²⁰and R²¹may be taken together with a carbon atom bonded thereto to form the following ring

wherein m14 is selected from an integer ranging from 1 to 6; or a prodrug thereof or a pharmaceutically acceptable salt thereof [hereinafter sometimes referred to as compound (1)];
[2] The compound of [1] above, wherein the substituted C_3-14hydrocarbon ring group or the substituted heterocyclic group in A¹is a group of the following formula:

wherein

ring A¹⁰is selected from a C_3-14hydrocarbon ring group and a heterocyclic group,

r is selected from an integer ranging from 1 to 4,

R²²is —(CH₂)_m4—X₄—(CH₂)_n4—R²⁴,

- wherein
  - m4 and n4 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
  - X₄is a linker selected from the above-mentioned group A and
  - R²⁴is a substituent selected from the above-mentioned group B,
    wherein the substituents R²²are the same or different
    when r is an integer selected from the range of 2 to 4,
    and

R²³is

wherein

m5 and n5 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X₅is a linker selected from the above-mentioned group A and

ring A¹¹is selected from a C_3-14hydrocarbon ring group and a heterocyclic group, and the ring A¹¹is optionally substituted by 1 to 5 groups of the formula “—(CH₂)_m6—X₆—(CH₂)_n6—R²⁵”, which are the same or different,

wherein

- m6 and n6 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
- X₆is a linker selected from the above-mentioned group A and
- R²⁵is a substituent selected from the above-mentioned group C;
  or the ring A¹⁰and the ring A¹¹may be taken together with a substituent thereof to form an optionally substituted fused ring group;
  the optionally substituted C_3-14hydrocarbon ring group or the optionally substituted heterocyclic group in A²is a group of the following formula:

wherein

ring A¹²is selected from a C_3-14hydrocarbon ring group and a heterocyclic group, and the ring A¹²is optionally substituted by 1 to 5 groups of the formula “—(CH₂)_m7—X₇—(CH₂)₇—R²⁶”, which are the same or different,

wherein

- m7 and n7 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
- X₇is a linker selected from the above-mentioned group A and
- R²⁶is a substituent selected from the above-mentioned group C;
  or R²⁶may be linked with R²⁷, together with ring A¹²to form an optionally substituted fused ring group,
  or R²⁶may be linked with R⁹of —C(O)NHR⁹or R³⁰, together with the ring A¹²and the cyclopropane ring to form an optionally further substituted fused ring;
  the optionally substituted C_3-14hydrocarbon ring group or the optionally substituted heterocyclic group in A³is a group of the following formula:

wherein

ring A¹³is selected from a C_3-14hydrocarbon ring group and a heterocyclic group, and the ring A¹³is optionally substituted by 1 to 5 groups of the formula “—(CH₂)_m11—X₁₁—(CH₂)_n11—R²⁹”, which are the same or different,

wherein

- m11 and n11 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
- X₁₁is a linker selected from the above-mentioned group A and
- R²⁹is a substituent selected from the above-mentioned group C;
  or a prodrug thereof or a pharmaceutically acceptable salt thereof;
  [3] The compound of [2] above, wherein R¹is —(CH₂)_m—X—(CH₂)_n-A¹; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
  [4] The compound of [3] above, wherein m and n are 0 and X is a single bond; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
  [5] The compound of [4], wherein A¹is

R²³is

m5 and n5 are 0 and X₅is a single bond; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[6] The compound of [5] above, wherein R⁴is selected from —CO₂R⁹and —C(O)NHOR⁹; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[7] The compound of [6] above, wherein R⁹is a hydrogen atom; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[8] The compound of [7] above, wherein R²is (CH₂)_p—X₁—(CH₂)_q-A²; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[9] The compound of [8] above, wherein p and q are 0 and X₁is a single bond; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[10] The compound of [1] above, which is selected from the group consisting of

4-[5-((1S,2R)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester,
(1S,2R)-2-Phenyl-1-[5-(1,2,3,6-tetrahydro-pyridin-4-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
4-[5-((1S,2R)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid methyl ester,
(1S,2R,3R)-1-[5-(4-Ethynyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1S,2R,3R)-1-{5-[5-(1,1-Difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*,3R*)-2-Hydroxymethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-(4-phenylcarbamoyl-piperazine-1-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Amino-4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,6aS*)-1-[4-(3,5-Dichloro-benzyloxy)-benzenesulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid hydroxyamide,
(1R*,2S*)-4-[5-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[3-(4-Chloro-phenoxy)-azetidine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-[5-(4-trifluoromethoxy-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(3,4-Dichloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-[5-(4-trifluoromethyl-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(5-p-tolyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Fluoro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(pyridin-3-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(pyridin-2-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(pyridin-3-yloxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-hydroxy-2-methyl-propoxy)-phenyl]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Methyl-thiazol-2-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(6-Chloro-pyridin-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-[4-(3-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-[4-(4-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-Chloro-3-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(3-Chloro-phenyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-3-ylaminomethyl)-phenyl]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(6-Methoxy-pyridazin-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(5′-Cyano-[2,2′]bithiophenyl-5-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Hydroxy-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Benzyloxy-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(methyl-pyridin-3-ylmethyl-amino)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Benzyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-(5′-Methyl-[2,2′]bithiophenyl-5-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(4′-methyl-biphenyl-2-yl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-cyclohexyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-2-methyl-propoxy)-phenyl]-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[5-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Pentafluoroethyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-vinyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-ylmethyl)-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-ethyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-dimethylamino-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(2-Methyl-thiazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Methyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenoxymethyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[2-(2-tert-Butylamino-ethoxy)-phenyl]-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(2-Methyl-thiazol-5-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-(3-pyrazol-1-ylmethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-(3-methoxymethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-cyclobutyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-isopropyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[5-(4-trifluoromethyl-thiazol-2-yl)-thiophene-2-sultonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-cyclopentyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-tert-Butyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-Methoxy-phenyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-Acetyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-Fluoro-phenyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[(2-methoxy-ethyl)-methyl-carbamoyl]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-pyridin-3-yl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{2-[(2-methoxy-ethyl)-methyl-carbamoyl]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-hydroxy-ethylcarbamoyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(morpholine-4-carbonyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-1,1-dimethyl-ethylcarbamoyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-ethylcarbamoyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(morpholine-4-carbonyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-hydroxy-1,1-dimethyl-ethylcarbamoyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(2-Methyl-oxazol-5-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4-Acetyl-benzenesulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-Benzenesulfonyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-Chloro-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R)-1-{5-[5-(1,1-Difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Methyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(4-methyl-thiazol-2-yl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(2-Methyl-oxazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(5-Chloro-2-methyl-oxazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-phenyl)-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[5-(5-propyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-morpholin-4-ylmethyl-phenyl)-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Ethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(5-propylcarbamoyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-Isopropylcarbamoyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-Cyclopentylcarbamoyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(5-phenylcarbamoyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-[5-(3,3,3-trifluoro-propylcarbamoyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Fluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Difluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(7-Bromo-9H-fluorene-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(5′-Difluoromethyl-[2,2′]bithiophenyl-5-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
5-((1R*,2S*)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-thiophene-2-carboxylic acid,
(1R*,2S*)-1-(5-Ethylcarbamoyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-Cyclopropylcarbamoyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-[5-(2,2,2-trifluoro-ethylcarbamoyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-{5-[5-(1,1-Difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(2-Acetoxy-ethyl)-phenyl]—[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-ethyl)-phenyl]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Methoxymethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Pentafluoroethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-1-[5-(5-pentafluoroethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(5-Benzo[b]thiophen-2-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[5-(5-phenyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Fluoromethyl-[1,2,4]thiadiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(5-propionyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-Butyryl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(5-Benzo[b]thiophen-3-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Difluoromethyl-isothiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Fluoromethyl-isothiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Fluoromethyl-isothiazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(5-Benzofuran-2-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-isopropyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-{5-[5-(1,1-Difluoro-ethyl)-isothiazol-3-yl]-thiophene-2-sulfonylamino}-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(1,3,4,9-tetrahydro-beta-carboline-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(3-phenyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine-7-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(2-phenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-Chloro-phenoxy)-piperidine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-ethyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Hydroxy-3-methyl-but-1-ynyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3,3-Dimethyl-but-1-ynyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(5-Pent-1-ynyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[5-(3-trifluoromethyl-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-(5-Indolizin-2-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-(3-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[4-(5-Fluoromethyl-isoxazol-3-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2S)-2-((R)-3-Benzyl-2-oxo-oxazolidin-5-yl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2S)-2-((S)-3-Benzyl-2-oxo-oxazolidin-5-yl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-((E)-2-phenyl-ethenesulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R)-1-(7-Fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(7-Chloro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4-Phenoxy-piperidine-1-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-[4-(4-trifluoromethyl-phenoxy)-piperidine-1-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-Fluoro-phenoxy)-piperidine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Ethyl-1-(7-fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2,2-dimethyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(4-phenyl-3,6-dihydro-2H-pyridine-1-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R,2S)-2-(3-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[(E)-2-(4-Chloro-phenyl)-ethenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[4-(5-Difluoromethyl-isoxazol-3-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[(E)-2-(3-Chloro-phenyl)-ethenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[5-(4,5,6,7-tetrahydro-benzo[d]isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(5-Bromo-pyrimidin-2-yl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(8-Chloro-3,4-dihydro-1H-pyrazino[1,2-a]indole-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4-Benzothiazol-2-yl-piperazine-1-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4-Benzyl-piperazine-1-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-Chloro-benzoyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(3-Chloro-benzoyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[(E)-2-(4-trifluoromethyl-phenyl)-ethenesulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[(E)-2-(3-trifluoromethyl-phenyl)-ethenesulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(2-Oxo-pyrrolidin-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(2-Oxo-piperidin-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-Amino-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(2-Cyclohexyl-2,3-dihydro-1H-isoindole-5-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(2-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R,2S)-2-(2-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-(3-Bromo-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-nitro-phenyl)-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[5-(3-trifluoromethyl-isoxazol-5-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(1-Methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[(pyridin-3-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1S,2R)-2-(3-amino-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
3-{(1R,2S)-2-Carboxy-2-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid,
(1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-dimethylamino-phenyl)-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(1-Acetyl-1,2,3,6-tetrahydro-pyridin-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-(2-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[2-(2-Carboxy-ethyl)-phenyl]-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(2-Carboxy-ethyl)-phenyl]-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Carboxymethyl-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(methyl-pyridin-3-ylmethyl-amino)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-3-{2-Carboxy-2-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid methyl ester,
(1R*,2S*)-2-Phenyl-1-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonylmethyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-Chloro-phenyl)-piperazine-1-sulfonylmethyl]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylmethyl]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methoxycarbonylmethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-dimethylcarbamoylmethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-morpholin-4-yl-2-oxo-ethyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-phenyl}-cyclopropanecarboxylic acid,
(1R,2S)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-(2-Bromo-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-morpholin-4-yl-2-oxo-ethyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{2-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{2-Carboxy-2-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Nitro-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(4-methyl-piperazine-1-carbonyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Amino-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-(4-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(4-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-dimethylcarbamoylmethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{2-Carboxy-2-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid methyl ester,
(1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Acetyl-1,2,3,4-tetrahydro-isoquinoline-4-spiro-2′-{1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-1′-cyclopropanecarboxylic acid},
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-methoxycarbonyl-ethyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(3-morpholin-4-yl-3-oxo-propyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(3-oxo-3-thiomorpholin-4-yl-propyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Carboxymethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{3-[(Pyridin-3-ylmethyl)-amino]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(Methyl-pyridin-3-ylmethyl-amino)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-dimethylcarbamoyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(4-methyl-piperazine-1-carbonyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(2-tert-Butoxycarbonylamino-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1aR*,7bS*)-5-(4-Chloro-phenyl)-thiophene-2-sulfonic acid (2-oxo-1,2,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-1a-yl)-amide,
(1R*,2S*)-2-(3-Methoxycarbonylmethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(2-Morpholin-4-yl-2-oxo-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{3-[2-(4-Methyl-piperazin-1-yl)-2-oxo-ethyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{3-[2-(4-Hydroxy-piperidin-1-yl)-2-oxo-ethyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(3-dimethylamino-propionylamino)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[3-(4-hydroxy-piperidin-1-yl)-3-oxo-propyl]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(4-Benzyloxy-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(4-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-hydroxy-propyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Dimethylamino-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-hydroxymethyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[2-(3-Morpholin-4-yl-3-oxo-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[2-(2-Dimethylcarbamoyl-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{2-[3-(4-Methyl-piperazin-1-yl)-3-oxo-propyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{3-[(4-trans-Hydroxy-cyclohexylcarbamoyl)-methyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(3-Morpholin-4-yl-3-oxo-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{3-[3-(4-Methyl-piperazin-1-yl)-3-oxo-propyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(3-Hydroxy-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*,3S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-4-Methyl-piperazine-1-carboxylic acid 3-(3-{2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester,
(1R*,2S*)-Morpholine-4-carboxylic acid 3-(3-{2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester,
(1R*,2S*)-2-[2-(2-Hydroxy-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Methyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-Morpholine-4-carboxylic acid 2-(2-{2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-ethyl ester,
(1R*,2S*)-2-[2-(2-Morpholin-4-yl-2-oxo-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R,2S)-1-(7-Fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(4-morpholin-4-yl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[4-(4-methyl-piperazin-1-yl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[4-(4-methyl-piperazin-1-yl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Hydroxy-propyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-morpholin-4-yl-propyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{3-[(Morpholine-4-carbonyl)-amino]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[(morpholine-4-carbonyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[2-(3-Hydroxy-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-Morpholine-4-carboxylic acid 3-(2-{2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester,
(S)-2-Hydroxymethyl-pyrrolidine-1-carboxylic acid 3-(2-{(1R*,2S*)-2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester,
(R)-3-Hydroxy-pyrrolidine-1-carboxylic acid 3-(2-{(1R*,2S*)-2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester,
(1S,2R)-1-[5-(4-Methyl-piperidin-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Morpholin-4-yl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(Morpholine-4-carbonyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-{2-[(Morpholine-4-carbonyl)-amino]-ethyl}-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(2-Morpholin-4-yl-acetylamino)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-morpholin-4-yl-acetylamino)-phenyl]-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxy-ethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Acetoxy-propyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(4-Aminomethyl-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(4-Dimethylcarbamoyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(Morpholine-4-sulfonylamino)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(2-Hydroxy-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(morpholine-4-sulfonylamino)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(2-Carbamoyloxy-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Acetoxy-propyl)-2-{4-[(2-methoxy-ethyl)-methyl-carbamoyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Acetylamino-propyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-(3-pyrazol-1-yl-propyl)-cyclopropanecarboxylic acid,
(1R*,3S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2,2-dimethyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,3S*)-2,2-Dimethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[3-(2-Oxo-pyrrolidin-1-yl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,1aS*,6aS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid,
(1S,2R)-2-[4-(2-Carbamoyl-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-[4-(3-Morpholin-4-yl-3-oxo-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-{4-[3-(4-Methyl-piperazin-1-yl)-3-oxo-propyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-[4-(2-Methylcarbamoyl-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-[4-(2-Dimethylcarbamoyl-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Hydroxymethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-tert-Butoxycarbonylamino-propyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Amino-propyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(7-Bromo-9H-fluorene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[5-(4-methyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1R,2S,3S)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R,2S)-2-(4-Aminomethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R,2S)-2-(4-Dimethylcarbamoylmethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R,2S)-2-[4-(2-Morpholin-4-yl-2-oxo-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R,2S)-2-(4-Carbamoylmethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R,2S)-2-(4-Methylcarbamoylmethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R,2S)-2-{4-[2-(4-Methyl-piperazin-1-yl)-2-oxo-ethyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-(2-Carbamoyloxy-ethyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid amide,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid methylamide,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-cyclopentyloxycarbonylamino-propyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*,3S*)-2-Ethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-[4-(2-Amino-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R,2S)-2-[4-(2-Hydroxy-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-[4-(3-Hydroxy-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-dimethylcarbamoyloxy-ethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-[3-(4-Isopropyl-piperazin-1-ylmethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,1aS*,8bS*)1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,2R*)-Morpholine-4-carboxylic acid 2-carboxy-1-phenyl-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropylmethyl ester,
(1S,2R)-1-[5-(4-Chloro-benzoyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-2-(2-Isopropoxy-ethylcarbamoyloxymethyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-Phenyl-2-[(R)-1-(tetrahydro-furan-2-yl)methylcarbamoyloxymethyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-Piperidine-1-carboxylic acid 2-carboxy-1-phenyl-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropylmethyl ester,
(1R*,2R*)-2-(3-Methyl-isoxazol-5-yl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonic acid
((1S*,5S*,6S*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hex-1-yl)-amide,
(1R*,2R*)-2-(5-Methyl-isoxazol-3-yl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(5-Methyl-isoxazol-3-yl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-[5-(2-Hydroxy-ethyl)-isoxazol-3-yl]—[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[5-(2-Hydroxy-ethyl)-isoxazol-3-yl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-(5-Hydroxymethyl-isoxazol-3-yl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(5-Hydroxymethyl-isoxazol-3-yl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-isobutyrylamino-propyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-2-Dimethylcarbamoyloxymethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-Ethylcarbamoyloxymethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Morpholin-4-ylmethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid hydroxyamide,
(1S,2R,3R)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid hydroxyamide,
(1R*,2R*,3S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*,3S*)-2-Ethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S*,2R*,3R*)-2-Ethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-2-pyrrolidin-1-ylmethyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-2-piperidin-1-ylmethyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-Cyclopropylcarbamoyloxymethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-{[(2-Hydroxy-ethyl)-methyl-carbamoyloxy]-methyl}-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-(2-Hydroxy-ethylcarbamoyloxymethyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-4-Methyl-piperazine-1-carboxylic acid 2-carboxy-1-phenyl-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropylmethyl ester,
(1R*,2R*)-2-Carbamoyloxymethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-{[(2-Methoxy-ethyl)-methyl-amino]-methyl}-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-dimethylamino-ethylsulfanylmethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(3-trifluoromethyl-isoxazol-5-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(4-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-(4-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-morpholin-4-ylmethyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(4-Methyl-piperazin-1-ylmethyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Diethylaminomethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-((2R,6S)-2,6-dimethyl-morpholin-4-ylmethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxy-ethylsulfanylmethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-imidazol-1-ylmethyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxy-ethoxymethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-(propane-2-sulfonylmethyl)-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-isopropylsulfanylmethyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,7bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid,
(1R*,1aS*,7bS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-ethoxycarbonylmethylsulfanylmethyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(5-Difluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(3-Difluoromethyl-isoxazol-5-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,7bS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid,
(1R*,2R*)-2-Benzyloxymethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-dimethylcarbamoylmethylsulfanylmethyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-2-Carboxymethylsulfanylmethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-morpholin-4-yl-2-oxo-ethylsulfanylmethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,7bS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid hydroxyamide,
(1R*,2S*)-2-Aminomethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-oxo-oxazolidin-3-ylmethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,8bS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,1aS*,7bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid hydroxyamide,
(1R*,1aS*,8bS*)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1S,2R,3R)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[5-(4-methyl-imidazol-1-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-{[(pyridine-2-carbonyl)-amino]-methyl}-cyclopropanecarboxylic acid,
(1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1a,2,3,8b-tetrahydro-1H-4-oxa-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,1aS*,8bS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1a,2,3,8b-tetrahydro-1H-4-oxa-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1S,2R)-2-Phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-furan-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-furan-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,1aS*,8bS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-furan-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1S,2R,3R)-2-Methyl-1-[5-(5-methyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,8bS*)-1-[5-(5-Methyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,2S*)-2-(Acetylamino-methyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(Butyrylamino-methyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3,3-dimethyl-ureidomethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(cyclopropanecarbonyl-amino)-methyl]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(cyclohexanecarbonyl-amino)-methyl]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{[(morpholine-4-carbonyl)-amino]-methyl}-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Difluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,8bS*)-1-[5-(5-Difluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(ethoxycarbonylamino-methyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)—[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-{[((S)-tetrahydro-furan-2-carbonyl)-amino]-methyl}-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methoxymethyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(1-Methyl-1H-pyrazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Nitro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-4-aza-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,1aS*,8bS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid hydroxyamide,
(1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid hydroxyamide,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(isopropylamino-methyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-{[(thiazol-2-ylmethyl)-amino]-methyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-{[(pyridine-3-carbonyl)-amino]-methyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(3-hydroxy-propionylamino)-methyl]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(3-ethyl-ureido)-methyl]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(isobutyrylamino-methyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(2-methoxy-acetylamino)-methyl]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(2-hydroxy-acetylamino)-methyl]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-oxo-morpholin-4-ylmethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(5-Difluoromethyl-isoxazol-3-yl)-benzenesulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Acetylamino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Methoxymethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-methyl-1-[5-(5-Methoxymethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-2-Carboxymethoxymethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-2-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Chloro-2-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(5-Isopropyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*)-2-Ethoxycarbonylmethylsulfanylmethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-2-Carboxymethylsulfanylmethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,1aS*,4R*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-4-hydroxy-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,1aS*,4S*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-4-hydroxy-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1S,2R)-1-[5-(3-Chloro-4-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Bromo-pyrimidin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1aR*,8bS*)-5-(4-Chloro-phenyl)-thiophene-2-sulfonic acid (2-oxo-2,3,4,8b-tetrahydro-1H-3-aza-benzo[a]cyclopropan[c]cyclohepten-1a-yl)-amide,
(1S,2R)-1-[5-(5-Fluoro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[5-(5-methyl-oxazol-2-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-1-[5-(5-methyl-oxazol-2-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(5-Dimethylamino-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Cyano-4-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-1-(5-morpholin-4-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Difluoromethyl-isoxazol-5-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-Dimethylamino-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Ethynyl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Acetyl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(4-Chloro-phenyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Bromo-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[4-(4-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-methoxy-ethoxymethyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-4-methyl-1,1a,2,3,4,8b-hexahydro-4-aza-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,1aS*,6aS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methylsulfanylmethyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(5-Cyclopropyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-3-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Chloro-3-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-1-[4-(4-methyl-cyclohexyl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,4R*,8bS*)-4-Hydroxy-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,1aS*,4S*,8bS*)-4-Hydroxy-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,1aS*,8bS*)-4-Acetyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-4-aza-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid,
(1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methanesulfonylmethyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[4-(4-methyl-cyclohexyl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Isopropyl-piperazin-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Chloro-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(8-Chloro-3,4-dihydro-1H-benzo[4,5]imidazol[1,2-a]pyrazine-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,6aS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid,
(1R*,1aS*,6aS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid hydroxyamide,
(1S,2R)-1-[5-(3,5-Dichloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(5-Benzo[1,3]dioxol-5-yl-thiophene-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[5-(1-methyl-1H-imidazol-4-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Amino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Methanesulfonylamino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(4-Chloro-phenyl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4,4-Difluoro-piperidin-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-(5-quinoxalin-2-yl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(5-Chloro-pyridin-2-yl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(4-Bromo-phenyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(4-Chloro-3-fluoro-phenyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(4-Chloro-2-fluoro-phenyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(5-Chloro-pyridin-2-yl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(5-Fluoro-pyridin-2-yl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(4-Benzothiazol-2-yl-piperazine-1-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(4-Benzoxazol-2-yl-piperazine-1-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[4-(5-methyl-[1,3,4]thiadiazol-2-yl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3,5-Difluoro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3,3-Difluoro-pyrrolidin-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[5-(2-oxo-2,3-dihydro-benzothiazol-6-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[5-(2-methyl-benzothiazol-5-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Benzo[1,3]dioxol-5-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(3-Chloro-phenyl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(4-Fluoro-phenyl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(4-Benzoylamino-benzenesulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-(4-phenylcarbamoyl-benzenesulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[4-(5-methyl-isoxazol-3-yl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[4-(5-methyl-isoxazol-3-yl)-3-oxo-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-3-nitro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-3-[5-((1S,2R)-1-Carboxy-2-methyl-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-benzoic acid ethyl ester,
3-[5-((1S,2R)-1-Carboxy-2-methyl-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-benzoic acid,
(1S,2R)-1-[5-(3-Acetylamino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[6-(4-Methyl-pyrazol-1-yl)-pyridine-3-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[6-(4-Methoxy-pyrazol-1-yl)-pyridine-3-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[4-(2-methyl-benzothiazol-5-yl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[4-(5-methyl-thiazol-2-yl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,7bS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid hydroxyamide,
(1S,2R)-1-[5-(3-Hydroxy-3H-benzotriazol-5-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-3-dimethylamino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Phenyl-1-(6-phenyl-imidazo[2,1-b]thiazole-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[6-(4-Chloro-phenyl)-imidazol[2,1-b]thiazole-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[6-(4-Fluoro-phenyl)-imidazol[2,1-b]thiazole-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Methoxy-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(1H-Indol-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Bromo-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,1aS*,6aS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid hydroxyamide,
(1S,2R,3R)-1-[5-(3-Amino-4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Benzo[2,1,3]thiadiazol-5-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-(6-phenyl-imidazo[2,1-b]thiazole-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[3-(4-Chloro-phenoxy)-pyrrolidine-1-sulfony-lamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[3-(3-Chloro-phenoxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(4-Chloro-phenyl)-3-oxo-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(6-Chloro-pyridazin-3-yl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[3-oxo-4-(4-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Bromo-1,3-dihydro-isoindole-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-[4-(4-trifluoromethyl-pyrazol-1-yl)-benzenesulfonylamino]-3-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[4-(4-trifluoromethyl-pyrazol-1-yl)-benzenesulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*,3S*)-1-(5-Benzyl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*,3S*)-1-[5-(3-Hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
4-((1S,2R)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-piperazine-1-carboxylic acid isopropyl ester,
(1S,2R)-1-[4-(3-Methyl-butyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(4-Ethylcarbamoyl-piperazine-1-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[4-(3-Methyl-butyryl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(3-trifluoromethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-1-[5-(methyl-phenyl-amino)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-3-methoxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Benzo[2,1,3]oxadiazol-5-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-(6-phenyl-imidazo[2,1-b]thiazole-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R)-1-(6-Methoxymethyl-imidazo[2,1-b]thiazole-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[6-(4-Chloro-pyrazol-1-ylmethyl)-imidazol[2,1-b]thiazole-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
1-[5-((1S,2R,3R)-1-Carboxy-2-methyl-3-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-1H-pyrazole-4-carboxylic acid ethyl ester,
1-[5-((1S,2R,3R)-1-Carboxy-2-methyl-3-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-1H-pyrazole-4-carboxylic acid,
(1S,2R,3R)-1-{5-[4-(1-Hydroxy-1-methyl-ethyl)-pyrazol-1-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Methanesulfonyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*,3S*)-1-[5-(3-Hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-(5-pyridin-4-yl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-(5-pyridin-3-yl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinoline-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(4-Benzylcarbamoyl-piperazine-1-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-[4-(3-methyl-butyl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-1-(4-phenethyl-piperazine-1-sulfonylamino)-3-phenyl-cyclopropanecarboxylic acid,
4-((1S,2R,3R)-1-Carboxy-2-methyl-3-phenyl-cyclopropylsulfamoyl)-piperazine-1-carboxylic acid benzyl ester,
(1S,2R,3R)-2-Methyl-3-phenyl-1-(4-pyridin-4-yl-piperazine-1-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(2-Methoxy-ethyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(3,4-Dihydro-1H-isoquinoline-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[4-(4-Methoxy-benzyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[4-((E)-3-phenyl-allyl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Chloro-1,3-dihydro-isoindole-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2R*,3R*)-2-Methoxymethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S,3S*)-2-Methyl-1-[5-(3-morpholin-4-ylmethyl-phenyl)-thiophene-2-sulfonylmethyl]-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*,3S*)-2-Methyl-1-(5-phenethyl-thiophene-2-sulfonylamino)-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-(5-pyrazol-1-yl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Iodo-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-{5-[4-(1-Chloro-vinyl)-pyrazol-1-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Acetyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-{5-[4-(1-Hydroxy-ethyl)-pyrazol-1-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Hydroxy-1,3-dihydro-isoindole-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[3-(3-Chloro-benzyloxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[3-(4-Chloro-benzyloxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[3-(2,5-Dichloro-benzyloxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Isopropylamino-1,3-dihydro-isoindole-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[3-(2,4-Dichloro-benzyloxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[6-(4-Chloro-pyrazol-1-yl)-pyridine-3-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
3-[5-((1S,2R,3R)-1-Carboxy-2-methyl-3-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-isoxazole-5-carboxylic acid ethyl ester,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[6-(4-trifluoromethyl-pyrazol-1-yl)-pyridine-3-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[6-(4-Chloro-pyrazol-1-yl)-pyridine-3-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Phenyl-1-[6-(4-trifluoromethyl-pyrazol-1-yl)-pyridine-3-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methoxy-propyl)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methoxy-propyl)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Hydroxymethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-[5-((E)-3,3,3-trifluoro-propenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-[5-((Z)-3,3,3-trifluoro-propenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Chloro-3-hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Chloro-3-hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(2,4-Dichloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Cyano-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(7-Chloro-9H-fluorene-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(7-Chloro-9H-fluorene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Imidazo[1,2-a]pyridin-2-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Imidazo[1,2-a]pyrimidin-2-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-[5-(4-trifluoromethyl-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Acetyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-{5-[3-(2-Hydroxy-ethoxy)-phenyl]-thiophene-2-sulfonylamino}-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-{5-[3-(3-Hydroxy-propoxy)-phenyl]-thiophene-2-sulfonylamino}-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(4-trifluoromethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(5-Carbamoyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(5-Cyano-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(4-Cyano-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3,4-Difluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Amino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(1H-Benzoimidazol-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-(5-phenyl-benzo[b]thiophene-3-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-1-[5-(3-methyl-3H-[1,2,3]triazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-1-[5-(1-methyl-1H-[1,2,3]triazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Methoxy-propyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Fluoro-4-hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(4-trifluoromethyl-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-(5-Benzothiazol-2-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Hydroxymethyl-4-methoxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Cyano-3-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Fluoro-4-hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-Chloro-4-methoxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-(2-phenyl-3H-benzoimidazole-5-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2R*,3S*)-2,3-Dimethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*,3R*)-2,3-Dimethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-Methyl-2-phenyl-1-[5-(4-trifluoromethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Fluoro-3-hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3,4-Difluoro-5-hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Methanesulfonyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Hydroxymethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(5-Chloro-1H-benzoimidazol-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-Bromo-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-{5-[3-(1,1-Difluoro-2-hydroxy-ethyl)-phenyl]-thiophene-2-sulfonylamino}-2-methyl-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R,3R)-1-[5-(5-Methoxy-1H-benzoimidazol-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(4-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Methoxy-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(2-Methoxy-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-Methanesulfonyl-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(2-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(2-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-Methyl-2-pyridin-3-yl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-(3-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-(3-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-(4-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-(4-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R,3R)-2-Methyl-3-phenyl-1-(2-phenyl-imidazo[1,2-a]pyridine-6-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2R,3R)-2,3-Dimethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-2-(3-Methoxy-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, and (1S,2R,3R)-1-{5-[5-(1,1-Difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2,3-dimethyl-2-phenyl-cyclopropanecarboxylic acid; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[11] The compound of [1] above, which is represented by the formula (1′):

wherein
R¹is selected from
(1) a substituted C_1-6alkyl group,
and
(2) —(CH₂)_m—X—(CH₂)_n-A¹,
wherein
m and n are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X is selected from a single bond, a C_1-6alkylene group, a C_2-6alkenylene group, a C_2-6alkynylene group, —O—, —N(R⁵)—, —S(O)_m1—, —CO—, —CON(R⁵)—, —N(R⁵)CO—, —SO₂N(R⁵)—, —N(R⁵)SO₂—, —N(R⁵)CON(R⁶)—, —N(R⁵)SO₂N(R⁶)—, —OCON(R⁵)— and —N(R⁵)COO—,
wherein
R⁵and R⁶are the same or different and each is selected from a hydrogen atom and a C_1-6alkyl group,
m1 is selected from 0 and an integer ranging from 1 to 2,
A¹is selected from a substituted C_3-14hydrocarbon ring group and a substituted heterocyclic group;
R²and R³are the same or different and each is selected from
(1) a hydrogen atom,
(2) a C_1-6alkyl group,
(3) a halogenated C_1-6alkyl group,
and
(4) —(CH₂)_p—X₁—(CH₂)_q-A²,
provided that R²and R³are not hydrogen atoms at the same time,
wherein
p and q are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X₁, is selected from a single bond, a C_1-6alkylene group, a C_2-6alkenylene group, a C_2-6alkynylene group, —O—, —N(R⁷)—, —S(O)_m2—, —CO—, —CON(R⁷)—, —N(R⁷)CO—, —SO₂N(R⁷)—, —N(R⁷)SO₂—, —N(R⁷)CON(R⁸)—, —N(R⁷)SO₂N(R⁸)—, —OCON(R⁷)— and —N(R⁷)COO—,
wherein
R⁷and R⁸are the same or different and each is selected from a hydrogen atom and a C_1-6alkyl group,
m2 is selected from 0 and an integer ranging from 1 to 2,
r is selected from 0 and an integer ranging from 1 to 2, and
A²is selected from an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group; and
R⁴is selected from

(1) —CO₂R⁹, (2) —C(O)NHOR⁹, (3) —C(O)NH—SO₂—R⁹, (4) —C(O)NHR⁹, (5) —SH, (6) —CH₂CO₂R⁹, (7) —C(O)R⁹, (8) —N(OH)COR⁹, (9) —SN₂H₂R⁹, (10) —SONHR⁹, (11) —CH₂CO₂H, (12) —PO(OH)₂, (13) —PO(OH)NHR⁹, (14) —CH₂SH

and

(15) —CH₂OH

wherein
R⁹is selected from a hydrogen atom, an optionally substituted C_1-10alkyl group and an optionally substituted C_6-14aryl-C_1-6alkyl group;
or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[12] The compound of [11] above, wherein R¹is —(CH₂)_m—X—(CH₂)_n-A¹and A¹is selected from
(1) an optionally substituted fused C_6-14hydrocarbon ring group,
(2) an optionally substituted fused heterocyclic group,
and

(3) —V—W-Z,

wherein
V is selected from an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group;
W is —(CH₂)_t—X₂—(CH₂)_u—;
wherein
t and u are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X₂is selected from a single bond, a C_1-6alkylene group, a C_2-6alkenylene group, a C_2-6alkynylene group, —O—, —N(R¹⁰)—, —S(O)_m3—, —CO—, —CON(R¹⁰)—, —N(R¹⁰)CO—, —SO₂N(R¹⁰)—, —N(R¹⁰)SO₂—, —N(R¹⁰)CON(R¹¹)—, —N(R¹⁰)SO₂N(R¹¹)—, —OCON(R¹⁰)— and —N(R¹⁰)COO—, wherein
R¹⁰and R¹¹are the same or different and each is selected from a hydrogen atom and a C_1-6alkyl group,
m3 is selected from 0 and an integer ranging from 1 to 2,
Z is selected from an optionally substituted C_1-6alkyl group, a halogen atom, a nitro group, a cyano group, a C_1-6alkoxy group, a hydroxyl group, a halogenated C_1-6alkyl group, a halogenated C_1-6alkoxy group, a carboxyl group, a C_1-6alkoxy-carbonyl group, an amino group, a mono(C_1-6alkyl)amino group, a di(C_1-6alkyl)amino group, an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group;
or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[13] The compound of [12] above, wherein m and n are 0, and X is a single bond; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[14] The compound of [13] above, wherein t and u are 0; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[15] The compound of [14] above, wherein R⁹is selected from —CO₂R⁹and —C(O)NHOR⁹; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[16] The compound of [15] above, wherein R⁹is a hydrogen atom; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[17] The compound of [16] above, wherein R²is —(CH₂)_p—X₁—(CH₂)_q-A²; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[18] The compound of [11] above, which is selected from the group consisting of

(1S,2R)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(2,4-dichloro-benzyloxy)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid hydroxyamide,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(pyridin-3-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-methoxy-phenyl)-cyclopropanecarboxylic acid,
(1S,2R)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R,2R)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R,2S)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R,2R)-2-benzyl-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1S,2S)-2-benzyl-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-phenoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(4-chloro-phenoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-methoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(2-methoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(2-phenoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(4-methoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(4-phenoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-nitro-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-amino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-piperidine-4-yl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-isobutoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-dimethylamino-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-bromo-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3,5-diphenoxy-phenyl)-cyclopropanecarboxylic acid,
(R*,2S*)-2-biphenyl-3-yl-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-benzyloxycarbonylamino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-isobutoxycarbonylamino-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4-phenoxy-benzenesulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-bromo-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-2-phenyl-1-[5-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(2-methyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(2-ethyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-phenyl-1-[4-(2-propyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(2-isopropyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(dibenzofurane-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-methanesulfonylamino-phenyl)-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-pentafluoroethyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-acetylamino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-methoxycarbonylamino-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-4-{3-[2-carboxy-2-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropyl]-phenylamino}-piperidine-1-carboxylic acid tert-butyl ester,
(1R*,2S*)-2-(3-benzylamino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-hydroxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-cyclohexyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-phenyl-1-(4-thiophen-2-yl-benzenesulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-phenyl-1-(4-thiophen-3-yl-benzenesulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-methyl-thiophen-2-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
5-[4-((1R*,2S*)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-phenyl]-thiophene-2-carboxylic acid,
(1R*,2S*)-1-(9-oxo-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-4-[2-carboxy-2-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropyl]-piperidine-1-carboxylic acid tert-butyl ester,
(1R*,2S*)-2-(3-benzenesulfonylamino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-methoxy-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-phenyl-1-[4-(5-phenyl-[1,2,4]oxadiazol-3-yl)-benzenesulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-phenyl-1-(5-phenyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(2-hydroxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-phenyl-1-[4-(5-phenyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-bromo-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(pyridin-2-ylamino)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(pyridin-2-carbonyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(pyridin-4-carbonyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(pyridin-3-carbonyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(2,4-dichloro-benzyloxy)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-hydroxy-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-dimethylamino-acetylamino)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(pyridin-3-yloxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-methoxy-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-dimethylamino-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(7-bromo-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-pyrazol-1-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(pyridin-3-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(2-isopropyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(2-benzyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(7-fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S*,2S*)-1-(7-fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(2-ethyl-thiazol-4-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-imidazol-1-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(2-benzyloxy-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(2-benzyloxy-phenyl)-1-[5-(4-chloro-phenylethynyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-3-yloxy)-phenyl]-cyclopropanecarboxylic acid,
(1S,2R)-2-phenyl-1-(1-phenyl-1H-pyrazole-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(3H-imidazol-4-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1S,2R)-1-(7-bromo-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(2-methyl-thiazol-4-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(1-hydroxy-ethyl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(7-chloro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[3-(6-chloro-pyridazin-3-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S*,2S*)-1-(7-chloro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[1-(4-chloro-phenyl)-1H-pyrazole-4-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-dimethylaminomethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(1-methyl-piperidine-4-ylamino)-phenyl]-cyclopropanecarboxylic acid,
(1S,2R)-1-[2-(4-chloro-phenyl)-thiazole-5-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(1-methyl-1H-imidazol-2-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-{[methyl-(1-methyl-piperidine-4-yl)-amino]-methyl}phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-hydroxy-acetylamino)-phenyl]-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(4-chloro-phenyl)-4-methyl-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-3-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-2-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R,2S)-1-(7-bromo-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(3-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(pyridine-3-sulfonylamino)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(1H-imidazol-2-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-3-{2-carboxy-2-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-dimethylcarbamoylmethoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-hydroxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-carbamoylmethoxy-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-methylcarbamoylmethoxy-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-carboxymethoxy-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(5-isooxazol-3-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-phenyl-1-[5-(5-trifluoromethyl-isooxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1S*,2R*)-1-(7-chloro-dibenzofurane-3-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S*,2S*)-1-(7-chloro-dibenzofurane-3-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(2-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(2,4-dichloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1S,2R)-1-(2-benzofuran-2-yl-ethansulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-nitro-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-amino-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[(pyridin-3-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methanesulfonylamino-phenyl)-cyclopropanecarboxylic acid,
(1S,2R)-1-[5-(5-chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-trifluoromethanesulfonylamino-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-dimethylamino-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-ureido-phenyl)-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridine-3-sulfonylamino)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(3-carbamoyl-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-hydroxy-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-2-(2-carboxymethoxy-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-(3-phenoxy-benzenesulfonylamino)-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[3-(4-fluoro-phenoxy)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[3-(4-chloro-phenoxy)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[3-(3,4-dichloro-phenoxy)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[4-(4-chloro-phenyl)-piperazin-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid,
(1R*,2S*)-2-[2-(benzylcarbamoyl-methoxy)-phenyl]-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-morpholin-4-yl-2-oxo-ethoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(isopropylcarbamoyl-methoxy)-phenyl]-cyclopropanecarboxylic acid,
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-3-ylaminomethyl)-phenyl]-cyclopropanecarboxylic acid, and
(1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid; or a prodrug thereof or a pharmaceutically acceptable salt thereof;
[19] A pharmaceutical composition comprising a compound of any of [1] to [18] above, a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier;
[20] An aggrecanase inhibitor comprising a compound of any of [1] to [18] above, or a prodrug thereof or a pharmaceutically acceptable salt thereof as an active ingredient;
[21] An MMP inhibitor comprising a compound of any of [1] to [18] above, or a prodrug thereof or a pharmaceutically acceptable salt thereof as an active ingredient;
[22] The MMP inhibitor of [21] above, which is an MMP-13 inhibitor;
[23] A prophylactic or therapeutic agent for osteoarthritis comprising a compound of any of [1] to [18] above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an active ingredient;
[24] A prophylactic or therapeutic agent for rheumatoid arthritis comprising a compound of any of [1] to [18] above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an active ingredient;
[25] A method for preventing or treating osteoarthritis, which comprises administering a compound of any of [1] to [18] above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal;
[26] A method for preventing or treating rheumatoid arthritis, which comprises administering a compound of any of [1] to [18] above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal;
[27] The agent of [23] above, which is used in combination with a different therapeutic agent for osteoarthritis;
[28] The agent of [23] above, which is used in combination with a different therapeutic agent for rheumatoid arthritis;
[29] The agent of [24] above, which is used in combination with a different therapeutic agent for osteoarthritis;
[30] The agent of [24] above, which is used in combination with a different therapeutic agent for rheumatoid arthritis;
[31] The method of [25] above, which is used in combination with a different therapeutic agent for osteoarthritis;
[32] The method of [25] above, which is used in combination with a different therapeutic agent for rheumatoid arthritis;
[33] The method of [26] above, which is used in combination with a different therapeutic agent for osteoarthritis;
[34] The method of [26] above, which is used in combination with a different therapeutic agent for rheumatoid arthritis.

DETAILED DESCRIPTION OF THE INVENTION

The definitions of respective substituents and moieties used in the present specification are as follows.

In the present specification, “C_1-6,” means that the number of carbon atoms ranges from 1 to 6.

The “single bond” means a direct connection. In —(CH₂)_m—X—(CH₂)_n-A¹, for example, when X is a “single bond”, it is —(CH₂)_m—(CH₂)_n-A¹.

The “halogen atom” is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, preferably a fluorine atom, a chlorine atom or a bromine atom.

The “C_1-10alkyl group” is a straight chain or branched chain alkyl group having 1 to 10 carbon atoms, and is exemplified by methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neo-pentyl, tert-pentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, decyl and the like. In some embodiments of the present invention, it is a straight chain or branched chain alkyl group having 1 to 6 carbon atoms.

The “C_1-6alkyl group” is a straight chain or branched chain alkyl group having 1 to 6 carbon atoms, and is exemplified by methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl and the like. In some embodiments of the present invention, it is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.

The “C_2-6alkenyl group” is a straight chain or branched chain alkenyl group having 2 to 6 carbon atoms, and is exemplified by ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-ethylvinyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-1-butenyl, 1-isopropylvinyl, 2,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2,4-hexadienyl, 1-methyl-1-pentenyl and the like. In some embodiments of the present invention, it is a straight chain or branched chain alkenyl group having 2 to 4 carbon atoms.

The “C_2-6alkynyl group” is a straight chain or branched chain alkynyl group having 2 to 6 carbon atoms, and is exemplified by ethynyl, propynyl, butynyl, 2-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl and the like.

The “C_1-6alkoxy group” is an alkyloxy group wherein the alkyl moiety thereof is the above-defined C_1-6alkyl group. Examples thereof include methoxy, ethoxy, propoxy, isopropyloxy, butoxy, isobutyloxy, tert-butyloxy, pentyloxy, hexyloxy and the like. In some embodiments of the present invention, it is an alkoxy group wherein the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.

The “halogenated C_1-6alkyl group” is the above-defined C_1-6alkyl group except that it is substituted by the above-defined halogen atom. Examples thereof include fluoromethyl, difluoromethyl, trifluoromethyl, bromomethyl, chloromethyl, 1,2-dichloromethyl, 2,2-dichloromethyl, 2,2,2-trifluoroethyl and the like. In some embodiments of the present invention, it is a halogenated alkyl group wherein the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.

The “halogenated C_1-6alkoxy group” is the above-defined C_1-6alkoxy group except that it is substituted by the above-defined halogen atom. Examples thereof include fluoromethoxy, difluoromethoxy, trifluoromethoxy, bromomethoxy, chloromethoxy, 1,2-dichloromethoxy, 2,2-dichloromethoxy, 2,2,2-trifluoroethoxy and the like. In some embodiments of the present invention, it is a halogenated alkoxy group wherein the alkoxy moiety thereof is a straight chain or branched chain alkoxy group having 1 to 4 carbon atoms.

The “mono(C_1-6alkyl)amino group” is a mono-alkylamino group wherein the alkyl moiety thereof is the above-defined C_1-6alkyl group. Examples thereof include methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, tert-butylamino, pentylamino, hexylamino and the like. In some embodiments of the present invention, it is a mono-alkylamino group wherein the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.

The “di(C_1-6alkyl)amino group” is a di-alkylamino group wherein the alkyl moiety thereof is the above-defined C_1-6alkyl group. Examples thereof include dimethylamino, diethylamino, dipropylamino and the like. In some embodiments of the present invention, it is a di-alkylamino group wherein the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.

The “C_1-6alkoxy-carbonyl group” is an alkyloxycarbonyl group wherein the alkoxy moiety thereof is the above-defined C_1-6alkoxy group. Examples thereof include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropyloxycarbonyl, butoxycarbonyl, isobutyloxycarbonyl, tert-butyloxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl and the like. In some embodiments of the present invention, it is an alkoxycarbonyl group wherein the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. The “C_1-6alkoxy-C_1-6alkyl group” is an alkoxy-alkyl group wherein the alkoxy moiety thereof is the above-defined C_1-6alkoxy group and the alkyl moiety thereof is the above-defined C_1-6alkyl group. Examples thereof include methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentyloxymethyl, hexyloxymethyl, methoxyethyl, ethoxyethyl, propoxyethyl, butoxyethyl, pentyloxyethyl, hexyloxyethyl and the like. In some embodiments of the present invention, it is a C_1-4alkoxy-C_1-4alkyl group wherein the alkoxy moiety thereof is a straight chain or branched chain alkoxy group having 1 to 4 carbon atoms and the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.

The “C_1-6alkyl-aminocarbonyl group” is a mono-alkyl-amino-carbonyl group wherein the alkyl moiety thereof is the above-defined C_1-6alkyl group. Examples thereof include methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, butylaminocarbonyl, isobutylaminocarbonyl, tert-butylaminocarbonyl, pentylaminocarbonyl, hexylaminocarbonyl and the like. In some embodiments of the present invention, it is a C_1-4alkyl-aminocarbonyl group wherein the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.

The “C_1-6alkyl-carbonylamino group” is a mono-alkylcarbonyl-amino group wherein the alkyl moiety thereof is the above-defined C_1-6alkyl group. Examples thereof include methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, isopropylcarbonylamino, butylcarbonylamino, isobutylcarbonylamino, tert-butylcarbonylamino, pentylcarbonylamino, hexylcarbonylamino and the like. In some embodiments of the present invention, it is a mono-alkylcarbonyl-amino group wherein the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.

The “C_1-6alkylsulfonyl group” is an alkylsulfonyl group wherein the alkyl moiety thereof is the above-defined C_1-6alkyl group. Examples thereof include methanesulfonyl, ethanesulfonyl, propanesulfonyl, butanesulfonyl, penanesulfonyl, hexanesulfonyl and the like. In some embodiments of the present invention, it is an alkylsulfonyl group wherein the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms. The “C_1-6alkylsulfonylamino group” is an alkylsulfonyl-amino group wherein the alkyl moiety thereof is the above-defined C_1-6alkyl group. Examples thereof include methanesulfonylamino, ethanesulfonylamino, propanesulfonylamino, butanesulfonylamino, pentanesulfonylamino, hexanesulfonylamino and the like. In some embodiments of the present invention, it is an alkylsulfonylamino group wherein the alkyl moiety thereof is a straight chain or branched chain alkyl group having 1 to 4 carbon atoms.

The “C_1-6alkylene group” is a straight chain or branched chain alkylene group having 1 to 6 carbon atoms, and is exemplified by methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene and the like.

The “C_2-6alkenylene group” is a straight chain or branched chain alkenylene group having 2 to 6 carbon atoms, and is exemplified by vinylene, propenylene, 1-butenylene, 1,3-butadienylene and the like.

The “C_2-6alkynylene group” is a straight chain or branched chain alkynylene group having 2 to 6 carbon atoms, such as a straight chain or branched chain alkynylene group having 2 to 4 carbon atoms, for example ethynylene.

The “C_2-6acyl group” is an alkanoyl group having 2 to 6 carbon atoms, and is exemplified by, acetyl, propionyl, butyryl, pivaloyl and the like. In some embodiments of the present invention, it is acetyl, pivaloyl and the like.

The “substituted C_1-6alkyl group” is the above-defined C_1-6alkyl group except that it is substituted by 1 to 5, for example 1 to 3, substituent(s). The substituent of the substituted C_1-6alkyl group include

(i) a halogen atom,
(ii) a nitro group,
(iii) a cyano group,
(iv) a C_1-6alkxy group,
(v) a hydroxyl group,
(vi) a halogenated C_1-6alkxy group,
(vii) a carboxyl group,
(viii) a C_1-6alkoxy-carbonyl group,
(ix) an amino group,
(x) a mono (C_1-6alkyl)amino group,
(xi) a di(C_1-6alkyl)amino group,
(xii) an optionally substituted C_3-14hydrocarbon ring group,
(xiii) an optionally substituted heterocyclic group,
(xiv) —W-Z (as defined above),
(xv) —W¹-Z¹(defined below),
(xvi) a group selected from the above-mentioned group B,
(xvii) a group selected from the above-mentioned group C, and the like.

The “optionally substituted C_1-6alkyl group” includes the above-defined substituted C_1-6alkyl group and an unsubstituted C_1-6alkyl-group.

The “optionally substituted C_1-10alkyl group” is that wherein the above-defined C_1-10alkyl group is optionally substituted by 1 to 5, for example 1 to 3, substituent(s) and includes an unsubstituted C_1-10alkyl group. Substituents of the optionally substituted C_1-10alkyl group include substituents similar to those mentioned above for a substituted C_1-6alkyl group. In some embodiments, it is a straight chain or branched chain alkyl group having 1 to 6 carbon atoms, which is substituted or unsubstituted by the above-mentioned substituents.

The “C_3-14hydrocarbon ring group” is a saturated or unsaturated cyclic hydrocarbon group having 3 to 14 carbon atoms and includes a C_6-14aryl group, a C_3-10cycloalkyl group, a C_3-8cycloalkenyl group and the like.

The “C_6-14aryl group” is an aromatic hydrocarbon group having 6 to 14 carbon atoms. Examples thereof include phenyl, naphthyl, azulenyl, anthryl, phenanthryl and the like, for example, some embodiments include phenyl.

The “C_3-10cycloalkyl group” is a saturated cycloalkyl group having 3 to 10 carbon atoms. Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornanyl and the like, for example, some embodiments include cyclopentyl, cyclohexyl or cycloheptyl.

The “C_3-8cycloalkenyl group” is a cycloalkenyl group having at least 1, preferably 1 or 2, double bond(s) and 3 to 8 carbon atoms. Examples thereof include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl (e.g., 2,4-cyclohexadien-1-yl, 2,5-cyclohexadien-1-yl, etc.), cycloheptenyl, cyclooctenyl and the like.

The “substituted C_3-14hydrocarbon ring group” is the above-defined C_3-14hydrocarbon ring group except that it is substituted by 1 to 5, for example 1 to 3, substituent(s). The substituent of the substituted C_3-14hydrocarbon ring group include

(i) an optionally substituted C_1-6alkyl group,
(ii) a halogen atom,
(iii) a nitro group,
(iv) a cyano group,
(v) a C_1-6alkoxy group,
(vi) a hydroxyl group,
(vii) a halogenated C_1-6alkyl group,
(viii) a halogenated C_1-6alkoxy group,
(ix) a carboxyl group,
(x) a C_1-6alkoxy-carbonyl group,
(xi) an amino group,
(xii) a mono(C_1-6alkyl)amino group,
(xiii) a di(C_1-6alkyl)amino group,
(xiv) an optionally substituted C_3-14hydrocarbon ring group,
(xv) an optionally substituted heterocyclic group,
(xvi) —W-Z (as defined above),
(xvii) —W-Z (defined below),
(xviii) a group represented by the formula —(CH₂)_m4—X₄—(CH₂)_n4—R²⁴wherein each symbol is as defined above,
(xix) a group represented by the formula

wherein each symbol is as defined above,
(xx) a group selected from the above-mentioned group B,
(xxi) a group selected from the above-mentioned group C, and the like.

The “substituted C_3-14hydrocarbon ring group” may take together with the substituent(s) to form an “optionally substituted fused C_6-14hydrocarbon ring group” or an “optionally substituted fused heterocyclic group”.

The “fused C_6-14hydrocarbon ring group” in the “optionally substituted fused C_6-14hydrocarbon ring group” includes, for example, a saturated or unsaturated (including partially unsaturated and completely unsaturated) fused hydrocarbon ring group having 6 to 14 carbon atoms, wherein C_3-14hydrocarbon ring groups defined above have been fused. Examples thereof include indenyl, indanyl, 1,4-dihydronaphthyl, fluorenyl, 9-oxo-fluorenyl, 1,2,3,4-tetrahydronaphthyl (1,2,3,4-tetrahydro-2-naphthyl, 5,6,7,8-tetrahydro-2-naphthyl and the like), perhydronaphthyl and the like. For example, it is a fused ring group of phenyl and a different ring group, and fluorenyl, 9-oxo-fluorenyl and the like.

Examples of substituent of the “optionally substituted fused C_6-14hydrocarbon ring group” include substituents similar to those mentioned above for the “substituted C_3-14hydrocarbon ring group”.

The “optionally substituted C_3-14hydrocarbon ring group” includes the “substituted C_3-14hydrocarbon ring group” and an unsubstituted C_3-14hydrocarbon ring group.

The “heterocyclic group” is a 5-membered or 6-membered saturated or unsaturated (including partially unsaturated and completely unsaturated) monocyclic heterocyclic group having, as an atom constituting the ring, at least 1, for example 1 to 4, heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, besides a carbon atom.

The “saturated monocyclic heterocyclic group” include, for example, pyrrolidinyl, 2-oxo-pyrrolidinyl, tetrahydrofuryl, tetrahydrothienyl, imidazolidinyl, 2-oxo-imidazolidinyl, 2,4-dioxo-imidazolidinyl, pyrazolydinyl, 1,3-dioxolanyl, 1,3-oxathiolanyl, oxazolidinyl, 2-oxo-oxazolidinyl, thiazolidinyl, 2-oxo-thiazolidinyl, 2,4-dioxo-thiazolidinyl, 4-oxo-2-thioxo-thiazolidinyl, piperidinyl, 2-oxopiperidinyl, piperazinyl, 2,5-dioxopiperazinyl, hexahydropyridazinyl, 3-oxotetrahydropyridazinyl, 2-oxotetrahydropyrimidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, dioxanyl, morpholinyl, 3-oxomorpholinyl, thiomorpholinyl, 3-oxothiomorpholinyl, 2-oxopyrrolidinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2,6-dioxopiperidinyl, 2-oxo-1,3-oxazinanyl, 2-oxo-1,3-thiazinanyl, azetidinyl, 1,4-diazepanyl,

and the like, preferably, pyrrolidinyl, piperidinyl and morpholinyl.

The “unsaturated monocyclic heterocyclic group” includes, for example, pyrrolyl, 1,5-dihydro-2-oxopyrrolyl, furyl, thienyl, imidazolyl, 1,2-dihydro-2-oxoimidazolyl, 1,3-dihydro-2-oxoimidazolyl, pyrazolyl, 1,2-dihydro-3-oxopyrazolyl, oxazolyl, 2-oxo-oxazolyl, isoxazolyl, thiazolyl, 2-oxothiazolyl, isothiazolyl, 1,2,4-triazolyl, 3-oxo-1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 5-oxo-1,2,4-oxadiazolyl, 1,3,4-thiadiazinyl, 1,3,4-thiadiazolyl, 2-thioxo-1,3,4-thiadiazolyl, 3-oxo-1,4-oxazinyl, 1,2,4-thiadiazolyl, 5-oxo-1,2,4-thiadiazolyl, furazanyl, pyridyl, 2-oxopyridyl, 4-oxopyridyl, 2-thioxopyridyl, 4-thioxopyridyl, pyrimidinyl, 2-oxopyrimidinyl, 3,4-dihydro-4-oxopyrimidinyl, 2,4,6-trioxopyrimidinyl, pyridazinyl, 3-oxopyridazinyl, pyrazinyl, 1,3,5-triazinyl, imidazolinyl, pyrazolinyl, oxazolinyl (2-oxazolinyl, 3-oxazolinyl, 4-oxazolinyl), isoxazolinyl, thiazolinyl, isothiazolinyl, pyranyl, 2-oxopyranyl, 4-oxopyranyl, 4-thioxopyranyl and the like, such as, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, 1,2,4-triazolyl, tetrazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl and oxazolinyl.

The “substituted heterocyclic group” is the above-defined heterocyclic group except that it is substituted by 1 to 5, for example 1 to 3, substituent(s). As the substituent thereof, examples include substituents similar to those mentioned above for “substituted C_3-14hydrocarbon ring group”.

The “substituted heterocyclic group” may take together with the substituent(s) thereof to form an “optionally substituted fused heterocyclic group”.

The “fused heterocyclic group” in the “optionally substituted fused heterocyclic group” includes, for example, a 6-membered to 14-membered saturated or unsaturated (including partially unsaturated and completely unsaturated) fused heterocyclic group having, as an atom constituting the ring, at least 1, for example 1 to 4, heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, besides a carbon atom. The fused heterocyclic group may be a fused ring group of a saturated or unsaturated heterocyclic group defined above and a C_3-14hydrocarbon ring group defined above, or may be a fused ring group of saturated or unsaturated heterocyclic groups defined above. Examples thereof include indolyl, isoindolyl, 2,3-dihydroindolyl, 2,3-dihydroisoindolyl, 1,3-dihydro-2-oxoisoindolyl, 2,3-dihydro-1-oxoisoindolyl, 1,3-dihydro-1,3-dioxoisoindolyl, benzimidazolyl, indazolyl, 4,5,6,7-tetrahydroindazolyl, benzotriazolyl, benzothiazolyl, benzoisothiazolyl, 4,5,6,7-tetrahydrobenzoisothiazolyl, 2-oxobenzothiazolyl, benzothiophenyl, dibenzothiophenyl, 4,5,6,7-tetrahydrobenzothiophenyl, benzofuranyl, dibenzofuranyl, isobenzofuranyl, 4,5,6,7-tetrahydrobenzofuranyl, 4,5,6,7-tetrahydroisobenzofuranyl, benzoxazolyl, benzoisooxazolyl, 2-oxobenzoxazolyl, 4,5,6,7-tetrahydroisobenzoxazolyl, indolizinyl, quinolyl, isoquinolyl, 1,2-dihydro-2-oxoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinolidinyl, carbazolyl, puryl, pteridinyl, indolinyl, isoindolinyl, 4,5,6,7-tetrahydroindolyl, 4,5,6,7-tetrahydroisoindolyl, 5,6,7,8-tetrahydroquinolyl, 1,2,3,4-tetrahydroquinolyl, 2-oxo-1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 2-oxo-1,2,3,4-tetrahydroisoquinolyl, 1,3-benzodioxolyl, 3,4-methylenedioxypyridyl, 4,5-ethylenedioxypyrimidinyl, chromenyl, chromanyl, isochromanyl, 1,2,4-benzotriazinyl, 6,7-dihydropyrindinyl, 6,7-dihydrocyclopentapyrazinyl, 6,7-dihydrocyclopentapyridazinyl, 6,7-dihydrocyclopentapyrimidinyl, 2,3,4,5-tetrahydrobenzoazepinyl,

and the like, for example, some embodiments include benzofuranyl, dibenzofuranyl, or isoquinolyl.

Examples of substituents of the “optionally substituted fused heterocyclic group” include substituents similar to those mentioned above for “substituted heterocyclic group”.

The “optionally substituted heterocyclic group” includes the above-defined “substituted heterocyclic group” and the unsubstituted heterocyclic group.

The “C_6-14aryl-C_1-6alkyl group” is an arylalkyl group wherein the alkyl moiety thereof is the above-defined C_1-6alkyl group and the aryl moiety is the above-defined C_6-14aryl group. Examples thereof include benzyl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 4-phenylbutyl and the like. In some embodiments of the present invention, it is an arylalkyl group wherein the alkyl moiety thereof is a straight chain alkyl group having 1 to 4 carbon atoms and the aryl moiety is phenyl.

The “optionally substituted C_6-14aryl-C_1-6alkyl group” is that wherein the above-defined C_6-14aryl-C_1-6alkyl group is optionally substituted by 1 to 5, preferably 1 to 3, substituent(s) and includes an unsubstituted C_6-14aryl-C_1-6alkyl group. Substituents of the optionally substituted C_6-14aryl-C_1-6alkyl group include substituents similar to those mentioned above for the substituted C_3-14hydrocarbon ring group. In some embodiments of the present invention, it is a phenyl-C_1-4alkyl group substituted or unsubstituted by the above-mentioned substituents.

Each symbol in the formula (1) of preferable compounds of the formula (1) is explained in the following.

In some embodiments of the inventive compounds of formula (1), R¹is for example —(CH₂)_m—X—(CH₂)_n-A¹wherein each symbol is as defined above.

m and n are the same or different and each is for example 0 or an integer ranging from 1 to 2, preferably 0.

X is for example a single bond or a C_2-6alkenylene group (e.g., vinylene), preferably a single bond.

A¹is for example a group of the following formula

wherein each symbol is as defined above.

The C_3-14hydrocarbon ring group at ring A¹⁰is for example a C_6-14aryl group, preferably phenyl.

The heterocyclic group at ring A¹⁰is for example a saturated monocyclic heterocyclic group (e.g., azetidinyl, pyrrolidinyl, piperazinyl, piperazinonyl, piperidinyl, 1,4-diazepanyl, 3-oxo-piperazinyl) or an unsaturated monocyclic heterocyclic group (e.g., thienyl, methylthienyl, pyrazolyl, thiazolyl, pyridyl, 1,2,3,6-tetrahydropyridyl), preferably thienyl, azetidinyl, pyrrolidinyl, piperazinyl, piperazinonyl, piperidinyl, thienyl, pyridyl, 1,2,3,6-tetrahydropyridyl or 3-oxo-piperazinyl.

r is for example 0 or an integer ranging from 2 to 4.

R²²is —(CH₂)_m4—X₄—(CH₂)_n4—R²⁴wherein each symbol is as defined above.

m4 and n4 is for example 0 or an integer ranging from 1 to 2, preferably 0.

X₄is for example a single bond, —O—, —CO—, a C_2-6alkynylene group (e.g., ethynylene) or —CON(R⁵)— (preferably R⁵is hydrogen atom), preferably a single bond.

R²⁴is for example a halogen atom (e.g., a chlorine atom, a bromine atom, a fluorine atom), a halogenated C_1-6alkyl group (e.g., trifluoromethyl) or a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl, ethyl, propyl, isopropyl, t-butyl, 1-hydroxyethyl, 1-hydroxy-1-methylethyl).

The substituents R²²are the same or different when r is an integer selected from the range of 2 to 4,

R²³is

wherein each symbol is as defined above.

m5 and n5 are the same or different and each is for example 0 or an integer ranging from 1 to 2, preferably 0.

X₅is for example a single bond, —O—, —CO—, —S(O)_m1— (preferably m1 is 2) or —CON(R⁵)— (preferably R⁵is a hydrogen atom), preferably a single bond.

The C_3-14hydrocarbon ring group at ring A¹¹is for example a C_3-10cycloalkyl group (e.g., cyclopropyl, cyclopentyl) or a C_6-14aryl group (e.g., phenyl), preferably cyclopropyl, cyclopentyl and phenyl.

The heterocyclic group at ring A¹¹is for example a saturated monocyclic heterocyclic group (e.g., pyrrolidinyl, 2-oxo-pyrrolidinyl, 2-oxo-piperidinyl, morpholinyl, piperazinyl, piperidinyl) or an unsaturated monocyclic heterocyclic group (e.g., pyrazolyl, imidazolyl, thiazolyl, pyridyl, 3,6-dihydro-2H-pyridyl, 1,2,3,6-tetrahydro-pyridyl, pyridazinyl, pyrimidinyl, 1,2,3-triazolyl, thienyl, oxazolyl, 4,5-dihydro-oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, tetrazolyl, isooxazolyl, 4,5-dihydroisooxazolyl, isothiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl).

The ring A¹¹is optionally substituted by 1 to 5 groups of the formula “—(CH₂)_m6—X₆—(CH₂)_n6—R²⁵”, which are the same or different. The number of substituents is for example 1 or 2.

m6 and n6 are the same or different and each is for example 0 or an integer ranging from 1 to 2, preferably 0.

X₆is for example a single bond, —O—, —CO— or —COO—, preferably a single bond.

R²⁵is for example

(a) a halogen atom (e.g., a chlorine atom, a bromine atom, a fluorine atom),
(b) a hydroxyl group,
(c) a cyano group,
(d) a carboxyl group,
(e) an amino group,
(f) a halogenated C_1-6alkyl group (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl),
(g) a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl, ethyl, propyl, isopropyl, t-butyl),
(h) a C_1-6alkoxy group optionally substituted by hydroxyl groups, (e.g., methoxy),
(i) a di(C_1-6alkyl)amino group (e.g., dimethylamino) or
(j) a C_3-14hydrocarbon ring group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B (e.g., a C_6-14aryl group, preferably phenyl).

The ring A¹¹is may take together with a group of the formula “—(CH₂)_m6—X₆—(CH₂)_n6—R²⁵” to form an optionally substituted fused ring group. The optionally substituted fused ring group is for example the above-defined “optionally substituted fused C_6-14hydrocarbon ring group”, the above-defined “optionally substituted fused heterocyclic group” or the like.

The “fused C_6-14hydrocarbon ring group” in the “optionally substituted fused C_6-14hydrocarbon ring group” is for example 9H-fluorenyl or 9-oxo-9H-fluorenyl, preferably 9H-fluorenyl. The substituent thereof is for example a halogen atom (e.g., a chlorine atom, a bromine atom, a fluorine atom). The number of substituents is for example 1. Examples thereof include 9H-fluoren-2-yl, 9-oxo-9H-fluoren-2-yl, 7-bromo-9H-fluoren-2-yl, 7-fluoro-9H-fluoren-2-yl, 7-chloro-9H-fluoren-2-yl and the like.

The “fused heterocyclic group” in the “optionally substituted fused heterocyclic group” is for example benzothienyl, benzothiazolyl, benzooxazolyl, benzofuranyl, benzoimidazolyl, indolyl, 5-indolizinyl, 4,5,6,7-tetrahydrobenzo[d]isooxazolyl, 1,3-benzodioxolyl, 5-quinoxalinyl, 2-oxo-2,3-dihydro-benzothiazolyl, 1,4-benzodioxanyl, 3H-benzotriazolyl, benzo[2,1,3]thiadiazolyl, benzo[2,1,3]oxadiazolyl, benzo[1,3]dioxazolyl, imidazo[1,2-a]pyrimidinyl or the like. The substituent thereof is for example a hydroxyl group, a halogen atom (e.g., a chlorine atom, a fluorine atom), a C_1-6alkyl group (e.g., methyl), a C_1-6alkoxy group (e.g., methoxy) or the like. The number of substituents is for example 1 or 2.

The ring A¹⁰and the ring A¹¹may be taken together with a substituent thereof to form an optionally substituted fused ring group. The optionally substituted fused ring group is for example the above-defined “optionally substituted fused C_6-14hydrocarbon ring group”, the above-defined “optionally substituted fused heterocyclic group” or the like.

The “fused C_6-14hydrocarbon ring group” in the “optionally substituted fused C_6-14hydrocarbon ring group” is for example 9H-fluorenyl or 9-oxo-9H-fluorenyl, preferably 9H-fluorenyl. The substituent thereof is for example a halogen atom (e.g., a chlorine atom, a bromine atom, a fluorine atom) or the like. The number of substituents is for example 1. Examples thereof include 9H-fluoren-2-yl, 9-oxo-9H-fluoren-2-yl, 7-bromo-9H-fluoren-2-yl, 7-fluoro-9H-fluoren-2-yl, 7-chloro-9H-fluoren-2-yl and the like.

The “fused heterocyclic group” in the “optionally substituted fused heterocyclic group” is for example benzofuranyl, dibenzofuranyl, 1,3,4,9-tetrahydro-β-carbolinyl, 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazinyl, 7,8-dihydro-5H-pyrido[4,3-d]pyrimidinyl, 3,4-dihydro-1H-pyrazino[1,2-a]indolyl, 2,3-dihydro-1H-isoindolyl, 3,4-dihydro-1H-benzo[4,5]imidazo[1,2-a]pyrazinyl, imidazo[2,1-b]thiazolyl, 1,3-dihydroisoindolyl, imidazothiazolyl, 3,4-dihydroisoquinolyl, dihydroisoindolyl, benzo[b]thienyl, benzoimidazolyl, imidazo[1,2-a]pyridyl or the like. The substituent thereof is for example a hydroxyl group, a halogen atom (e.g., a chlorine atom, a bromine atom, a fluorine atom), a C_1-6alkoxy group (e.g., methoxy), an optionally substituted C_3-14hydrocarbon ring group (e.g., an optionally substituted C_3-10cycloalkyl group (e.g., cyclohexyl), an optionally substituted C_6-14aryl group (e.g., phenyl, chlorophenyl, fluorophenyl), an optionally substituted heterocyclic group (e.g., chloropyrazolyl), a C_1-6-alkoxy-C_1-6alkyl group (e.g., methoxymethyl) or a C_1-6alkyl-amino group (e.g., isopropylamino). The number of substituents is for example 1 or 2.

In some embodiments of the inventive compounds of formula (1), R²and R³are the same or different and each is —(CH₂)_p—X₁—(CH₂)_q-A², wherein each symbol is as defined above, or —(CR₂)_m8—X₈—(CH₂)₈—R²⁷, wherein each symbol is as defined above, preferably, one of them is —(CH₂)_m8—X₈—(CH₂)_n8—R²⁷(preferably hydrogen atom or a C_1-6alkyl group optionally substituted by hydroxyl groups), and the other is —(CH₂)_p—X₁—(CH₂)_q-A², wherein each symbol is as defined above.

p and q are the same or different and each is for example 0 or an integer ranging from 1 to 2, preferably 0.

X₁is for example a single bond, —O—, —N(R⁵)— (preferably R⁵is a hydrogen atom, a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl)), —S(O)_m1— (preferably m1 is 0), —CO—, —COO—, —OCO—, —N(R⁵)CO— (preferably R⁵is a hydrogen atom), —OCON(R⁵)— (preferably R⁵is a hydrogen atom) or —S(O)_m1—(CH₂)_n1—CO— (preferably m1 is 0 and n1 is 1), preferably a single bond.

A²is for example a group of the following formula

wherein each symbol is as defined above.

The C_3-14hydrocarbon ring group at ring A¹²is for example a C_6-14aryl group (preferably phenyl) or a C_3-8cycloalkyl group (preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl).

The heterocyclic group at ring A¹²is for example a saturated monocyclic heterocyclic group (e.g., pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrofuryl, 2-oxazolidonyl, morpholinyl, 3-oxo-morpholinyl) or an unsaturated monocyclic heterocyclic group (e.g., pyrazolyl, pyridyl, imidazolyl, thiazolyl, isooxazolyl).

The ring A¹²is optionally substituted by 1 to 5 groups of the formula “—(CH₂)_m7—X₇—(CH₂)_n7—R²⁶”, which are the same or different. The number of substituents is for example 1 or 2.

m7 and n7 are the same or different and each is for example 0 or an integer ranging from 1 to 2, preferably 0.

X₇is for example a single bond, —O—, —N(R⁵)—, —S(O)_m1—, —CO—, —COO—, —OCO—, —CON(R⁵)—, —N(R⁵)CO—, —N(R⁵)SO₂—, —OCON(R⁵)— or —N(R⁵)COO— (preferably R⁵is a hydrogen atom and a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl), and m1 is 2), preferably a single bond.

R²⁶is for example

(a) a halogen atom (e.g., a chlorine atom, a bromine atom, a fluorine atom),
(b) a hydroxyl group,
(c) a nitro group,
(d) a carboxyl group,
(e) an amino group,
(f) a halogenated C_1-6alkyl group (e.g., trifluoromethyl),
(g) a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl, isobutyl, hydroxymethyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-1,1-dimethylethyl),
(h) a C_1-6alkoxy group optionally substituted by hydroxyl groups, (e.g., methoxy, tert-butoxy),
(i) a mono(C_1-6alkyl)amino group (e.g., methylamino, t-butylamino),
(j) a di(C_1-6alkyl)amino group (e.g., dimethylamino),
(k) a C_1-6alkylsulfonyl group (e.g., methanesulfonyl),
(l) a C_3-14hydrocarbon ring group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B,

- wherein the “C_3-14hydrocarbon ring group” is for example a C_3-10cycloalkyl group (e.g., cyclohexyl) or a C_6-14aryl group (e.g., phenyl), the substituent thereof is for example a halogen atom (e.g., chlorine atom), a hydroxyl group or a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl), and the number of substituents is for example 1;
  or
  (m) a heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B,
- wherein the “heterocyclic group” is for example a saturated monocyclic heterocyclic group (e.g., piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, morpholinyl, piperazinyl), an unsaturated monocyclic heterocyclic group (e.g., pyridyl, pyrazolyl, thiazolyl, imidazolyl, 4,5-dihydro-oxazolyl) or the like, the substituent thereof is for example a hydroxyl group, a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl, hydroxymethyl, isopropyl) or a C_1-6alkoxy-carbonyl group (e.g., tert-butoxy carbonyl), and the number of substituents is for example 1.

The ring A¹²is may take together with a group of the formula “—(CH₂)_m7—X₇—(CH₂)_n7—R²⁶” to form an optionally substituted fused ring group. The optionally substituted fused ring group is for example the above-defined “optionally substituted fused C_6-14hydrocarbon ring group”, the above-defined “optionally substituted fused heterocyclic group” or the like.

The “fused C_6-14hydrocarbon ring group” in the “optionally substituted fused C_6-14hydrocarbon ring group” is for example 9H-fluorenyl or 9-oxo-9H-fluorenyl. The substituent thereof is for example a halogen atom (e.g., a chlorine atom, a bromine atom, a fluorine atom), and the number of substituents is for example 1.

The “fused heterocyclic group” in the “optionally substituted fused heterocyclic group” is for example tetrahydroisoquinolyl or 4-oxo-4H-benzo[d][1,2,3]triazinyl. The substituent thereof is for example a C_1-6alkyl group (e.g., methyl, isopropyl) or a C_1-6alkyl group substituted by C_6-14aryl groups (e.g., benzyl), and the number of substituents is for example 1.

m8 and n8 in —(CH₂)_m8—X₈—(CH₂)_n8—R²⁷are for example the same or different and each is 0 or an integer ranging from 1 to 2.

The X₈is for example a single bond, —O—, —N(R⁵)—, —S(O)_m1—, —OCO—, —N(R⁵)CO—, —OCON(R⁵)— or —S(O)_m1—(CH₂)_n1—CO— (preferably R⁵is a hydrogen atom, a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl), m1 is 0, 1 or 2 and n1 is 1).

R²⁷is for example

(a) a hydrogen atom
(b) a hydroxyl group,
(c) a carboxyl group,
(d) an amino group,
(e) a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl, ethyl, isopropyl, t-butyl, hydroxymethyl, 2-hydroxyethyl),
(f) a C_2-6alkenyl group optionally substituted by halogen atoms (e.g., vinyl),
(g) a C_1-6alkoxy group optionally substituted by hydroxyl groups, (e.g., methoxy, ethoxy, isopropoxy, t-butoxy),
(h) a mono(C_1-6alkyl)amino group (e.g., ethylamino), or
(i) a di(C_1-16alkyl)amino group (e.g., dimethylamino, diethylamino).

A²and R²⁷may be taken together to form an optionally substituted fused ring group. R²⁶may be linked with R²⁷, together with the ring A¹²to form an optionally substituted fused ring group. The optionally substituted fused ring group is for example the above-defined “optionally substituted fused C_6-14hydrocarbon ring group”, the above-defined “optionally substituted fused heterocyclic group” or the like. Examples thereof include 1,2,3,4-tetrahydroisoquinoline and the like. The substituent thereof is for example a substituent selected from the above-mentioned group C, preferably a C_2-6acyl group (e.g., acetyl). The number of substituents is for example 1.

R²and R³may be taken together with a carbon atom bonded thereto to form the following ring

wherein each symbol is as defined above.

m13 is for example an integer of 1 to 4, preferably 1.

Provided that R²and R³are not hydrogen atoms at the same time.

In some embodiments of the inventive compounds of formula (1), R²⁰and R²¹are the same or different and each is —(CH₂)_m10—X₁₀—(CH₂)_n10-A³, wherein each symbol is as defined above, or—(CH₂)_m12—X₁₂—(CH₂)₁₂—R³⁰, wherein each symbol is as defined above, preferably —(CH₂)_m12—X₁₂—(CH₂)_n12—R³⁰(more preferably a hydrogen atom or a C_1-6alkyl group optionally substituted by hydroxyl groups).

m10 and n10 are the same or different and each is for example 0 or an integer ranging from 1 to 2, preferably 0.

X₁₀is for example a single bond.

A³is for example, a group of the following formula

wherein each symbol is as defined above.

m12 and nl2 are the same or different and each is for example 0 or an integer ranging from 1 to 2, preferably 0.

X₁₂is for example a single bond.

R³⁰is for example

(a) a hydrogen atom,
(b) a C_1-6alkyl group optionally substituted by hydroxyl groups (e.g., methyl, ethyl, 2-hydroxymethyl) or
(c) a C_1-6alkoxy-C_1-6alkyl group (e.g., methoxymethyl).

A², R³⁰and the cyclopropane ring may be taken together to form an optionally further substituted fused ring. R²⁶may be linked with R³⁰, together with the ring A¹²and the cyclopropane ring to form an optionally further substituted fused ring.

The “fused ring” is for example a fused C_6-14hydrocarbon ring in the above-defined fused C_6-14hydrocarbon ring group or a fused heterocyclic ring in the above-defined fused heterocyclic group, wherein the above-defined C_3-14hydrocarbon ring group and/or the above-defined heterocyclic group are/is fused with the cyclopropane ring, or the like. Examples thereof include 1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropa[c]cycloheptene, 1,1a,6,6a-tetrahydro-cyclopropa[a]indene, 1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene, 1a,2,3,8b-tetrahydro-1H-4-oxa-benzo[a]cyclopropa[c]cycloheptene, 1,1a,2,3,4,8b-hexahydro-4-aza-benzo[a]cyclopropa[c]cycloheptene and the like. The “fused ring” is optionally further substituted, and the substituent thereof is for example a substituent selected from the above-mentioned group C, preferably a hydroxyl group or a C_2-6acyl group (e.g., acetyl). The number of substituents is for example 1.

R²⁰and R²¹may be taken together with a carbon atom bonded thereto to form the following ring

wherein each symbol is as defined above.

m14 is for example an integer of 1 to 4, preferably 1.

In some embodiments of the inventive compounds of formula (1), R⁴is for example —CO₂R⁹, —C(O)NHOR⁹or —(CH₂)_r1—R⁵⁰, preferably —CO₂R⁹, wherein each symbol is as defined above.

R⁹is for example a hydrogen atom or —(CH₂)_m9—X₉—(CH₂)_n9—R²⁸, wherein each symbol is as defined above.

m9 and n9 are the same or different and each is for example 0 or an integer ranging from 1 to 2.

X₉is for example a single bond.

R²⁸is for example a C_3-14hydrocarbon ring group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B, a heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B or the like.

r1 is for example 0 or an integer ranging from 1 to 2.

The “optionally substituted C_3-14hydrocarbon ring group” at R²⁸and R⁵⁰is for example the above-defined “optionally substituted fused C_3-14hydrocarbon ring group” or the like.

The “optionally substituted heterocyclic group” at R²⁸and R⁵⁰is for example the above-defined “optionally substituted heterocyclic group” or the like. Examples thereof include 1-hydroxy-1H-pyridin-2-one, 3-hydroxy-1H-pyridin-2-one, 3-hydroxy-1,2-dimethyl-1H-pyridin-4-one, 3-hydroxy-pyran-4-one, 3-hydroxy-2-methyl-pyran-4-one, 3-hydroxy-1H-pyridin-2-one, 1-hydroxy-1H-pyridine-2-thione, 3-hydroxy-1,2-dimethyl-1H-pyridine-4-thione, 3-hydroxy-1H-pyridine-2-thione, 3-hydroxy-pyran-4-thione, 3-hydroxy-2-methyl-pyran-4-thione, 3H-[1,3,4]thiadiazole-2-thione, barbituric acid, 2-thioxo-thiazolidin-4-one, thiazolidine-2,4-dione, imidazolidine-2,4-dione, 6H-1,3,4-thiazine, nitropyrimidine and the like.

R⁹of —C(O)NHR⁹, A²and the cyclopropane ring may be taken together to form an optionally further substituted fused ring. R²⁶may be linked with R⁹of —C(O)NHR⁹or R³⁰, together with the ring A12 and the cyclopropane ring to form an optionally further substituted fused ring.

The “fused ring” is for example a fused C_6-14hydrocarbon ring in the above-defined fused C_6-14hydrocarbon ring group or a fused heterocyclic ring in the above-defined fused heterocyclic group, wherein the above-defined C_3-14hydrocarbon ring group and/or the above-defined heterocyclic group are/is fused with the cyclopropane ring, or the like. Examples thereof include 2-oxo-1,2,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalene, 2-oxo-2,3,4,8b-tetrahydro-1H-3-aza-benzo[a]cyclopropa[c]cycloheptene and the like. The “fused ring” is optionally further substituted, and the substituent thereof is for example a substituent selected from the above-mentioned group C. The number of substituents is for example 1.

R⁹of —CO₂R⁹, R²⁰and the cyclopropane ring may be taken together to form an optionally further substituted fused ring. The “fused ring” is for example a fused C_6-14hydrocarbon ring in the above-defined fused C_6-14hydrocarbon ring group or a fused heterocyclic ring in the above-defined fused heterocyclic group, wherein the above-defined C_3-14hydrocarbon ring group and/or the above-defined heterocyclic group are/is fused with the cyclopropane ring, or the like. Examples thereof include 2-oxo-3-oxa-bicyclo[3.1.0]hexyl and the like. The “fused ring” is optionally further substituted, and the substituent thereof is for example a substituent selected from the above-mentioned group C. The number of substituents is for example 1.

As the compound represented by the formula (1), the following compound is preferable.

[Compound A]

A compound wherein

R¹is the formula —(CH₂)_m—X—(CH₂)_n-A¹wherein each symbol is as defined above, preferably m and n are 0, X is a single bond, and A¹is a group of the following formula:

wherein ring A¹⁰, r and R²²are as defined above,

R²³is

wherein each symbol is as defined above, preferably m5 and n5 are 0 and X₅is a single bond;

R²is —(CH₂)_p—X₁—(CH₂)_q-A², wherein each symbol is as defined above, preferably p and q are 0, X₁is a single bond, and A²is a group of the following formula:

wherein each symbol is as defined above;

A³at R²⁰and R²¹is a group of the following formula:

wherein each symbol is as defined above; and

R⁴is —CO₂R⁹or —C(O)NHOR⁹, wherein each symbol is as defined above, preferably R⁹is hydrogen atom.

As the compound represented by the formula (1), the compound represented by the following formula (1′) is also preferable:

wherein
R¹is selected from
(1) a substituted C_1-6alkyl group,
and
(2) —(CH₂)_m—X—(CH₂)_n-A¹,
wherein
m and n are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X is selected from a single bond, a C_1-6alkylene group, a C_2-6alkenylene group, a C_2-6alkynylene group, —O—, —N(R⁵)—, —S(O)_m1—, —CO—, —CON(R⁵)—, —N(R⁵)CO—, —SO₂N(R⁵)—, —N(R⁵)SO₂—, —N(R⁵)CON(R⁶)—, —N(R⁵)SO₂N(R⁶)—, —OCON(R⁵⁾— and —N(R⁵)COO—, wherein
R⁵and R⁶are the same or different and each is selected from a hydrogen atom and a C_1-6alkyl group,
m1 is selected from 0 and an integer ranging from 1 to 2,
A¹is selected from a substituted C_3-14hydrocarbon ring group and a substituted heterocyclic group;
R²and R³are the same or different and each is selected from
(1) a hydrogen atom,
(2) a C_1-6alkyl group,
(3) a halogenated C_1-6alkyl group,
and
(4) —(CH₂)_p—X₁—(CH₂)_q-A²,
provided that R²and R³are not hydrogen atoms at the same time,
wherein
p and q are the same or different and each is selected from 0 and an integer ranging from 1 to 6,
X₁is selected from a single bond, a C_1-6alkylene group, a C_2-6alkenylene group, a C_2-6alkynylene group, —O—, —N(R⁷)—, —S(O)_m2—, —CO—, —CON(R⁷)—, —N(R⁷)CO—, —SO₂N(R⁷)—, —N(R⁷)SO₂—, —N(R⁷)CON(R⁸)—, —N(R⁷)SO₂N(R⁸)—, —OCON(R⁷)— and —N(R⁷)COO—,
wherein
R⁷and R⁸are the same or different and each is selected from a hydrogen atom and a C_1-6alkyl group,
m2 is selected from 0 and an integer ranging from 1 to 2,
r is selected from 0 and an integer ranging from 1 to 2, and
A²is selected from an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group; and
R⁴is selected from

(1) —CO₂R⁹, (2) —C(O)NHOR⁹, (3) —C(O)NH—SO₂—R⁹, (4) —C(O)NHR⁹, (5) —SH, (6) —CH₂CO₂R⁹, (7) —C(O)R⁹, (8) —N(OH)COR⁹, (9) —SN₂H₂R⁹, (10) —SONHR⁹, (11) —CH₂CO₂H, (12) —PO(OH)₂, (13) —PO(OH)NHR⁹, (14) —CH₂SH

and

(15) —CH₂OH

wherein
R⁹is selected from a hydrogen atom, an optionally substituted C_1-10alkyl group and an optionally substituted C_6-14aryl-C_1-6alkyl group.

In some embodiments of the inventive compounds of formula (1′), R¹is —(CH₂)_m—X—(CH₂)_n-A¹wherein each symbol is as defined above.

m and n are the same or different and each is selected from 0 and an integer ranging from 1 to 2, preferably 0.

X is for example a single bond.

A¹is for example

(1) an optionally substituted fused C_6-14hydrocarbon ring group;

such as an optionally substituted 9H-fluorenyl or an optionally substituted 9-oxo-9H-fluorenyl. The substituent thereof is for example at least one halogen atom (e.g., a chlorine atom, a bromine atom, a fluorine atom), and the number of substituents is for example 1. Examples thereof include 9H-fluoren-2-yl, 9-oxo-9H-fluoren-2-yl, 7-bromo-9H-fluoren-2-yl, 7-fluoro-9H-fluoren-2-yl, 7-chloro-9H-fluoren-2-yl and the like.

(2) an optionally substituted fused heterocyclic group;

such as an optionally substituted benzofuranyl or optionally substituted dibenzofuranyl. The substituent thereof is for example at least one halogen atom (e.g., a chlorine atom), and the number of substituents is for example 1. Examples thereof include 2-benzofuran-2-yl, dibenzofuran-2-yl, dibenzofuran-3-yl, 7-chloro-dibenzofuran-3-yl, 8-chloro-dibenzofuran-3-yl and the like.

or
(3) —V—W-Z, wherein each symbol is as defined above. The optionally substituted C_3-14hydrocarbon ring group at V is for example a C_6-14aryl group (e.g., phenyl).

The optionally substituted heterocyclic group at V is for example an optionally substituted saturated monocyclic heterocyclic group (e.g., piperazinyl) or an optionally substituted unsaturated monocyclic heterocyclic group (e.g., thienyl, methylthienyl, pyrazolyl, thiazolyl). The substituent thereof is for example a C_1-6alkyl group (e.g., methyl).

t and u at W represented by —(CH₂)_t—X₂—(CH₂)_u— are for example the same or different and each is 0 or an integer ranging from 1 to 2, more preferably 0.

The X₂at W is for example selected from a single bond, a C_2-6alkynylene group and —O—, preferably a single bond.

The C_2-6alkynylene group at X₂is for example ethynylene.

Z is for example selected from an optionally substituted C_1-6alkyl group, a halogen atom, an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group.

The optionally substituted C_1-6alkyl group at Z is for example selected from a C_1-6alkyl group substituted by a hydroxyl group (e.g., 1-hydroxyethyl).

The halogen atom at Z is for example selected from a chlorine atom, a bromine atom and a fluorine atom.

The optionally substituted C_3-14hydrocarbon ring group at Z is for example selected from an optionally substituted C_6-14aryl group, such as phenyl. The substituent thereof is for example selected from a halogen atom (e.g., a chlorine atom, a bromine atom), a C_1-6alkoxy group (e.g., methoxy) and a di(C_1-6alkyl)amino group (e.g., dimethylamino), and the number of the substituent is for example 1 or 2. Examples thereof include phenyl, chlorophenyl (e.g., 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl), dichlorophenyl (e.g., 2,4-dichlorophenyl, 3,4-dichlorophenyl), bromophenyl, methoxyphenyl (e.g., 4-methoxyphenyl), dimethylaminophenyl and the like.

The optionally substituted heterocyclic group at Z is for example selected from an optionally substituted unsaturated monocyclic heterocyclic group (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, tetrazolyl, thiophenyl, thiazolyl, pyridazinyl, isooxazolyl, pyridyl). The substituent thereof is for example selected from a halogen atom (e.g., a chlorine atom, a bromine atom), a C_1-6alkyl group (e.g., methyl, ethyl, propyl, isopropyl), a halogenated C_1-6alkyl group (e.g., trifluoromethyl, pentafluoroethyl), a C_1-6alkoxy group (e.g., methoxy), a di(C_1-6alkyl)amino group (e.g., dimethylamino), a carboxyl group and a C_6-14aryl group (e.g., phenyl), and the number of substituents is for example 1 or 2. Examples thereof include 5-trifluoromethyl-1,2,4-oxadiazol-3-yl, 5-pentafluoroethyl-1,2,4-oxadiazol-3-yl, 5-methyl-1,2,4-oxadiazol-3-yl, 5-phenyl-1,2,4-oxadiazol-3-yl, 5-phenyl-1,3,4-oxadiazol-2-yl, 2-methyl-2H-tetrazol-5-yl, 2-ethyl-2H-tetrazol-5-yl, 2-propyl-2H-tetrazol-5-yl, 2-isopropyl-2H-tetrazol-5-yl, thiophen-2-yl, thiophen-3-yl, 4-methyl-thiophen-2-yl, 5-carboxy-thiophen-2-yl, 2-ethyl-thiazol-4-yl, 2-methyl-thiazol-4-yl, 6-chloro-pyridazin-3-yl, isoxazol-3-yl, 5-trifluoromethyl-isoxazol-3-yl, 5-chloro-pyridin-2-yl and the like.

In some embodiments of the inventive compounds of formula (1′), R²and R³are the same or different and each is selected from a hydrogen atom, a C_1-6alkyl group and —(CH₂)_p—X₁—(CH₂)_q-A², in one embodiment, one of them is a hydrogen atom or a C_1-6alkyl group, and the other is —(CH₂)_p—X₁—(CH₂)_q-A².

The C_1-6alkyl group at R²and R³is for example methyl.

p and q are the same or different and each is for example selected from 0 and an integer ranging from 1 to 2, preferably 0.

X₁is for example a single bond.

A²is for example

(1) an optionally substituted fused C_6-14hydrocarbon ring group;

such as an optionally substituted 9H-fluorenyl or an optionally substituted 9-oxo-9H-fluorenyl. The substituent thereof is for example at least one halogen atom (e.g., a chlorine atom, a bromine atom, a fluorine atom), and the number of substituents is for example 1. Examples thereof include 9H-fluoren-2-yl, 9-oxo-9H-fluoren-2-yl, 7-bromo-9H-fluoren-2-yl, 7-fluoro-9H-fluoren-2-yl, 7-chloro-9H-fluoren-2-yl and the like.

(2) an optionally substituted fused heterocyclic group;

such as an optionally substituted tetrahydroisoquinolyl. The substituent thereof is for example selected from a C_1-6alkyl group (e.g., methyl, isopropyl) and a C_1-6alkyl group substituted by a C_6-14aryl group (e.g., benzyl), and the number of substituents is for example 1. Examples thereof include 2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl, 2-isopropyl-1,2,3,4-tetrahydroisoquinolin-7-yl, 2-benzyl-1,2,3,4-tetrahydroisoquinolin-7-yl and the like.

or

(3) —V¹—W¹-Z¹

V¹is an optionally substituted C_3-14hydrocarbon ring group or an optionally substituted heterocyclic group;

W¹is —X₃—(CH₂)_t1—X₄—(CH₂)_u1—

wherein

t1 and u1 are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X₃and X₄are the same or different and each is selected from a single bond, a C_1-6alkylene group, a C_2-6alkenylene group, a C_2-6alkynylene group, —O—, —N(R¹²)—, —S(O)_m4—, —CO—, —CON(R¹²)—, —N(R¹²)CO—, —SO₂N(R¹²)—, —N(R¹²)SO₂—, —N(R²)CON(R¹³)—, —N(R¹²)SO₂N(R¹³)—, —OCON(R¹²)— and —N(R¹²)COO—,

- wherein R¹²and R¹³are the same or different and each is selected from a hydrogen atom and a C_1-6alkyl group, and m4 is selected from 0 and an integer ranging from 1 to 2,

and

Z¹is selected from an optionally substituted C_1-6alkyl group, a halogen atom, a nitro group, a cyano group, a C_1-6alkoxy group, a hydroxyl group, a halogenated C_1-6alkyl group, a halogenated C_1-6alkoxy group, a carboxyl group, a C_1-6alkoxy-carbonyl group, an amino group, a mono(C_1-6alkyl)amino group, a di(C_1-6alkyl)amino group, an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group.

The optionally substituted C_3-14hydrocarbon ring group at V¹is preferably an optionally substituted C_6-14aryl group (for example phenyl) or a C_3-8cycloalkyl group (for example cyclohexyl).

The optionally substituted heterocyclic group at V¹is for example optionally substituted saturated monocyclic heterocyclic group (e.g., piperidinyl).

t1 and u1 at W¹are the same or different and each is for example selected from 0 and an integer ranging from 1 to 2, preferably 0.

X₃and X₄at W¹are the same or different and each is for example selected from a single bond, —O—, —CO—, —N(R¹²)—, —CON(R²)—, —N(R¹²)CO—, —N(R²)SO₂— and —N(R¹²)COO—, wherein R¹²is for example selected from a hydrogen atom and methyl.

Z¹is for example selected from an optionally substituted C_1-6alkyl group, a halogen atom, a nitro group, a hydroxyl group, a halogenated C_1-6alkyl group, an amino group, a di(C_1-6alkyl)amino group, an optionally substituted C_3-14hydrocarbon ring group and an optionally substituted heterocyclic group.

The optionally substituted C_1-6alkyl group at Z¹is for example methyl or isobutyl.

The halogen atom at Z¹is for example a bromine atom.

The C_1-6alkoxy group at Z¹is for example tert-butoxy.

The halogenated C_1-6alkyl group at Z¹is for example trifluoromethyl.

The di(C_1-6alkyl)amino group at Z¹is for example dimethylamino.

The optionally substituted C_3-14hydrocarbon ring group at Z¹is for example an optionally substituted C_6-14aryl group, for example phenyl. The substituent thereof is for example at least one halogen atom (e.g., a chlorine atom), and the number of substituents is for example 1. Examples thereof include phenyl, 4-chlorophenyl and the like.

The optionally substituted heterocyclic group at Z¹, is for example selected from an optionally substituted saturated monocyclic heterocyclic group and an optionally substituted unsaturated monocyclic heterocyclic group.

The optionally substituted saturated monocyclic heterocyclic group at Z¹is for example selected from an optionally substituted piperidinyl group, an optionally substituted pyrrolidinyl group, an optionally substituted morpholinyl group and an optionally substituted piperazinyl group. The substituent thereof is for example selected from a C_1-6alkyl group (e.g., methyl) and C_1-6alkoxy-carbonyl group (e.g., tert-butoxycarbonyl group), and the number of substituents is for example 1. Examples thereof include 1-methyl-piperidin-4-yl, 1-tert-butoxycarbonyl group-piperidin-4-yl, pyrrolidin-1-yl, morpholin-4-yl, 4-methyl-piperazin-1-yl and the like.

The optionally substituted saturated monocyclic heterocyclic group at Z¹is for example selected from an optionally substituted pyridyl group, an optionally substituted pyrazolyl group and an imidazolyl group. The substituent thereof is for example a C_1-6alkyl group (e.g., methyl), and the number of substituents is for example 1. Examples thereof include pyridin-3-yl, pyrazol-1-yl, 3H-imidazol-4-yl, 1H-imidazol-2-yl, 1-methyl-1H-imidazol-2-yl and the like.

In the compounds represented by the formula (1′), R⁴is for example selected from —CO₂R⁹and —C(O)NHOR⁹, such as —CO₂R⁹wherein R⁹is for example a hydrogen atom.

The “pharmaceutically acceptable salt” may be any as long as it forms a non-toxic salt with a compound of the above-mentioned formula (1). Such salt can be obtained by reacting the compound with an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; or an organic acid such as oxalic acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzylsulfonic acid and the like; or an inorganic bases such as sodium, potassium, lithium, calcium, magnesium, ammonium and the like; or an organic bases such as methylamine, diethylamine, triethylamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, guanidine, choline, cinchonine N-methyl-D-glucamine and the like; or an amino acid such as lysine, histidine, arginine, alanine and the like. The present invention encompasses water-retaining product, hydrate and solvate of each compound.

The compounds of the above-mentioned formula (1) have various isomers. For example, E compound and Z compound are present as geometric isomers, and when the compound has an asymmetric carbon, an enantiomer and a diastereomer are present due to the asymmetric carbon. A tautomer may be also present. The present invention encompasses all of these isomers and mixtures thereof.

The present invention also encompasses prodrug and metabolite of the compound represented by the formula (1).

The “prodrug” means a derivative having a chemically modified drug molecule, which does not show physiological activity by itself, but which shows inherent efficacy by reverting to the original compound in a body after administration. The “prodrug” in the present invention means a derivative of cyclopropane compound (1) having a group capable of chemical or metabolic decomposition and showing a pharmaceutical activity by hydrolysis or solvolysis or by decomposition under physiological condition. For example, those wherein a hydroxyl group of the compound is substituted by —CO-alkyl group, —CO₂-alkyl group, —CONH-alkyl group, —CO-alkenyl, —CO₂-alkenyl, —CONH-alkenyl, —CO-aryl group, —CO₂-aryl group, —CONH-aryl group, —CO-heterocyclic ring, —CO₂-heterocyclic ring, —CONH-heterocyclic ring (the alkyl group, alkenyl, aryl group, heterocyclic ring are optionally substituted by halogen atom, alkyl group, hydroxyl group, alkoxy group, carboxyl group, amino group, amino acid residue, —PO₃H₂, —SO₃H, —OPO₃H₂, —OSO₃H, and the like), or —CO— polyethylene glycol residue, —CO₂-polyethylene glycol residue, —CO-polyethylene glycol mono alkyl ether residue, —CO₂-polyethylene glycol mono alkyl ether residue, —PO₃H₂, saccharides (e.g., glucose), or other known macromolecule for a prodrug and the like;

those wherein an amino group of the compound is substituted by —CO-alkyl group, —CO₂-alkyl group, —CO-alkenyl, —CO₂-alkenyl, —CO₂-aryl group, —CO-aryl group, —CO-heterocyclic ring, —CO₂-heterocyclic ring (the alkyl group, alkenyl, aryl group, heterocyclic ring are optionally substituted by halogen atom, alkyl group, hydroxyl group, alkoxy group, carboxyl group, amino group, amino acid residue, —PO₃H₂, —SO₃H, —OPO₃H₂, —OSO₃H, and the like.), or —CO-polyethylene glycol residue, —CO₂-polyethylene glycol residue, —CO-polyethylene glycol mono alkyl ether residue, —CO₂-polyethylene glycol mono alkyl ether residue, —PO₃H₂, saccharides (e.g., glucose), or other known macromolecule for a prodrug and the like; and

those wherein a carboxyl group of the compound is substituted by alkoxy group, aryloxy group (the alkoxy group, aryloxy group are optionally substituted by halogen atom, alkyl group, hydroxyl group, alkoxy group, carboxyl group, amino group, amino acid residue, —PO₃H₂, —SO₃H, —OPO₃H₂, —OSO₃H, and the like.), or polyethylene glycol residue, polyethylene glycol mono alkyl ether residue, saccharides (e.g., glucose), or other known macromolecule for a prodrug and the like are mentioned as examples of embodiments of the present invention.

These prodrugs can be produced, for example, according to a method known per se by one of skill in the pertinent field, such as esterification, acylation, alkoxycarbonylation, and the like.

When the inventive compound is used as a pharmaceutical preparation, the inventive compound is generally admixed with pharmaceutically acceptable carriers, excipients, diluents, fillers, disintegrators, stabilizers, preservatives, buffers, emulsifiers, aromatics, coloring agents, sweeteners, thickeners, correctives, solubilizers, and other additives such as water, vegetable oil, alcohol such as ethanol, benzyl alcohol and the like, polyethylene glycol, glycerol triacetate, gelatin, lactose, carbohydrate such as starch and the like, magnesium stearate, talc, lanolin, petrolatum and the like, and prepared into a dosage form, for example, of tablets, pills, powders, granules, suppositories, injections, eye drops, liquids, capsules, troches, aerosols, elixirs, suspensions, emulsions, syrups and the like, which can be administered systemically or topically and orally or parenterally.

While the dose of the inventive compound varies depending on the age, body weight, general condition, treatment effect, administration route and the like, it is generally from 1 mg to 1000 mg for an adult per dose, which is given one to several times a day.

The inventive compound (1) can be administered to mammals (human, mouse, rat, rabbit, dog, cat, cattle, pig, monkey, etc.) as an aggrecanase inhibitor, an MMP inhibitor, a prophylactic or therapeutic agent for osteoarthritis (OA), a prophylactic or therapeutic agent for rheumatoid arthritis (RA), a prophylactic or therapeutic agent for a disorder mediated by aggrecanase, such as joint injury, reactive arthritis, cancer, asthma, allergic reaction, chronic pulmonary emphysema, fibroid lung, acute respiratory distress (ARDS), lung infection, interstitial pneumonia, bone resorption disorder, and the like.

The compound (1) of the present invention can be administered to mammals along with other therapeutic agents for osteoarthritis, for the purpose of prevention or treatment of osteoarthritis. The compound (1) of the present invention can be also administered to mammals along with other therapeutic agents for rheumatoid arthritis, for the purpose of prevention or treatment of rheumatoid arthritis.

“Prevention” include, for example, both preventing recurrence of the disease and preventing initial occurrence of the disease.

In the case of combined administration, the compound of the present invention can be administered simultaneously with other therapeutic agents for osteoarthritis or other therapeutic agents for rheumatoid arthritis (hereinafter combination drug) or administered at certain time intervals. In the case of combined administration, a pharmaceutical composition containing the compound of the present invention and a combination drug can be administered. Alternatively, a pharmaceutical composition containing the compound of the present invention and a pharmaceutical composition containing a combination drug may be administered separately. The administration route may be the same or different.

In the case of a combined administration, the compound of the present invention can be administered once a day or several times a day in a single dose of 1 mg to 1000 mg, or may be administered in a smaller dose. The combination drug can be administered in a dose generally used for the prevention or treatment of osteoarthritis or rheumatoid arthritis or in a smaller dose.

In addition, a compound having aggrecanase inhibitory activity or MMP inhibitory activity as does the compound (1) of the present invention, a prodrug thereof and a pharmaceutically acceptable salt thereof can be used as prophylactic or therapeutic agents for diseases mediated by aggrecanase, such as osteoarthritis, rheumatoid arthritis, and the like.

Examples of the production method of the compound (1) of the present invention are given in the following. However, the production method of the compound of the present invention is not limited to these examples.

It is also possible to previously protect, as necessary, the functional groups other than those involved in the reactions to be mentioned below, and to deprotect them at a later stage.

The treatment after reaction in each step may be a conventional one, for which typical methods, such as isolation and purification, crystallization, recrystallization, column chromatography, preparative HPLC and the like, can be appropriately selected and combined.

The compound (2), which is a starting material in the following production methods, is commercially available or can be easily synthesized by a method known per se by one of skill in the art.

Production Method 1

This production method is a production method for compound (1) wherein R²is a hydrogen atom and R⁴is a hydroxyl group or a hydroxyamino group.

wherein R¹and R³are as defined above and Z is a protective group of amino group (e.g., benzyloxycarbonyl, tert-butoxycarbonyl, etc.)

Step A-1

General deprotection is performed. A compound of the formula (2) is reacted in the presence of an acid in a solvent to give a compound of the formula (3).

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is dioxane.

As the acid to be used for the reaction is, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, etc.; and organic acids such as trifluoroacetic acid, trichloroacetic acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, etc. can be mentioned, with preference given to hydrochloric acid.

The reaction temperature is generally −30° C. to 60° C., preferably 0° C. to room temperature.

The reaction time is generally 1 hr to 24 hr, preferably 2 hr to 12 hr.

The obtained compound (3) can be used in the next reaction without isolation.

Step A-2

General sulfonylation is performed. A compound of the formula (3) is reacted with a compound of the formula (4) in a solvent in the presence of a base to give a compound of the formula (1-a), which is one of the objective compounds.

As the base to be used for the reaction is, for example, alkali metal hydrides such as sodium hydride, potassium hydride, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal carboxylates such as sodium acetate, potassium acetate, etc.; alkali metal phosphate such as sodium phosphate, potassium phosphate, etc.; organic bases such as triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine, N,N-dimethylaminopyridine, etc. can be mentioned, with preference given to triethylamine and N,N-dimethylaminopyridine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is a mixed solvent of dioxane and water.

The reaction temperature is generally −30° C. to 60° C., preferably 0° C. to room temperature.

The reaction time is generally 2 hr to 24 hr, preferably 4 hr to 12 hr.

Step A-3

General amidation is performed. A compound of the formula (1-a) is reacted with a hydroxyamine derivative using a condensing agent in a solvent in the presence of a base to give a compound of the formula (I-b), which is one of the objective compounds.

As the base to be used for the reaction, for example, alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal carboxylates such as sodium acetate, potassium acetate, etc.; alkali metal phosphates such as sodium phosphate, potassium phosphate, etc.; and organic bases such as triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine, etc. can be mentioned, with preference given to N-methylmorpholine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as acetone, N,N-dimethylformamide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. Preferable solvents in this reaction are tetrahydrofuran and N,N-dimethylformamide.

As the condensing agent, any condensing agent used for general peptide condensation method (e.g., acid chloride method, mixed acid anhydride method, etc.) can be used, with preference given to a combination of ethyl chlorocarbonate and N-methylmorpholine.

As the hydroxyamine derivative to be used for the reaction, for example, O-(trimethylsilyl)hydroxylamine, etc. can be mentioned.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 60° C.

The reaction time is generally 1 hr to 24 hr, preferably 2 hr to 12 hr.

Production Method 2

wherein as R², the same substituents as for R²can be mentioned;

as R^3′, the same substituents as for R³can be mentioned;

R⁴⁰is an amino group or a hydroxy group;

R⁶⁰is —OR⁹, —NHOR⁹, —NH—SO₂—R⁹, —NHR⁹or —R⁹, wherein R⁹is as defined above (provided that when R⁶⁰is —OR⁹, then R⁹should not be a hydrogen atom);

U′, X′ and Y′ are the same or different and each is an optionally substituted C_3-14hydrocarbon ring group or an optionally substituted heterocyclic group;

T₁, T₂, T₃, T₄, T₅, T₆, T₇, T₈, T₉, T₁₀, T₁₁, T₁₂, V′ and W′ are substituents to be used for subsequent conversion of functional group and, for example, a hydrogen atom, an alkyl group, a halogen atom, a haloalkyl group, an amino group, a hydroxyl group, a formyl group, an alkylcarbonyl group, an alkylboranyl group, an alkoxyboranyl group, a hydroxyboranyl group, a methylthio group, a benzenesulfonyloxy group, a p-toluenesulfonyloxy group, a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group, a nitro group, a cyano group, an alkoxycarbonyl group, an amido group, an azido group, an alkoxy group, a carboxyl group, etc. can be mentioned, and when conversion of functional group is not necessary, TL, T₂, T₃and T₄remain in V′ or W′ in the molecule of the compound of the claim;

P₁, P₂and P₄are conventional protecting groups of carboxyl group, and as the protecting group, for example, a methyl group, an ethyl group, a t-butyl group, a benzyl group, a p-methoxybenzyl group, an allyl group, a t-butyldimethylsilyl group, etc. can be mentioned, wherein, depending on the step, P₄may be a hydrogen atom;

P₃is a conventional protecting group of amino group, and as the protecting group, a t-butoxycarbonyl group, a benzyloxycarbonyl group, a 9-fluorenylmethoxycarbonyl group, etc. can be mentioned, wherein, depending on the step, P₃may be a hydrogen atom;

P₅is an alkyl type protecting group of nitrogen atom, and an allyl group, a trichloroethyl group, a trimethylsilylethyl group, a benzyl group and a p-methoxybenzyl group can be mentioned, wherein, depending on the step, P₅may be a hydrogen atom;

P₆is a conventional protecting group of a hydroxyl group, and as the protecting group, for example, ethers such as a tetrahydropyranyl group, a benzyl group, a methoxymethyl group, a benzyloxymethyl group, a trimethylsilylethyloxymethyl group, etc.; esters such as a pivaloyl group, an acetyl group, a benzoyl group, etc.; silyl ether protecting groups such as a trimethylsilyl group, a t-butyldimethylsilyl group, a t-butyldiphenylsilyl group, etc.; etc. can be mentioned, wherein, depending on the step, P₆may be a hydrogen atom.

Step 1-1

In this Step, the epoxide of the formula 10 is reacted with MeSH in the presence of a base to give an alcohol of the formula 11. For the reaction, a base is used, but an alkali metal salt of MeSH such as sodium thiomethoxide can be also used.

As the base, for example, alkyl lithiums such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal alcoholates such as potassium t-butoxide, sodium ethoxide, sodium methoxide, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; alkali metal carboxylate such as sodium acetate, potassium acetate, etc.; alkali metal phosphates such as sodium phosphates, potassium phosphates, etc.; organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned, with preference given to alkali metal hydroxide.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is alcohol solvent, and a mixed solvent of methanol and water is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 80° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula II can be used in the next reaction without isolation.

Step 1-2

In this Step, the alcohol of the formula II obtained in Step 1-1 is converted to a halide or sulfonate of the formula 12.

Either T₁₀or T₁₁of compound 12 obtained by this Step is a methylthio group (MeS group), and one of T₁₀and T₁₁is a leaving groups such as Cl, Br, I, OMs, OTs, OSO₂Ph, OTf, etc. Depending on the substituents R^2′, R^3′, R²⁰, R²¹, T₁and T₂, compound 12 becomes a mixture of isomers. For example, when the alcohol of the formula II is converted into a compound of formula 12 wherein one of T₁₁and T₁₀is Cl, the reagent to be used for this Step includes thionyl chloride, phosphorous oxychloride, phosphorus pentachloride, hydrogen chloride and the like, with preference given to thionyl chloride. In this case, the reaction can be also carried out in the presence of a base.

As the base, organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned, with preference given to pyridine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is hydrocarbon solvent, and toluene is more preferable.

The reaction temperature is generally −20° C. to 50° C., preferably 0° C. to room temperature.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 6 hr.

Thus obtained compound of the formula 12 can be used in the next reaction without isolation.

When one of T₁₁and T₁₀is sulfonate, the compound can be obtained with sulfonyl chloride in the presence of a base. As the sulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride, benzenesulfonyl chloride; etc. can be mentioned, with preference given to methanesulfonyl chloride. In this case, the reaction is carried out in the presence of a base.

As the base, organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned, with preference given to pyridine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is hydrocarbon solvent, and toluene is more preferable.

The reaction temperature is generally −20° C. to 50° C., preferably 0° C. to room temperature.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 6 hr.

Thus obtained compound of the formula 12 can be used in the next reaction without isolation.

Step 1-3

In this Step, the alkene of the formula 13 is reacted with sulfenyl halide based on the method known from Synthesis (1980, 9, 690-691) to give a compound of the formula 12. For example, when methanesulfenyl chloride obtained from sulfuryl chloride and dimethyl disulfide is used as a reaction reagent, one of T₁₀and T₁₁in the product 12 is a methylthio group (MeS group) and one of them is Cl (leaving group). Depending on the substituent R^2′, R^3′, R²⁰, R²¹, T₁and T₂, compound 12 becomes a mixture of isomers.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and 1,2-dimethoxyethane is more preferable.

The reaction temperature is generally −78° C. to 50° C., preferably −50° C. to room temperature.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 12 can be used in the next reaction without isolation.

Step 1-4

In this Step, one of T₁₀and T₁₁, the leaving group in the compound of the formula 14 obtained in Step 1-2 or 1-3 is substituted by a malonic acid diester based on the method known from Synthesis (1980, 9, 690-691) to give the halide of the formula 12). The reaction is carried out in the presence of a base.

As the base, for example, alkyl lithiums such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal alcoholates such as potassium t-butoxide, sodium t-butoxide, sodium ethoxide, sodium methoxide, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned. A preferable base is metal alcoholate, and when, for example, P₁and P₂are each ethyl, sodium ethoxide is preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxides such as, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is alcohol solvent, and when, for example, P₁and P₂are each an ethyl group, ethanol is more preferable.

The reaction temperature is generally −50° C. to 100° C., preferably 0° C. to room temperature to 50° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 14 can be used in the next reaction without isolation.

Step 1-5

In this Step, divalent sulfur in the compound of the formula 14 obtained in Step 1-4 is alkylated by a conventional method based on the method known from Synthesis (1980, 9, 690-691) to give a sulfonium salt of the formula 15). As the reagent for the sulfonium salt formation, methyl iodide, methyl p-toluenesulfonate, methyl trifluoromethanesulfonate, dimethyl sulfate; etc. can be mentioned, with preference given to dimethyl sulfate or methyl p-toluenesulfonate.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is hydrocarbon solvent, and no solvent is more preferable.

The reaction temperature is generally 0° C. to 150° C., preferably 50° C. to 120° C.

The reaction time is 1 hr to 48 hr, preferably 6 hr to 18 hr.

Thus obtained compound of the formula 15 can be used in the next reaction without isolation.

Step 1-6

In this Step, the compound of the formula 15 obtained in Step 1-5 is treated with a base to form a cyclopropane skeleton based on the method known from Synthesis (1980, 9, 690-691), thereby affording a compound of the formula 16.

As the base, for example, alkyl lithiums such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal alcoholates such as potassium t-butoxide, sodium ethoxide, sodium methoxide, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; alkali metal carboxylates such as sodium acetate, potassium acetate, etc.; organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned. A preferable base is metal alcoholate and when, for example, P₁and P₂are both an ethyl group, sodium ethoxide is more preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A solvent preferable for this reaction are alcohol solvents and when, for example, P₁and P₂are each an ethyl group, ethanol is more preferable.

The reaction temperature is generally −30° C. to 100° C., preferably 0° C. to 80° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 16 can be used in the next reaction without isolation.

Step 1-7

In this Step, the alkene of the formula 13 is reacted with bromomalonic acid diester in the presence of a catalyst and a base based on the method known from Bull. Chem. Soc. Jpn. (2, 55, 2687-2688) to give a compound of the formula 16.

As the catalyst, copper chloride, copper bromide, copper iodide, etc. can be used, with preference given to copper (II) bromide. As the base, for example, alkyl lithium such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal alcoholates such as potassium t-butoxide, sodium ethoxide, sodium methoxide, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; alkali metal carboxylates such as sodium acetate, potassium acetate, etc.; alkali metal phosphate such as sodium phosphate, potassium phosphate, etc.; organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned. A preferable base is organic base, and 1,8-diazabicyclo[5.4.0]undec-7-ene is more preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is hydrocarbon solvent, and toluene is more preferable.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to room temperature.

The reaction time is 1 hr to 48 hr, preferably 6 hr to 24 hr.

Thus obtained compound of the formula 16 can be used in the next reaction without isolation.

This Step can be also achieved by a conventional method using diazomalonic acid diester or the method known from Synlett (2001, 12, 1843-1846). In the latter case, for example, a compound of the formula 16 can be also obtained by reacting the alkene of the formula 13 with bis(methoxycarbonyl)(phenyliodono)methanide in the presence of a catalyst.

As the catalyst, rhodium complexs and copper complexs can be used, with preference given to rhodium (II) acetate dimer.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is halogenated solvent, and no solvent is more preferable.

The reaction temperature is generally room temperature to 180° C., preferably 80° C. to 150° C.

The reaction time is 10 min to 48 hr, preferably 10 min to 6 hr.

Thus obtained compound of the formula 16 can be used in the next reaction without isolation.

Step 1-8

In this Step, the cyclic sulfonate of the formula 17 is reacted with malonic acid diester based on the method known from Chirality (2000, 12, 551-557) to give a compound of the formula 16.

The reaction is carried out in the presence of a base, and as the base, for example, alkyl lithiums such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydride such as sodium hydride, potassium hydride, etc.; metal alcoholates such as potassium t-butoxide, sodium ethoxide, sodium methoxide, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; etc. can be mentioned. A preferable base is alkali metal hydride, and sodium hydride is more preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and 1,2-dimethoxyethane is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 50° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 16 can be used in the next reaction without isolation.

Step 1-9

In this Step, the malonic acid diester of the formula 19, which has a double bond in a molecule, is cyclized to afford a compound of the formula 16 based on the method known from J. Org. Chem. (2002, 67, 4062-4075). That is, this Step is a two-step reaction comprising treating compound 19 with sulfonyl azide in the presence of a base into a diazomalonate derivative, which is then treated with a transition metal catalyst in the coexistence of a ligand to give compound 16.

As the base to be used for the first step, for example, alkyl lithiums such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal alcoholates such as potassium t-butoxide, sodium ethoxide, sodium methoxide, etc.; alkali metal amides such as lithium diisopropylamide, sodium hexamethyl disilazide, lithium hexamethyl disilazide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogen carbonate, etc.; etc. can be mentioned, with preference given to potassium carbonate.

As the sulfonyl azide, benzenesulfonyl azide, p-toluenesulfonyl azide, p-acetylaminobenzenesulfonyl azide; etc. can be mentioned, with preference given to p-toluenesulfonyl azide.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is polar solvent, and acetonitrile is more preferable.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to 50° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 24 hr.

Thus obtained diazomalonate can be used in the next reaction without isolation.

As the transition metal catalyst to be used in the subsequent cyclization reaction, rhodium complexes and copper complexs can be used, with preference given to copper (I) iodide. As the ligand to be used simultaneously, trimethyl phosphite, triethyl phosphite and triphenyl phosphite can be mentioned, with preference given to triethyl phosphite.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is toluene.

The reaction temperature is generally room temperature to 150° C., preferably 50° C. to 130° C.

The reaction time is 1 hr to 48 hr, preferably 2 hr to 12 hr.

Thus obtained compound of the formula 16 can be used in the next reaction without isolation.

Step 1-10

In this Step, the alkylidenemalonic acid diester of the formula 18 is reacted with sulfonium methylide based on the method known from J. Med. Chem. (1992, 35, 1410-1417) to give a compound of the formula 16. Sulfonium methylide is produced by treating trimethylsulfoxonium or trimethylsulfonium halide with a base.

As the base, for example, alkyl lithiums such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal alcoholates such as potassium t-butoxide, sodium ethoxide, sodium methoxide, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; etc. can be mentioned. A preferable base is alkali metal hydride, and sodium hydride is more preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is polar solvent, and dimethyl sulfoxide is more preferable.

The reaction temperature is generally −78° C. to 100° C., preferably 0° C. to 60° C.

The reaction time is 30 min to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 16 can be used in the next reaction without isolation.

Step 1-11

In this Step, one of the esters of cyclopropane dicarboxylic acid diester of the formula 16 obtained in Step 1-6, 1-7, 1-8, 1-9 or 1-10 is selectively hydrolyzed to give a monoester of the formula 20. While the selectivity varies depending on R^2′, R^3′, R²⁰, R²¹, T₁and T₂, one of the two esters of less hindered or of being assisted by neighboring functional groups is preferentially hydrolyzed.

While the hydrolysis conditions vary depending on the kind of P₁and P₂, when, for example, P₂is a methyl group, the base includes, for example, alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; and alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; etc., with preference given to sodium hydroxide.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is alcohol solvent, and a mixed solvent of ethanol or methanol and water is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably 0° C. to room temperature.

The reaction time is 1 hr to 48 hr, preferably 6 hr to 24 hr.

Thus obtained compound of the formula 20 can be used in the next reaction without isolation.

When P₁and T₂are combined and forming single bond, the compound of the formula 16 is lactone and this Step may be performed by leading the compound to an intermediate (Weinreb amide). In this case, a CO₂P₁moiety of the resulting compound 20 is CONMe(OMe). T₂is a hydroxyl group derived from lactone, or a substituent derived from the hydroxyl group such as alkyl ether, etc.

Step 1-12

In this Step, the dicarboxylic acid monoester of the formula 20 obtained in Step 1-11 is led to a compound of the formula 21. In this Curtius rearrangement reaction, acyl azide obtained by converting compound 20 to an activated ester by a conventional method and reacting the ester with metal azide may be used as an intermediate. Alternatively, compound 21 can also be obtained from compound 20 via acyl azide by the use of diphenylphosphonic azide. In addition, this Step can be applied to a compound wherein a CO₂P₁moiety of compound 20, which is a starting material, is Weinreb amide (CONMe(OMe)).

As the base, for example, organic bases such as triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene etc. can be mentioned, with preference given to triethylamine or diisopropylethylamine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, xylene, etc.; alcohol solvents such as benzyl alcohol, fluorenylmethyl alcohol, t-butyl alcohol, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide etc.; etc. can be mentioned, which may be used alone or in combination. The solvent is appropriately chosen depending on P₃. For example, when P₃is t-butoxycarbonyl, t-butyl alcohol is used. The reaction temperature is generally 0° C. to 150° C., preferably room temperature to 120° C.

The reaction time is 1 hr to 48 hr, preferably 6 hr to 48 hr.

Thus obtained compound of the formula 21 can be used in the next reaction without isolation.

Step 2-1

In this Step, the alkene of the formula 22 is led to a cyclopropane derivative of the formula 23 by the method known from Synlett (2001, 12, 1843-1846) or a method using diazomalonic acid diester derived from malonic acid diester by a conventional method with a catalyst. In the formula of this Step, T₉is a protected hydroxyl group. When, for example, diazomalonic acid diester is used, the catalyst is preferably rhodium complex, copper complex, etc., and rhodium (II) acetate dimer is more preferable. As the malonic acid diester, diethyl malonate, dimethyl malonate, dibenzyl malonate, di-t-butyl malonate, etc. can be mentioned, with preference given to dimethyl malonate.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is hydrocarbon solvent, and no solvent is more preferable.

The reaction temperature is generally room temperature to 150° C., preferably 50° C. to 120° C.

The reaction time is 1 min to 48 hr, preferably 10 min to 3 hr.

Thus obtained compound of the formula 23 can be used in the next reaction without isolation.

Step 2-2

In this Step, the protecting group of the substituent T₉(protected hydroxyl group) of the compound of the formula 23 obtained in Step 2-1 is removed to give a lactone of the formula 24. The reaction conditions are appropriately chosen depending on the kind of the protecting group in T₉. For example, when the protecting group is t-butyldiphenylsilyl group, deprotection is possible with an acid or fluoride.

As the acid, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, etc. can be mentioned, with preference given to trifluoroacetic acid.

As the fluoride source, hydrogen fluoride, hydrogen fluoride-pyridine, tetrabutylammonium fluoride, potassium fluoride, cesium fluoride; etc. can be mentioned, with preference given to tetrabutylammonium fluoride.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and THF is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 50° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 24 can be used in the next reaction without isolation.

Step 2-3

In this Step, the epichlorohydrin of the formula 25 is reacted with malonic acid diester to give a lactone derivative condensed with the cyclopropane of the formula 24. R²in the compound of the formula 24 obtained by this Step is methylene. The reaction is carried out in the presence of a base. The kind of malonic acid diester is appropriately chosen depending on P₁, and dimethyl malonate, diethyl malonate, di-t-butyl malonate, dibenzyl malonate, etc. can be mentioned, with preference given to di-t-butyl malonate.

As the base, for example, alkyl lithium such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydride such as sodium hydride, potassium hydride, etc.; metal alcoholates such as potassium t-butoxide, sodium ethoxide, sodium methoxide, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; etc. can be mentioned, with preference given to potassium t-butoxide.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is a mixed solvent of t-butyl alcohol and THF.

The reaction temperature is generally 0° C. to 150° C., preferably room temperature to 80° C.

The reaction time is 1 hr to 48 hr, preferably 6 hr to 24 hr.

Thus obtained compound of the formula 24 can be used in the next reaction without isolation.

This Step can also include optical resolution process. When P₁is a t-butyl group, deprotection with an acid is performed and the obtained racemic carboxylic acid is led to a diastereomeric salt of a chiral amine and recrystallized. The obtained chiral acid is subjected to t-butyl esterification again to give an optically active compound 24. As the acid to be used for deprotection under acidic conditions, mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, etc., organic acids such as trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid and the like can be mentioned, with preference given to hydrochloric acid or trifluoroacetic acid.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, acetonitrile, water, etc.; etc. can be mentioned. Preferable solvents in this reaction are ethyl acetate and dioxane.

The reaction temperature is generally room temperature to 100° C., preferably room temperature to 80° C.

The reaction time is 1 hr to 48 hr, preferably 2 hr to 24 hr.

As the chiral amine to be used for optical resolution, alkaloids such as cinchonine, quinidine, cinchonidine, quinine, brucine, strychinine, etc.; amino acids or alcohols derived from amino acids such as alanine, phenylalanine, alaminol, phenylalaminol, etc.; phenethylamine, naphthylethylamine; etc. can be mentioned, with preference given to quinidine.

As the solvent to be used for recrystallization, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, etc.; hydrocarbon solvents such as benzene, toluene, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, 2-butanone, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this recrystallization is ethanol.

For t-butyl esterification, a method using isobutene in the presence of an acid catalyst to give t-butyl ester, or a method using N,N-dimethylformamide di-t-butylacetal can be mentioned. For example, when N,N-dimethylformamide di-t-butylacetal is used, as the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is hydrocarbon solvent, and toluene is more preferable.

The reaction temperature is generally room temperature to 150° C., preferably room temperature to 110° C.

The reaction time is 1 hr to 24 hr, preferably 2 hr to 12 hr.

Thus obtained compound of the formula 24 can be used in the next reaction without isolation.

Step 2-4

In this Step, the lactone of the formula 24 obtained in Step 2-2 or 2-3 is subjected to ring opening and a hydroxyl group is protected as necessary. The reaction conditions are appropriately chosen depending on the kind of R², R⁴⁰and P₆. For example, when P6 is a t-butyldimethylsilyl group and R⁴⁰is OH, this Step comprises three reactions including hydrolysis of compound 24 with alkali metal carbonates or alkali metal hydroxides to give alkali metal carboxylate, subsequent protection of newly formed hydroxyl group and carboxyl group with t-butyldimethylsilyl chloride, and selective hydrolysis of carboxylic acid silyl ester with a base.

As the alkali metal carbonates used in the hydrolysis of lactone, potassium carbonate, sodium carbonate, etc. can be mentioned. As the alkali metal hydroxides, sodium hydroxide, potassium hydroxide; etc. can be mentioned, with preference given to sodium hydroxide.

As the solvent used in the hydrolysis, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and a mixed solvent of THF and water is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 80° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

The subsequent protection of the newly formed hydroxyl group with a t-butyldimethylsilyl group is performed in the presence of a base. As the base, for example, organic bases such as triethylamine, pyridine, N-methylmorpholine, imidazol, etc.; etc. can be mentioned, with preference given to imidazol.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is polar solvent, and N,N-dimethylformamide is more preferable.

The hydrolysis of carboxylic acid silyl ester can be performed in one-pot together with the above-mentioned reaction. That is, after the completion of the above-mentioned reaction, water and an alcohol solvent, and a base are added to the reaction, whereby carboxylic acid silyl ester can be selectively hydrolyzed.

As the alcohol solvents, methanol can be preferably used.

As the base, alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; etc. can be mentioned. A preferable base is alkali metal carbonate, and potassium carbonate is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably 0° C. to 50° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 26 can be used in the next reaction without isolation.

For example, the compound of the formula 26 wherein R⁴⁰is a NH₂group and P₆is a hydrogen atom can be obtained by treating the lactone of the formula 24 obtained in Step 2-3 with ammonia.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is a mixed solvent of methanol, water and THF.

The reaction temperature is generally 0° C. to 100° C., preferably 0° C. to 50° C.

The reaction time is 1 hr to 48 hr. preferably 6 hr to 24 hr.

Thus obtained compound of the formula 26 can be used in the next reaction without isolation.

Step 2-5

In this Step, the compound of the formula 26 obtained in Step 2-4 is led to a cyclic urethane of the formula 27. For example, when R⁴⁰is OH and P₆is a trialkylsilyl-protecting group, compound 27 can be obtained by a Curtius rearrangement reaction and subsequent deprotection of the trialkylsilyl protecting group. That is, compound 26 is treated with diphenylphosphonic azide in the presence of a base to give an isocyanate, which is then led to compound 27 by addition of a fluoride to the reaction to deprotect the silyl group.

As the base, organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned, with preference given to triethylamine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is polar solvent, and N,N-dimethylformamide is more preferable.

The reaction temperature is generally room temperature to 150° C., preferably room temperature to 80° C.

The reaction time is 10 min to 48 hr, preferably 10 min to 6 hr.

As the fluoride source, after completion of Curtius rearrangement, hydrogen fluoride, hydrogen fluoride-pyridine, tetrabutylammonium fluoride, potassium fluoride, cesium fluoride; etc. can be mentioned, with preference given to cesium fluoride. The reaction temperature for this reaction is generally 0° C. to 100° C., preferably room temperature to 80° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 6 hr.

Thus obtained compound of the formula 27 can be used in the next reaction without isolation.

In addition, for example, a Hofmann rearrangement reaction can be used for the compound of the formula 26 wherein R⁴⁰is NH₂and P₆is a hydrogen atom. As the oxidizing agent to be used for the Hofmann rearrangement, N-bromosuccinimide, N-chlorosuccinimide, sulfuryl chloride, bromine, iodosobenzene diacetate and the like can be used, with preference given to iodosobenzene diacetate.

The reaction may be carried out in the presence of a base, and as the base, alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; etc. can be mentioned, with preference given to sodium hydroxide.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is a mixed solvent of acetonitrile, ethyl acetate and water.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to room temperature.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 27 can be used in the next reaction without isolation.

Step 2-6

In this Step, the cyclic urethane of the formula 27 obtained in Step 2-5 is subjected to ring opening reaction to give an N-protected alcohol of the formula 21. In the compound of the formula 21 obtained by this Step, T₂is OH. For example, when R^2′ is methylene and P₃is a t-butoxycarbonyl group, this Step comprises two sequential reactions. The first step is protection of a nitrogen atom of compound 27 with a t-butoxycarbonyl group, and the second step is hydrolysis of cyclic urethane. In this case, as the butoxycarbonylation reagent to be used in the first step, for example, di-t-butyl dicarbonate is used and the reaction is carried out in the presence of a base as necessary.

As the base to be used in the first step, for example, alkyl lithiums such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; etc. can be mentioned. A preferable base is one of alkali metal hydrides, and sodium hydride is more preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and THF is more preferable.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to 50° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 24 hr.

The second step is hydrolysis with a base.

As the base to be used in the second step, for example, alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; etc. can be mentioned, with preference given to alkali metal carbonate, and cesium carbonate is more preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is alcohol solvent, and methanol is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 50° C.

The reaction time is 10 min to 24 hr, preferably 30 min to 6 hr.

Thus obtained compound of the formula 21 can be used in the next reaction without isolation.

Step 3-1

In this Step, the glycine derivative of the formula 28 is reacted with dihaloalkane or dihaloalkene in the presence of a base to give a cyclopropane derivative of the formula 21. Dihaloalkane and dihaloalkene are appropriately chosen depending on R²⁰, R²¹, R^2′, R^3′, T₁and T₂.

As the base, for example, alkyl lithiums such as butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; metal alcoholates such as potassium t-butoxide, sodium ethoxide, sodium methoxide, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; etc. can be mentioned, with preference given to metal alcoholate, and potassium t-butoxide is more preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and THF is more preferable.

The reaction temperature is generally −100° C. to 50° C., preferably −78° C. to room temperature.

The reaction time is 1 hr to 24 hr, preferably 1 hr to 8 hr.

Thus obtained compound of the formula 21 can be used in the next reaction without isolation.

Step 4-1

In this Step, the alkene of the formula 13 is reacted with nitroacetic acid ester, in the presence of iodosobenzene diacetate and a catalyst based on the method known from J. Org. Chem. (2004, 69, 1262-1269), and the compound of the formula 21 is obtained via a subsequent reductive reaction.

The catalyst to be used for the reaction is rhodium complex or copper complex, with preference given to a rhodium (II) pivalate dimer.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is water or no solvent.

The reaction temperature is generally −20° C. to 100° C., preferably room temperature to 40° C.

The reaction time is 1 hr to 48 hr, preferably 2 hr to 24 hr.

As the reduction condition employed for the subsequent reaction, hydrogenation reaction in the presence of a palladium catalyst, reductive reaction using tin (II) chloride, iron, zinc and the like under acidic conditions reductive reaction using sodium borohydride in the presence of copper acetate can be mentioned, with preference given to conditions using zinc in the presence of hydrochloric acid.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is alcohol solvent, and isopropyl alcohol is more preferable.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to room temperature.

The reaction time is 1 hr to 48 hr, preferably 2 hr to 12 hr.

Thus obtained compound of the formula 21 can be used in the next reaction without isolation.

Step 5-1

In this Step, the ester of the formula 21 obtained in Step 1-12, 2-6, 3-1 or 4-1 is led to a carboxylic acid of the formula 29 by a-conventional method. The reaction conditions are appropriately chosen depending on P₁and when, for example, P₁is a methyl group or ethyl group, hydrolysis with a conventional base can be performed. In addition, when, for example, P₁is a t-butyl group, deprotection with an acid can be performed. Thus obtained racemic compound 29 can be subjected to optical resolution using a chiral amine, to give compound 29 of optically active.

As a base to be used for hydrolysis under basic conditions, for example, alkali metal carbonates such as cesium carbonate, sodium carbonate, potassium carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; etc. can be mentioned, with preference given to sodium hydroxide. As an acid to be used for deprotection under acidic conditions, mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, etc.; organic acids such as trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid, etc.; etc. can be mentioned, with preference given to hydrochloric acid or trifluoroacetic acid.

As the solvent, for example, for hydrolysis under basic conditions, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is a mixed solvent of ether and alcohol, and a mixed solvent of methanol, THF and water is more preferable.

The reaction temperature is generally room temperature to 100° C., preferably room temperature to 80° C.

The reaction time is 1 hr to 48 hr, preferably 2 hr to 24 hr. For deprotection under acidic conditions, as the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, acetonitrile, water, etc.; etc. can be mentioned. A preferable solvent is ethyl acetate, dioxane, dichloromethane, chloroform or no solvent.

Thus obtained compound of the formula 29 can be used in the next reaction without isolation.

In addition, an optically active compound of the formula 29 can be obtained by recrystallization of diastereomeric salt of the racemate with chiral amine.

As the chiral amine, alkaloids such as cinchonine, quinidine, cinchonidine, quinine, brucine, strychinine, etc.; amino acids or alcohols derived from amino acid such as alanine, phenylalanine, alaminol, phenylalaminol, etc.; phenethylamine, naphthylethylamine; etc. can be mentioned, with preference given to quinidine.

As the solvent to be used for recrystallization, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, etc.; hydrocarbon solvents such as benzene, toluene, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, 2-butanone, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this recrystallization is isopropyl alcohol, acetone, ethyl acetate or a mixed solvent thereof.

This Step is performed as necessary or may be omitted.

The compound of the formula 21 can be treated as the compound of the formula 30, 31 or 32.

Step 5-2

In this Step, the carboxylic acid of the formula 29 obtained in Step 5-1 is protected using a protecting group P₄by a conventional method. While P₄is appropriately chosen depending on P₃, T₁, or T₂, when, for example, P₄is a t-butyl group, a method using isobutene in the presence of an acid catalyst or a method using N,N-dimethylformamide di-tert-butyl acetal can be mentioned.

When, for example, N,N-dimethylformamide di-tert-butyl acetal is used, as the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is a hydrocarbon solvent, and toluene is more preferable.

The reaction temperature is generally room temperature to 150° C., preferably room temperature to 110° C.

The reaction time is 1 hr to 24 hr, preferably 2 hr to 12 hr.

Thus obtained compound of the formula 30 can be used in the next reaction without isolation.

This Step is performed as necessary, or may be omitted when the next Step and the following Steps have no problem, and the compound of the formula 29 wherein P₄is a hydrogen atom may be used as a starting material of the subsequent Steps.

Step 5-3

In this Step, substituent T₁on R^3′ and/or substituent T₂on R²′ of the compound of the formula 30 are/is converted to T₃and/or T₄, respectively, under conventional conditions.

For example, when R³′ is an aromatic ring and T₁is a halogen atom, so-called Negishi reaction, Suzuki-Miyaura reaction (Metal-catalyzed Cross Coupling Reactions; WILEY-VCH; New York, 1998), Buchwald reaction, Ullmann reaction (Tetrahedron 2002, 11, 2041-2075; J. Am. Chem. Soc. 2003, 125, 6653-6655) and the like can be applied, whereby a compound of the formula 31 wherein T₃is alkoxycarbonyl alkyl, carbonylamino group, alkoxycarbonyl group, aryl group, arylamino group, alkylamino group or aryl alkoxy group can be obtained respectively.

When, for example, R^2′ is an alkyl chain and T₂is a hydroxyl group, for example, a compound of the formula 31 wherein T₄is an amino group or alkylamino group can be obtained by a conventional method. Thus obtained compound of the formula 31 can be used in the next reaction without isolation.

When T₁and T₂are hydrogen atoms or when further conversion is not necessary, this Step is omitted and the compound of the formula 30 can be treated as a compound of the formula 31.

Step 5-4

In this Step, P₃, which is a nitrogen-protecting group in the compound of the formula 31, is deprotected by a conventional method. When Step(s) 5-1, 5-2 and/or 5-3 are/is omitted, this Step is also a step for deprotecting P₃of the compounds of the formulas 21, 29 or 30. In addition, this Step can be applied to compound 31, wherein a CO₂P₄moiety is Weinreb amide (CONMe(OMe)). The reaction conditions are appropriately chosen depending on P₃or P₄, when, for example, P₃is a t-butoxycarbonyl group and P₄is a t-butyl group, deprotection can be performed under acidic conditions.

As the acid, mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid, etc.; organic acids such as acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, etc. can be mentioned, with preference given to p-toluenesulfonic acid.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, alcohol solvent or acetonitrile.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 50° C.

The reaction time is 1 hr to 72 hr, preferably 6 hr to 48 hr.

Thus obtained compound of the formula 32 can be used in the next reaction without isolation.

When P₃is a hydrogen atom, this Step is not necessary, and the compound of the formula 31 can be treated as a compound of the formula 32.

Step 5-5

In this Step, the compound of the formula 32 obtained in Step 5-4 is led to a sulfonamide or sulfamide of the formula 33. T₅in the compound of the formula 33 obtained in this Step is a substituent, which is further led to other functional group in the next Step 5-6, 5-13 or 6-7.

When the compound of the formula 33 is a sulfonamide derivative, the compound 33 can be obtained by a conventional reaction of the compound of the formula 32 with ClSO₂—(CH₂)_m—U-T₅or O(SO₂—(CH₂)_m—U-T₅)₂in the presence of a base, for example.

As the base, organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned, with preference given to pyridine or 2,6-lutidine. These may be used as solvents.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as N,N-dimethylformamide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is halogenated solvent or ether solvent, and chloroform or THF is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 50° C.

The reaction time is 1 hr to 72 hr, preferably 1 hr to 48 hr.

When the compound of the formula 33 is a sulfamide derivative, based on the method known in Tetrahedron (1996, 52, 14217-14227), the derivative can be synthesized by two consecutive reactions. The first step is a reaction of 2-haloethanol with chlorosulfonyl isocyanate and then with the compound of the formula 32 in the presence of a base, to give an oxazolidin-2-one-3-ylsulfamide, and the second step is a reaction of the compound obtained above with a desired amine to give a sulfamide of the formula 33.

As the 2-haloethanol, for example, 2-chloroethanol, 2-bromoethanol and 2-iodoethanol can be mentioned, with preference given to 2-chloroethanol.

As the base, for example, organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned. A preferable base is organic base, and N-methylmorpholine is more preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is polar solvent, and acetonitrile is more preferable.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to 50° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 24 hr.

The second step is a nucleophilic substitution reaction with amine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is polar solvent, and acetonitrile is more preferable.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to 100° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 24 hr.

Thus obtained compound of the formula 33 can be used in the next reaction without isolation.

Step 5-6

In this Step, the compound of the formula 33 obtained in Step 5-5 is reacted with the compound of the formula 34 to give a compound of the formula 35. T₇in the compound of the formula 35 obtained in this Step is a substituent that can be led to the other substituents in Step 5-9, 5-14 or 6-10. In addition, U′ in the compound of the formula 33 changes structure by reacting with the compound of the formula 34, thereby forming a new ring X′, or may remain the structure (U′=X′).

As for one of the examples of structural change of U′ with this reaction, can be mentioned the case, in which U′-T₅is 2-aminothiazol-4-yl and the compound of the formula 34 is an α′-haloacetone possessing T₇at the α-position. In this case, U′-T₅structurally changes to an imidazo[2.1-b]thiazol-2-yl group possessing CH₂T₇at the 6-position. As the solvent in this case, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ester solvent, and ethyl acetate is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 80° C.

The reaction time is 1 hr to 48 hr, preferably 6 hr to 24 hr.

Thus obtained compound of the formula 35 can be used in the next reaction without isolation.

Step 5-7

In this Step, the compound of the formula 32 obtained in Step 5-4 is directly led to the compound of the formula 35 without going through the compound of the formula 33. T₇in the compound of the formula 35 obtained in this Step is a substituent that can be converted to the other substituent in Step 5-9, 5-14 or 6-10 when the compound of the formula 35 is a sulfonamide derivative, for example, ClSO₂—(CH₂)_n—X′—(CH₂)_n—Y′-T₇or O(SO₂— (CH₂)_m—X′—(CH₂)_n—Y′-T₇)₂is reacted with the compound of the formula 32, and when the compound of the formula 35 is a sulfamide derivative, for example, the compound can be obtained from the compound of the formula 32 by a method similar to that of Step 5-5. Thus obtained compound of the formula 35 can be used in the next reaction without isolation.

Step 5-8

In this Step, the carboxyl group-protecting group of the compound of the formula 35 obtained in Step 5-6 or 5-7 is deprotected by a conventional method. T₇in the compound of the formula 36 obtained in this Step is a substituent that can be converted to the other substituent in Step 5-9. The reaction conditions are similar to those in Step 5-1.

Thus obtained compound of the formula 36 can be used in the next reaction without isolation.

Step 5-9

In this Step, T7 in the compound of the formula 36 obtained in Step 5-8 is modified by a conventional method to give a compound of the formula 37. By this Step, a (CH₂)_m—X′—(CH₂)_n—Y′-T₇moiety in the compound of the formula 36 is converted to R¹of the compound of the formula 37. In this Step, T₃and T4 do not change and correspond to V′ and W′, respectively. The reaction conditions are appropriately chosen depending on the kind of T₇and desired compound, when, for example, T₇is a protecting group of an amino group involved in Y′, this can be deprotected by a conventional method and the amino group can be led to amide, urethane, urea, alkylamine by a conventional method. When, for example, Y′ is an aromatic ring and T₇is a halogen atom, T₇on Y′ can be led to other substituents by methods known in literature, such as so-called Sonogashira reaction, Heck reaction, Negishi reaction, Suzuki-Miyaura reaction (Metal-catalyzed Cross Coupling Reactions; WILEY-VCH; New York, 1998), Buchwald reaction, Ullmann reaction (Tetrahedron 2002, 11, 2041-2075; J. Am. Chem. Soc. 2003, 125, 6653-6655) and the like. It can be led to alkyne by the Sonogashira reaction, to alkene by Heck reaction, to an aromatic ring by Suzuki-Miyaura reaction, to amine by Buchwald reaction, and to ether by Ullmann reaction.

Step 5-10

In this Step, a hydrogen atom of the compound of the formula 46 is replaced with a chlorosulfonyl group. After leading the compound of the formula 46 to a sulfonic acid derivative, the derivative is subsequently chlorinated to give the sulfonyl chloride derivative of the formula 47. As the sulfonylation agent, sulfuric acid, chlorosulfonic acid and chlorosulfonic acid trimethylsilyl ester can be mentioned. As the solvent, no solvent, or halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetic acid, sulfuric acid, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is halogenated solvent, and chloroform is more preferable.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to 50° C.

The reaction time is 1 hr to 72 hr, preferably 1 hr to 48 hr.

The subsequent chlorination reaction is a conventional synthetic method for a sulfonyl chloride derivative, and as the chlorinating agent to be used for the reaction, for example, thionyl chloride, phosphorous oxychloride, phosphorus pentachloride and chlorosulfonic acid can be mentioned, with preference given to thionyl chloride. As the solvent, no solvent, or hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is no solvent, and a mixed solvent of thionyl chloride, which is a chlorinating agent, and a catalytic amount of N,N-dimethylformamide is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 80° C.

The reaction time is 1 hr to 48 hr, preferably 3 hr to 24 hr.

Thus obtained compound of the formula 47 can be used in the next reaction without isolation.

Step 5-11

In this Step, the amine of the formula 32 obtained in Step 5-4 is led to a sulfonamide derivative or sulfamide derivative of the formula 48. In addition, this Step can be also applied to a compound 32, wherein a CO₂P₄moiety is Weinreb amide (CONMe(OMe)). When the compound of the formula 48 is a sulfonamide derivative, for example, the derivative can be obtained by a reaction with the ClSO₂—R¹of the formula 47 obtained in Step 5-10, or O(SO₂—R¹)₂. The reaction conditions are the same as those in Step 5-5. When the compound of the formula 48 is a sulfamide derivative, the same procedure as in Step 5-5 can be applied.

Thus obtained compound of the formula 48 can be used in the next reaction without isolation.

Step 5-12

In this Step, the carboxyl-protecting group in the compound of the formula 48 obtained in Step 5-11 is deprotected and T₄in compound 48 is converted to W′ to give the compound of the formula 37.

P₄is deprotected and T₄is led to the other substituent simultaneously under the same conditions. In addition, P₄and T₄may be combined together to form a single bond, and when compound 48 is lactone, this Step can be also achieved by hydrolyzing the lactone to hydroxycarboxylic acid. In this case, the reaction is carried out by a base. As the base, alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; etc. can be mentioned, with preference given to sodium hydroxide.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as water, etc.; can be mentioned, which may be used alone or in combination. A preferable solvent is alcohol solvent, and a mixed solvent of methanol and water is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 60° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 37 can be used in the next reaction without isolation.

Step 5-13

In this Step, a carboxyl group of the compound of the formula 33 obtained in Step 5-5 is deprotected and then T₅is modified by a conventionally known method to give the compound of the formula 37. By this Step, a (CH₂)_m—U′-T₅moiety in the compound of the formula 33 is converted to R¹in the compound of the formula 37. In this Step, a substituent T₃at R^3′ and a substituent T₄at R^2′ are the same as V′ and W′, respectively.

The reaction conditions are appropriately chosen depending on the kind of T₅and a desired compound. For example, reductive alkylation of amino group, conversion to a hydroxymethyl group by reduction of alkoxycarbonyl group, conversion of halomethyl group to an alkoxymethyl group by substitution by alkoxide and the like can be mentioned. When T5 is a protecting group of amine included in U′, this is deprotected under conventional conditions and the amine was reacted with a desired isocyanide to give a urea derivative 37. In this case, the conditions of the deprotection are the same as in Step 5-4. As the isocyanide, methyl isocyanate, phenyl isocyanate and the like can be mentioned and the reaction with these is carried out in the presence of a base. As the base, organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, etc.; etc. can be mentioned, with preference given to triethylamine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and THF is more preferable.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to room temperature.

The reaction time is 1 hr to 24 hr, preferably 1 hr to 6 hr.

Thus obtained compound of the formula 37 can be used in the next reaction without isolation.

Step 5-14

In this Step, T₇of the compound of the formula 35 obtained in Step 5-6 or 5-7 is modified by a conventionally known method and P₄, which is a protecting group of carboxyl group, is simultaneously deprotected to give a compound of the formula 37. In this Step, a substituent T₃at R^3′ and a substituent T₄at R²correspond to V′ and W′, respectively. For example, when T₇is a nitro group and P₄is a t-butyl group, the compound of the formula 37 can be obtained using a conventional reducing agent of a nitro group in the presence of an acid. In this case, as a conventional reducing agent of a nitro group, for example, tin (II) chloride, iron, zinc can be mentioned, with preference given to tin (II) chloride. As the acid, hydrochloric acid, acetic acid, sulfuric acid, nitric acid, etc. can be mentioned, with preference given to hydrochloric acid.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is alcohol solvent, and ethanol is more preferable.

The reaction temperature is generally room temperature to 150° C., preferably room temperature to 100° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 37 can be used in the next reaction without isolation.

Step 5-15

In this Step, the carboxylic acid of the formula 37 obtained in Step 5-9, 5-12, 5-13, 5-14 or 6-11 is led to a compound of the formula 38. For example, when R⁶⁰is a NHOH group, carboxylic acid is converted to activated ester or acid chloride in a solvent, and a hydroxylamine or its equivalent wherein a hydroxylamine or hydroxyl group is protected is added to give a compound of the formula 38. This Step may be performed in the presence of a base. When a hydroxylamine equivalent wherein the hydroxyl group is protected is used, deprotection is necessary after the reaction.

As the activated ester, aryl imidazole, mixed acid anhydride, hydroxybenzotriazole ester, hydroxysuccinimide ester and the like can be mentioned, which are prepared by known methods. For preparation of acyl chloride, thionyl chloride, oxalyl chloride and the like are used. The reaction temperature for preparation of the activated ester or acyl chloride is generally −78° C. to 50° C., preferably −20° C. to room temperature.

The reaction time is 10 min to 6 hr, preferably 30 min to 6 hr. As the hydroxylamine equivalent wherein a hydroxyl group is protected, O-(trimethylsilyl)hydroxylamine, O-(benzyl)hydroxylamine; etc. can be mentioned, with preference given to O-(trimethylsilyl)hydroxylamine.

The temperature of the reaction with the hydroxylamine equivalent wherein the hydroxyl group is protected is generally −78° C. to 50° C., preferably −20° C. to room temperature.

The reaction time is 10 min to 6 hr, preferably 30 min to 6 hr.

As the base, organic bases such as triethylamine, pyridine, N-methylmorpholine, 2,6-lutidine, 1,8-diazabicyclo[5.4.0]undec-7-ene, etc.; etc. can be mentioned, with preference given to N-methylmorpholine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and THF is more preferable.

When a compound of the formula (1) wherein R⁴is a substituent other than —COR⁶⁰is desired, such compound can be produced from a compound of the formula 38 or 37 by a known method.

Step 6-1

In this Step, the cyclic urethane of the formula 27 obtained in Step 2-5 is sulfonylated and subsequently subjected to ring opening reaction with a nucleophilic agent to give a sulfonamide derivative of the formula 39. For example, when the nucleophilic agent is a base (hydroxide ion), T₈in the compound of the formula 39 obtained by this Step is a hydroxyl group. When, for example, the nucleophilic agent is alkylamine, T₈in the compound of the formula 39 obtained by this Step is an alkylcarbamoyloxy group. In this Step, moreover, the substituents T₁at R^3′ and P₁, a carboxylic protecting group of acid do not change and correspond to T₃and P₄, respectively.

The sulfonylation agent is appropriately depending on the desired R¹, and ClSO₂—R¹or O(SO₂—R¹)₂is used for the reaction. The reaction is carried out in the presence of a base, and as the base, for example, alkyl lithiums such as n-butyl lithium, t-butyl lithium, s-butyl lithium, etc.; alkali metal hydrides such as sodium hydride, potassium hydride, etc.; alkali metal amides such as lithium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, etc.; etc. can be mentioned, with preference given to sodium hydride.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and a mixed solvent of THF and 15-crown-5-ether is more preferable.

The reaction temperature is generally −20° C. to 100° C., preferably 0° C. to 50° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 24 hr.

When, for example, the nucleophilic agent in the subsequent ring-opening reactions is a base (hydroxyl anion), this reaction is conventional hydrolysis in the presence of a base, and the base to be used for the reaction includes, for example, alkali metal carbonates such as sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; etc. can be mentioned, with preference given to alkali metal hydroxide, and sodium hydroxide is more preferable.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is polar solvent, and a mixed solvent of THF, methanol and water is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 50° C.

The reaction time is 10 min to 48 hr, preferably 30 min to 24 hr.

Thus obtained compound of the formula 39 can be used in the next reaction without isolation.

When the nucleophilic agent is alkylamine, for example, isopropylamine, morpholine, benzylamine, etc. can be mentione as the alkylamine.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc. such as, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and THF is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 80° C.

The reaction time is 1 hr to 24 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 39 can be used in the next reaction without isolation.

Step 6-2

In this Step, a substituent T₈at R^2′ in the compound of the formula 39 obtained in Step 6-1 is led to T₁₂under 2′ conventional conditions. For example, when R^2′ is an alkyl chain and T₈is a hydroxyl group, this step includes protection of the hydroxyl group (T₈) with a conventional protecting group transforming into T₁₂.

T₁₂is appropriately chosen according to P₄, or T₃, R¹, and when, for example, T₁₂is a hydroxyl group protected by tetrahydropyranyl ether, a method using 3,4-dihydro-2H-pyran in the presence of an acid catalyst can be mentioned. In this case, as the acid, p-toluenesulfonic acid, pyridinium p-tolueneslufonate, camphorsulfonic acid, methanesulfonic acid, benzenesulfonic acid, hydrochloric acid, etc. can be mentioned.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is halogenated solvent, and chloroform is more preferable.

The reaction temperature is generally room temperature to 100° C., preferably room temperature to 70° C.

The reaction time is 1 hr to 24 hr, preferably 2 hr to 12 hr.

Thus obtained compound of the formula 40 can be used in the next reaction without isolation.

This Step is performed as necessary or may be omitted. In this case, the compound of the formula 39 can be treated as a compound of the formula 45.

Step 6-3

In this Step, a sulfonamide group of the compound of the formula 40 obtained in Step 6-2 is protected with a protecting group P₅by a conventional method. P₅is appropriately chosen depending on P₄, T₃, T₁₂or R¹. When, for example, P₅is a 2-trimethylsilylethyl group, a method using Mitsunobu reagents such as diethyl azodicarboxylate, etc. in the presence of 2-trimethylsilylethyl alcohol can be mentioned. As the solvent in this case, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and THF is more preferable.

The reaction temperature is generally room temperature to 100° C., preferably room temperature to 50° C.

The reaction time is 1 hr to 96 hr, preferably 2 hr to 24 hr.

Thus obtained compound of the formula 41 can be used in the next reaction without isolation.

Step 6-4

In this Step, a substituent T₁₂at R^2′ in the compound of the formula 41 obtained in Step 6-3 is led to T₄in a compound of the formula 42. For example, deprotection reaction of a hydroxyl group by a conventional method and the like can be mentioned. In this case, T₄is a hydroxyl group, and as T₁₂, for example, a hydroxyl group protected by tetrahydropyranyl ether, acetoxy group, t-butoxy group, or t-butyldimethylsilyloxy group, etc. can be mentioned. The reaction conditions are appropriately chosen depending on P₄, P₅, T₃, T₁₂and R¹. For example, when P₄is a t-butyl group, P₅is a 2-trimethylsilylethyl group and T₁₂is a hydroxyl group protected with tetrahydropyranyl ether, the deprotection can be carried out in the presence of an acid catalyst.

As the acid, mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid, etc.; organic acids such as acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, etc. can be mentioned, with preference given to p-toluenesulfonic acid.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is alcohol solvent, and methanol is more preferable.

The reaction temperature is generally 0° C. to 100° C., preferably room temperature to 50° C.

The reaction time is 30 min to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 42 can be used in the next reaction without isolation.

Step 6-5

In this Step, a substituent T₃at R^3′ and/or a substituent T₄at R²of the compound of the formula 42 obtained in Step 6-4 are/is converted to V′ and/or W′, respectively, under conventional conditions. For example, when R^3′ is a benzene ring and T₃is a halogen atom, so-called Negishi reaction, Suzuki-Miyaura reaction (Metal-catalyzed Cross Coupling Reactions; WILEY-VCH; New York, 1998), Buchwald reaction, Ullmann reaction (Tetrahedron 2002, 11, 2041-2075; J. Am. Chem. Soc. 2003, 125, 6653-6655) and the like can be applied, whereby the compound of the formula 43, wherein V′ is an alkoxycarbonyl alkyl, an aryl group, an arylamino group or an aryl alkoxy group can be obtained. When, for example, R^2′ is an alkyl chain and T₄is a hydroxyl group, for example, the compound of the formula 43 wherein W′ is an alkoxy group or acyloxy group can be obtained by a conventional method.

Step 6-6

In this Step, the sulfonamide group of the compound of the formula 33 obtained in Step 5-5 is protected with a protecting group P₅by a conventional method. While P₅can be appropriately chosen depending on P₄, T3, T₄or T₅, when, for example, P₅is a 2-trimethylsilylethyl group, a method using Mitsunobu reagents such as diethyl azodicarboxylate, etc. in the presence of 2-trimethylsilylethyl alcohol can be mentioned.

As the solvent in this case, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and THF is more preferable.

The reaction temperature is generally room temperature to 100° C., preferably room temperature to 50° C.

The reaction time is 1 hr to 96 hr, preferably 2 hr to 24 hr.

Thus obtained compound of the formula 44 can be used in the next reaction without isolation.

This Step is performed as necessary, or may be omitted when the next Step and the following Steps proceed without protection. In this case, the compound of the formula 33 may be treated as the compound of the formula 44 wherein P₅is a hydrogen atom.

Step 6-7

In this Step, a substituent T₅at U′ of the compound of the formula 44 obtained in Step 6-6 is led to the other substituent under conventional conditions to give a compound of the formula 43. In this Step, a substituent T₃at R³′ and a substituent T₄at R²′ do not change and correspond to V′ and W′, respectively.

For example, when U′ is an aromatic ring and T₅is a halogen atom, so-called Negishi reaction, Suzuki-Miyaura reaction (Metal-catalyzed Cross Coupling Reactions; WILEY-VCH; New York, 1998), Buchwald reaction, Ullmann reaction (Tetrahedron 2002, 11, 2041-2075; J. Am. Chem. Soc. 2003, 125, 6653-6655) and the like can be applied, whereby a compound of the formula 43, wherein R¹is a biaryl group or arylaminoaryl group can be obtained, for example.

Step 6-8

In this Step, P₅, which is a protecting group of sulfonamide, in the compound of the formula 43 obtained in Step 6-5 or 6-7 is deprotected by a conventional method. The reaction conditions are appropriately chosen depending on P₄, and, for example, when P₄is a t-butyl group and P₅is a 2-trimethylsilylethyl group, deprotection can be performed using an acid or fluoride.

As the acid, acetic acid, hydrochloric acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, etc. can be mentioned, with preference given to trifluoroacetic acid. As the fluoride source, hydrogen fluoride, hydrogen fluoride-pyridine, tetrabutylammonium fluoride, potassium fluoride, etc. can be mentioned, with preference given to tetrabutylammonium fluoride.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; ester solvents such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is ether solvent, and THF is more preferable.

The reaction temperature is generally 0° C. to 120° C., preferably room temperature to 100° C.

The reaction time is 1 hr to 48 hr, preferably 1 hr to 12 hr.

Thus obtained compound of the formula 45 can be used in the next reaction without isolation.

When Step 6-6 is omitted, this Step can be also omitted.

Step 6-9

In this Step, T₃and/or T₄of the compound of the formula 48 obtained in Step 5-11 are/is converted to V′ and/or W. The reaction conditions are appropriately chosen depending on P₄, T₃, T₄, V′ and W′ and when, for example, R³′ and/or R²′ are/is an aromatic ring and T₃and/or T₄are/is a halogen atom, so-called Negishi reaction, Suzuki-Miyaura reaction (Metal-catalyzed Cross Coupling Reactions; WILEY-VCH; New York, 1998), Buchwald reaction, Ullmann reaction (Tetrahedron 2002, 11, 2041-2075; J. Am. Chem. Soc. 2003, 125, 6653-6655) and the like can be applied, whereby the compound of the formula 45, wherein V′ and/or W′ are/is an alkoxycarbonyl alkyl group, a carbonylamino group, an alkoxycarbonyl group, an aryl group, an arylamino group, an alkylamino group or an aryl alkoxy group can be obtained.

In addition, when, for example, T₃and/or T₄are/is a nitro group, they can be converted to an amino group under conventional reduction conditions. It is also possible to be followed by reductive alkylation. As the reduction conditions, hydrogenation reaction in the presence of a palladium catalyst, reductive reaction under acidic conditions using tin (II) chloride, iron, zinc, etc., and reductive reaction using sodium borohydride in the presence of copper acetate can be mentioned. A preferable reducing agent in this reaction is sodium borohydride in the presence of copper (II) acetate.

As the solvent, for example, ether solvents such as diethyl ether, tetrahydrofuran (THF), dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbon solvents such as benzene, toluene, hexane, xylene, etc.; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohol solvents such as methanol, ethanol, isopropyl alcohol, t-butyl alcohol, etc.; polar solvents such as N,N-dimethylformamide, acetonitrile, water, etc.; etc. can be mentioned, which may be used alone or in combination. A preferable solvent in this reaction is alcohol solvent, and a mixed solvent of chloroform and ethanol is more preferable.

The reaction time is 10 min to 12 hr, preferably 30 min to 6 hr.

For example, when T₃and/or T₄are/is an azido group, for example, the compound can be led to compound 45 wherein V′ and/or W′ are/is an alkylamino group or an amino group by a conventional method. For example, when W′ is an alkylamino group, this Step is achieved by subjecting the amino group obtained via a conventional reduction step to reductive alkylation. In this case, the reducing agent for azide reduction is, for example, trialkylphosphine, with preference given to triphenyl phosphine. The subsequent reductive alkylation is performed by a conventional method.

Thus obtained compound of the formula 45 can be used in the next reaction without isolation. This Step is performed as necessary or may be omitted. In this case, the compound of the formula 48 can be treated as the compound of the formula 45.

Step 6-10

In this Step, T₇of the compound of the formula 35 obtained in Step 5-6 or 5-7 is modified by a conventional method to give the compound of the formula 45. By this Step, a (CH₂)_m—X′—(CH₂)_n—Y′-T₇moiety in the compound of the formula 35 is converted to R¹in the compound of the formula 45. The reaction conditions are appropriately chosen depending on T₇and the desired compound. For example, conversion of an alkoxycarbonyl group to a hydroxymethyl group, conversion of a halomethyl group to an alkoxymethyl group and the like can be mentioned.

Thus obtained compound of the formula 45 can be used in the next reaction without isolation.

Step 6-11

In this Step, a protecting group of the carboxyl group in the compound of the formula 45 obtained in Step 6-8, 6-9 or 6-10 is deprotected to give a compound of the formula 37. This Step can be also applied to a compound wherein a CO₂P₄moiety of compound 45 is Weinreb amide (CONMe(OMe)). The reaction conditions are appropriately chosen depending on the kind of P₄and the same as those in Step 5-1. In addition, this Step is performed as necessary, or omitted when P₄is a hydrogen atom.

The production methods described in the specification are among the examples of the production method of the compound of the present invention, and compounds other than those explained in the above can be produced by combining conventional methods known in the field of organic synthetic chemistry.

The compound represented by the formula (1) and production method thereof of the present invention is explained in detail in the following by way of Examples. It is needless to say that the present invention is not limited by these Examples.

PREPARATION EXAMPLE 1-1 (2R*,3R*)-3-methylsulfanyl-2-phenyl-butan-2-ol (step 1-1)

To a solution of trans-2,3-dimethyl-2-phenyloxirane (14 g, 76 mmol) in methanol (100 mL) was added 15% aqueous sodium methyl mercaptan solution (61 mL, 190 mmol) under nitrogen atmosphere at room temperature, and the mixture was warmed to 60° C. and stirred for 2 hours. The mixture was concentrated under reduced pressure, and the residue was extracted twice with diethyl ether (50 mL), sequentially washed with water (50 ml) and saturated aqueous sodium chloride solution (50 mL), and dried over sodium sulfate. The resultant mixture was filtrated and the solvent was evaporated to give the title compound (16 g, yield 99%) as a colorless oil.

PREPARATION EXAMPLE 1-2 (1R*,2R*)-(1-chloro-1-methyl-2-methylsulfanyl-propyl)benzene or (1R*,2R*)-(2-chloro-1-methyl-1-methylsulfanyl-propyl)benzene (step 1-2)

To a solution of (2R*,3R)-3-methylsulfanyl-2-phenyl-butan-2-ol (1.0 g, 5.1 mmol) obtained in Preparation Example 1-1 in toluene (3.0 mL) was added dropwise a solution of thionyl chloride (0.67 mL, 9.2 mmol) in toluene (2.0 mL) under argon atmosphere at 0° C., and the mixture was stirred for 1 hour. The solution was evaporated to give a mixture of two kinds of regioisomers of the title compound (1.0 g, yield 100%) as a yellow oil.

PREPARATION EXAMPLE 1-3 1-(1-chloro-1-methyl-2-methylsulfanyl-ethyl)-4-fluoro-benzene or 1-(2-chloro-1-methyl-1-methylsulfanyl-ethyl)-4-fluoro-benzene (step 1-3)

This procedure was performed according to the method described in Synthesis (1980, 9690-9691).

While cooling to −40° C., sulfuryl chloride (2.9 mL, 37 mmol) was added dropwise to a solution of dimethyl disulfide (3.3 mL, 37 mmol) in 1,2-dimethoxyethane (20 mL) under nitrogen atmosphere, and the mixture was stirred for 10 min. The obtained solution was added dropwise to a solution of 4-fluoro-α-methylstyrene (10 g, 73 mmol) in 1,2-dimethoxyethane (20 mL) while maintaining a temperature below −30° C. After stirring for 1 hour at room temperature, the solution was evaporated to give a crude product of the title compound. The obtained product was used in the next step without further purification.

PREPARATION EXAMPLE 1-4 diethyl 2-[1-(4-fluorophenyl)-1-methyl-2-methylsulfanyl-ethyl]malonate (step 1-4)

This procedure was performed according to the method described in Synthesis (1980, 9690-9691).

To a solution of diethyl malonate (12 mL, 81 mmol) in ethanol (40 mL) was added dropwise 21% sodium ethoxide ethanol solution (29 mL, 77 mmol) under nitrogen atmosphere under ice-cooling. The mixture was warmed to room temperature, stirred for 1 hour, and cooled again with ice. The crude product (73 mmol) of 1-(1-chloro-1-methyl-2-methylsulfanyl-ethyl)-4-fluorobenzene or 1-(2-chloro-1-methyl-1-methylsulfanyl-ethyl)-4-fluorobenzene obtained in Example 1-3 was added dropwise to the mixture while maintaining a temperature below 4° C. The obtained solution was stirred for 1 hour at room temperature and concentrated under reduced pressure. The residue was neutralized by adding a 2N aqueous hydrochloric acid solution and the aqueous layer was extracted with ethyl acetate (50 mL). The organic layer was dried over magnesium sulfate, filtrated and the solvent was evaporated. Then the obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=20:1 to 5:1) to give the title compound (24 g, yield 84%) as a pale-yellow oil.

PREPARATION EXAMPLE 1-5 [3,3-bis-ethoxycarbonyl-2-(4-fluorophenyl)-2-methylpropyl]dimethylsulfonium p-toluenesulfonate (step 1-5)

This procedure was performed according to the method described in Synthesis (1980, 9690-9691).

Diethyl 2-[1-(4-fluorophenyl)-1-methyl-2-methylsulfanylethyl]malonate (1.0 g, 2.9 mmol) obtained in Preparation Example 1-4 and methyl p-toluenesulfonate (0.47 mL, 3.1 mmol) were mixed under nitrogen atmosphere, and the mixture was stirred for 12 hours at 100° C. The obtained solution was cooled to room temperature to give a crude product of the title compound as a pale-yellow oil. The obtained product was used in the next step without purification.

PREPARATION EXAMPLE 1-6 2-(4-fluorophenyl)-2-methyl-cyclopropane-1,1-dicarboxylic acid diethyl ester (step 1-6)

This procedure was performed according to the method described in Synthesis (1980, 9690-9691).

Under ice-cooling and under nitrogen atmosphere, a solution of 21% sodium ethoxide in ethanol (1.6 mL, 4.4 mmol) was added to a solution of the crude product (2.9 mmol) of [3,3-bis-ethoxycarbonyl-2-(4-fluorophenyl)-2-methylpropyl]dimethylsulfonium p-toluenesulfonate in ethanol (10 mL), which was obtained in Preparation Example 1-5, and the mixture was stirred for 1 hour. The obtained solution was concentrated under reduced pressure, and the residue was neutralized by the addition of a 2N aqueous hydrochloric acid solution, and the aqueous layer was extracted with ethyl acetate (10 mL). The organic layer was dried over magnesium sulfate and filtrated, and the solvent was evaporated. Then, the obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=20:1 to 5:1) to give the title compound (0.64 g, yield 75%) as a pale-yellow oil.

PREPARATION EXAMPLE 1-7 2-methyl-2-phenyl-cyclopropane-1,1-dicarboxylic acid diethyl ester (step 1-7)

This procedure was performed according to the method described in Bull. Chem. Soc. Jpn. (1982, 55, 2687-2688).

To a solution of α-methylstyrene (570 mL, 4.4 mol), 1,8-diazabicyclo[5.4.0]undec-7-ene (240 mL, 1.6 mol) and copper (II) bromide (9.8 g, 44 mmol) in toluene (700 mL) was added diethyl bromomalonate (210 g, 0.88 mol) at 0° C., and the mixture was stirred for 22 hours at room temperature. The obtained solution was washed with saturated aqueous ammonium chloride solution and saturated aqueous sodium chloride solution, and dried over sodium sulfate. Then, the solution was filtrated and the solvent was evaporated. The obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=20:1) to give the title compound (110 g, yield 45%) as a colorless oil.

PREPARATION EXAMPLE 1-7-2 (2R*,3R*)-2-methyl-3-phenyl-cyclopropane-1,1-dicarboxylic acid dimethyl ester (step 1-7)

This procedure was performed according to the method described in Synlett (2001, 12, 1843-1846).

To a mixture of bis(methoxycarbonyl)(phenyliodono)methanide (30 g, 90 mmol) synthesized by a known method and cis-β-methylstylene (60 g) was added rhodium (II) acetate dimer (0.16 g, 0.72 mmol). After stirring for 20 min. at 120° C., the mixture was concentrated under reduced pressure. The procedure was repeated twice, and the obtained residues were combined.

Then a mixed solvent of hexane:ethyl acetate=5:1 (360 mL) and silica gel (30 g) were added, and the mixture was stirred for 30 min. Silica gel was removed and the mixture was concentrated under reduced pressure to give the title compound (38 g, yield 85%) as a pale-yellow oil.

PREPARATION EXAMPLE 1-8 (R)-2-benzyl-cyclopropane-1,1-dicarboxylic acid dimethyl ester (step 1-8)

A solution of (S)-4-benzyl-[1,3,2]dioxathiolane 2,2-dioxide (1.6 g, 7.5 mmol) in 1,2-dimethoxyethane (12 mL), which was synthesized from diol obtained by reducing L-phenyllacetic acid according to J. Am. Chem. Soc. (1988, 110, 7538-7539), and dimethyl malonate (0.86 mL, 7.5 mmol) was added dropwise to a suspension of sodium hydride (liquid paraffin 40% added, 0.63 g, 16 mmol) in 1,2-dimethoxyethane (25 mL) under argon atmosphere at 0° C. The mixture was warmed to room temperature and stirred for 2.5 hours. To the obtained solution was added saturated aqueous ammonium chloride solution (20 mL). The organic layer was extracted twice with diethyl ether (10 mL), washed with saturated aqueous sodium chloride solution (30 mL), and dried over sodium sulfate. After filtration and evaporation, the obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=9:1) to give the title compound (0.88 g, yield 47%).

PREPARATION EXAMPLE 1-9 a) t-butyl(Z)-3-phenyl-allyl 2-diazomalonate

To malonic acid t-butyl ester (Z)-3-phenyl allyl ester (15 g. 54 mmol) was added tolylsulfonylazide (12 g, 60 mmol), K₂CO₃(8.3 g, 60 mmol) in acetonitrile (110 mL). After stirring overnight at room temperature, the reaction mixture was concentrated and diluted with EtOAc. After washing with water (×2) and brine and drying over Na₂SO₄, a crude product was purified by column chromatography using 10:1 hexanes/EtOAc to afford 16 g (100%) of the desired product.

b) (1R*,5R*,6R*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hexane-1-carboxylic acid t-butyl ester (step 1-9)

To the 2-diazomalonic acid t-butyl ester (Z)-3-phenyl-allyl ester (16 g, 54 mmol) above were added triethyl phosphite (0.090 g, 0.54 mmol) and copper (I) iodide (0.10 g, 0.54 mmol) in toluene (490 mL). After heating at 130° C. for 5 hours, the solid was filtered off and the filtrate was concentrated. The reaction mixture was purified by column chromatography using dichloromethane as an eluent. Purification afforded 5.2 g of the desired diastereomer and 2.8 g of the other diastereomer.

PREPARATION EXAMPLE 1-10 2-(3-benzyloxyphenyl)-cyclopropane-1,1-dicarboxylic acid dimethyl ester (step 1-10)

This procedure was performed according to the method described in J. Med. Chem. (1992, 35, 1410-1417).

While water-bathing, to a suspension of sodium hydride (liquid paraffin 40% added, 5.0 g, 0.13 mol) in dimethyl sulfoxide (180 mL) was gradually added trimethylsulfoxonium iodide (28 g, 0.13 mmol) under argon atmosphere, and the mixture was stirred for 30 min. Then dimethyl 2-(3-benzyloxybenzylidene)malonate (37 g, 0.11 mol) synthesized by the method described in the above-mentioned reference was added dropwise. After stirring for 1 hour at 50° C., saturated aqueous ammonium chloride solution (200 mL) and toluene (100 mL) were added to the obtained solution. The mixture was separated into layers and extracted with toluene (100 mL). The organic layer was sequentially washed with water (100 mL) and saturated aqueous sodium chloride solution (20 mL) and dried over magnesium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:chloroform=4:1) to give the title compound (31 g, 79%) as a pale-yellow oil.

PREPARATION EXAMPLE 1-11 (1R*,2R*,3R*)-2-methyl-3-phenylcyclopropane-1,1-dicarboxylic acid mono-methyl ester (step 1-11)

To a solution of (2R*,3R*)-2-methyl-3-phenyl-cyclopropane-1,1-dicarboxylic acid dimethyl ester (39 g, 0.16 mol) obtained in Preparation Example 1-7-2 in methanol (390 mL) was added 4N aqueous sodium hydroxide solution (160 mL, 0.62 mol) at 0° C., and the mixture was stirred for 18 hours at room temperature. After the mixture was concentrated under reduced pressure, diethyl ether and water were added and the mixture was stirred. After the organic layer was removed, concentrated hydrochloric acid was added to the aqueous layer under ice-cooling until the pH level read about 1. The organic layer was extracted with ethyl acetate, washed with saturated aqueous sodium chloride solution, and dried over sodium sulfate. The solution was filtrated and the solvent was evaporated. The obtained crude product was azeotroped with toluene, and diethyl ether and hexane were added gradually. The precipitated crystals were filtrated and dried under reduced pressure to give the title compound (35 g, yield 96%) as while crystals.

PREPARATION EXAMPLE 1-11-2 (1R*,5S*,6S*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hexane-1-carboxylic acid (step 1-11)

To 0.18 g (0.65 mmol) of (1R*, SR*, 6R*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hexane-1-carboxylic acid t-butyl ester were added 1 mL of trifluoroacetic acid and 2 mL of dichloroethane. After stirring at room temperature for 20 min, the reaction mixture was concentrated and dried under high vacuum to afford 0.14 g (98%) of the desired acid.

PREPARATION EXAMPLE 1-11-3 a) (1R*,2R*,3R*)-2-hydroxymethyl-1-(methoxy-methyl-carbamoyl)-3-phenyl-cyclopropanecarboxylic acid t-butyl ester

In a 100 mL round-bottomed flask, a solution of N,O-dimethyl hydroxylamine HCl was suspended in 20 mL of dichloromethane. After cooling to 0° C., trimethyl aluminum (2M in toluene, 3.83 mL, 7.66 mmol) was added dropwise and the mixture was stirred at 0° C. for 45 min. A solution of the previously described (1R*,5R*,6R*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hexane-1-carboxylic acid tert-butyl ester (0.3 g, 1 mmol) in 10 mL of dichloromethane was added dropwise to the cooled stirring solution. After stirring at 0° C. for 5 min, the reaction mixture was warmed to room temperature and stirred for 3 hours. After the reaction was completed, the reaction mixture was again cooled in an ice bath and acidified with 10 mL of 1N HCl, extracted with dichloromethane (×3), dried over MgSO₄and concentrated to afford 0.32 g (86%) of the desired product as a clear oil.

b) (1R*,2R*,3R*)-2-methoxymethyl-1-(methoxy-methyl-carbamoyl)-3-phenyl-cyclopropanecarboxylic acid t-butyl ester

The above (1R*,2R*,3R*)-2-hydroxymethyl-1-(methoxy-methyl-carbamoyl)-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (0.050 g, 0.15 mmol) was dissolved in 1 mL of methyl iodide. To this solution was added silver oxide (0.69 g, 3.0 mmol) and the mixture was stirred overnight at room temperature under N₂(in the dark). This reaction was incomplete and additional methyl iodide and silver oxide were added. After stirring overnight, the reaction appeared stalled. The catalyst was filtered off through celite and the residue was rinsed with ether. The filtrate was concentrated to a clear oil and purified by prep-TLC using 1:1 hexanes/EtOAc to afford 30 mg of the desired product (58%). This reaction was repeated numerous times to bring up more material. Note: If a huge excess of silver oxide was not used, the reaction often led to a reversion to the lactone product.

c) (1R*,2R*,3R*)-2-methoxymethyl-1-(methoxy-methyl-carbamoyl)-3-phenyl-cyclopropanecarboxylic acid (step 1-11)

(1R*,2R*,3R*)-2-methoxymethyl-1-(methoxy-methyl-carbamoyl)-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (30 mg, 0.086 mmol) was dissolved in 1 mL of trifluoroacetic acid and 1 mL of dichloromethane. After stirring at room temperature for 2 hours, the reaction mixture was concentrated and azeotroped with toluene. The product was dried under high vacuum before use.

PREPARATION EXAMPLE 1-12 (1R*,2S*,3S*)-1-t-butoxycarbonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid methyl ester (step 1-12)

To a solution of 2-methyl-3-phenylcyclopropane-1,1-dicarboxylic acid mono-methyl ester (36 g, 0.16 mol) obtained in Preparation Example 1-11 and triethylamine (35 mL, 0.25 mol) in t-butylalcohol (370 mL) was added diphenylphosphoryl azide (44 mL, 0.20 mol). After stirring for 2 hours at room temperature, the mixture was warmed gradually and refluxed for 7 hours. After the solvent was evaporated under reduced pressure, a mixed solvent of hexane:ethyl acetate=4:1 (750 mL) and silica gel (200 g) were added and the mixture was stirred for 30 min. Then silica gel was removed, and the mixture was concentrated under reduced pressure. Hexane was added to the obtained residue, and the precipitated crystals were filtrated to give the title compound (35 g, yield 74%) as a white solid.

PREPARATION EXAMPLE 1-12-2 [(1R*-5R*,6R*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hexa-1-yl]carbamic acid t-butyl ester (step 1-12)

To 0.20 g (0.92 mmol) of (1R*,5S*,6S*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hexane-1-carboxylic acid were added diphenylphosphoryl azide (0.33 g, 1.2 mmol) and diisopropylethylamine (0.32 mL, 1.8 mmol) in tert-butyl alcohol. After heating at 90° C. for 2 hours, the reaction mixture was concentrated and purified using column chromatography (3:1 hexanes/EtOAc). The desired product was isolated as a white solid (0.23 g, yield 85%).

PREPARATION EXAMPLE 1-12-3 [(1R*,2R*,3R*)-2-methoxymethyl-1-(methoxy-methyl-carbamoyl)-3-phenyl-cyclopropyl]carbamic acid t-butyl ester (step 1-12)

(1R*,2R*,3R*)-2-methoxymethyl-1-(methoxy-methyl-carbamoyl)-3-phenyl-1-cyclopropanecarboxylic acid (0.10 g, 0.34 mmol) was dissolved in 8 mL of t-butyl alcohol. To this solution were added diisopropylethylamine (0.15 g, 0.85 mmol) and 4 Å molecular sieves. Then diphenylphosphoryl azide (0.11 mL, 0.51 mmol) was added in one portion. The reaction mixture was heated to 90° C. overnight. After cooling, the reaction mixture was poured into saturated NaHCO₃and extracted with EtOAc (2×). The combined organic layers were washed with brine and dried over MgSO₄. The crude product was purified using column chromatography (5:1->1:1 hexanes/EtOAc gradient) to afford the desired product (stains slightly with KMnO₄stain). A white solid (69 mg, 56% yield) was isolated, which contained about 50% desired product and 50% lactone. This material was carried through to the next step. NOTE: the above reaction was run in very dilute t-butyl alcohol and using 4 Å molecular sieves to prevent formation of free amine and subsequent self-condensation to form a urea byproduct.

PREPARATION EXAMPLE 2-1 2-[2-(t-butyldiphenylsilanyloxy)ethyl]-2-phenyl-cyclopropane-1,1-dicarboxylic acid dimethyl ester (step 2-1)

To a mixture of t-butyldiphenyl-(3-phenyl-3-butenyloxy)-silane (3.0 g, 7.0 mmol) and dimethyl diazomalonate (1.1 g, 7.0 mmol), which was synthesized by the method described in Synth. Commun. (1987, 17, 1709-1716), was added rhodium (II) acetate dimmer (62 mg, 0.14 mmol) under argon atmosphere, and the mixture was heated at 100° C. for 10 min. After cooling to room temperature, the mixture was diluted with chloroform (4 mL), separated and purified by silica gel chromatography (hexane:ethyl acetate=100:0 to 4:1) to give the title compound (2.5 g, yield 70%) as a colorless oil.

PREPARATION EXAMPLE 2-2 (1R*,6R*)-2-oxo-6-phenyl-3-oxa-bicyclo[4.1.0]heptan-1-carboxylic acid methyl ester (step 2-2)

To a solution of 2-[2-(t-butyldiphenylsilanyloxy)ethyl]-2-phenyl-cyclopropane-1,1-dicarboxylic acid dimethyl ester (1.3 g, 2.5 mmol) obtained in Preparation Example 2-1 in tetrahydrofuran (13 mL) was added tetrabutylammonium fluoride trihydrate (1.2 g, 3.7 mmol) under argon atmosphere at 0° C., and the mixture was stirred at room temperature for 12 hours. The obtained solution was diluted with ethyl acetate and washed with saturated aqueous sodium chloride solution. The aqueous layer was extracted twice with ethyl acetate, and the combined organic layers were dried over sodium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=10:1 to 1:1) to give the title compound (0.41 g, yield 67%) as a white solid.

PREPARATION EXAMPLE 2-3 (1R*,5S*)-2-oxo-5-phenyl-3-oxa-bicyclo[3.1.0]hexane-1-carboxylic acid t-butyl ester (step 2-3)

Under nitrogen atmosphere, potassium t-butoxide (110 g, 0.78 mol) was added to a solution of di-t-butyl malonate (170 g, 0.78 mol) in t-butyl alcohol (1.5 L) in 3 portions at room temperature. After stirring at room temperature for 1 hour, the mixture was heated to 70° C. Then a solution of 2-chloromethyl-2-phenyloxirane (120 g) in tetrahydrofuran (500 mL) synthesized by the method described in J. Org. Chem. (1962, 27, 2241-2243) was added dropwise over 90 min. After stirring for 12 hours at 70° C., the mixture was cooled to room temperature and the solvent was evaporated. 10% Aqueous citric acid solution (500 mL) was added to the residue. The mixture was extracted with ethyl acetate (2.0 L), sequentially washed with water (500 mL) and saturated aqueous sodium chloride solution (200 mL), and dried over magnesium sulfate. After filtration and evaporation, the title compound (120 g, 3 step, yield 54%) was recrystallized from a mixed solution of hexane:diisopropyl ether=1:1 (600 mL) as a white solid.

PREPARATION EXAMPLE 2-3-2 (1R,5S)-2-oxo-5-phenyl-3-oxa-bicyclo[3.1.0]hexane-1-carboxylic acid t-butyl ester (step 2-3)

To a suspension of the starting material (7.0 g, 32 mmol) obtained by deprotecting t-butyl group of (1R*,5S*)-2-oxo-5-phenyl-3-oxa-bicyclo[3.1.0]hexane-1-carboxylic acid t-butyl ester obtained in Preparation Example 2-3 in ethanol (210 mL) was added quinidine (10 g, 32 mmol) at room temperature. After stirring at room temperature for 5 hours, the resultant precipitate was filtrated to give an optically active compound as a quinidine salt. The quinidine salt was suspended in ethyl acetate (80 mL) and water (60 mL). Then 1N aqueous hydrochloric acid solution (20 mL, 20 mmol) was added to the suspension at 0° C. and the mixture was stirred. After the organic layer was washed with saturated aqueous sodium chloride solution and dried over magnesium sulfate, an optically active carboxylic acid compound (3.3 g, yield 47%, optical purity 96% ee) was obtained as a white amorphous form after filtration and evaporation. The compound was esterificated in a similar manner as in Example 5-2 to give the title compound [4.0 g, yield 95%, [α]_D²⁵−62.9° (c0.275, MeOH)] as white crystals.

PREPARATION EXAMPLE 2-4 a) sodium (1R*,2S*)-1-t-butoxycarbonyl-2-hydroxymethyl-2-phenyl-cyclopropanecarboxylate

To a solution of (1R*,5S)-2-oxo-5-phenyl-3-oxa-bicyclo[3.1.0]hexane-1-carboxylic acid t-butyl ester (30 g, 0.11 mol) obtained in Preparation Example 2-3 in tetrahydrofuran (300 mL) was added 4N aqueous sodium hydroxide solution (29 mL, 0.11 mol) at room temperature. After stirring at 60° C. for 2.5 hours, the mixture was concentrated under reduced pressure. Then the mixture was azeotroped with toluene to remove water. The title compound (39 g) was obtained as a white amorphous form. The obtained product was used in the next step without purification.

b) (1R*,2S*)-2-(t-butyldimethylsilanyloxymethyl)-2-phenyl-cyclopropane-1,1-dicarboxylic acid mono-t-butyl ester (step 2-4)

Imidazol (18 g, 0.27 mol) was added to a suspension of sodium (1R*,2S*)-1-t-butoxycarbonyl-2-hydroxymethyl-2-phenyl-cyclopropanecarboxylate (38 g, 0.11 mol) obtained in the above-mentioned Example a) in N,N-dimethylformamide (190 mL) under argon atmosphere at 0° C., and t-butyldimethylsilyl chloride (35 g, 0.24 mol) was further added in 2 portions. After warming to room temperature, the mixture was stirred for 12 hours. Then water (76 mL) and methanol (76 mL) were added to the mixture at 0° C., which was followed by addition of potassium carbonate (30 g, 0.21 mol). After the obtained suspension was stirred for 3 hours at room temperature, toluene (190 mL) was added and the mixture was separated into layers using 10% aqueous citric acid solution (400 mL) while adjusting pH to about 5. The aqueous layer was extracted twice with toluene, and the combined organic layer was sequentially washed with 10% aqueous citric acid solution and saturated aqueous sodium chloride solution, and dried over sodium sulfate. After filtration and evaporation, the product was azeotroped with xylene to remove t-butyldimethylsilanol. The title compound (44 g) was obtained as white crystals. The obtained product was used in the next step without purification.

PREPARATION EXAMPLE 2-4-2 (1R*,2S*)-cis-1-carbamoyl-2-(2-hydroxyethyl)-2-phenylcyclopropanecarboxylic acid methyl ester (Preparation EXAMPLE 2-4

To a solution of (1R*,6R*)-2-oxo-6-phenyl-3-oxa-bicyclo[4.1.0]heptan-1-carboxylic acid methyl ester (0.29 g, 1.2 mmol) obtained in Preparation Example 2-2 in a tetrahydrofuran:methanol=1:1 mixture (6 mL) was added 28% ammonia in water (6 mL) at room temperature, and the mixture was stirred for 12 hours. The obtained solution was concentrated under reduced pressure to give the title compound (0.32 g) as a colorless oil. The obtained product was used in the next step without purification.

PREPARATION EXAMPLE 2-5 (1R*,6R*)-3-oxo-6-phenyl-4-oxa-2-aza-bicyclo[4.1.0]heptan-1-carboxylic acid t-butyl ester PREPARATION EXAMPLE 2-5

To a solution of (1R*,2S*)-2-(t-butyldimethylsilanyloxymethyl)-2-phenyl-cyclopropane-1,1-dicarboxylic acid mono-t-butyl ester (42 g, 0.10 mol) obtained in Preparation Example 2-4 in N,N-dimethylformamide (310 mL) were sequentially added triethylamine (15 mL, 0.11 mol) and diphenylphosphoryl azide (24 mL, 0.11 mol) under argon atmosphere. After stirring at 80° C. for 30 min., the mixture was cooled to room temperature over 1 hour. Then, cesium fluoride (30 g, 0.20 mol) was added at once, and the mixture was stirred at 50° C. for 1.5 hours. To the obtained suspension were added water (300 mL), toluene (150 mL), diethyl ether (150 mL) and tetrahydrofuran (100 mL), and the insoluble solid was filtrated. The filtrate was separated into layers, and the aqueous layer was extracted twice with toluene. The residue was sequentially washed with 1N aqueous sodium hydroxide solution and water and dried over sodium sulfate. After filtration and evaporation, the obtained residue and the above-mentioned solid were combined. A mixed solvent of hexane:diisopropyl ether=2:1 (150 mL) was added and the mixture was stirred at room temperature for 30 min. After the obtained crystal was filtrated, the residue was dried under reduced pressure to give the title compound (21 g, 3 steps, yield 73%) as a white solid.

PREPARATION EXAMPLE 2-5-2 (1R*,7R*)-3-oxo-7-phenyl-4-oxa-2-azabicyclo[5.1.0]octane-1-carboxylic acid methyl ester (step 2-5)

To a solution of (1R*,2S*)-cis-1-carbamoyl-2-(2-hydroxyethyl)-2-phenylcyclopropanecarboxylic acid methyl ester (0.30 g, 1.1 mmol) obtained in Preparation Example 2-4-2 in an ethyl acetate:acetonitrile:water=1:2:1 mixture (12 mL) was added iodobenzene diacetate (0.48 g, 1.5 mmol) at 0° C. After stirring at room temperature for 1.5 hours, iodobenzene diacetate (64 mg, 0.23 mmol) was further added, and the mixture was stirred for 1.5 hours. After the obtained solution was diluted with ethyl acetate and separated into layers, the aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium chloride solution, and dried over sodium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=40:1 to 1:2) to give the title compound (0.11 g, 35%) as a white solid.

PREPARATION EXAMPLE 2-6 (1R*,2R*)-1-t-butoxycarbonylamino-2-hydroxymethyl-2-phenylcyclopropanecarboxylic acid t-butyl ester (step 2-6)

To a solution of (1R*,6R*)-3-oxo-6-phenyl-4-oxa-2-aza-bicyclo[4.1.0]heptan-1-carboxylic acid t-butyl ester (2.0 g, 6.9 mmol) obtained in Preparation Example 2-5 in tetrahydrofuran (40 mL) was added sodium hydride (liquid paraffin 40% added, 0.61 g, 15 mmol) under nitrogen atmosphere at 0° C., and the mixture was stirred for 30 min. Then a solution of di-t-butyl dicarbonate (2.4 g, 11 mmol) in tetrahydrofuran (20 mL) was added dropwise to the obtained solution. After stirring at 0° C. for 5 min., the mixture was warmed to room temperature and stirred for 20 hours. Then, acetic acid (1 mL) and water (30 mL) were added to the obtained solution, and the solution was extracted three times with ethyl acetate (50 mL). The residue was washed with water (30 mL) and saturated aqueous sodium chloride solution (30 mL), and dried over sodium sulfate. After filtration and evaporation, hexane (20 mL) was added to the obtained residue to allow precipitation of crystals. The crystals were filtrated and dried under reduced pressure to give (1R*,6R*)-3-oxo-6-phenyl-4-oxa-2-aza-bicyclo[4.1.0]heptan-1,2-dicarboxylic acid di-t-butyl (2.1 g) as a crude product.

To the obtained solution of (1R*,6R*)-3-oxo-6-phenyl-4-oxa-2-aza-bicyclo[4.1.0]heptan-1,2-dicarboxylic acid di-t-butyl ester (2.1 g, 5.5 mmol) in methanol (42 mL) was added cesium carbonate (0.54 g, 1.7 mmol) at room temperature. After stirring for 30 min., the mixture was concentrated to about half the amount under reduced pressure, and then saturated aqueous sodium chloride solution (40 mL) was added to the obtained residue. The mixture was extracted three times with ethyl acetate (30 mL), washed with water (50 mL) and saturated aqueous sodium chloride solution (50 mL), and dried over sodium sulfate. After filtration and evaporation, hexane (20 mL) was added to the obtained residue to allow precipitation of crystals. The crystals were filtrated and dried under reduced pressure to give the title compound (1.9 g, yield 74%) as a colorless amorphous form.

PREPARATION EXAMPLE 3-1 (1R*,2S*)-1-amino-2-vinyl-cyclopropanecarboxylic acid ethyl ester (step 3-1)

The title compound was synthesized according to the method described in WO0009543.

PREPARATION EXAMPLE 4-1 1-amino-1,1a,2,3,4,8b-hexahydrobenzo[a]cyclopropa[c]cyclohepten-1-carboxylic acid ethyl ester (step 4-1)

Nitroethyl acetate (3.8 mL, 34 mmol), rhodium (II) pivalate dimmer (0.11 g, 0.17 mmol) and iodobenzene diacetate (12 g, 38 mmol) were gradually added to 6,7-dihydro-5H-benzocycloheptene (5.0 g, 35 mmol) synthesized by the method described in J. Chem. Soc. Chem. Commun. (1990, 18, 1270-1271) under argon atmosphere, and the mixture was stirred at 40° C. for 14 hours. The obtained solution was cooled to room temperature, and separated and purified by silica gel chromatography (hexane:ethyl acetate=20:1) to give 1-nitro-1,1a,2,3,4,8b-hexahydrobenzo[a]cyclopropane[c]cyclohepten-1-carboxylic acid ethyl ester (1.5 g, yield 17%).

To the obtained solution of 1-nitro-1,1a,2,3,4,8b-hexahydrobenzo[a]cyclopropane[c]cyclohepten-1-carboxylic acid ethyl ester (1.9 g, 7.0 mmol) in isopropylalcohol (140 mL) were gradually added aqueous solution of 1N hydrochloric acid (70 mL, 70 mmol) and zinc powder (9.1 g, 0.14 mol), and the mixture was stirred at room temperature for 4 hours. The obtained solution was cooled to 0° C. Then, saturated aqueous sodium hydrogen carbonate solution (150 mL) was added to the solution, and the mixture was filtrated. After the filtrate was separated into layers, the aqueous layer was extracted twice with ethyl acetate (100 mL) and dried over magnesium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (chloroform:methanol=30:1) to give the title compound (1.5 g, yield 87%) as a pale-yellow oil.

PREPARATION EXAMPLE 5-1 (1R*,2S*,3S*)-1-t-butoxycarbonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid (step 5-1)

To a solution of (1R,2S*,3S*)-1-t-butoxycarbonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid methyl ester (37 g, 0.12 mol) obtained in Preparation Example 1-12 in a methanol:tetrahydrofuran=15:1 mixture (610 mL) was added 4N aqueous sodium hydroxide solution (95 mL, 0.38 mol), and the mixture was refluxed for 6 hours. The mixture was allowed to cool to room temperature and the solvent was evaporated. 4N aqueous hydrochloric acid solution was added to the residue at 0° C. until the pH level read about 3. After the aqueous layer was extracted with ethyl acetate (800 mL), the organic layer was washed with saturated aqueous sodium chloride solution. The solution was dried over magnesium sulfate and the solvent was evaporated under reduced pressure to give the title compound (38 g) as a crude product of a pale-yellow oil. The obtained product was used in the next step without further purification.

PREPARATION EXAMPLE 5-1-2 (1S,2R,3R)-1-t-butoxycarbonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid (step 5-1)

To a solution of (1R*,2S*,3S*)-1-t-butoxycarbonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid (38 g) obtained in Preparation Example 5-1 in isopropylalcohol (380 mL) was added quinidine (40 g, 0.12 mmol), and the mixture was stirred at room temperature for 20 hours. The obtained crystal was filtrated to give an optical active quinidine salt (28 g, 44 mmol) as a white solid. The quinidine salt was suspended in ethyl acetate (250 mL) and water (250 mL), and the suspension was stirred after addition of 1N aqueous hydrochloric acid solution (88 mL, 88 mmol) at 0° C. The organic layer was washed with saturated aqueous sodium chloride solution, and dried over magnesium sulfate. The title compound [13 g, 2 steps, yield 37%, [α]²⁵_D+111° (c1.00, MeOH), optical purity 97% ee] was obtained as a white amorphous form by filtration and evaporation.

PREPARATION EXAMPLE 5-2 (1S,2R,3R)-1-t-butoxycarbonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 5-2)

Under argon atmosphere, N,N-dimethylformamide di-t-butylacetal (5.0 mL, 21 mmol) was added dropwise to a solution of (1S,2R,3R)-1-t-butoxycarbonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid (1.5 g, 5.2 mmol) obtained in Preparation Example 5-1 in toluene (15 mL) at 80° C. over 15 min, and the mixture was stirred for 1 hour. The obtained solution was cooled to 0° C. After saturated aqueous sodium hydrogen carbonate solution (15 mL) was added to the mixture, the organic layer was washed three times with water (10 mL) and dried over magnesium sulfate. Then, the title compound (1.8 g, yield 99%) was obtained as a pale-yellow oil by filtration and evaporation. The obtained product was used in the next step without further purification.

PREPARATION EXAMPLE 5-3 (1R*,2S*)-1-t-butoxycarbonylamino-2-[2-(2-ethoxycarbonyl-ethyl)-phenyl]-cyclopropanecarboxylic acid methyl ester (step 5-3)

To a solution of (1R*,2S*)-2-(2-bromo-phenyl)-1-t-butoxycarbonylamino-cyclopropanecarboxylic acid methyl ester (50 mg, 0.14 mmol) obtained in a similar manner as described in Preparation Example 1-12 in tetrahydrofuran (0.5 mL) were added dibenzylidene acetone palladium (7.8 mg, 14 μmol), 1,2,3,4,5-pentaphenyl-1′-(di-t-butylphosphino)ferrocene (9.6 mg, 14 μmol) and 0.5M solution of 3-ethoxy-3-oxopropylzinc bromide in tetrahydrofuran (0.81 mL, 0.41 mmol), and the mixture was stirred at room temperature for 2 hours. To the mixture were added 1N aqueous hydrochloric acid solution (0.5 mL) and water (5.0 mL), and the mixture was extracted twice with ethyl acetate (10 mL). Then the organic layer was sequentially washed with water (5.0 mL) and saturated aqueous sodium chloride solution (5.0 mL), and dried over magnesium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=5:1) to give the title compound (50 mg, yield 95%) as a brown oil.

PREPARATION EXAMPLE 5-4 (1S,2R,3R)-1-amino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 5-4)

Under argon atmosphere, p-toluenesulfonic acid monohydrate (3.5 g, 18 mmol) was added to a solution of (1S,2R,3R)-1-t-butoxycarbonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (3.2 g, 9.1 mmol) obtained in Preparation Example 5-2 in acetonitrile (30 mL) at 0° C., and the mixture was stirred at room temperature for 16 hours. The obtained solution was cooled to 0° C., and 1N aqueous sodium hydroxide solution (20 mL) was added. The aqueous layer was extracted twice with ethyl acetate (15 mL) and dried over magnesium sulfate. Then, the residue was filtrated and the solvent was evaporated to give a crude product of the title compound (1.8 g, yield 99%) as a crude product of a pale-yellow oil. The obtained product was used in the next step without purification.

PREPARATION EXAMPLE 5-4-2 (1R*,2S*)-1-amino-2-azidomethyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 5-4)

p-Toluenesulfonic acid monohydrate (5.2 g, 27 mmol) was added to a solution of the crude product (5.0 g) of (1R*,2S*)-2-azidomethyl-1-t-butoxycarbonylamino-2-phenyl-cyclopropanecarboxylic acid t-butyl ester, which was made from (1R*,2S*)-1-t-butoxycarbonylamino-2-hydroxymethyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester obtained in Preparation Example 2-6 by general method step 5-3, in acetonitrile (40 mL). The mixture was stirred at room temperature for 14 hours. After water (16 mL) was added, the mixture was further stirred for 7 hours and separated into layers by adding ethyl acetate (50 mL). The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution (30 mL), water (30 mL) and saturated aqueous sodium chloride solution (50 mL), and dried over sodium sulfate. The residue was filtrated and the solvent was evaporated to give a crude product of the title compound (2.8 g). The obtained product was used in the next step without further purification.

PREPARATION EXAMPLE 5-4-3 (1R*,5R*,6R*)-1-amino-6-phenyl-3-oxa-bicyclo[3.1.0]hexane-2-one (step 5-4)

[(1R*,5R*,6R*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hex-1-yl]-carboxylic acid t-butyl ester (0.22 g, 0.76 mmol) was dissolved in 4 mL of dichloroethane and 2 mL of trifluoroacetic acid. This reaction was started at 0° C. and the reaction mixture was warmed to room temperature over 30 min. After concentration, the reaction mixture was diluted with saturated NaHCO₃(5 mL) and extracted with dichloromethane (5×10 mL). The combined organic layers were washed with brine (×2), dried over Na₂SO₄and concentrated to afford a free base as a clear oil (yield 97%).

PREPARATION EXAMPLE 5-4-4 (1R*,2R*,3R*)-1-amino-2-methoxymethyl-3-phenyl-cyclopropanecarboxylic acid methoxy-methyl-amide hydrochloride (step 5-4)

[(1R*,2R*,3R*)-2-methoxymethyl-1-(methoxy-methyl-carbamoyl)-3-phenyl-cyclopropyl]-carbamic acid t-butyl ester (25 mg, 0.69 mmol) was dissolved in 4 mL of HCl in dioxane (4M). After stirring at room temperature for 1 hour, the solution was concentrated and dried under high vacuum to afford 100% of an HCl salt product.

PREPARATION EXAMPLE 5-5 (1S,2R,3R,)-1-(5-bromothiophene-2-sulfonylamino)-2-methyl-3-phenylcyclopropanecarboxylic acid t-butyl ester (step 5-5)

To a solution of (1S,2R,3R)-1-amino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (2.7 g, 11 mmol) obtained in Preparation Example 5-4 in pyridine (25 mL) was added 5-bromothiophene-2-sulfonyl chloride (3.4 g, 13 mmol) at room temperature under argon atmosphere. After stirring, the mixture was concentrated under reduced pressure. The obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=10:1) to give a crude product of the title compound as a pale-yellow oil. The crude product was washed with water to give the title compound (2.9 g, yield 58%) as a yellow solid.

PREPARATION EXAMPLE 5-5-2 4-[(1S,2R,3R)-1-t-butoxycarbonyl-2-methyl-3-phenyl-cyclopropylsulfamoyl]-piperazine-1-carboxylic acid t-butyl ester (step 5-5)

To a solution of chlorosulfonyl isocyanate (18 μL, 0.20 mmol) in acetonitrile (2 mL) was added 2-chloroethanol (14 μL, 0.20 mmol) at 0° C. The mixture was stirred at 0° C. for 30 min and then at room temperature for 1 hour. To this reaction mixture were added N-methylmorpholine (89 μL, 0.81 mmol) and (1S,2R,3R)-1-amino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (50 mg, 0.20 mmol). The reaction mixture was then stirred at 50° C. for 3 hours. This crude solution was used directly in the next step.

Under argon atmosphere, this (1S,2R,3R)-2-methyl-1-(2-oxo-oxazolidine-3-sulfonylamino)-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (0.61 mmol) and t-butyl-1-piperazinecarboxylic acid (0.14 g, 0.73 mmol) were mixed, and the mixture was refluxed for 18 hours under heating. The obtained solution was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (hexane:ethyl acetate=10:0 to 5:1) to give the title compound (0.24 g, yield 79%).

PREPARATION EXAMPLE 5-6 (1S,2R)-1-(6-bromomethyl-imidazo[2,1-b]thiazol-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid methyl ester (step 5-6)

To a solution of (1S,2R)-1-(2-amino-thiazol-5-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid methyl ester (0.21 g, 0.58 mmol) in ethyl acetate (6.4 mL) was added 1,3-dibromoacetone (0.18 mL, 0.87 mmol), and the mixture was stirred at 60° C. for 18 hours. After cooling to room temperature, the mixture was washed with saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium chloride solution, and dried over sodium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=1:1) to give the title compound (68 mg, yield 24%) as a pale-yellow solid.

PREPARATION EXAMPLE 5-7 (1S,2R,3R)-1-[5-(4-iodo-pyrazole-1-yl)-thiophene-2-sulfonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 5-7)

To a solution of (1S,2R,3R)-1-amino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (1.7 g, 6.7 mmol) obtained in Preparation Example 5-4 in chloroform (17 mL) was sequentially added triethylamine (1.4 mL, 10 mmol) and 5-(4-iodo-pyrazole-1-yl)-thiophene-2-sulfonyl chloride (3.0 g, 8.0 mmol) at room temperature under nitrogen atmosphere. The obtained solution was warmed to 50° C., and stirred for 2 hours. Then, the obtained solution was purified by silica gel chromatography (hexane:ethyl acetate=7:3) to give the title compound as a pale-yellow crude product. The crude product was slurry-washed with diisopropyl ether:hexane=1:1 (30 mL) to give the title compound (3.2 g, yield 82%) as a colorless amorphous form.

PREPARATION EXAMPLE 5-10 a) 1-(3-thiophene-2-yl-isoxazole-5-yl)-ethanone

The title compound was synthesized according to the method described in known Heterocycles (1993, 35, 591-598).

To a solution of 4-nitro-benzoic acid 1-methylene-2-oxo-propyl ester (10 g, 43 mmol) synthesized by the method of Helv. Chim. Acta (1981, 64, 188-197) and 2-thiophenecarbohydroxymoyl chloride (10 g, 62 mmol) synthesized by the method of Bioorg. Med. Chem. Lett. (2003, 13, 1795-1799) in chloroform (100 mL) was added dropwise triethylamine (9.0 mL, 62 mmol) under argon atmosphere at 0° C. over 30 min., and the mixture was stirred for 30 min. Then triethylamine (6.0 mL, 42 mmol) was added dropwise and the mixture was warmed gradually to room temperature.

After stirring at room temperature for 12 hours, water (100 mL) was added to the obtained solution, and the mixture was filtrated through celite. The filtrate was separated into layers and extracted with chloroform (100 mL). After the organic layer was washed with 1N aqueous sodium hydroxide solution (40 mL), 1N aqueous hydrochloric acid solution (80 mL) and saturated aqueous sodium chloride solution (40 mL) were added sequentially, and the mixture was dried over sodium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:chloroform=1:1) to give the title compound (5.4 g, yield 66%) as pale-brown crystals.

b) 5-(1,1-difluoroethyl)-3-thiophene-2-yl-isoxazole

Under argon atmosphere, to a suspension of 1-(3-thiophene-2-yl-isoxazole-5-yl)-ethanone (6.0 g, 31 mmol) obtained in Preparation Example 5-10-a) in dichloromethane (30 mL) was added dropwise diethylaminosulfur trifluoride (DAST) (16 mL, 0.12 mol) over 5 min. at 0° C., and the suspension was warmed gradually to room temperature. After stirring at room temperature for 23 hours, the obtained solution was transferred to a separatory funnel and added dropwise over 30 min. to 4N aqueous sodium hydroxide solution (105 mL) cooled at 0° C. Then the obtained solution was warmed gradually to room temperature and filtrated through celite. The filtrate was separated into layers and extracted with chloroform (60 mL). Then the organic layer was sequentially washed with saturated aqueous sodium hydrogen carbonate solution (90 mL), 1N aqueous hydrochloric acid solution (60 mL) and saturated aqueous sodium chloride solution (30 mL), and dried over magnesium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=15:1) to give the title compound (6.2 g, 94%) as a brown oil.

c) 5-[5-(1,1-difluoroethyl)-isoxazol-3-yl]-thiophene-2-sulfonic acid

Under argon atmosphere, to a solution of 5-(1,1-difluoroethyl)-3-thiophene-2-yl-isoxazole (6.2 g, 31 mmol) obtained in Preparation Example 5-10-b) in chloroform (100 mL) was added chlorosulfonic acid (2.5 mL, 38 mmol), and the mixture was stirred at room temperature for 3 days. The obtained solution was filtrated and dried under reduced pressure to give the title compound (7.9 g, yield 93%) as a pale-brown powder.

d) 5-[5-(1,1-difluoroethyl)-isoxazol-3-yl]-thiophene-2-sulfonic acid chloride (step 5-10)

To a suspension of 5-[5-(1,1-difluoroethyl)-isoxazol-3-yl]-thiophene-2-sulfonic acid (9.5 g, 32 mmol) obtained in Preparation Example 5-10-c) in thionyl chloride (50 mL) was added dimethylformamide (1.0 mL) under argon atmosphere, and the suspension was stirred at 80° C. for 16 hours. The obtained solution was concentrated, and chloroform (100 mL) was added. After azeotropic removal of residual solvent with chloroform, chloroform (50 mL) was added to the residue. The obtained mixture was extracted twice, sequentially washed with water (20 mL) and saturated aqueous sodium chloride solution (10 mL), and dried over magnesium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=15:1) to give the title compound (6.9 g, 68%) as a yellow solid.

PREPARATION EXAMPLE 5-11 (1S,2R,3R)-1-{5-[5-(1,1-difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 5-11)

To a solution of (1S,2R,3R)-1-amino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (3.0 g, 12 mmol) obtained in Preparation Example 5-4 in tetrahydrofuran (60 mL) were sequentially added 5-[5-(1,1-difluoroethyl)-isoxazol-3-yl]-thiophene-2-sulfonic acid chloride (3.8 g, 12 mmol) obtained in Example 5-10 and 2,6-lutidine (3.1 mL, 27 mmol) at room temperature under argon atmosphere. The obtained solution was warmed to 50° C., and stirred for 15 hours. Then, to the obtained solution was added saturated aqueous sodium chloride solution (60 mL), and the mixture was extracted twice with ethyl acetate (60 mL), sequentially washed with 2N aqueous hydrochloric acid solution (30 mL) and saturated aqueous sodium chloride solution (10 mL), and dried over magnesium sulfate. After filtration and evaporation, the obtained crude product was separated and purified by silica gel chromatography (hexane:ethyl acetate=10:1). The crude product was slurry-washed with hexane (60 mL) to give the title compound (3.8 g, 60%) as a pale-yellow solid.

PREPARATION EXAMPLE 5-11-2 (1R*,1aS*,8bS*)-1-[5-(4-chloro-phenyl)thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydrobenzo[a]cyclopropa[c]cyclohepten-1-carboxylic acid ethyl ester (step 5-11)

To a solution of (1R*,1aS*,8bS*)-1-amino-1,1a,2,3,4,8b-hexahydrobenzo[a]cyclopropa[c]cyclohepten-1-carboxylic acid ethyl ester (0.22 g, 0.91 mmol) obtained in Preparation Example 4-1 in pyridine (2.0 mL) was added 5-(4-chlorophenyl)-thiophene-2-sulfonyl chloride (0.32 g, 1.1 mmol) at room temperature under argon atmosphere. After stirring for 4 hours, the mixture was concentrated under reduced pressure. The obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=10:1) to give the title compound (0.26 g, yield 56%) as a pale-yellow amorphous form.

PREPARATION EXAMPLE 5-11-3 (1S,2R,3R)-2-methyl-1-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 5-11)

To a solution of chlorosulfonyl isocyanate (18 μL, 0.20 mmol) in acetonitrile (2 mL) was added 2-chloroethanol (14 μL, 0.20 mmol) at 0° C. The mixture was stirred at 0° C. for 30 min and then at room temperature for 1 hour. To this reaction mixture were added N-methylmorpholine (89 μL, 0.81 mmol) and (1S,2R,3R)-1-amino-2-methyl-3-phenyl-cyclopropanecarboxylic acid tert-butyl ester (50 mg, 0.20 mmol). The reaction mixture was then stirred at 50° C. for 3 hours. This crude solution was used directly in the next step.

To the crude (1S,2R,2R)-2-methyl-1-(2-oxo-oxazolidine-3-sulfonylamino)-3-phenyl-cyclopropanecarboxylic acid tert-butyl ester (120 mg, 0.30 mmol) was added commercially available 1-(5-trifluoromethyl-pyridin-2-yl)-piperazine (70 mg, 0.30 mmol) and the reaction mixture was heated at 80° C. for 30 min. N,N-dimethylacetamide (0.5 mL) was added to completely dissolve piperazine. After heating for 24 hours, the reaction mixture was diluted with ethyl acetate and the organic layer was washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution. After drying over magnesium sulfate, the solvent was removed in vacuo. The crude material was purified using prep TLC eluting with 1:1 Hexanes/ethyl acetate (R_f0.7) to afford the desired sulfamide in a 20% isolated yield.

PREPARATION EXAMPLE 5-11-4 5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonic acid[(1R*,5R*,6R*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hexan-1-yl]-amide (step 5-11)

(1R*,5R*,6R*)-1-amino-6-phenyl-3-oxa-bicyclo[3.1.0]hexan-2-one (0.14 g, 0.74 mmol) was dissolved in 3 mL of pyridine. After cooling to 0° C., 5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonyl chloride (0.31 g, 0.96 mmol) was added in one portion. The reaction mixture was warmed to room temperature and stirred overnight. After concentration, the reaction mixture was diluted with EtOAc, washed with 10% citric acid, water (×2), 5% NaHCO₃and brine and dried over Na₂SO₄. After concentration, the crude product was purified by column chromatography using 2:1 hexanes/EtOAc to afford 0.26 g (75%) of the desired product.

PREPARATION EXAMPLE 5-11-5 (1R*,2R*,3R*)-2-methoxymethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid methoxy-methyl-amide (step 5-11)

The (1R*,2R*,3R*)-1-amino-2-methoxymethyl-3-phenyl-cyclopropanecarboxylic acid methoxy-methyl-amide hydrochloride (22 mg, 0.082 mmol) was dissolved in 1 mL of pyridine. To this solution was added 5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonyl chloride (25 mg, 0.079 mmol) and the mixture was stirred at room temperature overnight. After concentration, the reaction mixture was diluted with EtOAc and washed with sat. NaHCO₃(2×) and brine. After drying over MgSO₄, the solution was concentrated and purified using prep-TLC (1:1 hexanes/EtOAc) to afford 13 mg of the desired product (32%).

PREPARATION EXAMPLE 6-1 (1R*,2R)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-hydroxymethyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 6-1)

To a solution of (1R*,6R*)-3-oxo-6-phenyl-4-oxa-2-aza-bicyclo[4.1.0]heptan-1-carboxylic acid t-butyl ester (5.0 g, 17 mmol) obtained in Preparation Example 2-5 in tetrahydrofuran (50 mL) was sequentially added 15-crown-5 (0.34 mL, 1.7 mmol) and sodium hydride (liquid paraffin 40% added, 1.7 g, 41 mmol) at 0° C. under nitrogen atmosphere. After stirring for 5 min., the mixture was further stirred at room temperature for 30 min. The obtained solution was cooled to 0° C., and 5-(4-chlorophenyl)-thiophene-2-sulfonyl chloride (6.1 g, 21 mmol) was added. After stirring at 0° C. for 15 min., the mixture was stirred at room temperature for 6 hours. To the obtained solution were sequentially added tetrahydrofuran (50 mL), methanol (100 mL) and 2N aqueous sodium hydroxide solution (17 mL, 69 mmol). After stirring for 15 hours, the mixture was concentrated to about half the amount under reduced pressure. To the obtained solution was added 5% aqueous potassium hydrogen sulfate solution until the pH level read about 6. Then the solution was extracted three times with ethyl acetate (50 mL), washed with water (30 mL) and saturated aqueous sodium chloride solution (30 mL), and dried over sodium sulfate. After filtration and evaporation, the obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=7:3) to give the title compound (3.6 g, yield 40%) as a pale-yellow amorphous form.

PREPARATION EXAMPLE 6-2 (1R*,2R*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-(tetrahydro-pyran-2-yloxymethyl)-cyclopropanecarboxylic acid t-butyl ester (step 6-2)

To a solution of (1R*,2R*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-hydroxymethyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (4.5 g, 8.7 mmol) obtained in Preparation Example 6-1 in chloroform (45 mL) were sequentially added 3,4-dihydro-2H-pyran (2.0 mL, 22 mmol) and p-toluenesulfonic acid monohydrate (0.17 g, 0.87 mmol) at room temperature under nitrogen atmosphere. After stirring for 1 hour, saturated aqueous sodium hydrogen carbonate solution (40 mL) was added to the mixture. Then the aqueous layer was extracted three times with ethyl acetate (20 mL). The organic layer was washed with water (30 mL) and saturated aqueous sodium chloride solution (30 mL), and dried over sodium sulfate. After filtration and evaporation, the obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=7:3) to give the title compound (4.9 g, yield 93%) as a pale-yellow powder.

PREPARATION EXAMPLE 6-3 (1R*,2R*)-1-[[5-(4-chloro-phenyl)-thiophene-2-sulfonyl]-(2-trimethylsilanyl-ethyl)-amino]-2-phenyl-2-(tetrahydro-pyran-2-yloxymethyl)-cyclopropanecarboxylic acid t-butyl ester (step 6-3)

To a solution of (1R*,2R*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-(tetrahydro-pyran-2-yloxymethyl)-cyclopropanecarboxylic acid t-butyl ester (4.9 g, 8.0 mmol) obtained in Preparation Example 6-2, triphenylphosphine (3.2 g, 12 mmol) and 2-trimethylsilylethanol (1.7 mL, 12 mmol) in tetrahydrofuran (49 mL) was dropwise added azodicarboxylic acid diisopropyl ester (2.4 mL, 12 mmol) at room temperature under nitrogen atmosphere, and the mixture was stirred for 15 hours. The obtained solution was purified by silica gel chromatography (hexane:ethyl acetate=4:1) to give the title compound (5.1 g, yield 91%) as a pale-yellow amorphous form.

PREPARATION EXAMPLE 6-4 (1R*,2R*)-1-[[5-(4-chloro-phenyl)-thiophene-2-sulfonyl]-(2-trimethylsilanyl-ethyl)-amino]-2-hydroxymethyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 6-4)

To a solution of (1R*,2R*)-1-[[5-(4-chloro-phenyl)-thiophene-2-sulfonyl](2-trimethylsilanyl-ethyl)-amino]-2-phenyl-2-(tetrahydro-pyran-2-yloxymethyl)-cyclopropanecarboxylic acid t-butyl ester (5.1 g, 7.3 mmol) obtained in Preparation Example 6-3 in methanol (50 mL) was added p-toluenesulfonic acid monohydrate (0.14 g, 0.73 mmol) at room temperature under nitrogen atmosphere. After stirring for 1 hour, saturated aqueous sodium hydrogen carbonate solution (10 mL) was added. The mixture was extracted three times with ethyl acetate (20 mL). The organic layer was washed twice with water (30 mL) and also washed twice with saturated aqueous sodium chloride solution (30 mL), and dried over sodium sulfate. After filtration and evaporation, the obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=7:3) to give the title compound 35 (4.5 g, yield 99%) as a pale-yellow amorphous form.

PREPARATION EXAMPLE 6-5 (1R*,2R*)-1-[[5-(4-chloro-phenyl)-thiophene-2-sulfonyl]-(2-trimethylsilanyl-ethyl)-amino]-2-methoxymethyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 6-5)

To a solution of (1R*,2R*)-1-[[5-(4-chloro-phenyl)-thiophene-2-sulfonyl]-(2-trimethylsilanyl-ethyl)-amino]-2-hydroxymethyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (0.10 g, 0.16 mmol) obtained in Preparation Example 6-4 in tetrahydrofuran (1.0 mL) were sequentially added methyl iodide (20 μL, 0.32 mmol) and sodium hydride (liquid paraffin 40% added, 13 mg, 0.32 mmol) at 0° C. under nitrogen atmosphere. After stirring for 30 min., the mixture was further stirred at room temperature for 26 hours. To the obtained solution were added 5% aqueous potassium hydrogen sulfate solution (1.0 mL) and ethyl acetate (2.0 mL). The aqueous layer was extracted three times with ethyl acetate (2.0 mL). The organic layer was washed with water (5.0 mL) and saturated aqueous sodium chloride solution (5.0 mL), and dried over sodium sulfate. After filtration and evaporation, the obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=7:3) to give the title compound (99 mg, yield 98%) as a pale-yellow oil.

PREPARATION EXAMPLE 6-6 (1R*,2S*)-1-[(5-bromo-thiophene-2-sulfonyl)-(2-trimethylsilanyl-ethyl)-amino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 6-6)

To a solution of (1R,2S*)-1-(5-bromo-thiophene-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (0.90 g, 1.9 mmol) obtained in a similar manner as in Preparation Example 5-5 in tetrahydrofuran (9.0 mL) were sequentially added triphenylphosphine (0.75 g, 2.8 mmol), 2-trimethylsilylethanol (0.33 mL, 2.8 mmol) and azodicarboxylic acid diisopropyl ester (0.56 mL, 2.8 mmol) under argon atmosphere, and the mixture was stirred at room temperature for 12 hours. After evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=20:1) to give the title compound (0.90 g, yield 83%) as a colorless oil.

PREPARATION EXAMPLE 6-7 (1S,2R)-1-(5-benzo[1,3]dioxo-5-yl-thiophene-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 6-7)

To a solution of (1S,2R)-1-(5-bromo-thiophene-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (52 mg, 0.11 mmol) obtained in a similar manner as in Preparation Example 5-5 in 1,2-dimethoxyethane (1.0 mL) were sequentially added 3,4-(methylenedioxy)phenylboronic acid (24 mg, 0.15 mmol), potassium carbonate (46 mg, 0.33 mmol) and a catalytic amount of tetrakis(triphenylphosphine)palladium (0) under argon atmosphere. After stirring at 80° C. for 8 hours, the mixture was filtrated through celite. After evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=10:1) to give the title compound (65 mg, purity 80%) as a colorless amorphous form.

PREPARATION EXAMPLE 6-7-2 (1R*,2S*)-2-methyl-1-[(5-morpholin-4-yl-thiophene-2-sulfonyl)-(2-trimethylsilanyl-ethyl)-amino]-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 6-7)

To a solution of (1R*,2S*)-1-[(5-bromo-thiophene-2-sulfonyl)-(2-trimethylsilanyl-ethyl)-amino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (52 mg, 91 μmol) obtained in Preparation Example 6-6 in toluene (1.0 mL) were added sodium t-butoxide (26 mg, 0.27 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl (13 mg, 27 μmol), tris(dibenzylideneacetone)dipalladium (9.0 mg, 9.0 μmol) and morpholine (40 μL, 0.46 mmol) under argon atmosphere, and the mixture was stirred for 6 hours under refluxing. The obtained suspension was cooled to 0° C. and water (1.0 mL) was added. The mixture was extracted twice with ethyl acetate (5.0 mL). The organic layer was sequentially washed with water (1.0 mL) and saturated aqueous sodium chloride solution (1.0 mL), and dried over magnesium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=10:1) to give the title compound (36 mg, yield 70%) as a white solid.

PREPARATION EXAMPLE 6-8 (1R*,2S*)-2-methyl-1-(5-morpholin-4-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 6-8)

To (1R*,2S*)-2-methyl-1-[(5-morpholin-4-yl-thiophene-2-sulfonyl)-(2-trimethylsilanyl-ethyl)-amino]-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (36 mg, 63 μmol) obtained in Preparation Example 6-7-2 was added 1.0 M solution of tetrabutylammonium fluoride in tetrahydrofuran (1.0 mL) under argon atmosphere, and the mixture was stirred for 12 hours under refluxing. The obtained solution was cooled to 0° C. and water (1.0 mL) was added. The mixture was extracted twice with ethyl acetate (5.0 mL). The organic layer was sequentially washed with water (1.0 mL) and saturated aqueous sodium chloride solution (1.0 mL), and dried over magnesium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=3:1) to give the title compound (22 mg, yield 73%) as a white solid.

PREPARATION EXAMPLE 6-9 (1R*,2S*)-2-(3-amino-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid t-butyl ester (step 6-9)

To a solution of (1R*,2S*)-2-(3-nitro-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid t-butyl ester (0.46 g, 0.82 mmol) obtained in a similar manner as in Preparation Example 5-11 in a ethanol:chloroform=1:1 (5.0 mL) mixture was added copper (II) acetate (0.23 g, 1.2 mmol), and the mixture was stirred at room temperature for 5 min. to give a homogenous blue solution. Then sodium borohydride (0.22 g, 5.8 mmol) was added slowly at room temperature, and the mixture was stirred for 30 min. After the obtained solution was diluted with diethyl ether (5.0 mL) and ethyl acetate (5.0 mL), the organic layer was sequentially washed with saturated aqueous sodium hydrogen carbonate solution (10 mL) and saturated aqueous sodium chloride solution (10 mL), and dried over sodium sulfate. After filtration and evaporation, the residue were gradually added ethyl acetate and hexane to allow precipitation of crystals. The crystals was filtrated to give the title compound (0.20 g, yield 46%) as a pale-yellow powder.

PREPARATION EXAMPLE 6-9-2 1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(isopropylamino-methyl)-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (step 6-9)

To a solution of 2-azidomethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (2.2 g, 4.0 mmol), which was produced in a similar manner as in Preparation Example 5-11 from (1R*,2S*)-1-amino-2-azidomethyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester obtained in Preparation Example 5-4-2, in toluene (22 mL) was added triphenylphosphine (1.1 g, 4.2 mmol) under argon atmosphere, and the mixture was stirred at room temperature for 3 hours. To the obtained solution was added water (20 mL) and the mixture was stirred at 100° C. for 1 hour. After evaporation, the obtained residue was purified by silica gel chromatography (chloroform:methanol=100:1 to 20:1) to give 2-aminomethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (1.8 g, yield 86%).

To the obtained 2-aminomethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (60 mg, 0.12 mmol) in tetrahydrofuran (1.0 mL) were added acetone (13 μL, 0.17 mmol) and sodium triacetoxyborohydride (37 mg, 0.17 mmol) at 0° C. under argon atmosphere, and the mixture was stirred at room temperature for 20 hours. To the obtained solution was added acetic acid (50 μL), and the mixture was further stirred for 21 hours. Then saturated aqueous sodium hydrogen carbonate solution (2.0 mL) was added and the aqueous layer was extracted with ethyl acetate (3.0 mL). The organic layer was washed with water (2.0 mL) and saturated aqueous sodium chloride solution (2.0 mL), and dried over magnesium sulfate. After filtration and evaporation, the obtained residue was purified by silica gel chromatography (chloroform:methanol=25:2) to give the title compound (45 mg, yield 69%) as a pale-yellow oil.

PREPARATION EXAMPLE 6-10 (1S,2R)-1-(6-methoxymethyl-imidazo[2,1-b]thiazol-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid methyl ester (step 6-10)

To a solution of (1S,2R)-1-(6-bromomethyl-imidazo[2,1-b]thiazol-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid methyl ester (32 mg, 65 μmol) obtained in Preparation Example 5-6 in dimethylformamide (3.0 mL) were added methanol (0.60 mL) and a solution of 28% sodium methoxide in methanol (0.13 mL, 0.65 mmol) under argon atmosphere, and the mixture was stirred for 18 hours. To the mixture was added saturated aqueous ammonium chloride solution (15 mL), and the aqueous layer was extracted with ethyl acetate (15 mL). The organic layer was washed with saturated aqueous sodium chloride solution and dried over sodium sulfate. After filtration and evaporation, the obtained residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=1:2) to give the title compound (25 mg, yield 88%) as a white solid.

PREPARATION EXAMPLE 6-11 (1R*,2R*,3R*)-2-methoxymethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid (step 6-11)

(1R*,2R*,3R*)-2-methoxymethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid methoxy-methyl-amide (55 mg, 0.10 mmol) was dissolved in 6 mL of dichloromethane.

Diisobutylaluminum hydride (1M, 0.22 mL, 0.22 mmol) was added dropwise at −78° C. This mixture was monitored by LC/MS and supplemental diisobutylaluminum hydride was repeatedly added until the reaction was completed. After quenching with methanol, the reaction mixture was partitioned between dichloromethane and 1N HCl. The organic layer was washed with brine, dried over MgSO₄and concentrated. The crude product was used directly in the next step.

The crude mixture (assumed 0.1 mmol) was dissolved in 12 mL of 3:1 acetone/water. To this solution were added NaClO₂(31 mg, 0.34 mmol, 3.4 equiv), NaH₂PO₄(12 mg, 0.10 mmol, 1.0 equiv) and 2-methyl-2-butene (few drops). After stirring at room temperature for 4 hours, the reaction mixture was concentrated and partitioned between EtOAc and water. The aqueous solution was further extracted with EtOAc (×2). The combined organic layers were dried over MgSO₄and concentrated to give a yellow oil. This material was given to our purification group to purify and quite a lot of material was lost during repeated purifications. Further purification using prep TLC afforded the product (2 mg) in a 50% purity.

EXAMPLE 1 (1S,2R)-1-(4′-Chlorobiphenyl-4-sulfonylamino)-2-phenylcyclopropanecarboxylic acid a) (1S,2R)-1-Amino-2-phenylcyclopropanecarboxylic acid

To commercially available (1R,2S)-1-tert-butoxycarbonylamino-2-phenylcyclopropanecarboxylic acid (130 mg, 0.45 mmol) was added 4N hydrochloric acid-1,4-dioxane solution (2.0 mL, 16 v/w) and the mixturewas stirred for 1 hr at room temperature. Diethyl ether (1.0 mL) was added thereto and the mixture was stirred for 5 min, after which the resulting crystals were collected by filtration. The crystals were washed with diethyl ether (1.0 mL) and dried under reduced pressure to give the title compound (81 mg, white powder, yield 84%).

¹H-NMR (DMSO, 300 MHz): 1.84 (dd, J=6.0, 9.0 Hz, 1H), 2.03 (dd, J=6.0, 9.0 Hz, 1H), 2.99 (t, J=10.5 Hz, 1H), 7.20-7.40 (m, 5H), 8.29 (br, 3H)

b) (1S,2R)-1-(4′-Chlorobiphenyl-4-sulfonylamino)-2-phenylcyclopropanecarboxylic acid

To a suspension of (1S,2R)-1-amino-2-phenylcyclopropanecarboxylic acid (80 mg, 0.38 mol) obtained in Example 1-a) in 1,4-dioxane:water=1:1 (3.2 mL, 40 v/w) were successively added triethylamine (0.18 mL, 1.3 mmol), 4-chlorobiphenylsulfonic acid chloride (110 mg, 1.1 mol) and N,N-dimethylaminopyridine (9.0 mg, 0.20 mmol) at 0° C. The mixture was stirred for 12 hr at room temperature, and 1N hydrochloric acid was added thereto until its pH reached approximately 1. The organic layer was extracted twice with ethyl acetate (4.0 mL) and concentrated. Then, the obtained crude product was separated and purified by thin-layer silica gel chromatography (chloroform:methanol=7:1) to give the title compound (60 mg, white amorphous solid, 37%).

EXAMPLE 1-2 1-[4-(2,4-Dichlorobenzyloxy)benzenesulfonylamino]-2-phenylcyclopropanecarboxylic acid hydroxyamide

Under an argon atmosphere of, 1-[4-(2,4-dichlorobenzyloxy)benzenesulfonylamino]-2-phenylcyclopropanecarboxylic acid (120 mg, 0.24 mmol) obtained in the same manner as in Example 1 was dissolved in tetrahydrofuran (1.2 mL, 10 v/w) and a methylene chloride solution of 2N oxalyl chloride (0.13 mL, 0.26 mmol) and a catalytic amount of N,N-dimethylformamide were added dropwise thereto at −20° C. After warming to 0° C. over 1 hr, 0-(trimethylsilyl)hydroxylamino (0.064 mL, 0.52 mmol) and N-methylmorpholine (0.052 mL, 0.48 mmol) were successively added dropwise thereto. The mixture was stirred at 0° C. for 1.5 hr, and 1N-hydrochloric acid (1.0 mL) and water (5.0 mL) were added thereto. The mixture was extracted twice with ethyl acetate (5.0 mL). The organic layer was successively washed with water (5.0 mL) and saturated brine (5.0 mL), and dried over magnesium sulfate (1.0 g). After filtration, the solvent was evaporated off under reduced pressure, and the obtained crude product was purified by silica gel chromatography (chloroform:methanol=10:1). The solvent was evaporated off, and diethyl ether was added to the obtained colorless oil. The mixture was stirred for 10 min at room temperature and the precipitated crystals were collected by filtration and dried under reduced pressure to give the title compound (88 mg, yield 73%) as a white solid.

Melting point 164.0-169.0° C.

EXAMPLES 1-3 TO 1-149

In the same manner as in Examples 1 and 1-2, the compounds of Examples 1-3 to 1-149 were obtained.

The structural formulas of the compounds of Examples 1 to 1-149 are shown in Tables 1-1 to 1-30.

EXAMPLE 2 4-[5-((1S,2R)-1-carboxy-2-phenyl-cyclopropanesulfamoyl)-thiophene-2-yl]-3,6-dihydro-2H-pyridin-1-carboxylic acid t-butyl ester (step 5-8)

The title compound (0.11 g, yield 90%) was obtained in a similar manner as in Preparation Example 5-1 from 4-{5-[(1S,2R)-1-methoxycarbonyl-2-phenyl-cyclopropylsulfamyl]-thiophen-2-yl}-3,6-dihydro-2H-pyridin-1-carboxylic acid t-butyl ester (0.13 g, 0.24 mmol).

EXAMPLE 2-2 (1S,2R)-2-phenyl-1-[5-(1,2,3,6-tetrahydro-pyridin-4-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid hydrochloride (step 5-9)

To a solution of 4-[5-((1S,2R)-1-carboxy-2-phenyl-cyclopropanesulfamoyl)-thiophen-2-yl]-3,6-dihydro-2H-pyridin-1-carboxylic acid t-butyl ester (0.11 g, 0.22 mmol) obtained in Example 2 in methanol (0.86 mL) was added 4N hydrochloric acid dioxane solution (2.2 mL) under argon atmosphere, and the mixture was stirred at room temperature for 1 hour. The title compound (0.11 g, yield 100%) was obtained by evaporation under reduced pressure.

EXAMPLE 2-3 4-[5-((1S,2R)-1-carboxy-2-phenyl-cyclopropanesulfamoyl)-thiophene-2-yl]-3,6-dihydro-2H-pyridin-1-carboxylic acid methyl ester (step 5-9)

To a solution of (1S,2R)-2-phenyl-1-[5-(1,2,3,6-tetrahydro-pyridin-4-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid hydrochloride (30 mg, 69 μmol) obtained in Example 2-2 in chloroform (0.60 mL) were added triethylamine (39 μL, 0.28 mmol) and methyl chlorocarbonate

(6.4 μL, 83 μmol) under argon atmosphere, and the mixture was stirred at room temperature for 18 hours. Saturated aqueous ammonium chloride solution, a small amount of ethyl acetate and diisopropyl ether were added to the mixture to allow precipitation of crystal, and the obtained crystals were filtrated to give the title compound (13 mg, yield 42%).

EXAMPLE 2-4 (1S,2R,3R)-1-[5-(4-ethynyl-pyrazole-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid (step 5-9)

To a solution of a deprotected compound of (1S,2R,3R)-1-[5-(4-iodo-pyrazol-1-yl)-thiophene-2-sulfonylamino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (0.10 g, 0.19 mmol) obtained in Preparation Example 5-7 in chloroform (1.0 mL) were sequentially added triethylamine (0.13 mL, 0.94 mmol), trimethylsilylacetylene (54 μL, 0.38 mmol), copper iodide (I) (1.8 mg, 9.4 μmol) and dichlorobis(triphenylphosphine)palladium (II) (6.6 mg, 9.4 μmol) at room temperature under nitrogen atmosphere. After stirring for 1 hour without any modification, 5% aqueous potassium hydrogen sulfate solution (1 mL) was added to the mixture. The aqueous layer was extracted three times with ethyl acetate (2 mL). The organic layer was washed with water (3 mL) and saturated aqueous sodium chloride solution (3 mL), and dried over sodium sulfate. After filtration and evaporation, the obtained crude product was purified by silica gel chromatography (hexane:ethyl acetate=1:1) to give (1S,2R,3R)-2-methyl-3-phenyl-1-[5-(4-trimethylsilanylethynyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid (75 mg, yield 79%) as a brown oil.

To a solution of (1S,2R,3R)-2-methyl-3-phenyl-1-[5-(4-trimethylsilanylethynyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid (66 mg, 0.13 mmol) in methanol (1.0 mL) was added potassium carbonate (36 mg, 0.26 mmol) at room temperature. After stirring for 1 hour without any modification, to the mixture was added 5% aqueous potassium hydrogen sulfate solution (3.0 mL). The aqueous layer was extracted three times with ethyl acetate (2.0 mL). The organic layer was washed with water (3.0 mL) and saturated aqueous sodium chloride solution (3.0 mL), and dried over sodium sulfate. After filtration and evaporation of the residue, chloroform (1.0 mL) was added to the obtained residue to allow precipitation of crystals. After slurry-washing and filtration, the residue was dried under reduced pressure to give the title compound (54 mg, yield 98%) as a pale-yellow powder.

EXAMPLE 2-5 (1S,2R,3R)-2-methyl-3-phenyl-1-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid (step 6-11)

To a solution of (1S,2R,3R)-2-methyl-3-phenyl-1-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid t-butyl ester (33 mg, 0.061 mmol) obtained in Preparation Example 5-11-3 in dichloromethane (1.5 mL) was added trifuluoroacetic acid (1.5 mL). The reaction mixture was stirred at room temperature for 3 hours. The excess trifuluoroacetic acid was removed by azeotropic distillation (twice) with toluene. Toluene was removed by azeotroping twice with dichloromethane and drying under hivac. The material was purified by prep TLC eluting with 9:1 chloroform/methanol (R_f0.3). The product was further purified by dissolving in a small amount of dichloromethane and adding hexane to allow precipitation of the product as a white solid (88% yield).

EXAMPLE 2-6 (1S,2R)-2-methyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid (step 6-11)

To a solution of (1S,2R)-2-methyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid t-butyl ester (5.0 g, 9.4 mmol) obtained in a similar manner as in Preparation Example 5-11 in chloroform (50 mL) was added trifluoroacetic acid (25 mL), and the mixture was stirred at room temperature for 21 hours. The solvent was evaporated under reduced pressure. After azeotropic removal of residual solvent with methanol, the residue was dissolved in a small amount of methanol. To the mixture was added water at 0° C. to allow precipitation of crystals. The crystals were filtrated and dried to give the title compound (4.3 g, yield 97%, [α]²⁵_D+72.6° (c1.00, MeOH),

m.p. 130-132° C.) as a white amorphous form.

EXAMPLE 2-7 (1S,2R,3R)-2-methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid (step 6-11)

(1S,2R,3R)-2-methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid t-butyl ester (7.2 g, 14 mmol) obtained in a similar manner as in Preparation Example 5-11 was deprotected in a similar manner as in Example 2-6 to give the title compound [5.9 g, yield 90%, [α]²⁵_D+81.00 (c 1.10, MeOH)] as white crystals.

EXAMPLE 2-8 (1R*,1aS*,8bS*)-1-[5-(4-chloro-phenyl)thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydrobenzo[a]cyclopropane[c]cyclohepten-1-carboxylic acid (step 6-11)

To a solution of (1R*,1aS*,8bS*)—[5-(4-chloro-phenyl)thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydrobenzo[a]cyclopropane[c]cyclohepten-1-carboxylic acid ethyl ester (0.25 g, 0.50 mmol) obtained in Preparation Example 5-11-2 in a methanol:tetrahydrofuran=1:1 (5.0 mL) mixture was added 4N aqueous sodium hydroxide solution (1.0 mL, 4.0 mmol), and the mixture was refluxed for 5 days. After putting back to room temperature, ethyl acetate (5.0 mL) and 1N aqueous hydrochloric acid solution (5.0 mL) were sequentially added to the mixture. After separating into layers, the aqueous layer was extracted twice with ethyl acetate (100 mL), and dried over magnesium sulfate. After filtration and evaporation, the residue was separated and purified by silica gel chromatography (hexane:ethyl acetate=1:1) to give the title compound (0.15 g, yield 65%) as a white amorphous form.

EXAMPLE 2-9 (1S,2R,3R)-1-{5-[5-(1,1-difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid (step 6-11)

To a solution of (1S,2R,3R)-1-{5-[5-(1,1-difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester (4.1 g, 7.8 mmol) obtained in Preparation Example 5-11 in chloroform (40 mL) was added trifluoroacetic acid (20 mL), and the mixture was stirred at room temperature for 20 hours. Then the mixture was evaporated under reduced pressure. The residue was azeotroped with a mixed solvent of chloroform and hexane, and dissolved in methanol (30 mL). After treatment with activated carbon (1 g), the solvent was evaporated and the residue was dissolved in methanol (30 mL). To the obtained solution was added water at 0° C. to allow precipitation of crystals. The crystals were filtrated and dried to give the title compound [3.3 g, yield 90%, [a]²⁵_D+83.6° (c 0.45, MeOH), m.p. 177-178° C.] as white crystals.

EXAMPLE 2-10 (1R*,2R*,3R*)-2-hydroxymethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid (step 5-12)

To 5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonic acid [(1R*,5R*,6R*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hex-1-yl]-amide (53 mg, 11 mmol) were added LiOH—H₂O (11 mg, 0.27 mmol), 1 mL of THF and 0.5 mL of water. After stirring overnight at room temperature, the reaction mixture was concentrated, diluted with water (2 mL), and acidified to pH 4 with 2N KHSO₄. The product was extracted with EtOAc, washed with water (×2), brine and dried over Na₂SO₄. After concentrating, the product was precipitated from dichloromethane/hexane to afford the desired product as a white solid (46 mg, 86% yield).

EXAMPLE 2-11 (1S,2R,3R)-2-methyl-3-phenyl-1-(4-phenylcarbamoyl-piperazine-1-sulfamoylamino)-cyclopropanecarboxylic acid (step 5-13)

4-((1S,2R,3R)-1-t-butoxycarbonyl-2-methyl-3-phenyl-cyclopropylsulfamoyl)-piperazine-1-carboxylic acid t-butyl ester (0.24 g, 0.48 mmol) obtained in Preparation Example 5-5-2, dioxane (0.20 mL) and 4N hydrochloric acid in dioxane (2.0 mL) were mixed, and the mixture was stirred at room temperature for 16 hours. After the obtained solution was concentrated, the residue was slurry-washed with ethyl acetate (5.0 mL) to give (1S,2R,3R)-2-methyl-3-phenyl-1-(piperazine-1-sulfamoylamino)-cyclopropanecarboxylic acid (0.15 g, yield 84%) as a white solid.

To a solution of the obtained (1S,2R,3R)-2-methyl-3-phenyl-1-(piperazine-1-sulfamoylamino)-cyclopropanecarboxylic acid (20 mg, 53 μmol) in tetrahydrofuran (1.0 mL) were added triethylamine (11 μL, 80 μmol) and phenyl isocyanate (8.7 μL, 80 μmol) at 0° C., and the mixture was stirred for 3 hours. To the obtained solution was added 10% aqueous potassium hydrogen sulfate solution (1.0 mL), and the aqueous layer was extracted twice with ethyl acetate (2.0 mL). After the organic layer was concentrated, the residue was purified by silica gel chromatography (chloroform:methanol=10:1) to give the title compound (20 mg, yield 80%) as a colorless amorphous form.

EXAMPLE 2-12 (1S,2R)-1-[5-(3-amino-4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid (step 5-14)

To a solution of (1S,2R)-1-[5-(4-chloro-3-nitro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid t-butyl ester (23 mg, 41 μmol), which was obtained from (1S,2R,3R)-1-amino-2-methyl-3-phenyl-cyclopropanecarboxylic acid t-butyl ester obtained in Preparation Example 5-4 by the general method of steps 5-5 and 5-6, in ethanol (0.30 mL) was added tin dichloride dihydrate (37 mg, 0.16 mmol), and the mixture was stirred at 100° C. for 2 hours. To the obtained solution were added saturated aqueous sodium hydrogen carbonate solution (1.0 mL) and methanol (1.0 mL), and the mixture was filtrated. The eluent was evaporated and the residue was separated and purified by silica gel chromatography (chloroform:methanol=9:1) to give the title compound (8.3 mg, yield 43%) as a white amorphous form.

EXAMPLE 2-13 (1R*,1aS*,6aS*)-1-[4-(2,4-dichloro-benzyloxy)-benzenesulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]inden-1-carboxylic acid hydroxyamide (step 5-15)

After (1R*,1aS*,6aS*)-1-[4-(2,4-dichloro-benzyloxy)-benzenesulfonylamino]-3-1,1a,6,6a-tetrahydro-cyclopropane[a]inden-1-carboxylic acid (92 mg, 0.18 mmol) obtained in a similar manner as in Preparation Example 6-11 was azeotroped with toluene, the residue was dissolved in tetrahydrofuran (2.0 mL). Under argon atmosphere, 2 M oxalyl chloride dichloromethane solution (0.12 mL, 0.24 mmol) and a catalytic amount of N,N-dimethylformamide were sequentially added dropwise at −20° C. After stirring at 0° C. for 1 hour, 0-(trimethylsilyl)hydroxylamine (59 μL, 0.48 mmol) and N-methylmorpholin (40 μL, 0.36 mmol) were sequentially added dropwise at −20° C. After stirring at 0° C. for 1 hour, 1N aqueous hydrochloric acid solution (1.0 mL) was added, and the mixture was extracted twice with ethyl acetate (20 mL). The organic layer was washed with water (3.0 mL) and dried over magnesium sulfate. After filtration and evaporation, the obtained residue was purified by silica gel chromatography (hexane:ethyl acetate=1:1). Further, diisopropyl ether was added to the obtained residue to allow precipitation. After filtration, a white solid (43 mg, yield 46%) was obtained under reduced pressure.

EXAMPLE 2-14 TO 2-625

The compounds of Examples 2-14 to 2-625 were produced from the compounds obtained in Preparation Examples or by known preparation methods and using similar methods of Examples 1, 1-2, 2-1 to 2-13.

The structural formulas of the compounds of Examples 2 to 2-625 are shown in Tables 2-1 to 2-125.

TABLE 1-1 Example Structural formula NMR 1 (DMSO-d6-300)1.50 (dd, J = 6.0, 9.0 Hz, 1 H),1.88-1.97 (m, 1 H), 2.57-2.66 (m,1 H), 7.12-7.26 (m, 5 H),7.57 (dd, J = 3.0, 6.0 Hz, 2 H),7.78 (dd, J = 3.0, 6.0 Hz, 2 H),7.85 (br, 4 H) 1-2 (DMSO-d6-300)1.01-1.10 (m, 1 H), 1.90 (dd,J = 6.0, 9.0 Hz, 1 H), 2.40-2.52(m, 1 H), 5.24 (s, 2 H),7.07-7.24 (m, 7 H), 7.49 (dd,J = 3.0, 9.0 Hz, 1 H), 7.65 (d,J = 9.0 Hz, 1 H), 7.72 (d, J = 3.0 Hz,1 H), 7.76 (d, J = 6.0 Hz, 2 H),8.50 (brs, 2 H), 10.20 (brs, 1 H) 1-3 (DMSO-d6-300)1.45 (dd, J = 9.8, 4.8 Hz, 1 H),1.73 (dd, J = 8.2, 5.2 Hz, 1 H),2.37 (t, J = 9.20 Hz, 1 H), 4.21 (d,J = 5.5 Hz, 2 H), 6.00-6.09 (m,1 H), 6.29-6.50 (m, 3 H), 6.85 (t,J = 7.7 Hz, 1 H), 7.32 (dd, J = 7.9,4.9 Hz, 1 H), 7.53-7.60 (m, 2 H),7.68-7.80 (m, 3 H), 7.85 (s, 4 H),8.42 (dd, J = 4.8, 1.8 Hz, 1 H),8.55 (d, J = 1.8 Hz, 1 H) 1-4 (DMSO-d6-300)0.84 (dd, J = 3.0, 9.0 Hz, 1 H),0.97 (dd, J = 6.0, 9.0 Hz, 1 H),2.58 (t, J = 9.0 Hz, 1 H), 3.75 (s,3 H), 6.81 (t, J = 7.5 Hz, 1 H),6.89 (brd, J = 9.0 Hz, 1 H),7.03 (brd, J = 9.0 Hz, 1 H),7.17 (t, J = 9.0 Hz, 1 H),7.53 (brd, J = 9.0 Hz, 2 H),7.56 (d, J = 3.0 Hz, 1 H), 7.58 (d,J = 3.0 Hz, 1 H), 7.76 (brd,J = 9.0 Hz, 2 H), 9.01 (br, 1 H),11.98 (br, 1 H) 1-5 (DMSO-d6-300)1.79-1.87 (m, 1 H), 1.96-2.03 (m,1 H), 2.53-2.58 (m, 1 H), 7.10-7.16(m, 2 H), 7.20-7.28 (m, 3 H),7.58 (d, J = 9.0 Hz, 2 H), 7.74-7.86(m, 6 H)

TABLE 1-2 Example Structural formula NMR 1-6 (DMSO-d6-300)1.79-1.87 (m, 1 H), 1.96-2.03 (m,1 H), 2.53-2.58 (m, 1 H), 7.10-7.16(m, 2 H), 7.20-7.28 (m, 3 H),7.58 (d, J = 9.0 Hz, 2 H), 7.74-7.86(m, 6 H) 1-7 (DMSO-d6-300)1.50 (dd, J = 6.0, 9.0 Hz, 1 H),1.88-1.97 (m, 1 H), 2.57-2.66 (m,1 H), 7.12-7.26 (m, 5 H),7.57 (dd, J = 3.0, 6.0 Hz, 2 H),7.78 (dd, J = 3.0, 6.0 Hz, 2 H),7.85 (br, 4 H) 1-8 (DMSO-d6-300)1.18-1.26 (m, 1 H), 1.31-1.41 (m,1 H), 1.58-1.71 (m, 1 H), 2.69-2.78(m, 2 H), 7.13-7.32 (m,5 H), 7.58 (brd, J = 9.0 Hz,2 H), 7.74-7.81 (m, 4 H), 7.85 (brd,J = 9.0, Hz, 2 H) 1-9 (DMSO-d6-300)0.60 (dd, J = 3.0, 9.0 Hz, 1 H),0.67 (dd, J = 3.0, 6.0 Hz, 1 H),0.82 (dd, J = 6.0, 9.0 Hz, 1 H),2.73 (t, J = 7.5 Hz, 2 H), 7.16-7.32(m, 5 H), 7.58 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 4 H),7.86 (d, J = 9.0 Hz, 2 H) 1-10 (CDCL3-400)1.81-1.93 (m, 1 H), 1.96-2.05 (m,1 H), 2.81 (t, J = 8.0 Hz, 1 H),5.84 (brs, 1 H), 6.76-6.85 (m,2 H), 6.87-6.94 (m, 3 H), 7.07 (t,J = 8.0 Hz, 1 H), 7.14 (t, J = 8.0 Hz,1 H), 7.28 (d, J = 8.0 Hz, 2 H),7.43 (d, J = 8.0 Hz, 2 H), 7.50 (d,J = 8.0 Hz, 2 H), 7.61 (d, J = 8.0 Hz,2 H), 7.88 (d, J = 8.0 Hz, 2 H)

TABLE 1-3 Example Structural formula NMR 1-11 (DMSO-d6-300)1.48-1.56 (m, 1 H), 1.84-1.93 (m,1 H), 2.56-2.65 (m, 1 H),6.81 (br, 2 H), 6.95 (d, J = 9.0 Hz,2 H), 6.97-7.03 (m, 1 H), 7.25 (t,J = 9.0 Hz, 1 H), 7.39 (d, J = 9.0 Hz,2 H), 7.57 (dd, J = 3.0, 9.0 Hz,2 H), 7.77 (dd, J = 3.0, 9.0 Hz,2 H), 7.83 (br, 4 H), 7.89 (d,J = 3.0 Hz, 1 H) 1-12 (DMSO-d6-300)1.45 (dd, J = 6.0, 12.0 Hz, 1 H),1.93 (dd, J = 6.0, 9.0 Hz, 1 H),2.64 (t, J = 10.5 Hz, 1 H), 3.69 (s,3 H), 6.72-6.81 (m, 3 H), 7.15 (t,J = 7.5 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.83-7.91 (m, 4 H) 1-13 (DMSO-d6-300)1.50-1.62 (m, 1 H), 1.79-1.92 (m,1 H), 2.42-2.55 (m, 1 H), 3.74 (s,3 H), 6.78 (t, J = 7.5 Hz, 1 H),6.87 (d, J = 9.0 Hz, 1 H), 6.99 (d,J = 9.0 Hz, 1 H), 7.14 (t, J = 7.5 Hz,1 H), 7.57 (d, J = 9.0 Hz, 2 H),7.78 (d, J = 9.0 Hz, 2 H), 7.87 (s,4 H) 1-14 (DMSO-d6-300)1.49 (dd, J = 5.7, 9.4 Hz, 1 H),1.97 (dd, J = 5.7, 8.7 Hz, 1 H),2.59 (dd, J = 8.7, 9.4 Hz, 1 H),6.69 (d, J = 7.9 Hz, 1 H), 6.94-7.04(m, 3 H), 7.09-7.22 (m, 3 H),7.38 (dd, J = 7.5, 8.3 Hz, 2 H),7.57 (d, J = 8.7 Hz, 2 H), 7.77 (d,J = 8.3 Hz, 2 H), 7.85 (s, 4 H),8.83 (s, 1 H), 12.20 (s, 1 H). 1-15 (DMSO-d6-300)1.43 (dd, J = 5.7, 9.4 Hz, 1 H),1.92 (dd, J = 5.7, 8.7 Hz, 1 H),2.61 (dd, J = 8.7, 9.4 Hz, 1 H),3.69 (s, 3 H), 6.81 (d, J = 8.7 Hz,2 H), 7.12 (d, J = 8.7 Hz, 2 H),7.57 (d, J = 8.3 Hz, 2 H), 7.78 (d,J = 8.6 Hz, 2 H), 7.87 (s, 4 H),8.90 (s, 4 H), 12.05 (s, 4 H).

TABLE 1-4 Example Structural formula NMR 1-16 (DMSO-d6-300)1.50 (dd, J = 6.0, 9.0 Hz, 1 H),1.92 (dd, J = 6.0, 9.0 Hz, 1 H),2.57-2.67 (m, 1 H), 6.87 (d,J = 9.0 Hz, 2 H), 6.94 (d, J = 9.0 Hz,2 H), 7.12 (t, J = 7.5 Hz, 1 H),7.20 (d, J = 9.0 Hz, 2 H), 7.31-7.41(m, 2 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.87 (s, 4 H) 1-17 (CDCL3-300)2.08-2.20 (m, 2 H), 3.01 (t,J = 9.0 Hz, 1 H), 5.79 (brs, 1 H),7.39-7.59 (m, 3 H), 7.69 (d,J = 9.0 Hz, 2 H), 7.96 (d, J = 9.0 Hz,2 H), 8.03-8.11 (m, 2 H) 1-18 (DMSO-d6-300)1.37 (dd, J = 6.0, 12.0 Hz, 1 H),1.81 (dd, J = 3.0, 9.0 Hz, 1 H),2.45-2.54 (m, 1 H), 4.93 (brs,1 H), 6.32-6.45 (m, 3 H), 6.85 (t,J = 7.5 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.74-7.90 (m, 4 H), 8.92 (brs,1 H) 1-19 (DMSO-d6-300)1.04-1.84 (m, 8 H), 2.60-2.95 (m,2 H), 3.15-3.28 (m, 2 H), 7.58 (d,J = 9.0 Hz, 2 H), 7.74-7.91 (m,6 H), 8.36-8.87 (m, 3 H),12.60 (brs, 1 H) 1-20 (DMSO-d6-300)0.93 (d, J = 6.0 Hz, 6 H), 1.55 (dd,J = 6.0, 9.0 Hz, 1 H), 1.76 (dd,J = 6.0, 9.0 Hz, 1 H), 1.88-1.99(m, 1 H), 2.41 (t, J = 9.0 Hz,1 H), 3.61 (d, J = 6.0 Hz, 2 H),6.62-6.70 (m, 3 H), 7.04 (t,J = 7.5 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.77 (d, J = 9.0 Hz, 2 H),7.84 (d, J = 9.0 Hz, 2 H), 7.87 (d,J = 9.0 Hz, 2 H)

TABLE 1-5 Example Structural formula NMR 1-21 (DMSO-d6-300)1.42 (dd, J = 3.0, 9.0 Hz, 1 H),1.90 (dd, J = 6.0, 9.0 Hz, 1 H),2.61 (t, J = 9.0 Hz, 1 H), 2.83 (s,6 H), 6.47-6.58 (m, 3 H), 7.03 (t,J = 7.5 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.82-7.91 (m, 4 H), 8.91 (brs,1 H), 12.05 (brs, 1 H) 1-22 (DMSO-d6-300)1.58 (dd, J = 6.0, 9.0 Hz, 1 H),2.07 (dd, J = 6.0, 9.0 Hz, 1 H),2.81 (t, J = 9.0 Hz, 1 H), 7.48-7.60(m, 4 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.87 (s, 4 H), 8.96 (brs, 1 H),12.26 (brs, 1 H) 1-23 (DMSO-d6-300)1.52 (dd, J = 5.7, 9.8 Hz, 1 H),2.00 (dd, J = 5.7, 8.7 Hz, 1 H),2.71 (dd, J = 8.7, 9.8 Hz, 1 H),7.19-7.26 (m, 2 H), 7.35-7.41 (m,2 H), 7.57 (d, J = 8.3 Hz, 2 H),7.78 (d, J = 8.7 Hz, 2 H), 7.87 (s,4 H), 8.93 (s, 1 H), 12.27 (s,1 H). 1-24 (DMSO-d6-300)0.92 (d, J = 6.8 Hz, 6 H), 1.47 (dd,J = 5.3, 9.4 Hz, 1 H), 1.90 (dd,J = 5.3, 8.7 Hz, 1 H), 2.00-2.12(m, 1 H), 2.16 (d, J = 6.8 Hz,2 H), 2.66 (dd, J = 8.7, 9.4 Hz,1 H), 6.86 (d, J = 7.2 Hz, 1 H),7.14 (dd, J = 7.5, 8.3 Hz, 1 H),7.44 (d, J = 8.3 Hz, 1 H), 7.47 (d,1 H), 7.57 (d, J = 8.7 Hz, 2 H),7.78 (d, J = 8.7 Hz, 2 H), 7.87 (s,4 H), 8.96 (s, 1 H), 9.78 (s, 1 H),12.12 (s, 1 H). 1-25 (DMSO-d6-300)1.46 (dd, J = 5.7, 9.4 Hz, 1 H),1.88 (dd, J = 5.7, 8.7 Hz, 1 H),2.65 (dd, J = 8.7, 9.4 Hz, 1 H),6.43 (s, 1 H), 6.64 (s, 2 H),6.99 (d, J = 7.5 Hz, 4 H), 7.14 (t,J = 7.5 Hz, 2 H), 7.38 (t, J = 7.5 Hz,4 H), 7.57 (d, J = 8.6 Hz, 2 H),7.73-7.89 (m, 6 H), 8.88 (s, 1 H),12.29 (s, 1 H)

TABLE 1-6 Example Structural formula NMR 1-26 (DMSO-d6-300)1.56 (dd, J = 6.0, 12.0 Hz, 1 H),1.96 (dd, J = 6.0, 9.0 Hz, 1 H),2.65 (t, J = 9.0 Hz, 1 H),7.17 (brd, J = 9.0 Hz, 1 H), 7.25-7.37 (m, 2 H), 7.39-7.46 (m, 4 H),7.53-7.59 (m, 4 H), 7.76 (d,J = 9.0 Hz, 2 H), 7.85 (d, J = 9.0 Hz,2 H), 7.88 (d, J = 9.0 Hz, 2 H) 1-27 (DMSO-d6-300)1.55 (dd, J = 6.0, 9.0 Hz, 1 H),1.55 (dd, J = 6.0, 9.0 Hz, 1 H),1.73 (dd, J = 3.0, 6.0 Hz, 1 H),2.40 (t, J = 9.0 Hz, 1 H), 5.12 (s,2 H), 6.75 (d, J = 9.0 Hz, 1 H),7.04 (t, J = 9.0 Hz, 1 H), 7.20-7.43 (m, 6 H), 7.56 (d, J = 9.0 Hz,2 H), 7.77 (d, J = 9.0 Hz, 2 H),7.84 (d, J = 9.0 Hz, 2 H), 7.88 (d,J = 9.0 Hz, 2 H), 9.61 (s, 1 H) 1-28 (DMSO-d6-300)0.92 (d, J = 6.0 Hz, 6 H), 1.44 (dd,J = 6.0, 9.0 Hz, 1 H), 1.89 (dd,J = 6.0, 12.0 Hz, 1 H), 2.66 (t,J = 9.0 Hz, 1 H), 3.85 (d, J = 6.0 Hz,2 H), 6.83 (d, J = 9.0 Hz, 1 H),7.13 (t, J = 7.5 Hz, 1 H), 7.28 (d,J = 9.0 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.87 (s, 4 H), 8.97 (s, 1 H),9.55 (s, 1 H) 1-29 (METHANOL-d4-400)1.84 (dd, J = 6.0, 9.0 Hz, 1 H),2.09 (dd, J = 6.0, 9.0 Hz, 1 H),2.77 (t, J = 9.0 Hz, 1 H), 7.11-7.25 (m, 5 H), 7.39 (t, J = 6.0 Hz,1 H), 7.46 (t, J = 6.0 Hz, 2 H),7.67 (d, J = 6.0 Hz, 2 H), 7.78 (d,J = 6.0 Hz, 2 H), 7.95 (d, J = 6.0 Hz,2 H) 1-30 (METHANOL-d4-400)1.84 (dd, J = 8.0, 4.0 Hz, 1 H),2.07 (dd, J = 4.0, 8.0 Hz, 1 H),2.76 (t, J = 8.0 Hz, 1 H), 7.03 (d,J = 8.0 Hz, 2 H), 7.07 (d, J = 8.0 Hz,2 H), 7.13-7.26 (m, 6 H), 7.41 (t,J = 8.0 Hz, 2 H), 7.84 (d, J = 8.0 Hz,2 H)

TABLE 1-7 Example Structural formula NMR 1-31 (METHANOL-d4-400)1.83 (dd, J = 4.0, 8.0 Hz, 1 H),2.08 (dd, J = 8.0, 4.0 Hz, 1 H),2.77 (t, J = 8.0 Hz, 1 H), 7.11-7.28 (m, 5 H), 7.57-7.65 (m, 4 H),7.78 (d, J = 8.0 Hz, 2 H), 7.95 (d,J = 8.0 Hz, 2 H) 1-32 (DMSO-d6-300)1.63 (dd, J = 6.0, 9.0 Hz, 1 H),2.04 (dd, J = 6.0, 9.0 Hz, 1 H),2.75 (t, J = 9.0 Hz, 1 H), 7.10-7.27 (m, 5 H), 7.70 (d, J = 3.0 Hz,1 H), 7.94 (d, J = 3.0 Hz, 1 H) 1-33 (ACETONE-d6-400)1.86 (dd, J = 8.0, 4.0 Hz, 1 H),2.13 (dd, J = 4.0, 8.0 Hz, 1 H),2.85 (t, J = 8.0 Hz, 1 H), 4.48 (s,3 H), 7.14-7.30 (m, 5 H), 8.06 (d,J = 8.0 Hz, 2 H), 8.27 (d, J = 8.0 Hz,2 H) 1-34 (ACETONE-d6-400)1.67 (t, J = 8.0 Hz, 3 H), 1.86 (dd,J = 4.0, 8.0 Hz, 1 H), 2.13 (dd,J = 4.0, 8.0 Hz, 1 H), 2.82 (t,J = 8.0 Hz, 1 H), 4.81 (q, J = 8.0 Hz,2 H), 7.13-7.30 (m, 5 H), 8.06 (d,J = 8.0 Hz, 2 H), 8.28 (d, J = 8.0 Hz,2 H) 1-35 (METHANOL-d4-400)1.24 (t, J = 6.0 Hz, 3 H), 1.87 (dd,J = 8.0, 4.0 Hz, 1 H), 2.02-2.13 (m, 3 H), 2.76 (t, J = 8.0 Hz,1 H), 4.70 (t, J = 6.0 Hz, 3 H),7.12-7.26 (m, 5 H), 8.03 (d,J = 8.0 Hz, 2 H), 8.27 (d, J = 8.0 Hz,2 H)

TABLE 1-8 Example Structural formula NMR 1-36 (METHANOL-d4-400)1.69 (d, J = 6.7 Hz, 6 H), 1.87 (dd,J = 9.8, 5.9 Hz, 1 H), 2.10 (dd,J = 8.6, 5.5 Hz, 1 H), 2.7 (t,J = 9.2 Hz, 1 H), 5.19 (Septet,J = 6.7 Hz, 1 H), 7.11-7.27 (m,5 H), 8.01-8.06 (m, 2 H), 8.25-8.29 (m, 2 H) 1-37 (METHANOL-d4-400)1.91 (dd, J = 9.8, 5.5 Hz, H 1),2.11 (dd, J = 8.6, 5.5 Hz, 1 H),2.80 (t, J = 9.0 Hz, 1 H) 7.10-7.25 (m, 4 H), 7.43 (t, J = 8.1 Hz,1 H), 7.53-7.58 (m, 1 H), 7.62-7.66 (m, 1 H), 7.72 (d, J = 9.4 Hz,1 H), 8.01-8.05 (m, 1 H), 8.08-8.14 (m, 2 H), 8.57-8.60 (m, 1 H) 1-38 (DMSO-d6-300)1.49 (dd, J = 5.2, 9.8 Hz, 1 H),1.92 (dd, J = 5.2, 9.0 Hz, 1 H),2.69 (dd, J = 9.0, 9.8 Hz, 1 H),2.92 (s, 3 H), 6.96 (d, J = 7.9 Hz,1 H), 7.01 (d, J = 7.9 Hz, 1 H),7.11 (s, 1 H), 7.20 (t, J = 7.9 Hz,1 H) , 7.57 (d, J = 8.7 Hz, 2 H),7.78 (d, J = 8.6 Hz, 2 H), 7.87 (s,4 H), 8.99 (s, 1 H), 9.67 (s, 1 H),12.17 (s, 1 H) 1-39 (DMSO-d6-300)1.62 (dd, J = 6.0, 9.0 Hz, 1 H),2.03 (dd, J = 6.0, 9.0 Hz, 1 H),2.75 (t, J = 9.0 Hz, 1 H), 7.11-7.27 (m, 5 H), 7.70 (d, J = 3.0 Hz,1 H), 7.94 (d, J = 3.0 Hz, 1 H) 1-40 (DMSO-d6-300)1.46 (dd, J = 6.0, 9.0 Hz, 1 H),1.89 (dd, J = 6.0, 9.0 Hz, 1 H),2.01 (s, 3 H), 2.64 (t, J = 9.0 Hz,1 H), 6.86 (d, J = 9.0 Hz, 1 H),7.14 (t, J = 7.5 Hz, 1 H), 7.38-7.46 (m, 2 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.87 (s, 4 H), 8.93 (brs, 1 H),9.86 (s, 1 H), 12.13 (brs, 1 H)

TABLE 1-9 Example Structural formula NMR 1-41 (DMSO-d6-300)1.46 (dd, J = 6.0, 9.0 Hz, 1 H),1.88 (dd, J = 6.0, 9.0 Hz, 1 H),2.64 (t, J = 9.0 Hz, 1 H), 3.64 (s,3 H), 6.83 (d, J = 9.0 Hz, 1 H),7.13 (t, J = 7.5 Hz, 1 H), 7.27 (d,J = 9.0 Hz, 1 H), 7.35 (s, 1 H),7.57 (d, J = 9.0 Hz, 2 H), 7.78 (d,J = 9.0 Hz, 2 H), 7.87 (s, 4 H),8.95 (brs, 1 H), 9.57 (s, 1 H),12.11 (brs, 1 H) 1-42 (DMSO-d6-300)1.12-1.26 (m, 2 H), 1.34-1.39 (m, 2 H), 1.40(s, 9 H), 1.80-1.89 (m, 2 H) 2.56 (t,J = 9.0, 1 H), 2.80-2.96 (m, 2 H), 3.27-3.35 (m, 1 H), 3.81-3.89 (m, 2 H), 5.36-5.43 (m, 1 H), 6.36-6.43 (m, 3 H), 6.92 (t,J = 7.5 Hz, 1 H),7.58 (d,J = 9.0 Hz, 2 H), 7.79 (d,J = 9.0 Hz, 2 H),7.86 (d J = 9.0 Hz, 2 H),7.89 (d, J = 9.0Hz, 2 H) 8.91 (s,1 H), 12.07 (s, 1 H) 1-43 (DMSO-d6-300)1.35 (dd, J = 6.0, 9.0 Hz, 1 H),1.83 (dd, J = 6.0, 9.0 Hz, 1 H),2.53 (t, J = 9.0 Hz, 1 H), 4.20 (d,J = 3.0 Hz, 2 H), 6.12 (t, J = 6.0 Hz,1 H), 6.37 (t, J = 6.0 Hz, 2 H),6.49 (s, 1 H), 6.89 (t, J = 7.5 Hz,1 H), 7.17-7.25 (m, 1 H), 7.26-7.36 (m, 4 H), 7.26-7.36 (m, 4 H),7.57 (d, J = 9.0 Hz, 2 H), 7.78 (d,J = 9.0 Hz, 2 H), 8.90 (brs, 1 H),12.07 (brs, 1 H) 1-44 (DMSO-d6-300)1.42 (dd, J = 6.0, 9.0 Hz, 1 H),1.87 (dd, J = 6.0, 9.0 Hz, 1 H),2.59 (t, J = 9.0 Hz, 1 H), 6.57 (d,J = 9.0 Hz, 1 H), 6.63 (m, 2 H),7.01 (t, J = 9.0 Hz, 1 H), 7.57 (d,J = 9.0 Hz, 2 H), 7.78 (d, J = 9.0 Hz,2 H), 7.84-7.90 (m, 4 H) 1-45 (DMSO-d6-300)0.94-1.29 (m, 9 H), 1.49-1.70 (m,5 H), 7.54-7.61 (m, 2 H), 7.72-7.90 (m, 6 H), 8.53-8.74 (m, 1 H)

TABLE 1-10 Example Structural formula NMR 1-46 (ACETONE-d6-500)1.84-1.92 (m, 1 H), 2.13-2.20 (m,1 H), 2.83-2.89 (m, 1 H), 7.13-7.30 (m, 6 H), 7.80-7.92 (m, 1 H),8.03-8.08 (m, 3 H), 8.22-8.33 (m,3 H) 1-47 (METHANOL-d4-400)1.48-1.56 (m, 1 H), 1.83-1.90 (m,1 H), 2.31-2.38 (m, 1 H), 7.02-7.08 (m, 1 H), 7.09-7.16 (m, 3 H),7.18-7.22 (m, 2 H), 7.43-7.47 (m,1 H), 7.49-7.52 (m, 1 H), 7.71-7.77 (m, 2 H), 7.71-7.77 (m, 2 H) 1-48 (ACETONE-d6-400)1.83-1.89 (m, 1 H), 1.96 (s, 3 H),2.09-2.15 (m, 1 H), 2.82-2.89 (m,1 H), 7.14-7.30 (m, 6 H), 7.45-7.48 (m, 1 H), 7.71-7.73 (m, 1 H),7.78-7.83 (m, 2 H), 7.88-7.94 (m,2 H) 1-49 (METHANOL-d4-400)1.33 (dd, J = 9.4, 5.1 Hz, 1 H),1.81 (dd, J = 7.6, 5.1 Hz, 1 H),2.30 (t, J = 8.8 Hz, 1 H), 7.01-7.07 (m, 1 H), 7.09-7.16 (m, 2 H),7.18-7.24 (m, 2 H), 7.40-7.44 (m,1 H), 7.50-7.54 (m, 1 H), 7.72-7.78 (m, 2 H), 7.86-7.93 (m, 2 H) 1-50 (ACETONE-d6-400)1.90 (dd, J = 9.8, 5.9 Hz, 1 H),2.11 (dd, J = 8.6, 5.5 Hz, 1 H),2.82 (t, J = 9.2 Hz, 1 H), 7.10-7.29 (m, 5 H), 7.47-7.52 (m, 1 H),7.64-7.73 (m, 2 H), 7.86-7.94 (m,2 H), 8.02-8.06 (m, 1 H), 8.08-8.13 (m, 1 H)

TABLE 1-11 Example Structural formula NMR 1-51 (DMSO-d6-300)0.99-1.64 (m, 17 H), 2.55-2.78 (m, 2 H), 3.76-3.98 (m, 2 H),7.57 (d, J = 6.0 Hz, 2 H), 7.78 (d,J = 9.0 Hz, 2 H), 7.80 (d, J = 9.0 Hz,2 H), 7.87 (d, J = 9.0 Hz, 2 H),8.64 (brs, 1 H), 12.55 (brs, 1 H) 1-52 (DMSO-d6-300)1.45 (dd, J = 9.5, 4.9 Hz, 1 H),1.77-1.85 (m, 1 H), 2.51-2.61 (m,7.09 (m, 2 H), 7.45-7.63 (m, 6 H),7.68-7.81 (m, 5 H), 7.86 (s, 4 H) 1-53 (MeOH-d4-400)1.83 (dd, J = 9.8, 5.5 Hz, 1 H),2.09 (dd, J = 8.6, 5.9 Hz, 1 H),2.77 (t, J = 9.2 Hz, 1 H), 3.83 (s,3 H), 7.00-7.04 (m, 2 H), 7.14-7.28 (m, 5 H), 7.61-7.66 (m, 2 H),7.73-7.77 (m, 2 H), 7.89-7.93 (m,2 H) 1-54 (ACETONE-d6-400)1.88 (dd, J = 9.8, 5.5 Hz, 1 H),2.10 (dd, J = 8.6, 5.9 Hz, 1 H),2.80 (t, J = 9.2 Hz, 1 H), 7.12-7.27 (m, 5 H), 7.38-7.48 (m, 2 H),7.63-7.68 (m, 1 H), 7.69-7.83 (m,1 H), 7.91-8.03 (m, 3 H), 8.08 (s,1 H) 1-55 (ACETONE-d6-400)1.83 (dd, J = 4.0, 8.0 Hz, 1 H),2.11 (dd, J = 4.0, 8.0 Hz, 1 H),2.68 (s, 3 H), 2.86 (t, J = 10.0 Hz,1 H), 7.12-7.28 (m, 5 H), 8.04 (d,J = 8.0 Hz, 2 H), 8.19 (d, J = 8.0 Hz,2 H)

TABLE 1-12 Example Structural formula NMR 1-56 (ACETONE-d6-400)1.85 (dd, J = 8.0, 12.0 Hz, 1 H),2.08-2.13 (m, 1 H), 2.81 (t,J = 10.0 Hz, 1 H), 7.12-7.26 (m,5 H), 7.64-7.77 (m, 3 H), 8.08 (d,J = 8.0 Hz, 2 H), 8.24 (d, J = 8.0 Hz,2 H), 8.30 (d, J = 8.0 Hz, 2 H) 1-57 (ACETONE-d6-400)1.94 (dd, J = 4.0, 8.0 Hz, 1 H),2.17 (dd, J = 4.0, 8.0 Hz, 1 H),2.91 (t, J = l0.0 Hz, 1 H), 7.15-7.31 (m, 5 H), 7.38-7.49 (m, 4 H),7.61 (dd, J = 1.0, 4.0 Hz, 1 H),7.71 (dt, J = 8.0, 1.0 Hz, 2 H),7.95 (brs, 1 H) 1-58 (DMSO-d6-300)1.85 (dd, J = 6.0, 9.0 Hz, 1 H),1.96 (dd, J = 6.0, 9.0 Hz, 1 H),2.77 (t, J = 9.0 Hz, 1 H), 6.61-6.71 (m, 2 H), 6.81 (d, J = 6.0 Hz,1 H), 7.01-7.09 (m, 1 H), 7.58 (d,J = 9.0 Hz, 2 H), 7.71-7.90 (m,7 H), 9.45 (brs, 1 H), 12.39 (brs,1 H) 1-59 (ACETONE-d6-400)1.86 (dd, J = 4.0, 8.0 Hz, 1 H),2.05-2.09 (m, 1 H), 2.78 (t,J = 10.0 Hz, 1 H), 7.13-7.26 (m,5 H), 7.62-7.68 (m, 3 H), 8.10 (d,J = 8.0 Hz, 2 H), 8.20 (dd, J = 4.0,8.0 Hz, 2 H), 8.32 (d, J = 8.0 Hz,2 H) 1-60 (CDCL3-400)2.13-2.22 (m, 2 H), 2.98 (t,J = 10.0 Hz, 1 H), 5.93 (s, 1 H),6.94 (d, J = 4.0 Hz, 1 H), 7.17-7.22 (m, 2 H), 7.24-7.33 (m, 3 H),7.36 (d, J = 4.0 Hz, 1 H)

TABLE 1-13 Example Structural formula NMR 1-61 (DMSO-d6-300)1.45 (dd, J = 5.2, 9.4 Hz, 1 H),1.92 (dd, J = 5.2, 8.7 Hz, 1 H),2.67 (dd, J = 8.7, 9.4 Hz, 1 H),6.68-6.76 (m, 2 H), 6.82 (d,J = 8.3 Hz, 1 H), 7.12 (t, J = 7.9 Hz,1 H), 7.42 (s, 1 H), 7.49-7.61 (m,2 H), 7.57 (d, J = 8.7 Hz, 2 H),7.78 (d, J = 8.7 Hz, 2 H), 7.88 (s,4 H), 8.13 (dd, J = 1.1, 4.9 Hz,1 H), 8.93 (s, 1 H), 8.96 (s, 1 H),12.13 (s, 1 H) 1-62 (DMSO-d6-300)1.47-1.57 (m, 1 H), 1.83-1.95 (m,1 H), 2.54-2.65 (m, 1 H), 6.96 (d,J = 9.0 Hz, 1 H), 7.19 (t, J = 7.5 Hz,1 H), 7.55 (d, J = 9.0 Hz, 2 H),7.64-7.73 (m, 3 H), 7.77 (d,J = 9.0 Hz, 2 H), 7.83-7.93 (m,4 H), 8.07 (t, J = 7.5 Hz, 1 H),8.15 (d, J = 9.0 Hz, 1 H), 8.70-8.74 (m, 1 H), 10.45 (brs, 1 H) 1-63 (DMSO-d6-300)1.51 (dd, J = 6.0, 9.0 Hz, 1 H),1.95 (dd, J = 6.0, 9.0 Hz, 1 H),2.73 (t, J = 9.0 Hz, 1 H), 6.99 (d,J = 9.0 Hz, 1 H), 7.25 (t, J = 7.5 Hz,1 H), 7.57 (d, J = 9.0 Hz, 2 H),7.59 (t, J = 9.0 Hz, 1 H), 7.70 (s,1 H), 7.78 (d, J = 9.0 Hz, 2 H),7.84 (d, J = 6.0 Hz, 2 H), 7.86-7.91 (m, 4 H), 8.78 (d, J = 6.0 Hz,2 H), 8.99 (s, 1 H), 10.46 (s,1 H), 12.16 (brs, 1 H) 1-64 (DMSO-d6-400)1.51 (dd, J = 9.5, 4.6 Hz, 1 H),1.89-1.95 (m, 1 H), 2.60-2.72 (m,1 H), 6.95 (d, J = 8.3 Hz, 1 H),7.21 (t, J = 8.3 Hz, 1 H), 7.49-7.78 (m, 8 H), 7.87 (s, 4 H),8.24-8.28 (m, 1 H), 8.74 (dd,J = 4.9, 1.6 Hz, 1 H), 9.07 (d,J = 1.9 Hz, 1 H), 10.39 (s, 1 H) 1-65 (DMSO-d6-300)1.42 (dd, J = 5.4, 9.3 Hz, 1 H),1.92 (t, J = 7.4 Hz, 1 H), 2.63 (t,J = 9.4 Hz, 1 H), 5.22 (s, 2 H),7.10-7.29 (m, 7 H), 7.49 (dd,J = 2.1, 8.1 Hz, 1 H), 7.64 (d,J = 8.1 Hz, 1 H), 7.71 (d, J = 2.1 Hz,1 H), 7.74 (d, J = 9.0 Hz, 2 H),8.71 (brs, 1 H), 12.07 (brs, 1 H)

TABLE 1-14 Example Structural formula NMR 1-66 (DMSO-d6-300)1.41-1.50 (m, 1 H), 1.88-1.97 (m,1 H), 2.64 (t, J = 9.0 Hz, 1 H),3.64 (br, 2 H), 3.86 (br, 2 H),4.78 (br, 1 H), 6.71-6.80 (m,3 H), 7.14 (t, J = 7.5 Hz, 1 H),7.57 (d, J = 6.0 Hz, 2 H), 7.78 (d,J = 6.0 Hz, 2 H), 7.83 (br, 4 H),8.81 (br, 1 H) 1-67 (DMSO-d6-300)1.39-1.55 (m, 1 H), 1.86-1.96 (m,1 H), 2.26 (s, 6 H), 2.58-2.68 (m,1 H), 3.03 (s, 2 H), 6.85-6.90 (m,1 H), 7.15 (t, J = 7.5 Hz, 1 H),7.45-7.72 (m, 5 H), 7.75-7.81 (m,2 H), 7.87 (s, 4 H), 9.60 (s, 1 H) 1-68 (DMSO-d6-300)1.51-1.59 (m, 1 H), 1.70-1.79 (m,1 H), 2.39-2.52 (m, 1 H), 6.75-6.88 (m, 2 H), 6.99 (d, J = 9.0 Hz,1 H), 7.20 (t, J = 9.0 Hz, 1 H),7.31-7.40 (m, 2 H), 7.55 (d,J = 6.0 Hz, 2 H), 7.75 (d, J = 6.0 Hz,2 H), 7.83 (d, 3 = 9.0 Hz, 2 H),7.89 (d, J = 9.0 Hz, 2 H), 8.28-8.32 (m, 2 H) 1-69 (ACETONE-d6-400)1.96 (dd, J = 4.0, 8.0 Hz, 1 H),2.19 (dd, J = 4.0, 8.0 Hz, 1 H),2.92 (t, J = 8.0 Hz, 1 H), 7.15-7.33 (m, 5 H), 7.47-7.54 (m, 3 H),7.62 (d, J = 4.0 Hz, 1 H), 7.74 (d,J = 8.0 Hz, 2 H), 8.00 (s, 1 H) 1-70 (ACETONE-d6-400)1.95 (dd, J = 8.0, 12.0 Hz, 1 H),2.17 (dd, J = 8.0, 12.0 Hz, 1 H),2.91 (t, J = 10.0 Hz, 1 H), 3.85 (s,3 H), 7.02 (d, J = 8.0 Hz, 2 H),7.15-7.34 (m, 6 H), 7.57 (d,J = 4.0 Hz, 1 H), 7.64 (d, J = 8.0 Hz,2 H), 7.86 (s, 1 H)

TABLE 1-15 Example Structural formula NMR 1-71 (ACETONE-d6-400)1.95 (dd, J = 8.0, 8.0 Hz, 1 H),2.18 (dd, J = 8.0, 8.0 Hz, 1 H),2.93 (t, J = 10.0 Hz, 1 H), 3.17 (s,6 H), 7.15-7.33 (m, 5 H), 7.53 (d,J = 4.0 Hz, 18), 7.63 (d, J = 8.0 Hz,1 H), 7.87 (d, J = 12.0 Hz, 2 H),7.92 (d, J = 8.0 Hz, 2 H) 1-72 (DMSO-d6-300)1.50 (dd, J = 6.0, 9.0 Hz, 1 H),1.96 (dd, J = 6.0, 9.0 Hz, 1 H),2.68 (t, J = 9.0 Hz, 1 H), 4.05 (s,7.64 (dd, J = 3.0, 9.0 Hz, 1 H),7.83 (dd, J = 3.0, 9.0 Hz, 1 H),7.87 (d, J = 3.0 Hz, 1 H), 7.98 (d,J = 9.0 Hz, I H), 8.00 (d, J = 3.0 Hz,1 H), 8.10 (d, J = 6.0 Hz, 1 H),8.88 (brs, 1 H), 12.04 (brs, 1 H) 1-73 (DMSO-d6-300)1.47 (dd, J = 6.0, 9.0 Hz, 1 H),1.72 (br, 4 H), 1.95 (dd, J = 6.0,9.0 Hz, 1 H), 2.65 (t, J = 9.0 Hz,1 H), 2.76 (br, 4 H), 3.01 (br,2 H), 4.08 (t, J = 4.5 Hz, 2 H),6.74-6.85 (m, 3 H), 7.16 (t,J = 7.5 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.85 (br, 4 H), 8.83 (br, 1 H) 1-74 (DMSO-d6-300)1.58-1.71 (m, 2 H), 2.26 (t,J = 9.0 Hz, 1 H), 2.41 (t, J = 6.0 Hz,4 H), 2.57 (t, J = 6.0 Hz, 2 H),3.55 (t, J = 4.5 Hz, 4 H), 3.91 (t,J = 6.0 Hz, 2 H), 6.97 (t, J = 9.0 Hz,1 H), 7.57 (d, J = 9.0 Hz, 2 H),7.75-7.93 (m, 7 H) 1-75 (DMSO-d6-300)1.54 (dd, J = 6.0, 9.0 Hz, 1 H),1.77-1.87 (m, 1 H), 4.23 (t,J = 4.5 Hz, 2 H), 4.44 (t, J = 4.5 Hz,2 H), 6.22 (t, J = 3.0 Hz, 1 H),6.63-6.76 (m, 3 H), 7.07 (t,J = 7.5 Hz, 1 H), 7.44 (dd, J = 0.0,0.0 Hz, 1 H), 7.56 (d, J = 9.0 Hz,2 H), 7.74 (d, J = 3.0 Hz, 1 H),7.77 (d, J = 9.0 Hz, 2 H), 7.81-7.89 (m, 4 H)

TABLE 1-16 Example Structural formula NMR 1-76 (DMSO-d6-300)1.47 (dd, J = 6.0, 9.0 Hz, 1 H),1.97 (dd, J = 6.0, 9.0 Hz, 1 H),2.68 (t, J = 9.0 Hz, 1 H), 5.15 (s,2 H), 6.82-6.91 (m, 3 H), 7.19 (t,J = 9.0 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.66 (dd, J = 6.0, 9.0 Hz,1 H), 7.78 (d, J = 9.0 Hz, 2 H),7.85-7.92 (m, 4 H), 8.12 (d,J = 9.0 Hz, 1 H), 8.67 (d, J = 6.0 Hz,1 H), 8.78 (s, 1 H), 8.94 (s, 1 H),11.91-12.38 (m, 1 H) 1-77 (DMSO-d6-400)1.44 (dd, J = 9.8, 5.2 Hz, 1 H),1.87 (dd, J = 8.2, 5.5 Hz, 1 H),2.28 (s, 3 H), 2.48-2.58 (m, 3 H),2.69-2.73 (m, 2 H), 3.36 (s, 2 H),6.75-6.79 (m, 1 H), 6.91 (s, 2 H),7.53-7.58 (m, 2 H), 7.71-7.80 (m,3 H), 7.85 (s, 4 H) 1-78 (DMSO-d6-400)0.99 (d, J = 6.5 Hz, 6 H), 1.45 (dd,J = 10.0, 5.1 Hz, 1 H), 1.78-1.84 (m, 1 H), 2.45-2.49 (m, 1 H),2.57-2.69 (m, 4 H), 2.72-2.83 (m,1 H), 3.46 (s, 2 H), 6.64-6.72 (m,1 H), 6.86 (s, 2 H), 7.52-7.58 (m,2 H), 7.71-7.79 (m, 3 H), 7.85 (s,4 H) 1-79 (DMSO-d6-400)1.47 (dd, J = 9.8, 4.7 Hz, 1 H),1.72-1.78 (m, 1 H), 2.37-2.44 (m,1 H), 2.56-2.62 (m, 2 H), 2.67-2.72 (m, 2 H), 3.36 (s, 2 H),3.56 (s, 2 H), 6.60-6.64 (m, 1 H),6.85 (s, 2 H), 7.21-7.27 (m, 1 H),7.29-7.33 (m, 4 H), 7.53-7.58 (m,2 H), 7.73-7.77 (m, 2 H), 7.80-7.87 (m, 5 H) 1-80 (ACETONE-d4-400)1.87 (dd, J = 5.9, 9.8 Hz, 1 H),2.11 (dd, J = 5.9, 8.7 Hz, 1 H),2.82 (dd, J = 8.7, 9.8 Hz, 1 H),4.05 (s, 2 H), 7.11-7.28 (m, 6 H),7.41-7.47 (m, 1 H), 7.65-7.74 (brs, 1 H), 7.90-7.94 (m,1 H), 7.98-8.03 (m, 2 H), 8.06-8.09 (m, 1 H)

TABLE 1-17 Example Structural formula NMR 1-81 (ACETONE-d4-400)2.01-2.06 (m, 1 H), 2.21 (dd,J = 5.9, 7.9 Hz, 1 H), 2.72 (dd,J = 7.9, 9.4 Hz, 1 H), 4.06 (s,2 H), 6.85 (s, 1 H), 7.14-7.20 (m,2 H), 7.20-7.30 (m, 4 H), 7.46 (d,J = 9.0 Hz, 1 H), 7.85 (d, J = 8.2 Hz,1 H), 7.96 (s, 1 H), 8.00 (d,J = 8.2 Hz, 1 H), 8.03 (dd, J = 8.6,5.5 Hz, 1 H) 1-82 (METHANOL-d4-400)1.42 (t, J = 7.5 Hz, 3 H), 1.76-1.88 (m, 1 H), 2.00-2.14 (m, 1 H),2.66-2.77 (m, 1 H), 3.09 (q,J = 7.5 Hz, 2 H), 7.10-7.30 (m,5 H), 7.85 (s, 1 H), 7.93 (d,J = 7.9 Hz, 2 H), 8.07 (d, J = 7.9 Hz,2 H) 1-83 (DMSO-d6-300)1.46 (dd, J = 6.0, 12.0 Hz, 1 H),1.95 (dd, J = 6.0, 9.0 Hz, 1 H),2.66 (t, J = 7.5 Hz, 1 H), 4.21 (t,J = 6.0 Hz, 2 H), 4.41 (t, J = 6.0 Hz,2 H), 6.72-6.84 (m, 3 H), 7.10-7.19 (m, 2 H), 7.39 (s, 1 H),7.57 (d, J = 9.0 Hz, 2 H), 7.78 (d,J = 9.0 Hz, 2 H), 7.82-7.91 (m,4 H), 8.13 (s, 1 H), 8.91 (s, 1 H) 1-84 (DMSO-d6-300)1.62-1.76 (m, 1 H), 1.93-2.05 (m,1 H), 2.62-2.74 (m, 1 H), 5.16 (s,2 H), 6.79 (t, J = 7.5 Hz, 1 H),6.86 (d, J = 9.0 Hz, 1 H), 7.02-7.14 (m, 2 H), 7.24-7.39 (m, 3 H),7.47-7.61 (m, 6 H), 7.76 (d,J = 9.0 Hz, 2 H), 8.91 (brs, 1 H),12.17 (brs, 1 H) 1-85 (ACETONE-d6-300)1.94 (dd, J = 6.0, 9.0 Hz, 1 H),2.16 (dd, J = 6.0, 9.0 Hz, 1 H),2.91 (t, J = 10.5 Hz, 1 H), 7.15-7.31 (m, 5 H), 7.44-7.52 (m, 3 H),7.61 (d, J = 3.0 Hz, 1 H), 7.74 (d,J = 9.0 Hz, 2 H), 7.95 (brs, 1 H)

TABLE 1-18 Example Structural formula NMR 1-86 (DMSO-d6-300)1.71 (dd, J = 6.0, 9.0 Hz, 1 H),1.78 (dd, J = 6.0, 9.0 Hz, 1 H),2.27 (t, J = 9.0 Hz, 1 H), 3.64 (t,J = 6.0 Hz, 2 H), 3.86 (t, J = 6.0 Hz,2 H), 6.61 (dd, J = 3.0, 9.0 Hz,1 H), 6.69-6.73 (m, 2 H), 7.00 (t,J = 9.0 Hz, 1 H), 7.52 (d, J = 9.0 Hz,2 H), 7.55 (d, J = 6.0 Hz, 1 H),7.59 (d, J = 6.0 Hz, 1 H) 1-87 (DMSO-d6-300)0.82 (dd, J = 3.0, 9.0 Hz, 1 H),0.99 (dd, J = 6.0, 9.0 Hz, 1 H),2.70 (t, J = 10.5 Hz, 1 H), 5.17 (s,2 H), 6.76-6.89 (m, 2 H), 7.02-7.14 (m, 2 H), 7.26-7.41 (m, 3 H),7.43-7.58 (m, 6 H), 7.60-7.67 (m,2 H), 8.98 (br, 1 H), 11.96 (br,1 H) 1-88 (DMSO-d6-300)1.63 (dd, J = 6.0, 9.0 Hz, 1 H),2.02 (dd, J = 6.0, 9.0 Hz, 1 H),2.77 (t, J = 9.0 Hz, 1 H), 6.88-6.96 (m, 2 H), 7.08 (d, J = 6.0 Hz,1 H), 7.28-7.44 (m, 3H), 7.49-7.59 (m, 4H), 7.75 (d, J = 9.0 Hz,2 H), 8.31-8.37 (m, 2H), 9.16 (s,1 H), 12.33 (brs, 1 H) 1-89 (DMSO-d6-300)1.71 (dd, J = 6.0, 9.0 Hz, 1 H),1.99 (dd, J = 6.0, 9.0 Hz, 1 H),2.70 (t, J = 9.0 Hz, 1 H), 7.11-7.27 (m, 5 H), 7.40 (t, J = 7.5 Hz,1 H), 7.54 (t, J = 7.5 Hz, 2 H),7.90 (d, J = 6.0 Hz, 2 H), 7.99 (s,1 H), 8.97 (s, 1 H), 12.01 (br,1 H) 1-90 (DMSO-d6-300)1.38 (dd, J = 9.5, 5.5 Hz, 1 H),1.87 (dd, J = 8.8, 5.5 Hz, 1 H),2.56 (t, J = 9.0 Hz, 1 H), 4.07 (s,2 H), 5.62-5.73 (m, 1 H), 6.37-6.55 (m, 3 H), 6.87-6.98 (m, 2H),7.53-7.61 (m, 3 H), 7.74-7.81 (m,2 H), 7.87 (s, 4 H)

TABLE 1-19 Example Structural formula NMR 1-91 (DMSO-d6-300)1.50 (dd, J = 6.0, 9.0 Hz, 1 H),1.96 (dd, J = 6.0, 9.0 Hz, 1 H),2.68 (t, J = 9.0 Hz, 1 H), 4.05 (s,2 H), 7.13-7.28 (m, 5 H),7.64 (dd, J = 3.0, 9.0 Hz, 1 H),7.83 (dd, J = 3.0, 9.0 Hz, 1 H),7.87 (d, J = 0.0 Hz, 1 H), 7.98 (d,J = 9.0 Hz, 1 H), 8.00 (d, J = 0.0 Hz,1 H), 8.10 (d, J = 9.0 Hz, 1 H),8.83 (brs, 1 H), 11.98 (brs, 1 H) 1-92 (METHANOL-d4-400)1.81 (dd, J = 5.5, 9.8 Hz, 1 H),2.03-2.09 (m, 1 H), 2.72 (dd,J = 9.0, 9.8 Hz, 1 H), 2.75 (s,3 H), 7.10-7.28 (m, 5 H), 7.83 (s,1 H), 7.92 (d, J = 8.6 Hz, 2 H),8.05 (d, J = 8.7 Hz, 2 H) 1-93 (METHANOL-d4-400)1.44 (d, J = 6.7 Hz, 3 H), 1.72 (dd,J = 5.1, 9.4 Hz, 1 H), 1.99-2.06 (m, 1 H), 2.67 (dd, J = 9.0,9.4 Hz, 1 H), 4.82-4.94 (m, 1 H),7.10-7.25 (m, 5 H), 7.53 (d,J = 8.3 Hz, 2 H), 7.85 (d, J = 0.2 Hz,2 H) 1-94 (ACETONE-d4-400)1.88 (dd, J = 5.9, 9.8 Hz, 1 H),2.12 (dd, J = 5.9, 8.6 Hz, 1 H),2.84 (dd, J = 8.6, 9.8 Hz, 1 H),4.04 (s, 2 H), 7.12-7.29 (m, 5 H),7.47 (d, J = 8.2 Hz, 1 H), 7.67 (s,1 H), 7.94 (d, J = 8.2 Hz, 1 H),7.97 (d, J = 8.2 Hz, 1 H), 8.02 (d,J = 8.2 Hz, 1 H), 8.09 (s, 1 H) 1-95 (ACETONE-d6-400)0.93 (dd, J = 4.0, 8.0 Hz, 1 H),1.07 (dd, J = 4.0, 8.0 Hz, 1 H),2.90 (t, J = 8.0 Hz, 1 H), 7.13-7.30 (m, 5 H), 7.78 (t, J = 8.0 Hz,1 H), 7.88 (br, 1 H), 7.94 (d,J = 12.0 Hz, 1 H), 8.06-8.11 (m,1 H), 8.32 (d, J = 12.0 Hz, 1 H),8.39-8.41 (m, 1 H), 8.67-8.68 (m,1 H)

TABLE 1-20 Example Structural formula NMR 1-96 (ACETONE-d6-400)2.08-2.09 (m, 1 H), 1.11 (dd,J = 4.0, 8.0 Hz, 1 H), 2.74 (t,J = 8.0 Hz, 1 H), 4.12 (s, 2 H),6.93 (br, 1 H), 7.16-7.18 (m,2 H), 7.24-7.29 (m, 3 H), 7.42-7.50 (m, 2 H), 7.66 (brd,J = 8.0 Hz, 1 H), 7.91 (brd,J = 8.0 Hz, 1 H), 8.00 (br, 1 H),8.53 (d, J = 8.0 Hz, 1 H) 1-97 (DMSO-d6-300)1.69 (dd, J = 6.0, 9.0 Hz, 1 H),2.01 (dd, J = 6.0, 9.0 Hz, 1 H),2.74 (t, J = 9.0 Hz, 1 H), 7.16-7.28 (m, 5 H), 7.60 (d, J = 9.0 Hz,2 H), 7.95 (d, J = 9.0 Hz, 2 H),8.01 (s, 1 H), 9.02 (s, 1 H),12.13 (br, 1 H) 1-98 (DMSO-d6-300)1.65 (dd, J = 6.0, 9.0 Hz, 1 H),1.99 (dd, J = 6.0, 9.0 Hz, 1 H),2.09 (s, 6 H), 2.69 (t, J = 9.0 Hz,1 H), 3.30 (s, 2 H), 7.04-7.21 (m,4 H), 7.50-7.59 (m, 4 H), 7.76 (d,J = 9.0 Hz, 2 H) 1-99 (DMSO-d6-300)1.30-1.48 (m, 3 H), 1.81-1.93 (m,3 H), 2.28 (s, 3 H), 2.17-2.32 (m,1 H), 2.46-2.59 (m, 1 H), 2.78-2.92 (m, 2 H), 3.08-3.25 (m, 2 H),5.34 (brs, 1 H), 6.32-6.45 (m,3 H), 6.90 (t, J = 9.0 Hz, 1 H),7.57 (d, J = 9.0 Hz, 2 H), 7.78 (d,J = 9.0 Hz, 2 H), 7.82-7.91 (m,4 H), 8.83 (brs, 1 H) 1-100 (DMSO-d6-300)1.70 (dd, J = 5.6, 9.8 Hz, 1 H),2.07 (dd, J = 5.6, 8.7 Hz, 1 H),2.81 (dd, J = 8.7, 9.8 Hz, 1 H),7.14-7.30 (m, 5 H), 7.62 (d,J = 8.7 Hz, 2 H), 8.03 (d, J = 9.1 Hz,2 H), 8.27 (s, 1 H), 9.49 (s, 1 H),12.27 (s, 1 H)

TABLE 1-21 Example Structural formula NMR 1-101 (DMSO-d6-300)1.42 (dd, J = 10.3, 5.5 Hz, 1 H),1.83 (dd, J = 8.4, 5.2 Hz, 1 H),2.45-2.54 (m, 1 H), 3.60 (s, 3 H),4.20 (d, J = 4.4 Hz, 2 H), 5.82-5.90 (m, 1 H), 6.42 (d, J = 7.7 Hz,1 H), 6.51-6.59 (m, 2 H), 6.78 (s,1 H), 6.91 (t, J = 7.3 Hz, 1 H),7.05 (s, 1 H), 7.57 (d, J = 8.4 Hz,2 H), 7.78 (d, J = 8.4 Hz, 2 H),7.87 (s, 4 H) 1-102 (DMSO-d6-300)0.81 (dd, J = 6.0, 9.0 Hz, 1 H),0.98 (dd, J = 6.0, 9.0 Hz, 1 H),2.60 (t, J = 9.0 Hz, 1 H), 6.62-6.76 (m, 2 H), 6.93-7.05 (m, 2 H),7.49-7.61 (m, 4 H), 7.72-7.80 (m,2 H), 8.99 (br, 1 H), 9.16 (br,1 H), 11.92 (br, 1 H) 1-103 (DMSO-d6-300)1.65 (dd, J = 6.0, 9.0 Hz, 1 H),1.97 (dd, J = 6.0, 9.0 Hz, 1 H),2.13 (s, 3 H), 2.23-2.36 (m, 8 H),2.66 (t, J = 9.0 Hz, 1 H), 7.04-7.21 (m, 4 H), 7.49-7.59 (m, 4 H),7.76 (d, J = 9.0 Hz, 2 H) 1-104 (DMSO-d6-300)1.01-1.50 (m, 4 H), 1.62 (dd,J = 6.0, 9.0 Hz, 1 H), 1.85-1.92 (m, 1 H), 2.14 (s, 3 H),2.23-2.31 (m, 2 H), 2.37 (s, 3 H),2.81-2.96 (m, 3 H), 7.05-7.19 (m,4 H), 7.48-7.57 (m, 4 H), 7.73 (d,J = 9.0 Hz, 2 H) 1-105 (METHANOL-d4-300)1.85 (dd, J = 6.0, 9.0 Hz, 1 H),2.06 (dd, J = 6.0, 9.0 Hz, 1 H),2.73 (t, J = 9.0 Hz, 1 H), 4.07 (s,2 H), 7.03 (d, J = 9.0 Hz, 1 H),7.17 (t, J = 9.0 Hz, 1 H), 7.42-7.50 (m, 4 H), 7.67 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.96 (d, J = 9.0 Hz, 2 H)

TABLE 1-22 Example Structural formula NMR 1-106 (DMSO-d6-300)1.62 (dd, J = 6.0, 12.0 Hz, 1 H),1.98 (dd, J = 6.0, 9.0 Hz, 1 H),2.26 (s, 3 H), 2.67 (t, J = 9.0 Hz,1 H), 7.15-7.27 (m, 5 H), 7.47 (s,1 H), 7.54 (d, J = 9.0 Hz, 2 H),7.55 (d, J = 9.0 Hz, 2 H) 1-107 (DMSO-d6-300)1.60 (dd, J = 6.0, 12.0 Hz, 1 H),2.01 (dd, J = 6.0, 9.0 Hz, 1 H),2.74 (t, J = 9.0 Hz, 1 H), 5.18 (s,2 H), 6.85-6.92 (m, 3 H), 7.21 (t,J = 7.5 Hz, 1 H), 7.53 (d, J = 9.0 Hz,2 H), 7.56 (d, J = 6.0 Hz, 1 H),7.58 (d, J = 6.0 Hz, 1 H), 7.68-7.75 (m, 1 H), 7.76 (d, J = 9.0 Hz,2 H), 8.17-8.21 (m, 1 H), 8.70 (d,J = 6.0 Hz, 1 H), 8.81 (s, 1 H),9.18 (s, 1 H), 12.20 (brs, 1 H) 1-108 (DMSO-d6-300)1.59 (dd, J = 6.0, 12.0 Hz, 1 H),2.00 (dd, J = 6.0, 9.0 Hz, 1 H),2.73 (t, J = 9.0 Hz, 1 H), 5.11 (s,2 H), 6.82-6.88 (m, 2 H), 6.89 (s,1 H), 7.18 (t, J = 7.5 Hz, 1 H),7.34 (dd, J = 6.0, 9.0 Hz, 1 H),7.49 (d, J = 6.0 Hz, 2 H), 7.53 (t,J = 3.0 Hz, 1 H), 7.56 (d, J = 3.0 Hz,1 H), 7.58 (d, J = 3.0 Hz, 1 H),7.76 (d, J = 9.0 Hz, 2 H), 7.82 (dt,J = 3.0, 9.0 Hz, 1 H), 7.55-7.59 (m, 1 H), 9.17 (s, 1 H),12.23 (brs, 1 H) 1-109 (DMSO-d6-300)1.50 (dd, J = 5.7, 9.8 Hz, 1 H),1.96 (dd, J = 5.7, 8.3 Hz, 1 H),2.68 (dd, J = 8.3, 9.8 Hz, 1 H),4.05 (s, 2 H), 7.12-7.28 (m, 5 H),7.64 (dd, J = 1.5, 8.3 Hz, 1 H),7.83 (dd, J = 1.5, 8.3 Hz, 1 H),7.87 (d, J = 1.5 Hz, 1 H), 7.98 (d,J = 8.3 Hz, 1 H), 8.00 (d, J = 1.5 Hz,1 H), 8.10 (d, J = 8.3 Hz, 1 H),8.88 (s, 1 H), 12.05 (s, 1 H) 1-110 (DMSO-d6-300)1.62 (dd, J = 5.7, 9.8 Hz, 1 H),2.04 (dd, J = 5.7, 8.7 Hz, 1 H),2.76 (dd, J = 8.7, 9.8 Hz, 1 H),7.15-7.30 (m, 5 H), 7.43-7.53 (m,2 H), 7.57 (d, J = 3.8 Hz, 1 H),7.65 (d, J = 3.7 Hz, 1 H),7.68 (ddd, J = 1.8, 2.7, 6.4 Hz,1 H), 7.81-7.84 (m, 1 H), 9.21 (s,1 H), 12.20 (s, 1 H)

TABLE 1-23 Example Structural formula NMR 1-111 (DMSO-d6-300)1.49 (dd, J = 9.5, 5.5 Hz, 1 H),1.73 (dd, J = 8.2, 4.9 Hz, 1 H),2.39 (t, J = 9.2 Hz, 1 H), 6.69-6.79 (m, 3 H), 6.91-6.99 (m, 2 H), 7.50 (dd, J = 8.1, 4.8 Hz,1 H), 7.56 (d, J = 8.4 Hz, 2 H),7.78 (d, J = 8.4 Hz, 2 H), 7.81-7.91 (m, 4 H), 8.00-8.08 (m, 1 H),8.65-8.70 (m, 1 H), 8.85 (d, J = 2.2 Hz, 1 H) 1-112 (DMSO-d6-300)1.37 (dd, J = 9.9, 5.5 Hz, 1 H),1.86 (dd, J = 8.1, 5.6 Hz, 1 H),2.56 (t, J = 9.5 Hz, 1 H),4.18 (d, J = 4.4 Hz, 2 H), 5.86-5.93 (m, 1 H), 6.40-6.55 (m, 2 H), 6.89-6.96 (m, 3 H),7.53-7.61 (m, 2 H), 7.74-7.82 (m, 2 H), 7.87 (s, 4 H) 1-113 (DMSO-d6-300)1.69 (dd, J = 6.0, 9.0 Hz, 1 H),2.06 (dd, J = 6.0, 9.0 Hz, 1 H),2.81 (t, J = 9.0 Hz, 1 H), 7.34-7.47 (m, 2 H), 7.49-7.59 (m, 4 H),7.72-7.80 (m, 3 H), 7.86 (s, 1 H) 1-114 (DMSO-d6-300)1.46 (dd, J = 3.0, 9.0 Hz, 1 H),1.93 (dd, J = 6.0, 9.0 Hz, 1 H),2.63 (t, J = 9.0 Hz, 1 H), 2.83 (s,3 H), 2.98 (s, 3 H), 4.70 (s, 2 H),6.68-6.83 (m, 3 H), 7.13 (t,J = 9.0 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.83-7.91 (m, 4 H), 8.89 (brs,1 H), 12.16 (brs, 1 H) 1-115 (DMSO-d16-300)1.66-1.74 (m, 1 H), 1.78-1.87 (m,1 H), 2.34-2.45 (m, 1 H), 3.66 (s,3 H), 6.63-6.77 (m,3 H), 7.03-7.10 (m, 1 H), 7.52 (d, J = 9.0 Hz,2 H), 7.54-7.59 (m, 2 H), 7.75 (d,J = 9.0 Hz, 2 H)

TABLE 1-24 Example Structural formula NMR 1-116 (DMSO-d6-300)1.55-1.61 (m, 1 H), 1.85-1.93 (m,1 H), 2.58 (t, J = 9.0 Hz, 1 H),6.53-6.65 (m, 3 H), 7.00 (t,J = 7.5 Hz, 1 H), 7.51-7.58 (m,4 H), 7.75 (d, J = 6.0 Hz, 1 H) 1-117 (DMSO-d6-300)1.47 (dd, J = 6.0, 9.0 Hz, 1 H),1.95 (dd, J = 6.0, 9.0 Hz, 1 H),2.66 (t, J = 9.0 Hz, 1 H), 4.34 (s,2 H), 6.73-6.86 (m, 3 H), 7.17 (t,J = 7.5 Hz, 1 H), 7.36 (brs, 1 H),7.47 (brs, 1 H), 7.57 (d,J = 9.0 Hz, 2 H), 7.78 (d, J = 9.0 Hz,2 H), 7.82-7.91 (m, 4 H),8.93 (brs, 1 H), 12.14 (brs, 1 H) 1-118 (DMSO-d6-300)1.47 (dd, J = 6.0, 9.0 Hz, 1 H),1.95 (dd, J = 6.0, 9.0 Hz, 1 H),2.65 (d, J = 6.0 Hz, 3 H), 2.69 (t,J = 4.5 Hz, 1 H), 4.38 (s, 2 H),6.74-6.86 (m, 3 H), 7.17 (t,J = 9.0 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.83-7.91 (m, 4 H), 7.98 (brs,1 H), 8.92 (s, 1 H), 12.13 (brs,1 H) 1-119 (DMSO-d6-300)1.45 (dd, J = 6.0, 9.0 Hz, 1 H),1.95 (dd, J = 6.0, 9.0 Hz, m),2.65 (t, J = 9.0 Hz, 1 H), 4.59 (s,2 H), 6.68-6.84 (m, 3 H), 7.16 (t,J = 7.5 Hz, 1 H), 7.57 (d, J = 9.0 Hz,2 H), 7.78 (d, J = 9.0 Hz, 2 H),7.83-7.91 (m, 4 H), 8.92 (s, m),12.18 (brs, 1 H), 12.91 (brs, 1 H) 1-120 (ACETONE-d6-400)1.94-1.99 (m, 1 H), 2.17-2.22 (m,1 H), 2.94 (t, J = 10.0 Hz, 1 H),6.94 (d, J = 1.0 Hz, 1 H), 7.16-7.31 (m, 5 H), 7.65 (d, J = 4.0 Hz,1 H), 7.69 (d, J = 4.0 Hz, 1 H),8.55 (d, J = 1.0 Hz, 1 H)

TABLE 1-25 Example Structural formula NMR 1-121 (ACETONE-d6-400)0.97 (dd, J = 8.0, 12.0 Hz, 1 H),1.10 (dd, J = 8.0, 12.0 Hz, 1 H),2.95 (t, J = 8.0 Hz, 1 H), 7.17-7.31 (m, 5 H), 7.72 (d, J = 8.0 Hz,1 H), 7.81 (d, J = 8.0 Hz, 1 H),7.82-7.85 (m, 2 H), 8.24 (br, 1 H) 1-122 (ACETONE-d6-400)0.95 (dd, J = 8.0, 12.0 Hz, 1 H),1.07 (dd, J = 8.0, 8.0 Hz, 1 H),2.87 (t, J = 8.0 Hz, 1 H), 7.13-7.27 (m, 5 H), 7.13-7.27 (m, 5 H),3.74 (dt, J = 12.0, 2.0 Hz, 1 H),7.82 (d, J = 4.0 Hz, 1 H), 3.97 (dt,J = 8.0, 2.0 Hz, 1 H), 3.97 (dt,J = 8.0, 2.0 Hz, 1 H), 8.21 (d,J = 8.0 Hz, 1 H), 8.28 (d, J = 8.0 Hz,1 H) 1-123 (ACETONE-d6-400)1.28-1.32 (m, 1 H), 0.95 (dd,J = 8.0, 12.0 Hz, 1 H), 2.13-2.17 (m, 1 H), 7.13-7.28 (m, 5 H),7.65 (ddd, J = 0.0, 4.0, 8.0 Hz,5 H), 7.76 (dd, J = 1.0, 12.0 Hz,1 H), 7.96 (dt, J = 1.0, 8.0 Hz,1 H), 8.14 (d, J = 1.0 Hz, 1 H),8.31 (d, J = 4.0 Hz, 1 H), 8.34 (d,J = 12.0 Hz, 1 H) 1-124 (DMSO-d6-300)1.60 (dd, J = 5.7, 9.8 Hz, 1 H),2.04 (dd, J = 5.7, 8.6 Hz, 1 H),2.76 (dd, J = 8.6, 9.8 Hz, 1 H),7.14-7.30 (m, 5 H), 7.45 (d,J = 3.4 Hz, 1 H), 7.46 (d, J = 3.7 Hz,1 H), 7.48 (d, J = 3.0 Hz, 1 H),7.60 (d, J = 3.8 Hz, 1 H), 7.63 (dd,J = 3.4, 6.0 Hz, 1 H), 7.72 (dd,J = 3.8, 6.0 Hz, 1 H), 9.21 (s,1 H), 12.22 (s, 1 H) 1-125 (DMSO-d6-300)1.60 (dd, J = 6.0, 9.4 Hz, 1 H),2.05 (dd, J = 5.6, 8.7 Hz, 1 H),2.77 (dd, J = 8.7, 9.4 Hz, 1 H),7.15-7.31 (m, 5 H), 7.49 (d,J = 3.8 Hz, 1 H), 7.56 (dd, J = 2.2,8.3 Hz, 1 H), 7.61 (d, J = 4.2 Hz,1 H), 7.75 (d, J = 8.3 Hz, 1 H),7.82 (d, J = 1.9 Hz, 1 H), 9.23 (s,1 H), 12.23 (s, 1 H)

TABLE I-26 Example Structural formula NMR 1-126 (CDCL3-300)1.89 (dd, J = 6.0, 9.0 Hz, 1 H),2.17 (dd, J = 6.0, 9.0 Hz, 1 H),3.02 (t, J = 9.0 Hz, 1 H), 3.30 (t,J = 7.5 Hz, 2 H), 3.45-3.54 (m,2 H), 5.46 (br, 1 H), 6.45 (br,1 H), 7.14-7.27 (m, 7 H),7.41 (d, J = 9.0 Hz, 1 H),7.51 (dd, J = 3.0, 6.0 Hz, 1 H) 1-127 (DMSO-d6-300)1.77 (dd, J = 9.6, 5.6 Hz, 1 H),2.06 (dd, J = 8.8, 5.1 Hz, 1 H),2.78 (t, J = 8.8 Hz, 1 H), 7.49-7.61 (m, 5 H), 7.63-7.69 (m,1 H), 7.72-7.78 (m, 3 H), 8.01-8.08 (m, 2 H) 1-128 (DMSO-d6-300)1.52 (dd, J = 9.5, 5.5 Hz, 1 H),1.80 (dd, J = 8.4, 5.1 Hz, 1 H),2.42-2.50 (m, 1 H), 6.28-6.41 (m, 3 H), 6.81 (t, J = 7.7 Hz,1 H), 7.45-7.54 (m, 5 H), 7.68-7.74 (m, 2 H) 1-129 (DMSO-d6-400)1.54 (dd, J = 9.7, 5.0 Hz, 1 H),1.78 (dd, J = 8.7, 5.0 Hz, 1 H),2.40 (t, J = 9.0 Hz, 1 H), 4.20 (d,J = 5.6 Hz, 1 H), 6.05 (t,J = 6.0 Hz, 1 H), 6.32 (dd, J = 8.1,1.9 Hz, 1 H), 6.37 (d, J = 7.7 Hz,1 H), 6.46-6.49 (m, 1 H),6.83 (t, J = 7.8 Hz, 1 H),7.29 (dd, J = 7.7, 4.9 Hz, 1 H),7.45-7.53 (m, 4 H), 7.66-7.73 (m,3 H), 8.39 (dd, J = 4.9,1.6 Hz, 1 H), 8.52 (d, J = 2.1 Hz,1 H) 1-130 (DMSO-d6-300)1.69 (dd, J = 6.0, 12.0 Hz, 1 H),1.81 (dd, J = 6.0, 9.0 Hz, 1 H),2.44 (t, J = 9.0 Hz, 1 H), 2.94 (s,3 H), 6.93 (brd, J = 9.0 Hz, 1 H),6.96 (brd, J = 9.0 Hz, 1 H),7.09 (d, J = 6.0 Hz, 1 H), 7.13 (d,J = 9.0 Hz, 1 H), 7.52 (d,J = 9.0 Hz, 2 H), 7.55 (d,J = 3.0 Hz, 1 H), 7.62 (d,J = 3.0 Hz, 1 H), 7.75 (d,J = 9.0 Hz, 2 H)

TABLE 1-27 Example Structural formula NMR 1-131 (CDCL3-300)1.62 (dd, J = 6.0, 9.0 Hz, 1 H),2.00 (dd, J = 6.0, 9.0 Hz, 1 H),2.71 (t, J = 9.0 Hz, 1 H), 7.14-7.27 (m, 5 H), 7.59 (d, J = 3.0 Hz,1 H), 7.85 (d, J = 3.0 Hz, 1 H),8.04 (dd, J = 238494.0, 9.0 Hz,1 H), 8.09 (d, J = 6.0 Hz, 1 H),8.64 (d, J = 3.0 Hz, 1 H),12.20 (brs, 1 H) 1-132 (DMSO-d6-300)1.63 (dd, J = 3.0, 9.0 Hz, 1 H),1.97 (dd, J = 6.0, 9.0 Hz, 1 H),2.75 (t, J = 9.0 Hz, 1 H), 7.05-7.13 (m, 3 H), 7.26 (t, J = 7.5 Hz,1 H), 7.53 (d, J = 9.0 Hz, 2 H),7.57 (s, 2 H), 7.76 (d, J = 9.0 Hz,2 H), 9.22 (s, 1 H), 11.85 (brs,1 H), 12.27 (brs, 1 H) 1-133 (DMSO-d6-300)1.58 (dd, J = 6.0, 9.0 Hz, 1 H),1.99 (dd, J = 6.0, 9.0 Hz, 1 H),2.70 (t, J = 9.0 Hz, 1 H), 6.60-6.76 (m, 3 H), 7.10 (t, J = 9.0 Hz,1 H), 7.53 (d, J = 9.0 Hz, 2 H),7.56 (d, J = 3.0 Hz, 1 H), 7.58 (d,J = 3.0 Hz, 1 H), 7.76 (d, J = 9.0 Hz,2 H), 9.17 (s, 1 H) 1-134 (CDCL3-300)2.03 (dd, J = 6.0, 9.0 Hz, 1 H),2.09-2.17 (m, 1 H), 2.88 (t,J = 9.0 Hz, 1 H), 4.48 (s, 2 H),6.46 (brs, 1 H), 7.07-7.28 (m,5 H), 7.37 (d, J = 9.0 Hz, 2 H),7.50 (d, J = 9.0 Hz, 2 H), 7.56 (d,J = 6.0 Hz, 1 H) 1-135 (DMSO-d6-300)1.58 (dd, J = 6.0, 9.0 Hz, 1 H),1.94 (dd, J = 6.0, 9.0 Hz, 1 H),2.70 (t, J = 9.0 Hz, 1 H),5.81 (brs, 2 H), 6.75 (d,J = 6.0 Hz, 1 H), 7.08 (t, J = 7.5 Hz,1 H), 7.22-7.31 (m, 2 H), 7.49-7.58 (m, 4 H), 7.76 (d, J = 9.0 Hz,2 H), 8.52 (brs, 1 H), 9.20 (brs,1 H)

TABLE 1-28 Example Structural formula NMR 1-136 (DMSO-d6-300)1.58 (dd, J = 6.0, 9.0 Hz, 1 H),1.90 (dd, J = 6.0, 9.0 Hz, 1 H),2.69 (t, J = 9.0 Hz, 1 H), 6.87 (d,J = 6.0 Hz, 1 H), 6.94 (d, J = 6.0 Hz,1 H), 7.09 (s, 1 H), 7.12 (t,J = 6.0 Hz, 1 H), 7.53 (d, J = 9.0 Hz,2 H), 7.54-7.59 (m, 3 H), 7.76 (d,J = 9.0 Hz, 2 H), 8.05 (dt, J = 9.0,6.0 Hz, 1 H), 8.76 (dd, J = 1.0,6.0 Hz, 1 H), 8.87 (d, J = 1.0 Hz,1 H), 9.21 (s, 1 H), 10.41 (s, 1 H) 1-137 (METHANOL-d4-300)1.77-1.86 (m, 1 H), 2.13 (dd,J = 6.0, 9.0 Hz, 1 H), 2.71 (t,J = 10.5 Hz, 1 H), 7.25-7.52 (m,5 H), 7.58-7.76 (m, 5 H) 1-138 (DMSO-d6-300)0.84 (dd, J = 6.0, 12.0 Hz, 1 H),0.99 (dd, J = 6.0, 9.0 Hz, 1 H),2.64 (t, J = 9.0 Hz, 1 H), 3.73-3.82 (m, 2 H), 3.85-4.03 (m, 2 H),4.75 (br, 1 H), 6.82 (t, J = 7.5 Hz,1 H), 6.90 (d, J = 9.0 Hz, 1 H),7.04 (d, J = 9.0 Hz, 1 H), 7.15 (t,J = 9.0 Hz, 1 H), 7.53 (brd,J = 9.0 Hz, 2 H), 7.57 (d, J = 6.0 Hz,1 H), 7.59 (d, J = 3.0 Hz, 1 H),7.76 (brd, J = 9.0 Hz, 2 H),8.82 (br, 1 H), 11.95 (br, 1 H) 1-139 (DMSO-d6-300)0.88 (dd, J = 6.0, 9.0 Hz, 1 H),1.00 (dd, J = 6.0, 9.0 Hz, 1 H),2.64 (t, J = 9.0 Hz, 1 H), 2.64 (t,J = 9.0 Hz, 1 H), 4.56 (d,J = 15.0 Hz, 1 H), 4.66 (d,J = 15.0 Hz, 1 H), 6.79-6.89 (m,2 H), 7.02-7.09 (m, 1 H), 7.10-7.20 (m, 1 H), 7.49-7.60 (m, 4 H),7.71-7.78 (m, 2 H), 8.69 (brs,1 H), 11.90 (brs, 1 H),12.83 (brs, 1 H) 1-140 (ACETONE-d6-400)0.92 (dd, J = 4.0, 8.0 Hz, 1 H),1.04 (dd, J = 8.0, 12.0 Hz, 1 H),2.83 (t, J = 10.0 Hz, 1 H),7.11 (dt, J = 8.0, 2.0 Hz, 1 H),7.16-7.28 (m, 7 H), 7.40-7.46 (m,3 H), 7.57 (t, J = 8.0 Hz, 1 H),7.62 (dt, J = 10.0, 1.0 Hz, 1 H),7.80 (br, 1 H)

TABLE 1-29 Example Structural formula NMR 1-141 (ACETONE-d6-400)0.92 (dd, J = 8.0, 12.0 Hz, 1 H),1.05 (dd, J = 4.0, 8.0 Hz, 1 H),2.84 (t, J = 10.0 Hz, 1 H), 7.13-7.28 (m, 9 H), 7.41 (t, J = 2.0 Hz,1 H), 7.57 (t, J = 8.0 Hz, 1 H),7.62 (dt, J = 8.0, 2.0 Hz, 1 H),7.78 (br, 1 H) 1-142 (ACETONE-d6-400)0.93 (dd, J = 4.0, 8.0 Hz, 1 H),1.05 (dd, J = 4.0, 8.0 Hz, 1 H),2.85 (t, J = 10.0 Hz, 1 H), 7.12 (d,J = 8.0 Hz, 2 H), 7.16-7.30 (m,6 H), 7.41-7.46 (m, 3 H), 7.59 (t,J = 8.0 Hz, 1 H), 7.67 (d, J = 8.0 Hz,1 H), 7.82 (br, 1 H) 1-143 (ACETONE-d6-400)0.93 (dd, J = 4.0, 8.0 Hz, 1 H),1.06 (dd, J = 4.0, 8.0 Hz, 1 H),2.86 (t, J = 10.0 Hz, 1 H),7.08 (dd, J = 4.0, 8.0 Hz, 1 H),7.16-7.28 (m, 4 H), 7.34-7.37 (m,2 H), 7.52 (t, J = 2.0 Hz, 1 H),7.59 (d, J = 8.0 Hz, 1 H), 7.62 (t,J = 8.0 Hz, 1 H), 7.70 (dt, J = 8.0,2.0 Hz, 1 H), 7.86 (brs, 1 H) 1-144 (METHANOL-d4-400)0.97 (dd, J = 4.0, 8.0 Hz, 1 H),1.05 (dd, J = 4.0, 8.0 Hz, 1 H),2.78 (t, J = 10.0 Hz, 1 H), 3.15-3.25 (m, 4 H), 3.33-3.42 (m, 4 H),6.94 (d, J = 8.0 Hz, 2 H), 7.15-7.29 (m, 7 H), 8.38 (brs, 1 H) 1-145 (DMSO-d6-300)1.68 (dd, J = 6.0, 9.0 Hz, 1 H),1.98-2.08 (m, 1 H), 2.68-2.80 (m,1 H), 4.35 (ddd, J = 6.0, 15.0,27.0 Hz, 1 H), 4.54 (dd, J = 15.0,21.0 Hz, 2 H), 6.78-6.93 (m, 2 H),7.03-7.32 (m, 7 H), 7.48-7.62 (m,4 H), 7.74 (d, J = 9.0 Hz, 2 H),8.32 (brs, 1 H), 9.08 (brs, 1 H),12.22 (brs, 1 H)

TABLE 1-30 Example Structural formula NMR 1-146 (DMSO-d6-300)1.76 (dd, J = 6.0, 12.0 Hz, 1 H),1.96-2.08 (m, 1 H), 2.55-2.67 (m,1 H), 3.40-3.68 (m, 4 H),4.75 (dd, J = 15.0, 45.0 Hz, 2 H),6.78-6.94 (m, 2 H), 7.05 (d,J = 6.0 Hz, 1 H), 7.15 (t, J = 9.0 Hz,1 H), 7.47-7.62 (m, 4 H), 7.75 (d,J = 6.0 Hz, 2 H), 8.90 (brs, 1 H),12.02 (brs, 1 H) 1-147 (DMSO-d6-300)1.10 (d, J = 6.0 Hz, 3 H), 1.15 (d,J = 6.0 Hz, 3 H), 1.55-1.66 (m,1 H), 1.91-2.02 (m, 1 H), 2.60-2.75 (m, 1 H), 3.92-4.05 (m, 1 H),4.36 (d, J = 15.0 Hz, 1 H), 4.47 (d,J = 15.0 Hz, 1 H), 6.80-6.89 (m,2 H), 7.04-7.08 (m, 1 H), 7.13-7.20 (m, 1 H), 7.53 (d, J = 9.0 Hz,2 H), 7.57 (d, J = 6.0 Hz, 1 H),7.60 (d, J = 6.0 Hz, 1 H), 7.76 (d,J = 9.0 Hz, 2 H) 1-148 (ACETONE-d6-300)1.94 (dd, J = 6.0, 9.0 Hz, 1 H),2.17 (dd, J = 6.0, 9.0 Hz, 1 H),2.92 (t, J = 9.0 Hz, 1 H), 4.11 (s,3 H), 7.15-7.33 (m, 6 H), 7.63 (d,J = 6.0 Hz, 1 H), 7.70 (d, J = 6.0 Hz,1 H), 8.15 (d, J = 9.0 Hz, 1 H) 1-149 (DMSO-d6-400)1.38-1.41 (m, 1 H), 1.39 (s, 3 H),2.09 (d, J = 5.3 Hz, 1 H), 7.11 (m,5 H), 7.49-7.57 (m, 4 H), 7.71-7.76 (m, 2 H), 9.19 (brs, 1 H),12.11 (brs, 1 H).

TABLE 2-1 Example Structural formula NMR 2 (DMSO-d6-400)1.41 (s, 9 H), 1.55 (dd, J = 9.7,5.1 Hz, 1 H), 1.94 (dd, J = 8.3,5.6 Hz, 1 H), 2.40-2.47 (m, 2 H),2.62 (t, J = 9.0 Hz, 1 H), 3.48-3.55 (m, 2 H), 3.94-4.02 (m, 2 H),6.26 (brs, 1 H), 7.43 (d, J = 3.7 Hz,1 H), 7.11-7.24 (m, 5 H), 7.43 (d,J = 3.7 Hz, 1 H) 2-2 (DMSO-d6-400)1.53 (dd, J = 10.2, 5.6 Hz, 1 H),1.97-2.02 (m, 1 H), 2.66 (brs, 2 H),2.71 (t, J = 9.3 Hz, 1 H), 3.26-3.32 (m, 2 H), 3.73 (brs, 2 H),6.27 (brs, 1 H), 7.14-7.27 (m, 6 H),7.48 (d, J = 4.2 Hz, 1 H), 9.18 (brs,2 H) 2-3 (DMSO-d6-400)1.60 (dd, J = 9.3, 5.6 Hz, 1 H),1.84 (dd, J = 8.3, 5.1 Hz, 1 H), 2.43-2.50 (m, 3 H), 3.56 (t, J = 5.8 Hz,2 H), 3.62 (s, 3 H), 4.03 (brs, 2 H),6.26 (brs, 1 H), 7.21-7.07 (m, 6 H),7.44 (d, J = 3.7 Hz, 1 H) 2-4 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 2.00 (dq,J = 10.5, 6.8 Hz, 1 H), 2.79 (d,J = 10.5 Hz, 1 H), 4.24 (s, 1 H), 7.13-7.17 (m, 5 H), 7.38 (d, J = 4.1 Hz,1 H), 7.51 (d, J = 4.1 Hz, 1 H),7.98 (s, 1 H), 8.91 (s, 1 H),9.06 (brs, 1 H), 12.29 (brs, 1 H) 2-5 (CDCl3-400)1.33 (d, J = 6.6 Hz, 3 H), 2.18 (brs,1 H), 3.1O (d, J = 10.8 Hz, 1 H),3.31 (brs, 4 H), 3.69 (brs, 4 H),6.65 (d, J = 9.0 Hz, 1 H), 7.21-7.28 (m, 5 H), 7.66 (dd, J = 2.3,9.0 Hz, 1 H), 8.37 (s, 1 H)

TABLE 2-2 Example Structural formula NMR 2-6 (DMSO-d6-400)1.40 (s, 3 H), 1.43 (d, J = 5.6 Hz,1 H), 2.12 (d, J = 5.6 Hz, 1 H), 7.13-7.26 (m, 5 H), 7.68 (d, J = 3.7 Hz,1 H), 7.85 (d, J = 3.7 Hz, 1 H),8.17 (s, 1 H), 9.41 (brs, 1 H),12.14 (brs, 1 H) 2-7 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 2.00 (dd,J = 10.2, 6.4 Hz, 1 H), 2.79 (d,J = 10.2 Hz, 1 H), 7.09-7.35 (m, 5 H),7.70 (d, J = 3.8 Hz, 1 H), 7.85 (d,J = 3.8 Hz, 1 H), 8.17 (s, 1 H),9.28 (brs, 0 H), 12.34 (brs, 1 H) 2-8 (DMSO-d6-400)1.45-1.59 (m, 2 H), 1.68-1.84 (m,3 H), 2.44 (dd, J = 13.0, 6.0 Hz, 1 H),2.69 (d, J = 9.3 Hz, 1 H), 3.00 (td,J = 13.0, 5.6 Hz, 1 H), 6.95-7.10 (m,4 H), 7.48-7.61 (m, 4 H), 7.70-7.76 (m, 2 H) 2-9 (MeOH-d4-300)1.37 (d, J = 9.0 Hz, 3 H), 2.06 (t,J = 18.0 Hz, 3 H), 2.15-2.27 (m, 1 H),2.94 (d, J = 9.0 Hz, 1 H), 7.16-7.28 (m, 6 H), 7.61 (d, J = 3.0 Hz,1 H), 7.64 (d, J = 3.0 Hz, 1 H) 2-10 (CD3CN-400)2.32 (dd, J = 7.4, 17.5 Hz, 1 H),3.08 (d, J = 10.4 Hz, 1 H), 3.79 (dd,J = 7.2, 11.4 Hz, 1 H), 3.96 (dd,J = 7.6, 11.3 Hz, 1 H), 7.16-7.29 (m,5 H), 7.44 (brs, 1 H), 7.57-7.61 (m,1 H), 7.68-7.72 (m, 1 H)

TABLE 2-3 Example Structural formula NMR 2-11 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 1.95-2.05 (m, 1 H), 2.86 (d, J = 10.5 Hz,1 H), 3.05-3.15 (m, 4 H), 3.44-3.58 (m, 4 H), 6.93 (t, J = 7.9 Hz,1 H), 7.15-7.30 (m, 8 H), 7.44 (d,J = 7.9 Hz, 2 H), 8.28 (s, 1 H),8.59 (s, 1 H), 12.37 (s, 1 H) 2-12 (DMSO-d6-300)1.39 (d, J = 3.4 Hz, 3 H), 1.40 (d,J = 3.4 Hz, 1 H), 2.06 (d, J = 6.4 Hz,1 H), 5.56 (brs, 2 H), 6.89 (dd,J = 8.3, 2.3 Hz, 1 H), 7.09 (d,J = 2.3 Hz, 1 H), 7.12-7.27 (m, 6 H),7.37 (d, J = 4.1 Hz, 1 H), 7.50 (d,J = 4.1 Hz, 1 H), 9.13 (brs, 1 H),12.02 (brs, 1 H) 2-13 (DMSO-d6-300)2.03 (dd, J = 6.8, 7.2 Hz, 1 H),2.60 (d, J = 6.8 Hz, 1 H), 2.99 (dd,J = 17.3, 7.2 Hz, 1 H), 3.21-3.36 (m,1 H), 5.25 (s, 2 H), 6.98-7.09 (m,3 H), 7.13-7.19 (m, 1 H), 7.22 (d,J = 8.7 Hz, 2 H), 7.49 (dd, J = 8.3,2.3 Hz, 1 H), 7.64 (d, J = 8.3 Hz, 1 H),7.71 (d, J = 2.3 Hz, 1 H), 7.81 (d,J = 8.7 Hz, 2 H), 8.26 (brs, 1 H),8.40 (s, 1 H), 9.87 (s, 1 H) 2-14 (MeOH-d4-400)1.95-2.01 (m, 1 H), 2.08-2.16 (m,1 H), 2.69-2.76 (m, 1 H), 4.03 (s,3 H), 6.88 (s, 1 H), 7.12-7.28 (m,5 H), 7.36 (d, J = 3.9 Hz, 1 H),7.65 (d, J = 3.9 Hz, 1 H), 8.45 (s, 1 H) 2-15 (MeOH-d4-400)1.19-1.35 (m, 1 H), 1.88-1.94 (m,1 H), 2.08-2.14 (m, 1 H), 2.77-2.83 (m, 1 H), 3.86-3.94 (m, 1 H),4.22-4.32 (m, 1 H), 4.86-4.97 (m,2 H), 6.81 (d, J = 8.6 Hz, 1 H), 7.14-7.32 (m, 8 H), 8.39 (s, 1 H)

TABLE 2-4 Example Structural formula NMR 2-16 (MeOH-d4-400)1.18-1.25 (m, 1 H), 1.90 (dd, J = 9.4,5.5 Hz, 1 H), 2.12 (dd, J = 9.4,5.5 Hz, 1 H), 2.77 (t, J = 9.4 Hz, 1 H),4.01 (s, 3 H), 7.12-7.28 (m, 6 H),7.39 (d, J = 3.9 Hz, 1 H), 7.55 (d,J = 3.9 Hz, 1 H), 8.37 (s, 1 H) 2-17 (MeOH-d4-400)1.93 (dd, J = 9.4, 5.5 Hz, 1 H),2.13 (dd, J = 9.4, 5.5 Hz, 1 H),2.78 (t, J = 9.4 Hz, 1 H), 7.12-7.28 (m, 5 H), 7.34 (d, J = 9.4 Hz,2 H), 7.41 (d, J = 3.9 Hz, 1 H),7.59 (d, J = 3.9 Hz, 1 H), 7.77 (d,J = 9.4 Hz, 2 H), 8.39 (s, 1 H) 2-18 (CDCl3-400)2.00-2.07 (m, 1 H), 2.11-2.13 (m,1 H), 2.90-2.96 (m, 1 H), 6.29 (brs,1 H), 7.10-7.85 (m, 10 H) 2-19 (CDCl3-400)1.25-1.52 (m, 2 H), 2.11 (m, 1 H),2.87 (t, J = 9.3 Hz, 1 H), 6.75 (d,J = 8.7 Hz, 1 H), 7.147.26 (m, 5 H),7.59-7.73 (m, 6 H) 2-20 (CDCl3-400)2.00-2.02 (m, 2 H), 2.40 (s, 3 H),2.89 (t, J = 9.4 Hz, 1 H), 5.89 (brs,1 H), 7.03-7.26 (m, 8 H), 7.44-7.48 (m, 3 H)

TABLE 2-5 Example Structural formula NMR 2-21 (CDCl3-400)1.98-2.06 (m, 2 H), 2.90 (t, J = 9.3 Hz,1 H), 6.11 (brs, 1 H), 7.06-7.26 (m,8 H), 7.49-7.55 (m, 3 H) 2-22 (DMSO-d6-300)1.67 (dd, J = 9.8, 5.7 Hz, 1 H),2.01 (dd, J = 8.7, 5.7 Hz, 1 H),2.71 (dd, J = 9.4, 4.7 Hz, 1 H), 5.23 (d,J = 13.2 Hz, 1 H), 5.28 (d, J = 13.2 Hz,1 H), 6.83 (t, J = 7.2 Hz, 1 H), 6.93 (d,J = 7.5 Hz, 1 H), 7.07 (d, J = 7.5 Hz, 1 H),7.13 (t, J = 7.9 Hz, 1 H), 7.50-7.61 (m,5 H), 7.76 (d, J = 8.7 Hz, 2 H), 8.13 (d,J = 7.9 Hz, 1 H), 8.60 (dd, J = 5.3,1.5 Hz, 1 H), 8.81 (d, J = 1.5 Hz, 1 H),9.01 (s, 1 H), 12.03-12.29 (m, 1 H) 2-23 (DMSO-d6-300)1.72 (dd, J = 9.4, 5.7 Hz, 1 H),2.06 (dd, J = 8.9, 5.8 Hz, 1 H),2.79 (dd, J = 9.2, 4.6 Hz, 1 H), 5.32 (d,J = 14.3 Hz, 1 H), 5.44 (d, J = 14.3 Hz,1 H), 6.88 (t, J = 7.3 Hz, 1 H), 6.95 (d,J = 7.9 Hz, 1 H), 7.10 (d, J = 7.5 Hz, 1 H),7.16 (t, J = 7.9 Hz, 1 H), 7.53 (d,J = 8.3 Hz, 2 H), 7.59 (s, 2 H), 7.67-7.73 (m, 1 H), 7.76 (d, J = 8.7 Hz, 1 H),7.88 (d, J = 8.3 Hz, 1 H), 8.20 (t,J = 7.7 Hz, 1 H), 8.79 (d, J = 5.3 Hz, 1 H),9.28 (s, 1 H) 2-24 (DMSO-d6-300)1.70-1.79 (m, 1 H), 1.90-1.99 (m, 1 H),6.74 (d, J = 7.2 Hz, 1 H), 7.04 (d,J = 6.8 Hz, 1 H), 7.20-7.33 (m, 3 H),7.49-7.54 (m, 5 H), 7.71-7.74 (m, 3 H),8.31-8.32 (m, 2 H) 2-25 (DMSO-d6-300)1.23 (s, 7 H), 1.25 (s, 7 H), 1.63 (dd,J = 9.8, 5.7 Hz, 1 H), 1.99 (dd, J = 9.0,5.7 Hz, 1 H), 2.67 (t, J = 10.2 Hz, 1 H),3.67 (dd, J = 46.0, 9.2 Hz, 2 H),4.62 (brs, 1 H), 6.79 (t, J = 7.5 Hz,J = 7.2 Hz, 1 H), 7.13 (t, J = 7.9 Hz, 1 H),7.50-7.54 (m, 2 H), 7.57 (dd, J = 5.7,3.8 Hz, 2 H), 7.74 (dd, J = 6.6, 2.1 Hz,2 H), 8.75 (brs, 1 H)

TABLE 2-6 Example Structural formula NMR 2-26 (DMSO-d6-300)1.61 (dd, J = 5.1, 2.6 Hz, 1 H),2.01 (dd, J = 8.7, 5.7 Hz, 1 H),2.48 (s, 3 H), 2.73 (t, J = 9.0 Hz,1 H), 7.14-7.26 (m, 5 H), 7.53 (dd,J = 5.8, 4.0 Hz, 2 H), 7.58-7.58 (m,1 H), 12.20 (brs, 1 H) 2-27 (DMSO-d6-300)1.59-1.67 (m, 1 H), 1.95-2.03 (m,1 H), 2.64-2.74 (m, 1 H), 7.13-7.25(m, 5 H), 7.60 (s, 1 H), 7.62 (d,J = 4.5 Hz, 1 H), 7.69 (d, J = 3.8 Hz,1 H), 8.20 (dd, J = 8.3, 2.6 Hz, 1 H),8.81 (d, J = 2.6 Hz, 1 H) 2-28 (MeOH-d4-400)1.96 (dd, J = 5.4, 9.6 Hz, 1 H), 2.10-2.15(m, 1 H), 2.80 (t, J = 9.0 Hz,1 H), 3.25-3.45 (m, 8 H), 7.09 (d,J = 7.6 Hz, 1 H), 7.15-7.30 (m, 7 H),7.40 (t, J = 7.9 Hz, 1 H) 2-29 (MeOH-d4-400)1.83-2.19 (m, 2 H), 2.70-2.84 (m,1 H), 3.06-3.53 (m, 8 H), 7.06-7.50(m, 9 H) 2-30 (MeOH-d4-400)1.96 (dd, J = 5.6, 9.8 Hz, 1 H),2.13 (dd, J = 5.8, 8.5 Hz, 1 H),2.80 (t, J = 9.1 Hz, 1 H) 3.25-3.34 (m,4 H), 3.34-3.44 (m, 4 H), 7.14-7.29(m, 7 H), 7.40 (d, J = 7.4 Hz, 1 H)

TABLE 2-7 Example Structural formula NMR 2-31 (MeOH-d4-400)1.95 (dd, J = 5.6, 9.8 Hz, 1 H),2.12 (dd, J = 5.8, 8.3 Hz, 1 H),2.79 (t, J = 9.1 Hz, 1 H), 3.20-3.42(m, 8 H), 6.81 (d, J = 8.6 Hz,1 H), 6.88 (d, J = 8.6 Hz, 1 H),6.95 (s, 1 H), 7.15-7.29 (m, 6 H) 2-32 (DMSO-d6-300)1.61 (dd, J = 9.6, 5.8 Hz, 1 H), 1.99-2.01(m, 1 H), 2.73 (t, J = 8.9 Hz,1 H), 4.31 (d, J = 5.3 Hz, 2 H), 7.11-7.56(m, 10 H), 7.73 (d, J = 8.7 Hz,2 H), 7.94 (d, J = 4.9 Hz, 1 H),8.00 (d, J = 2.6 Hz, 1 H), 9.17 (s, 1 H) 2-33 (Aceton-d6-300)1.94 (dd, J = 6.0, 9.0 Hz, 1 H),2.17 (dd, J = 6.0, 9.0 Hz, 1 H),2.92 (t, J = 9.0 Hz, 1 H), 4.11 (s,3 H), 7.15-7.33 (m, 6 H), 7.63 (d,J = 6.0 Hz, 1 H), 7.70 (d, J = 6.0 Hz,1 H), 8.15 (d, J = 9.0 Hz, 1 H) 2-34 (DMSO-d6-300)1.62 (dd, J = 9.8, 5.7 Hz, 1 H),2.02 (dd, J = 8.7, 5.7 Hz, 1 H),2.74 (t, J = 9.2 Hz, 1 H), 7.17-7.27(m, 5 H), 7.54-7.55 (m, 2 H),7.63 (d, J = 4.1 Hz, 1 H), 7.98 (d,J = 3.8 Hz, 1 H), 9.31 (brs, 1 H),12.23 (brs, 1 H) 2-35 (DMSO-d6-300)1.56-1.57 (m, 1 H), 2.00 (dd,J = 11.7, 6.0 Hz, 1 H), 2.72 (t,J = 8.9 Hz, 1 H), 3.58 (d, J = 18.5 Hz,1 H), 3.96 (d, J = 18.5 Hz, 1 H), 7.19-7.25(m, 5 H), 7.49 (d, J = 4.1 Hz,1 H), 7.59 (d, J = 4.1 Hz, 1 H)

TABLE 2-8 Example Structural formula NMR 2-36 (DMSO-d6-300)1.61 (dd, J = 9.9, 5.1 Hz, 1 H),1.91 (dd, J = 8.3, 5.3 Hz, 1 H),2.59 (t, J = 9.0 Hz, 1 H), 5.00 (s,2 H), 6.74-6.87 (m, 3 H), 7.11 (t,J = 7.9 Hz, 1 H), 7.26-7.44 (m, 5 H),7.46-7.57 (m, 4 H), 7.73 (d,J = 8.4 Hz, 2 H) 2-37 (DMSO-d6-400)1.60 (dd, J = 10.2, 4.6 Hz, 1 H),1.81 (dd, J = 8.3, 4.6 Hz, 1 H),2.42 (t, J = 9.3 Hz, 1 H), 2.88 (s,3 H), 4.50 (s, 2 H), 6.47-6.52 (m,2 H), 6.67 (s, 1 H), 6.94 (t,J = 7.9 Hz, 1 H), 7.29 (dd, J = 7.7,4.9 Hz, 1 H), 7.47-7.59 (m, 5 H),7.72 (d, J = 8.8 Hz, 2 H), 8.40-8.45(m, 2 H) 2-38 (DMSO-d6-400)1.19-1.26 (m, 1 H), 1.24-1.25 (m,2 H), 1.36-1.49 (m, 2 H), 7.09-7.25(m, 5 H), 7.45-7.54 (m, 4 H),7.72 (d, J = 8.3 Hz, 2 H) 2-39 (DMSO-d6-300)1.61 (dd, J = 9.6, 5.5 Hz, 1 H), 1.95-2.04(m, 1 H), 2.47 (s, 3 H), 2.69 (t,J = 9.6 Hz, 1 H), 6.83 (d, J = 2.6 Hz,1 H), 7.12-7.29 (m, 7 H), 7.47 (d,J = 3.8 Hz, 1 H), 12.22 (brs, 1 H) 2-40 (DMSO-d6-300)1.65-1.80 (m, 2 H), 2.37 (s, 3 H),7.09-7.22 (m, 4 H), 7.22-7.31 (m,4 H), 7.51-7.56 (m, 4 H), 7.75 (d,J = 10.0 Hz, 2 H)

TABLE 2-9 Example Structural formula NMR 2-41 (DMSO-d6-300)0.67-1.68 (m, 13 H), 7.46-7.56 (m,4 H), 7.73 (d, J = 7.2 Hz, 2 H) 2-42 (DMSO-d6-300)1.18 (s, 6 H), 1.61 (dd, J = 9.8,5.7 Hz, 1 H), 2.00 (dd, J = 8.5,5.7 Hz, 1 H), 2.71 (dd, J = 9.8,8.5 Hz, 1 H), 3.63 (s, 2 H),4.61 (brs, 1 H), 6.72-6.82 (m, 3 H),7.14 (dd, J = 7.9, 7.9 Hz, 1 H),7.52 (d, J = 8.7 Hz, 2 H), 7.56 (d,J = 3.8 Hz, 1 H), 7.58 (d, J = 3.8 Hz,1 H), 7.75 (d, J = 8.7 Hz, 2 H),9.17 (s, 1 H), 12.23 (s, 1 H) 2-43 (DMSO-d6-300)1.61-1.63 (m, 1 H), 2.04 (dd, J = 8.8,5.5 Hz, 1 H), 2.76 (t, J = 8.8 Hz, 1 H),7.19-7.24 (m, 5 H), 7.69 (d,J = 4.0 Hz, 1 H), 7.85 (d, J = 4.0 Hz,1 H), 8.16 (s, 1 H), 9.39 (brs, 1 H),12.22 (brs, 1 H) 2-44 (DMSO-d6-300)1.63 (dd, J = 6.0, 9.0 Hz, 1 H),2.04 (dd, J = 6.0, 9.0 Hz, 1 H),2.75 (t, J = 9.0 Hz, 1 H), 7.10-7.27(m, 5 H), 7.70 (d, J = 3.0 Hz,1 H), 7.94 (d, J = 3.0 Hz, 1 H) 2-45 (DMSO-d6-300)1.62 (dd, J = 6.0, 9.0 Hz, 1 H),2.03 (dd, J = 6.0, 9.0 Hz, 1 H),2.75 (t, J = 9.0 Hz, 1 H), 7.11-7.27(m, 5 H), 7.70 (d, J = 3.0 Hz,1 H), 7.94 (d, J = 3.0 Hz, 1 H)

TABLE 2-10 Example Structural formula NMR 2-46 (CDCl3-300)1.73 (dd, J = 6.0, 9.0 Hz, 1 H), 1.99-2.05(m, 1 H), 2.33 (q, J = 9.0 Hz,1 H), 5.14 (d, J = 9.0 Hz, 1 H),5.30 (d, J = 18.0 Hz, 1 H), 5.50-5.59(m, 1 H), 5.63 (brs, 1 H),7.20 (d, J = 3.0 Hz, 1 H), 7.41 (d,J = 9.0 Hz, 2 H), 7.49-7.56 (m, 3 H) 2-47 (MeOH-d4-300)1.62-1.75 (m, 2 H), 2.18-2.34 (m,1 H), 4.67 (dd, J = 6.0, 12.0 Hz, 1 H),4.74-4.84 (m, 1 H), 7.33 (d,J = 3.0 Hz, 1 H), 7.40-7.47 (m, 3 H),7.63 (d, J = 9.0 Hz, 2 H), 7.89 (t,J = 7.5 Hz, 1 H), 8.04 (t, J = 7.5 Hz,1 H), 8.15 (d, J = 9.0 Hz, 1 H),8.32 (d, J = 9.0 Hz, 1 H) 2-48 (CDCl3-300)0.92 (t, J = 7.5 Hz, 3 H), 1.36-1.70(m, 4 H), 1.79 (dd, J = 6.0,9.0 Hz, 1 H), 5.59 (brs, 1 H),7.21 (d, J = 3.0 Hz, 1 H), 7.37-7.44(m, 2 H), 7.50-7.57 (m, 3 H) 2-49 (DMSO-d6-300)1.59 (dd, J = 5.3, 2.6 Hz, 1 H),1.98 (dd, J = 8.7, 5.7 Hz, 1 H), 2.79-2.86(m, 1 H), 2.87 (s, 3 H), 3.51-3.70(m, 2 H), 4.14-4.24 (m, 1 H),4.34-4.45 (m, 1 H), 6.87 (t,J = 7.3 Hz, 1 H), 6.95 (d, J = 7.9 Hz,1 H), 7.07 (d, J = 7.2 Hz, 1 H),7.20 (t, J = 7.7 Hz, 1 H), 7.54 (d,J = 8.7 Hz, 2 H), 7.61 (d, J = 4.1 Hz,1 H), 7.62 (d, J = 4.1 Hz, 1 H),7.76 (d, J = 8.7 Hz, 2 H) 2-50 (DMSO-d6-300)1.59 (dd, J = 9.8, 5.5 Hz, 1 H),2.01 (dd, J = 8.5, 5.5 Hz, 1 H), 2.66-2.77(m, 1 H), 2.70 (s, 3 H), 7.14-7.30(m, 5 H), 7.53 (d, J = 3.8 Hz,1 H), 7.55 (d, J = 3.8 Hz, 1 H),8.05 (s, 1 H), 9.13 (s, 1 H),12.17 (s, 1 H)

TABLE 2-11 Example Structural formula NMR 2-51 (DMSO-d6-300)1.62 (dd, J = 10.0, 6.5 Hz, 1 H),2.03 (dd, J = 10.0, 6.5 Hz, 2 H),2.65 (s, 3 H), 2.75 (t, J = 10.0 Hz,1 H), 7.12-7.28 (m, 5 H), 7.63 (d,J = 3.8 Hz, 1 H), 7.75 (d, J = 10.0 Hz,1 H), 9.34 (brs, 1 H), 12.20 (brs,1 H) 2-52 (CDCl3-300)1.65 (dd, J = 6.0, 9.0 Hz, 1 H), 1.89-1.98(m, 1 H), 2.10-2.26 (m, 1 H),3.85-3.96 (m, 1 H), 4.26 (dd, J = 6.0,9.0 Hz, 1 H), 5.80 (brs, 1 H),6.82 (d, J = 9.0 Hz, 2 H), 6.93 (t,J = 7.5 Hz, 1 H), 7.16 (d, J = 6.0 Hz,1 H), 7.20-7.28 (m, 2 H), 7.39 (d,J = 9.0 Hz, 2 H), 7.51 (d, J = 9.0 Hz,2 H), 7.55 (d, J = 6.0 Hz, 1 H) 2-53 (DMSO-d6-300)1.38 (s, 9 H), 1.59 (dd, J = 9.6,5.5 Hz, 1 H), 2.00 (dd, J = 8.5,5.8 Hz, 1 H), 2.84 (dd, J = 9.4,4.7 Hz, 1 H), 3.33-3.53 (m, 2 H),4.09-4.21 (m, 1 H), 4.21-4.32 (m,1 H), 6.88 (t, J = 7.5 Hz, 1 H),6.95 (d, J = 7.9 Hz, 1 H), 7.08 (d,J = 7.5 Hz, 1 H), 7.21 (t, J = 7.5 Hz,1 H), 7.54 (d, J = 8.7 Hz, 2 H),7.60 (s, 2 H), 7.76 (d, J = 8.7 Hz,2 H), 8.44-8.74 (m, 1 H), 8.83-9.24(m, 1 H), 12.31 (brs, 1 H) 2-54 (DMSO-d6-300)1.26 (s, 6 H), 1.58 (dd, J = 9.8,5.7 Hz, 1 H), 2.01 (dd, J = 8.7,5.3 Hz, 1 H), 2.74 (t, J = 9.2 Hz, 1 H),4.13 (s, 2 H), 7.17-7.27 (m, 5 H),7.51 (d, J = 3.8 Hz, 1 H), 7.53 (d,J = 4.1 Hz, 1 H), 9.32 (brs, 1 H),12.20 (brs, 1 H) 2-55 (DMSO-d6-300)1.61 (dd, J = 9.8, 5.7 Hz, 1 H),2.03 (dd, J = 8.7, 5.7 Hz, 1 H),2.68 (s, 3 H), 2.75 (dd, J = 9.8,8.7 Hz, 1 H), 7.14-7.30 (m, 5 H),7.33 (d, J = 4.1 Hz, 1 H), 7.52 (d,J = 4.1 Hz, 1 H), 8.02 (s, 1 H),9.22 (s, 1 H), 12.22 (s, 1 H)

TABLE 2-12 Example Structural formula NMR 2-56 (DMSO-d6-300)1.61 (dd, J = 8.9, 5.8 Hz, 1 H),1.99 (dd, J = 8.9, 5.8 Hz, 1 H),2.69 (d, J = 8.9 Hz, 1 H), 5.25 (s,2 H), 6.24 (t, J = 2.1 Hz, 1 H),6.98 (d, J = 7.5 Hz, 1 H), 7.10-7.23(m, 3 H), 7.43 (d, J = 1.5 Hz,1 H), 7.56 (d, J = 3.8 Hz, 1 H),7.72 (d, J = 1.9 Hz, 1 H), 7.83 (d,J = 3.8 Hz, 1 H), 8.01-8.10 (m, 2 H),8.62 (d, J = 1.5 Hz, 1 H), 9.20 (s,1 H), 12.20 (brs, 1 H) 2-57 (DMSO-d6-300)1.62 (dd, J = 9.0, 5.7 Hz, 1 H),2.00 (dd, J = 9.0, 5.7 Hz, 1 H),2.71 (t, J = 9.0 Hz, 1 H), 3.24 (s,3 H), 4.33 (s, 2 H), 7.06-7.24 (m,4 H), 7.56 (d, J = 3.8 Hz, 1 H),7.83 (d, J = 4.1 Hz, 1 H), 8.00-8.10(m, 2 H), 8.62 (d, J = 2.3 Hz,1 H), 9.18 (brs, 1 H), 12.17 (brs,1 H) 2-58 (DMSO-d6-300)1.13 (m, 1 H), 1.26 (q, J = 4.8 Hz,1 H), 1.46 (d, J = 7.9 Hz, 1 H), 1.66-1.86(m, 5 H), 1.91-2.06 (m, 1 H),2.15-2.27 (m, 1 H), 7.45-7.55 (m,4 H), 7.73 (d, J = 8.7 Hz, 2 H),8.78 (brs, 1 H), 12.33 (brs, 2 H) 2-59 (DMSO-d6-300)0.87-0.90 (m, 6 H), 1.15-1.23 (m,3 H), 1.37-1.40 (m, 1 H), 7.48-7.54(m, 4 H), 7.73 (dd, J = 6.8,1.9 Hz, 2 H), 8.89 (s, 1 H), 12.52 (s,1 H) 2-60 (CDCl3-300)2.04-2.16 (m, 2 H), 2.95 (t,J = 9.6 Hz, 1 H), 6.11 (brs, 1 H),7.11-7.29 (m, 5 H), 7.39 (d,J = 4.1 Hz, 1 H), 7.51 (d, J = 3.8 Hz,1 H), 7.79 (s, 1 H)

TABLE 2-13 Example Structural formula NMR 2-61 (CDCl3-300)1.17-1.37 (m, 2 H), 1.42-1.84 (m,10 H), 5.63 (brs, 1 H), 7.20 (d,J = 6.0 Hz, 1 H), 7.41 (d, J = 9.0 Hz,2 H), 7.49-7.58 (m, 3 H) 2-62 (CDCl3-300)0.92 (s, 9 H), 1.49 (t, J = 9.0 Hz,1 H), 1.62-1.73 (m, 2 H), 5.70 (brs,1 H), 7.22 (d, J = 3.0 Hz, 1 H),7.41 (d, J = 9.0 Hz, 2 H), 7.51-7.57(m, 3 H) 2-63 (DMSO-d6-300)1.67 (dd, J = 9.6, 5.8 Hz, 1 H),2.09 (dd, J = 8.5, 5.8 Hz, 1 H),2.66 (t, J = 9.0 Hz, 1 H), 4.52 (d,J = 14.7 Hz, 1 H), 4.73 (d, J = 14.7 Hz,1 H), 5.05 (brs, 1 H), 7.04 (d,J = 7.2 Hz, 1 H), 7.11 (t, J = 7.3 Hz,1 H), 7.19 (t, J = 7.5 Hz, 1 H),7.37 (d, J = 6.8 Hz, 1 H), 7.53 (d,J = 8.7 Hz, 2 H), 7.58 (q, J = 3.8 Hz,2 H), 7.76 (d, J = 8.7 Hz, 2 H),9.25 (brs, 1 H), 12.17 (brs, 1 H) 2-64 (acetone-d6-400)1.58-2.04 (m, 2 H), 2.51-3.47(complexm, 12 H), 6.81-7.41 (m,9 H) 2-65 (DMSO-d6-400)1.60 (dd, J = 5.5, 9.7 Hz, 1 H),2.01 (dd, J = 5.6, 8.6 Hz, 1 H),2.72 (t, J = 9.2 Hz, 1 H), 6.83 (d,J = 8.7 Hz, 2 H), 7.16-7.33 (m, 7 H),7.47-7.54 (m, 3 H), 9.09 (bs, 1 H),9.87 (bs, 1 H), 12.2 (bs, 1 H)

TABLE 2-14 Example Structural formula NMR 2-66 (MeOH-d4-400)1.89 (dd, J = 5.8, 9.8 Hz, 1 H),2.14 (dd, J = 5.8, 8.6 Hz, 1 H),2.57 (s, 3 H), 2.83 (t, J = 9.2 Hz,1 H), 7.15-7.27 (m, 5 H), 7.61 (d,J = 4.0 Hz, 1 H), 7.77 (d, J = 4.0 Hz,1 H) 2-67 (MeOH-d4-400)1.96 (dd, J = 5.4, 9.5 Hz, 1 H),2.06 (dd, J = 6.0, 8.2 Hz, 1 H), 2.53-2.57(m, 1 H), 3.10-3.19 (m, 4 H),3.34-3.49 (m, 4 H), 6.93-6.99 (m,4 H), 7.10-7.28 (m, 5 H) 2-68 (MeOH-d4-400)1.96 (dd, J = 5.7, 9.8 Hz, 1 H),2.12 (dd, J = 5.7, 8.5 Hz, 1 H), 2.75-2.79(m, 1 H), 3.12-3.41 (m, 4 H),3.46-3.83 (m, 4 H), 6.91 (d,J = 9.1 Hz, 1 H), 7.15-7.29 (m, 5 H),7.73 (dd, J = 2.5, 9.0 Hz, 1 H),8.34 (s, 1 H) 2-69 (DMSO-d6-300)1.67 (q, J = 5.1 Hz, 1 H), 2.05 (q,J = 5.1 Hz, 1 H), 2.69-3.60 (m, 11 H),7.15-7.31 (m, 4 H), 7.51-7.61 (m,4 H), 7.72-7.79 (m, 2 H), 9.13 (brs,1 H), 12.31 (brs, 1 H) 2-70 (MeOH-d4-300)2.14 (dd, J = 6.0, 9.0 Hz, 1 H),2.31 (dd, J = 6.0, 9.0 Hz, 1 H),3.18 (t, J = 9.0 Hz, 1 H), 7.38-7.46(m, 3 H), 7.61 (d, J = 6.0 Hz,1 H), 7.66 (d, J = 9.0 Hz, 2 H),8.04 (t, J = 6.0 Hz, 1 H), 8.63 (d,J = 6.0 Hz, 1 H), 8.73 (d, J = 6.0 Hz,1 H), 8.80 (s, 1 H)

TABLE 2-15 Example Structural formula NMR 2-71 (DMSO-d6-300)1.46-1.76 (m, 1 H), 1.77-2.00 (m,1 H), 2.65-2.75 (m, 4 H), 2.95-3.43(m, 5 H), 3.53-3.64 (m, 2 H),7.12-7.28 (m, 3 H), 7.53-7.57 (m,4 H), 7.72-7.78 (m, 3 H), 8.97 (brs,1 H), 12.41 (brs, 1 H) 2-72 (DMSO-d6-300)1.69 (dd, J = 5.1, 2.6 Hz, 1 H),1.87 (dd, J = 8.9, 5.8 Hz, 1 H),2.96 (t, J = 9.0 Hz, 1 H), 3.28-3.31(m, 2 H), 3.53-3.55 (m, 2 H),4.98 (brs, 1 H), 7.20-7.34 (m, 5 H),7.53-7.57 (m, 4 H), 7.75-7.76 (m,2 H), 8.10 (t, J = 5.7 Hz, 1 H),8.85 (brs, 1 H), 12.31 (brs, 1 H) 2-73 (DMSO-d6-300)1.66 (dd, J = 9.6, 5.8 Hz, 1 H),2.08 (dd, J = 8.5, 6.2 Hz, 1 H),2.81 (t, J = 8.9 Hz, 1 H), 3.49-3.64(m, 8 H), 7.22-7.33 (m, 4 H),7.49-7.59 (m, 4 H), 7.76 (d,J = 8.7 Hz, 2 H), 9.20 (brs, 1 H),12.30 (brs, 1 H) 2-74 (DMSO-d6-300)1.30 (s, 6 H), 1.68 (dd, J = 9.0,5.7 Hz, 1 H), 2.08 (dd, J = 8.1,7.0 Hz, 1 H), 2.80 (t, J = 9.0 Hz, 1 H),3.49 (d, J = 6.0 Hz, 2 H), 4.92 (t,J = 6.2 Hz, 1 H), 7.29-7.35 (m, 2 H),7.40-7.80 (m, 9 H), 9.22 (brs, 1 H),12.25 (brs, 1 H) 2-75 (DMSO-d6-300)1.67 (dd, J = 9.8, 5.7 Hz, 1 H),2.09 (dd, J = 8.3, 5.7 Hz, 1 H),2.80 (t, J = 9.4 Hz, 1 H), 3.30 (t,J = 5.8 Hz, 2 H), 3.49 (brt, J = 5.7 Hz,2 H), 4.71 (brs, 1 H), 7.30-7.36 (m,2 H), 7.50-7.59 (m, 4 H), 7.65-7.78(m, 4 H), 8.37 (t, J = 5.1 Hz,1 H), 9.23 (brs, 1 H), 12.25 (brs,1 H)

TABLE 2-16 Example Structural formula NMR 2-76 (DMSO-d6-300)1.25 (brs, 1 H), 1.97 (brs, 1 H),2.73 (brs, 1 H), 3.40-3.64 (m, 8 H),7.14-7.30 (m, 4 H), 7.52 (d,J = 8.7 Hz, 2 H), 7.58 (s, 2 H),7.76 (d, J = 8.7 Hz, 2 H) 2-77 (DMSO-d6-300)1.33 (s, 3 H), 1.37 (s, 3 H),1.75 (dd, J = 5.0, 2.5 Hz, 1 H),2.03 (dd, J = 9.0, 5.7 Hz, 1 H),3.00 (t, J = 9.4 Hz, 1 H), 4.02-4.15(m, 2 H), 7.28-7.33 (m, 2 H),7.53 (d, J = 8.7 Hz, 2 H), 7.60-7.61(m, 2 H), 7.74-7.76 (m, 4 H) 2-78 (DMSO-d6-300)1.28 (s, 3 H), 1.29 (s, 3 H),1.63 (dd, J = 5.1, 2.6 Hz, 1 H),1.89 (dd, J = 8.5, 5.5 Hz, 1 H), 2.75-2.88(m, 1 H), 3.48 (d, J = 10.9 Hz,1 H), 3.55 (d, J = 10.5 Hz, 1 H), 7.14-7.27(m, 4 H), 7.55 (dt, J = 12.4,4.8 Hz, 4 H), 7.75 (d, J = 8.7 Hz, 2 H) 2-79 (DMSO-d6-300)1.61 (dd, J = 8.9, 6.0 Hz, 1 H),2.00 (dd, J = 8.3, 6.0 Hz, 1 H),2.48 (s, 3 H), 2.70 (dd, J = 8.9,8.3 Hz, 1 H), 7.13-7.28 (m, 5 H),7.39 (d, J = 4.1 Hz, 1 H), 7.56 (d,J = 4.1 Hz, 1 H), 7.58 (s, 1 H) 2-80 (MeOH-d4-400)1.78-1.84 (m, 1 H), 2.05-2.08 (m,1 H), 2.63 (s, 3 H), 2.71 (t,J = 8.7 Hz, 1 H), 7.12-7.24 (m, 5 H),7.99 (d, J = 8.3 Hz, 2 H), 8.11 (d,J = 8.1 Hz, 2 H)

TABLE 2-17 Example Structural formula NMR 2-81 (MeOH-d4-400)1.86 (dd, J = 5.8, 9.9 Hz, 1 H),2.13 (dd, J = 5.8, 8.7 Hz, 1 H),2.83 (t, J = 9.3 Hz, 1 H), 7.14-7.26(m, 5 H), 7.57-7.70 (m, 5 H),7.98-8.02 (m, 2 H) 2-82 (MeOH-d4-400)1.90 (dd, J = 5.8, 9.8 Hz, 1 H),2.12 (dd, J = 5.8, 8.7 Hz, 1 H),2.81 (t, J = 9.2 Hz, 1 H), 7.02 (d,J = 4.0 Hz, 1 H), 7.14-7.27 (m, 5 H),7.43 (d, J = 4.1 Hz, 1 H) 2-83 (MeOH-d4-400)1.83 (dd, J = 5.7, 9.8 Hz, 1 H),2.09 (dd, J = 5.7, 8.6 Hz, 1 H),2.78 (t, J = 9.2 Hz, 1 H), 7.09-7.26(m, 6 H), 7.62 (dd, J = 1.3,3.7 Hz, 1 H), 7.75 (dd, J = 1.3,5.0 Hz, 1 H) 2-84 (DMSO-d6-300)1.61-1.73 (m, 1 H), 1.92-2.02 (m,1 H), 2.12 (t, J = 19.2 Hz, 3 H), 7.07-7.27(m, 5 H), 7.67 (d, J = 3.8 Hz,1 H), 7.70 (s, 1 H), 7.80 (d,J = 3.8 Hz, 1 H) 2-85 (DMSO-d6-300)1.60 (dd, J = 9.6, 5.5 Hz, 1 H),2.02 (dd, J = 8.7, 5.7 Hz, 1 H),2.45 (s, 3 H), 2.74 (t, J = 9.2 Hz,1 H), 6.82 (s, 1 H), 7.16-7.25 (m,5 H), 7.59 (d, J = 4.0 Hz, 1 H),7.64 (d, J = 4.0 Hz, 1 H), 9.28 (s,1 H), 12.20 (brs, 1 H)

TABLE 2-18 Example Structural formula NMR 2-86 (DMSO-d6-300)1.69 (dd, J = 9.6, 5.5 Hz, 1 H),2.05 (dd, J = 8.7, 5.3 Hz, 1 H),2.40 (s, 3 H), 2.79 (t, J = 8.5 Hz,1 H), 7.24-7.30 (m, 2 H), 7.35 (t,J = 9.0 Hz, 1 H), 7.51 (d, J = 9.0 Hz,2 H), 7.56 (s, 2 H), 7.68-7.81 (m,4 H), 9.21 (s, 1 H), 12.29 (brs, 1 H) 2-87 (DMSO-d6-300)1.55-1.63 (m, 1 H), 1.96-2.04 (m,1 H), 2.46 (s, 3 H), 2.65-2.76 (m,1 H), 7.13-7.29 (m, 6 H), 7.38 (d,J = 4.1 Hz, 1 H), 7.54 (d, J = 4.1 Hz,1 H), 8.55 (s, 1 H), 9.12 (s, 1 H),12.19 (s, 1 H) 2-88 (DMSO-d6-300)1.59 (dd, J = 5.5, 9.2 Hz, 1 H),2.02 (dd, J = 9.2, 5.5 Hz, 1 H),2.47 (s, 3 H), 2.74 (t, J = 9.2 Hz,1 H), 7.15-7.30 (m, 5 H), 7.45 (d,J = 4.1 Hz, 1 H), 7.59 (d, J = 4.1 Hz,1 H), 9.23 (s, 1 H), 12.19 (s, 1 H) 2-89 (DMSO-d6-300)1.71-1.74 (m, 1 H), 2.07 (brs, 1 H),2.11 (s, 3 H), 2.60-2.67 (m, 1 H),3.26 (s, 3 H), 3.48-3.53 (m, 3 H),3.67 (d, J = 13.2 Hz, 1 H), 7.08-7.20(m, 4 H), 7.54-7.57 (m, 4 H),7.75 (d, J = 9.0 Hz, 2 H) 2-90 (DMSO-d6-300)0.94 (t, J = 7.3 Hz, 3 H), 1.63-1.69(m, 3 H), 1.97-2.03 (m, 1 H),2.69-2.79 (m, 3 H), 6.88 (s, 1 H),7.16-7.23 (m, 5 H), 7.60 (d,J = 4.1 Hz, 1 H), 7.65 (d, J = 4.1 Hz,1 H), 12.19 (brs, 1 H)

TABLE 2-19 Example Structural formula NMR 2-91 (DMSO-d6-300)1.78-1.83 (m, 1 H), 1.93-1.98 (m,1 H), 2.35-2.39 (m, 4 H), 2.66-2.70(m, 1 H), 3.27 (d, J = 12.1 Hz,1 H), 3.48-3.57 (m, 4 H), 3.72 (d,J = 13.6 Hz, 1 H), 7.02-7.09 (m, 3 H),7.17-7.20 (m, 1 H), 7.50 (d,J = 8.3 Hz, 2 H), 7.55 (s, 2 H),7.73 (d, J = 8.3 Hz, 2 H) 2-92 (DMSO-d6-300)1.25 (t, J = 7.7 Hz, 3 H), 1.61 (dd,J = 5.1, 2.6 Hz, 1 H), 2.01 (dd,J = 8.7, 5.7 Hz, 1 H), 2.72 (t,J = 8.9 Hz, 1 H), 2.80 (q, J = 7.5 Hz,1 H), 6.88 (s, 1 H), 7.16-7.27 (m,5 H), 7.61 (d, J = 3.8 Hz, 1 H),7.66 (d, J = 4.1 Hz, 1 H), 12.23 (brs,1 H) 2-93 (MeOH-d4-400)0.95 (t, J = 7.41 Hz, 3 H), 1.57-1.66(m, 2 H), 1.89 (dd, J = 5.6,9.6 Hz, 1 H), 2.10 (dd, J = 5.9,8.0 Hz, 1 H), 2.72 (t, J = 9.0 Hz, 1 H),3.28-3.30 (m, 2 H), 7.12-7.25 (m,5 H), 7.56 (d, J = 3.9 Hz, 1 H),7.59 (d, J = 3.9 Hz, 1 H) 2-94 (MeOH-d4-400)1.23 (d, J = 6.6 Hz, 6 H), 1.85-1.91(m, 1 H), 2.09-2.13 (m, 1 H),2.76 (t, J = 7.9 Hz, 1 H), 4.11-4.18(m, 1 H), 7.12-7.27 (m, 5 H),7.55 (s, 1 H), 7.63 (s, 1 H) 2-95 (MeOH-d4-400)1.52-2.17 (m, 10 H), 2.79 (t,J = 9.3 Hz, 1 H), 4.22-4.30 (m, 1 H),7.12-7.28 (m, 5 H), 7.55 (s, 1 H),7.64 (s, 1 H),

TABLE 2-20 Example Structural formula NMR 2-96 (MeOH-d4-400)1.92 (dd, J = 5.4, 9.2 Hz, 1 H), 2.13-2.18(m, 1 H), 2.81 (t, J = 8.9 Hz,1 H), 7.14-7.37 (m, 8 H), 7.61-7.66(m, 3 H), 7.83 (s, 1 H) 2-97 (MeOH-d4-400)1.85-1.92 (m, 1 H), 2.09-2.15 (m,1 H), 2.43-2.54 (m, 2 H), 2.78 (t,J = 9.3 Hz, 1 H), 3.59 (t, J = 6.9 Hz,2 H), 7.11-7.29 (m, 5 H), 7.58 (s,2 H) 2-98 (CDCl3-300)2.15-2.17 (m, 1 H), 2.35-2.39 (m,1 H), 2.87 (t, J = 9.4 Hz, 1 H), 5.35-5.46(m, 2 H), 6.65 (d, J = 2.3 Hz,1 H), 7.20-7.26 (m, 5 H), 7.37 (d,J = 3.8 Hz, 1 H), 7.61 (d, J = 3.8 Hz,1 H) 2-99 (DMSO-d6-300)1.62 (dd, J = 9.8, 5.7 Hz, 1 H), 1.99-2.02(m, 1 H), 2.71 (t, J = 8.9 Hz,1 H), 7.31-7.43 (m, 6 H), 7.65 (d,J = 4.1 Hz, 1 H), 7.68 (s, 1 H),7.82 (d, J = 4.1 Hz, 1 H) 2-100 (DMSO-d6-300)1.27 (d, J = 5.1 Hz, 1 H), 1.34 (s,3 H), 2.02 (d, J = 5.1 Hz, 1 H),4.03 (s, 2 H), 7.12-7.19 (m, 5 H),7.62 (dd, J = 8.3, 1.7 Hz, 1 H),7.79 (dd, J = 8.3, 1.7 Hz, 1 H),7.86 (s, 1 H), 7.95-7.97 (m, 2 H),8.08 (d, J = 8.3 Hz, 1 H), 8.86 (s,1 H), 11.91 (s, 1 H)

TABLE 2-21 Example Structural formula NMR 2-101 (DMSO-d6-400)1.38-1.42 (m, 4 H), 2.10 (d,J = 5.6 Hz, 1 H), 7.11-7.26 (m, 5 H),7.49-7.60 (m, 4 H), 7.72-7.77 (m,2 H), 9.20 (brs, 1 H), 12.11 (brs,1 H) 2-102 (CDCl3-300)2.10-2.15 (m, 2 H), 2.94 (t,J = 9.4 Hz, 1 H), 5.85 (brs, 1 H),6.83 (t, J = 55.8 Hz, 1 H), 7.06 (d,J = 3.8 Hz, 1 H), 7.20 (d, J = 47.5 Hz,7 H), 7.49 (d, J = 4.1 Hz, 1 H) 2-103 (MeOH-d4-400)1.80-1.84 (m, 1 H), 2.07-2.13 (m,1 H), 2.73 (t, J = 8.6 Hz, 1 H), 7.09-7.26 (m, 5 H), 7.45 (s, 1 H), 7.51 (s,1 H) 2-104 (MeOH-d4-400)1.20 (t, J = 7.24 Hz, 3 H), 1.89 (dd,J = 5.6, 9.8 Hz, 1 H), 2.12 (dd,J = 5.8, 8.7 Hz, 1 H), 2.80 (t,J = 9.2 Hz, 1 H), 3.37 (q, J = 7.2 Hz,2 H), 7.13-7.27 (m, 5 H), 7.56 (d,J = 4.0 Hz, 1 H), 7.58 (d, J = 4.0 Hz,1 H) 2-105 (MeOH-d4-400)0.60-0.64 (m, 2 H), 0.79 (dt, J = 5.0,7.1 Hz, 2 H), 1.89 (dd, J = 5.7,9.8 Hz, 1 H), 2.10 (dd, J = 5.6,8.7 Hz, 1 H), 2.74 (t, J = 9.1 Hz, 1 H),2.77-2.84 (m, 1 H), 7.12-7.25 (m,5 H), 7.54 (d, J = 4.0 Hz, 1 H),7.56 (d, J = 4.0 Hz, 1 H)

TABLE 2-22 Example Structural formula NMR 2-106 (MeOH-d4-400)1.91 (dd, J = 5.8, 9.8 Hz, 1 H), 2.12-2.18 (m, 1 H), 2.84 (t, J = 9.3 Hz,1 H), 4.05 (dd, J = 9.8, 18.9 Hz, 2 H),7.15-7.27 (m, 5 H), 7.59 (d,J = 4.0 Hz, 1 H), 7.67 (d, J = 4.0 Hz,1 H) 2-107 (DMSO-d6-300)1.39 (s, 3 H), 1.42 (d, J = 5.7 Hz,1 H), 2.06-2.19 (m, 1 H), 2.11 (t,J = 10.2 Hz, 3 H), 7.08-7.12 (m, 3 H),7.24 (t, J = 7.3 Hz, 2 H), 7.65 (d,J = 3.8 Hz, 1 H), 7.71 (s, 1 H),7.80 (d, J = 4.1 Hz, 1 H), 9.37 (brs,1 H), 12.12 (brs, 1 H) 2-108 (MeOH-d4-300)1.92 (dd, J = 9.8, 5.7 Hz, 1 H),1.98 (s, 3 H), 2.11 (dd, J = 8.7,5.7 Hz, 1 H), 2.75 (t, J = 9.2 Hz, 1 H),2.86 (t, J = 7.0 Hz, 2 H), 4.20 (t,J = 7.0 Hz, 2 H), 7.02-7.06 (m, 1 H),7.08-7.18 (m, 3 H), 7.36-7.45 (m,3 H), 7.58 (d, J = 3.8 Hz, 1 H),7.66 (d, J = 8.3 Hz, 2 H) 2-109 (MeOH-d4-300)1.92 (dd, J = 9.8, 5.7 Hz, 1 H), 2.08-2.13 (m, 1 H), 2.71-2.78 (m, 3 H),3.69 (t, J = 6.8 Hz, 2 H), 7.03 (d,J = 6.0 Hz, 1 H), 7.07-7.18 (m, 3 H),7.36-7.45 (m, 3 H), 7.58 (dd, J = 4.1,0.4 Hz, 1 H), 7.62-7.68 (m, 2 H) 2-110 (DMSO-d6-300)1.62 (dd, J = 9.8, 5.7 Hz, 1 H), 1.98-1.99 (m, 1 H), 2.68 (t, J = 8.9 Hz,1 H), 3.34 (s, 3 H), 4.59 (s, 2 H),7.16-7.23 (m, 6 H), 7.60 (d,J = 4.1 Hz, 1 H), 7.71 (d, J = 4.1 Hz,1 H)

TABLE 2-23 Example Structural formula NMR 2-111 (DMSO-d6-300)1.63 (dd, J = 8.5, 5.8 Hz, 1 H),2.03 (dd, J = 8.5, 5.8 Hz, 1 H),2.75 (t, J = 8.5 Hz, 1 H), 6.55 (s,1 H), 7.18-7.28 (m, 5 H), 7.70 (d,J = 4.1 Hz, 1 H), 7.89 (d, J = 4.1 Hz,1 H), 8.28 (s, 1 H) 2-112 (DMSO-d6-300)1.39 (s, 3 H), 1.42 (d, J = 5.7 Hz,1 H), 2.11 (d, J = 5.7 Hz, 1 H), 7.12-7.28 (m, 5 H), 7.68 (d, J = 3.8 Hz,1 H), 7.89 (d, J = 3.8 Hz, 1 H),8.28 (s, 1 H), 9.42 (s, 1 H),12.13 (s, 1 H) 2-113 (DMSO-d6-300)1.66 (dd, J = 9.8, 5.7 Hz, 1 H),2.06 (dd, J = 8.5, 5.5 Hz, 1 H),2.78 (t, J = 9.4 Hz, 1 H), 7.20-7.30 (m, 5 H), 7.41-7.43 (m, 2 H),7.47 (d, J = 4.1 Hz, 1 H), 7.57 (d,J = 3.8 Hz, 1 H), 7.87-7.89 (m, 2 H),8.00-8.02 (m, 1 H), 9.29 (brs, 1 H),12.26 (brs, 1 H) 2-114 (DMSO-d6-300)1.66 (dd, J = 9.8, 5.7 Hz, 1 H),2.05 (dd, J = 8.5, 5.8 Hz, 1 H),2.77 (t, J = 9.4 Hz, 1 H), 7.19-7.27 (m, 5 H), 7.56-7.64 (m, 3 H),7.68-7.69 (m, 2 H), 7.74 (d,J = 3.8 Hz, 1 H), 7.91-7.93 (m, 2 H),12.27 (brs, 1 H) 2-115 (DMSO-d6-400)1.64 (dd, J = 10.2, 5.8 Hz, 1 H),2.04 (dd, J = 8.6, 5.8 Hz, 1 H),2.76 (t, J = 9.3 Hz, 1 H), 6.03 (d,J = 45.5 Hz, 2 H), 7.14-7.28 (m, 5 H),7.61 (d, J = 4.2 Hz, 1 H), 7.82 (d,J = 4.2 Hz, 1 H), 9.35 (brs, 1 H),12.20 (brs, 1 H)

TABLE 2-24 Example Structural formula NMR 2-116 (acetone-d6-400)1.15 (t, J = 7.3 Hz, 3 H), 1.92 (dd,J = 5.7, 9.8 Hz, 1 H), 2.16 (dd,J = 5.7, 8.7 Hz, 1 H), 2.91 (t,J = 9.3 Hz, 1 H), 3.03 (q, J = 7.3 Hz,2 H), 7.16-7.29 (m, 5 H), 8.01 (s,1 H), 8.41 (s, 1 H) 2-117 (acetone-d6-400)0.98 (t, J = 7.4 Hz, 3 H),1.72 (sextet, J = 3.7 Hz, 2 H),1.91 (dd, J = 5.7, 9.8 Hz, 1 H),2.16 (dd, J = 5.8, 8.7 Hz, 1 H),2.91 (t, J = 9.3 Hz, 1 H), 2.98 (t,J = 7.2 Hz, 2 H), 7.16-7.29 (m, 5 H),8.03 (s, 1 H), 8.42 (s, 1 H) 2-118 (DMSO-d6-300)1.65 (dd, J = 5.1, 2.6 Hz, 1 H),2.05 (dd, J = 8.3, 5.7 Hz, 1 H),2.77 (t, J = 9.2 Hz, 1 H), 7.20-7.27 (m, 5 H), 7.48-7.53 (m, 3 H),7.65 (d, J = 3.8 Hz, 1 H), 8.11 (d,J = 7.9 Hz, 2 H), 8.17 (s, 1 H),9.23 (brs, 1 H), 12.25 (brs, 1 H) 2-119 (CDCl3-300)2.05-2.16 (m, 2 H), 2.92 (t,J = 9.0 Hz, 1 H), 6.11 (brs, 1 H),6.99 (t, J = 54.0 Hz, 1 H), 7.12-7.28 (m, 5 H), 7.36 (d, J = 3.0 Hz,1 H), 7.57 (d, J = 3.0 Hz, 1 H),7.64 (s, 1 H) 2-120 (DMSO-d6-400)1.63 (dd, J = 9.7, 5.6 Hz, 1 H),2.03 (dd, J = 8.6, 5.8 Hz, 1 H),2.74 (t, J = 9.3 Hz, 1 H), 5.83 (d,J = 46.8 Hz, 2 H), 7.15-7.28 (m, 5 H),7.59 (d, J = 4.2 Hz, 1 H), 7.73 (d,J = 4.2 Hz, 1 H), 8.03 (d, J = 2.3 Hz,1 H), 9.27 (brs, 1 H), 12.20 (brs,1 H)

TABLE 2-25 Example Structural formula NMR 2-121 (DMSO-d6-400)1.39 (s, 3 H), 1.42 (d, J = 5.6 Hz,1 H), 2.10 (d, J = 5.6 Hz, 1 H),5.83 (d, J = 46.4 Hz, 2 H), 7.10-7.27 (m, 5 H), 7.57 (d, J = 3.7 Hz,1 H), 7.73 (d, J = 3.7 Hz, 1 H),8.03 (d, J = 2.3 Hz, 1 H), 9.27 (brs,1 H), 12.11 (brs, 1 H) 2-122 (DMSO-d6-400)1.66 (dd, J = 5.1, 2.6 Hz, 1 H),2.04 (dd, J = 8.3, 5.6 Hz, 1 H),2.74 (t, J = 9.5 Hz, 1 H), 7.14-7.27 (m, 5 H), 7.30 (t, J = 7.9 Hz,1 H), 7.37 (t, J = 7.9 Hz, 1 H),7.50 (s, 1 H), 7.61 (d, J = 3.7 Hz,1 H), 7.62-7.71 (m, 3 H), 12.27 (brs,1 H) 2-123 (MeOH-d4-300)0.85 (d, J = 9.0 Hz, 3 H), 0.92 (d,J = 9.0 Hz, 3 H), 1.91-2.05 (m, 1 H),1.93 (d, J = 6.0 Hz, 1 H), 2.02 (d,J = 6.0 Hz, 1 H), 7.09-7.24 (m, 5 H),7.36 (d, J = 6.0 Hz, 1 H), 7.42 (d,J = 9.0 Hz, 2 H), 7.55 (d, J = 6.0 Hz,1 H), 7.64 (d, J = 9.0 Hz, 2 H) 2-124 (CDCl3-300)2.08 (t, J = 18.0 Hz, 3 H), 2.16-2.25 (m, 2 H), 2.92-3.01 (m, 1 H),6.03 (brs, 1 H), 7.17-7.32 (m, 5 H),7.38 (d, J = 3.0 Hz, 1 H), 7.57 (s,1 H), 7.62 (d, J = 3.0 Hz, 1 H) 2-125 (MeOH-d4-400)1.93 (dd, J = 5.5, 9.7 Hz, 1 H),2.11 (dd, J = 5.7, 8.4 Hz, 1 H),2.77 (t, J = 9.1 Hz, 1 H), 2.83-2.86 (m, 2 H), 3.58-3.70 (m, 2 H),4.51 (q, J = 15.2 Hz, 2 H), 6.95-7.39 (m, 9 H)

TABLE 2-26 Example Structural formula NMR 2-126 (MeOH-d4-400)1.94-1.99 (m, 1 H), 2.14 (dd, J = 5.8,8.4 Hz, 1 H), 2.80 (t, J = 9.2 Hz, 1 H),3.71-3.85 (m, 2 H), 4.23-4.25 (m,2 H), 4.70-4.79 (m, 2 H), 7.12-7.75 (m, 10 H) 2-127 (MeOH-d4-400)1.97 (dd, J = 5.6, 9.8 Hz, 1 H),2.13 (dd, J = 5.7, 8.5 Hz, 1 H),2.81 (t, J = 9.1 Hz, 1 H), 3.10 (t,J = 5.6 Hz, 2 H), 3.70 (m, 2 H),4.52 (q, J = 15.9 Hz, 2 H), 7.14-8.36 (m, 10 H), 8.60 (s, 1 H) 2-128 (MeOH-d4-400)1.76-1.86 (m, 2 H), 1.92-1.99 (m,3 H), 2.12 (dd, J = 5.8, 8.5 Hz, 1 H),2.82 (t, J = 9.1 Hz, 1 H), 3.17-3.27 (m, 2 H), 3.43-3.52 (m, 2 H),4.48 (td, J = 3.2, 9.9 Hz, 1 H), 6.90-6.94 (m, 2 H), 7.16-7.29 (m, 7 H) 2-129 (MeOH-d4-400)0.71-0.80 (m, 3 H), 1.49-1.99 (m,3 H), 2.04-2.15 (m, 1 H), 7.14-7.65 (m, 11 H) 2-130 (DMSO-d6-300)1.46 (s, 6 H), 1.61 (dd, J = 9.8,5.7 Hz, 1 H), 2.00-2.02 (m, 1 H),2.71 (t, J = 8.5 Hz, 1 H), 5.64 (brs,1 H), 7.19-7.29 (m, 6 H), 7.47 (d,J = 3.8 Hz, 1 H), 12.24 (brs, 1 H)

TABLE 2-27 Example Structural formula NMR 2-131 (DMSO-d6-300)1.36 (s, 3 H), 1.46 (d, J = 4.5 Hz,1 H), 2.03 (d, J = 4.5 Hz, 1 H), 7.09-7.25 (m, 6 H), 7.56 (d, J = 4.1 Hz,1 H), 7.84 (d, J = 3.4 Hz, 1 H),8.07 (dd, J = 14.5, 8.5 Hz, 2 H),8.65 (s, 1 H), 11.87 (brs, 1 H) 2-132 (DMSO-d6-300)1.30 (s, 9 H), 1.59 (dd, J = 9.8,5.7 Hz, 1 H), 2.02 (dd, J = 8.7,5.7 Hz, 1 H), 2.74 (t, J = 9.2 Hz, 1 H),7.19-7.29 (m, 5 H), 7.44 (d,J = 3.8 Hz, 1 H), 9.24 (brs, 1 H),12.22 (brs, 1 H) 2-133 (DMSO-d6-300)0.98 (t, J = 7.3 Hz, 3 H), 1.48-1.64 (m, 3 H), 1.88-2.05 (m, 1 H),2.37-2.40 (m, 2 H), 2.60-2.76 (m,1 H), 7.11-7.29 (m, 6 H), 7.44 (d,J = 4.1 Hz, 1 H), 12.23 (brs, 1 H) 2-134 (DMSO-d6-300)1.68 (dd, J = 9.6, 5.5 Hz, 1 H),1.95 (dd, J = 6.8, 5.3 Hz, 1 H), 2.51-2.65 (m, 1 H), 7.09-7.34 (m, 5 H),7.52-7.81 (m, 5 H), 7.93-8.08 (m,2 H), 12.38 (brs, 1 H) 2-135 (DMSO-d6-300)1.62 (dd, J = 9.6, 5.5 Hz, 1 H),2.02 (dd, J = 8.5, 5.8 Hz, 1 H),2.74 (t, J = 9.0 Hz, 1 H), 6.59 (t,J = 6.4 Hz, 1 H), 6.68-6.78 (m, 2 H),7.15-7.30 (m, 5 H), 7.34 (d,J = 3.8 Hz, 1 H), 7.41 (d, J = 9.0 Hz,1 H), 7.52 (d, J = 3.8 Hz, 1 H),7.99 (d, J = 1.1 Hz, 1 H), 8.23 (d,J = 6.8 Hz, 1 H), 9.11 (brs, 1 H),12.23 (brs, 1 H)

TABLE 2-28 Example Structural formula NMR 2-136 (DMSO-d6-300)1.72 (dd, J = 8.9, 5.5 Hz, 1 H),1.90 (dd, J = 11.9, 5.5 Hz, 1 H),2.52-2.60 (m, 1 H), 7.11-7.22 (m,2 H), 7.26-7.38 (m, 2 H), 7.48-7.63 (m, 5 H), 7.76 (d, J = 8.7 Hz,2 H), 12.19 (brs, 1 H) 2-137 (DMSO-d6-300)1.52 (dd, J = 9.4, 5.7 Hz, 1 H), 1.92-1.94 (m, 1 H), 2.61-2.65 (m, 1 H),5.65 (d, J = 47.1 Hz, 2 H), 7.17-7.22 (m, 5 H), 7.38 (d, J = 3.4 Hz,1 H), 7.93 (d, J = 8.7 Hz, 2 H),8.08 (d, J = 8.7 Hz, 2 H) 2-138 (CDCl3-300)1.42-1.52 (m, 1 H), 1.57-1.66 (m,1 H), 1.79-1.92 (m, 1 H), 3.40-3.54 (m, 2 H), 4.33 (s, 2 H), 4.63-4.76 (m, 1 H), 6.54 (brs, 1 H),7.06 (d, J = 3.8 Hz, 1 H), 7.24 (q,J = 45.2 Hz, 6 H), 7.36 (d, J = 8.7 Hz,2 H), 7.43 (d, J = 8.7 Hz, 2 H) 2-139 (CDCl3-300)1.64-1.82 (m, 2 H), 1.92-2.04 (m,1 H), 3.23 (dd, J = 8.7, 4.9 Hz, 1 H),3.52 (dd, J = 8.9, 4.4 Hz, 1 H),4.33 (d, J = 14.7 Hz, 1 H), 4.40 (d,J = 14.7 Hz, 1 H), 4.57-4.69 (m, 1 H),7.14-7.36 (m, 8 H), 7.49 (d,J = 7.9 Hz, 2 H), 7.64 (d, J = 3.8 Hz,1 H) 2-140 (CDCl3-300)2.06 (dd, J = 6.0, 9.0 Hz, 1 H),2.15 (dd, J = 6.0, 9.0 Hz, 1 H),3.04 (t, J = 9.0 Hz, 1 H), 5.71 (brs,1 H), 6.80 (d, J = 15.0 Hz, 1 H), 7.16-7.29 (m, 5 H), 7.36-7.46 (m, 5 H),7.52 (d, J = 15.0 Hz, 1 H)

TABLE 2-29 Example Structural formula NMR 2-141 (acetone-d6-400)1.90 (dd, J = 9.2, 5.7 Hz, 1 H),2.14 (dd, J = 8.8, 5.7 Hz, 1 H),2.85 (dd, J = 9.2, 8.8 Hz, 1 H),4.07 (s, 2 H), 7.15-7.30 (m, 6 H),7.44-7.48 (m, 1 H), 7.68 (brs, 1 H),7.92-7.96 (m, 1 H), 7.99-8.05 (m,2 H), 8.07-8.11 (m, 1 H) 2-142 (acetone-d6-400)1.90 (dd, J = 9.4, 5.3 Hz, 1 H),2.14 (dd, J = 8.8, 5.3 Hz, 1 H),2.85 (dd, J = 9.4, 8.8 Hz, 1 H),4.08 (s, 2 H), 7.15-7.32 (m, 6 H),7.48-7.52 (m, 1 H), 7.72 (s, 1 H),7.94-8.08 (m, 3 H), 8.10-8.15 (m,1 H) 2-143 (MeOH-d4-400)1.76-1.87 (m, 2 H), 1.95 (dd, J = 5.7,9.8 Hz, 1 H), 1.99-2.06 (m, 2 H),2.10 (dd, J = 5.7, 8.5 Hz, 1 H),2.74 (t, J = 9.1 Hz, 1 H), 3.16-3.30 (m, 2 H), 3.45-3.56 (m, 2 H),4.47-4.52 (m, 1 H), 6.89-6.94 (m,3 H), 7.15-7.29 (m, 7 H) 2-144 (MeOH-d4-400)1.80-1.89 (m, 2 H), 1.95 (dd, J = 5.7,9.8 Hz, 1 H), 2.00-2.09 (m, 2 H),2.13 (dd, J = 5.7, 8.6 Hz, 1 H),2.81 (t, J = 9.2 Hz, 1 H), 3.20-3.30 (m, 2 H), 3.46-3.55 (m, 2 H),4.62 (tt, J = 3.4, 7.0 Hz, 1 H),7.08 (d, J = 8.7 Hz, 2 H), 7.16-7.29 (m, 5 H), 7.56 (d, J = 8.7 Hz, 2 H) 2-145 (MeOH-d4-400)1.75-1.85 (m, 2 H), 1.92-2.03 (m,3 H), 2.12 (dd, J = 5.7, 8.6 Hz, 1 H),2.81 (t, J = 9.2 Hz, 1 H), 3.16-3.26 (m, 2 H), 3.44-3.52 (m, 2 H),4.42 (tt, 3.4, 7.0 Hz, 1 H), 6.91-7.01 (m, 4 H), 7.16-7.29 (m, 5 H)

TABLE 2-30 Example Structural formula NMR 2-146 (MeOH-d4-400)0.69-0.78 (m, 3 H), 1.52-2.09 (m,4 H), 3.93-3.98 (m, 2 H), 7.09-8.09 (m, 11 H) 2-147 (MeOH-d4-400)1.13 (s, 3 H), 1.25 (s, 3 H), 1.38-1.43 (m, 1 H), 1.51 (d, J = 5.5 Hz,1 H), 7.38-7.69 (m, 6 H) 2-148 (MeOH-d4-400)1.94 (dd, J = 5.6, 9.8 Hz, 1 H),2.13 (dd, J = 5.7, 8.5 Hz, 1 H), 2.58-2.66 (m, 2 H), 2.84 (d, J = 9.2 Hz,1 H), 3.42-3.55 (m, 2 H), 3.93 (dq,J = 3.0, 17.2 Hz, 2 H), 6.10 (s, 1 H),7.15-7.43 (m, 10 H) 2-149 (MeOH-d4-400)1.94 (dd, J = 5.6, 9.8 Hz, 1 H),2.13 (dd, J = 5.7, 8.5 Hz, 1 H),2.59 (brs, 2 H), 2.83 (t, J = 9.2 Hz,1 H), 3.42-3.55 (m, 2 H), 3.93 (dq,J = 3.1, 17.5 Hz, 2 H), 6.14 (s, 1 H),7.15-7.42 (m, 9 H) 2-150 (DMSO-d6-300)1.72 (dd, J = 8.9, 5.5 Hz, 1 H),1.90 (dd, J = 11.9, 5.5 Hz, 1 H),2.52-2.60 (m, 1 H), 7.11-7.22 (m,2 H), 7.26-7.38 (m, 2 H), 7.48-7.63 (m, 5 H), 7.76 (d, J = 8.7 Hz,2 H), 12.19 (brs, 1 H)

TABLE 2-31 Example Structural formula NMR 2-151 (MeOH-d4-300)1.83 (dd, J = 9.8, 5.7 Hz, 1 H),2.07 (dd, J = 8.5, 5.5 Hz, 1 H),2.75 (t, J = 9.2 Hz, 1 H), 7.10-7.18 (m, 4 H), 7.27 (d, J = 7.5 Hz,2 H), 7.38-7.44 (m, 3 H), 7.57 (d,J = 8.3 Hz, 2 H) 2-152 (DMSO-d6-300)1.52 (dd, J = 8.7, 5.7 Hz, 1 H),1.96 (dd, J = 8.7, 5.7 Hz, 1 H),2.67 (t, J = 8.7 Hz, 1 H), 7.18-7.22 (m, 5 H), 7.44 (t,J = 52.7 Hz,1 H), 7.71 (s, 1 H), 7.94 (d,J = 8.7 Hz, 2 H), 8.13 (d, J = 8.7 Hz,2 H) 2-153 (CDCl3-400)1.99 (dd, J = 9.5, 6.0 Hz, 1 H),2.12 (dd, J = 8.8, 6.0 Hz, 1 H),3.01 (dd, J = 9.5, 8.8 Hz, 1 H),5.86 (brs, 1 H), 6.79 (d, J = 15.3 Hz,1 H), 7.14-7.23 (m, 5 H), 7.27-7.44 (m, 5 H) 2-154 (DMSO-d6-300)1.63-1.65 (m, 1 H), 1.70-1.88 (m,4 H), 1.89-2.01 (m, 1 H), 2.62 (t,J = 5.5 Hz, 2 H), 2.73 (t, J = 5.3 Hz,2 H), 7.07-7.26 (m, 5 H), 7.51 (d,J = 4.1 Hz, 1 H), 7.62 (d, J = 4.1 Hz,1 H) 2-155 (MeOH-d4-400)1.94 (dd, J = 5.7, 9.8 Hz, 1 H),2.11 (dd, J = 5.7, 8.5 Hz, 1 H), 2.70-2.78 (m, 1 H), 3.11-3.30 (m, 4 H),3.84-3.86 (m, 4 H), 7.12-7.28 (m,5 H), 8.35-8.40 (m, 2 H)

TABLE 2-32 Example Structural formula NMR 2-156 (MeOH-d4-400)1.93 (dd, J = 5.5, 9.8 Hz, 1 H),2.11 (dd, J = 5.8, 8.2 Hz, 1 H),2.58 (t, J = 7.7 Hz, 1 H), 2.78 (t,J = 9.1 Hz, 1 H), 2.90 (t, J = 7.7 Hz,1 H), 3.72-3.87 (m, 1 H), 4.11 (t,J = 5.2 Hz, 2 H), 6.23 (s, 1 H),7.06 (dd, J = 2.0, 8.6 Hz, 1 H), 7.13-7.27 (m, 6 H), 7.44 (d, J = 1.9 Hz, 1 H) 2-157 (MeOH-d4-400)1.96 (dd, J = 5.7, 9.8 Hz, 1 H),2.15 (dd, J = 5.8, 8.6 Hz, 1 H),2.84 (t, J = 9.2 Hz, 1 H), 3.32-3.43 (m, 4 H), 3.66-3.68 (m, 4 H),7.07-7.31 (m, 7 H), 7.48 (d,J = 8.0 Hz, 1 H), 7.64 (d, J = 7.9 Hz,1 H) 2-158 (MeOH-d4-400)1.92 (dd, J = 5.9, 9.9 Hz, 1 H),2.14 (dd, J = 5.8, 8.6 Hz, 1 H),2.59 (t, J = 7.7 Hz, 1 H), 3.19-3.58 (m, 8 H), 3.62 (s, 2 H), 7.14-7.55 (m, 10 H) 2-159 (MeOH-d4-400)1.95 (dd, J = 5.7, 9.8 Hz, 1 H),2.13 (dd, J = 5.8, 8.5 Hz, 1 H), 2.80-2.85 (m, 1 H), 3.26-3.38 (m, 4 H)3.49-3.79 (m, 4 H), 7.16-7.29 (m,5 H), 7.41-7.49 (m, 4 H) 2-160 (MeOH-d4-400)1.95 (dd, J = 5.7, 9.8 Hz, 1 H),2.13 (dd, J = 5.8, 8.6 Hz, 1 H), 2.80-2.86 (m, 1 H), 3.16-3.38 (m, 4 H),3.41-3.54 (m, 2 H), 3.67-3.88 (m,2 H), 7.16-7.53 (m, 9 H)

TABLE 2-33 Example Structural formula NMR 2-161 (DMSO-d6-300)1.70 (dd, J = 9.0, 5.7 Hz, 1 H),2.02 (dd, J = 8.7, 5.7 Hz, 1 H),2.81 (dd, J = 9.0, 8.7 Hz, 1 H), 7.13-7.28 (m, 5 H), 7.36 (d, J = 15.4 Hz,1 H), 7.45 (d, J = 15.4 Hz, 1 H),7.78 (d, J = 8.3 Hz, 2 H), 7.92 (d,J = 8.3 Hz, 2 H), 8.70 (brs, 1 H),12.39 (brs, 1 H) 2-162 (CDCl3-300)2.00 (dd, J = 9.2, 5.3 Hz, 1 H),2.15 (dd, J = 9.0, 5.3 Hz, 1 H),3.03 (dd, J = 9.2, 9.0 Hz, 1 H),5.86 (brs, 1 H), 6.90 (d, J = 15.4 Hz,1 H), 7.14-7.24 (m, 5 H), 7.47-7.56 (m, 2 H), 7.59-7.71 (m, 3 H) 2-163 (CDCl3-300)1.82-1.86 (m, 1 H), 2.00-2.04 (m,1 H), 2.17-2.30 (m, 2 H), 2.61 (t,J = 7.9 Hz, 2 H), 2.73 (t, J = 8.9 Hz,1 H), 3.86 (t, J = 7.2 Hz, 2 H),6.39 (d, J = 4.1 Hz, 1 H), 7.05-7.24 (m, 5 H), 7.37 (d, J = 4.1 Hz,1 H), 7.45 (d, J = 4.1 Hz, 1 H) 2-164 (CDCl3-300)1.91-2.02 (m, 9 H), 3.76-3.78 (m,2 H), 6.51 (d, J = 4.1 Hz, 1 H), 7.17-7.19 (m, 5 H), 7.38 (d, J = 4.5 Hz,1 H), 7.47 (d, J = 4.1 Hz, 1 H) 2-165 (DMSO-d6-300)1.45-1.47 (m, 1 H), 1.91 (dd, J = 8.7,6.0 Hz, 1 H), 2.63-2.71 (m, 1 H),5.79 (d, J = 4.1 Hz, 1 H), 7.07 (d,J = 4.1 Hz, 1 H), 7.20-7.22 (m, 5 H),8.48 (s, 1 H)

TABLE 2-34 Example Structural formula NMR 2-166 (CDCl3-300)0.98-1.20 (m, 5 H), 1.50-1.79 (m,5 H), 1.90-2.02 (m, 2 H), 2.50-2.74 (m, 2 H), 3.85-4.09 (m, 3 H),6.91 (brs, 1 H), 7.09-7.24 (m, 6 H),7.61 (s, 1 H), 7.75 (d, J = 8.7 Hz, 1 H) 2-167 (DMSO-d6-300)1.87 (dd, J = 9.8, 5.7 Hz, 1 H),2.09 (dd, J = 8.9, 5.5 Hz, 1 H),2.66 (t, J = 8.7 Hz, 1 H), 7.17-7.27 (m, 3 H), 7.52-7.55 (m, 3 H),7.59 (s, 2 H), 7.76 (d, J = 8.7 Hz,2 H), 9.07 (brs, 1 H), 12.31 (brs,1 H) 2-168 (DMSO-d6-300)1.87 (dd, J = 9.8, 5.7 Hz, 1 H),2.09 (dd, J = 8.9, 5.5 Hz, 1 H),2.66 (t, J = 8.7 Hz, 1 H), 7.17-7.27 (m, 3 H), 7.52-7.55 (m, 3 H),7.59 (s, 2 H), 7.76 (d, J = 8.7 Hz,2 H), 9.07 (brs, 1 H), 12.31 (brs,1 H) 2-169 (DMSO-d6-300)1.67 (dd, J = 9.8, 5.7 Hz, 1 H),2.03 (dd, J = 7.5, 5.7 Hz, 1 H),2.73 (t, J = 7.0 Hz, 1 H), 7.19-7.25 (m, 2 H), 7.34-7.41 (m, 2 H),7.69 (q, J = 3.6 Hz, 1 H), 7.86 (d,J = 3.8 Hz, 1 H), 8.18 (d, J = 1.1 Hz,1 H), 9.33 (brs, 1 H), 12.44 (brs,1 H) 2-170 (DMSO-d6-300)1.78 (dd, J = 9.6, 5.5 Hz, 1 H),2.01 (dd, J = 7.7, 5.5 Hz, 1 H),2.71 (t, J = 7.2 Hz, 1 H), 7.43-7.54 (m, 1 H), 7.52 (d, J = 8.7 Hz,2 H), 7.58 (q, J = 3.9 Hz, 2 H),7.65 (d, J = 7.2 Hz, 1 H), 7.75 (d,J = 8.7 Hz, 2 H), 7.98-8.05 (m, 2 H),8.80 (brs, 1 H), 12.32 (brs, 1 H)

TABLE 2-35 Example Structural formula NMR 2-171 (DMSO-d6-300)1.64 (dd, J = 9.6, 5.5 Hz, 1 H), 1.99-2.02 (m, 1 H), 2.67-2.72 (m, 1 H),7.17-7.22 (m, 5 H), 7.69 (d,J = 3.8 Hz, 1 H), 7.80 (s, 1 H),7.83 (d, J = 3.8 Hz, 1 H) 2-172 (DMSO-d6-400)1.53 (dd, J = 9.7, 5.6 Hz, 1 H),1.98 (dd, J = 8.3, 5.8 Hz, 1 H),2.70 (t, J = 9.7 Hz, 1 H), 2.71-2.76 (m, 5 H), 3.26-3.31 (m, 2 H),3.67-3.76 (m, 2 H), 6.26 (brs, 1 H),7.16-7.25 (m, 6 H), 7.47 (d,J = 4.2 Hz, 1 H), 9.16 (brs, 1 H),12.18 (brs, 1 H) 2-173 (DMSO-d6-300)1.51 (dd, J = 9.6, 5.8 Hz, 1 H),1.90 (dd, J = 8.7, 5.7 Hz, 1 H),2.61 (t, J = 9.2 Hz, 1 H), 3.09-3.90 (brs, 2 H), 4.34 (s, 2 H), 6.39-6.50 (m, 3 H), 6.93 (t, J = 7.9 Hz,1 H), 7.51-7.58 (m, 4 H), 7.65 (t,J = 6.4 Hz, 1 H), 7.75 (dt, J = 8.8,2.0 Hz, 2 H), 8.07 (d, J = 7.2 Hz, 1 H),8.60 (d, J = 5.7 Hz, 1 H), 8.69 (s,1 H), 9.16 (s, 1 H), 12.15 (brs, 1 H) 2-174 (DMSO-d6-300)1.65-1.72 (m, 2 H), 2.17 (t,J = 9.0 Hz, 1 H), 4.72 (brs, 2 H),6.29 (t, J = 9.6 Hz, 2 H), 6.39 (s,1 H), 6.75 (t, J = 9.6 Hz, 1 H), 7.48-7.59 (m, 4 H), 7.75 (d, J = 7.9 Hz,2 H), 12.42 (brs, 1 H) 2-175 (DMSO-d6-300)1.68 (q, J = 4.9 Hz, 1 H), 2.06 (dd,J = 8.5, 5.5 Hz, 1 H), 2.82 (t,J = 9.2 Hz, 1 H), 7.35-7.59 (m, 6 H),7.73-7.79 (m, 3 H), 7.86 (s, 1 H),9.21 (brs, 1 H), 12.43 (brs, 1 H),12.93 (brs, 1 H)

TABLE 2-36 Example Structural formula NMR 2-176 (DMSO-d6-300)1.58 (dd, J = 9.8, 5.7 Hz, 1 H),1.98 (dd, J = 8.7, 5.3 Hz, 1 H),2.69 (t, J = 9.2 Hz, 1 H), 2.86 (s,6 H), 6.65-6.69 (m, 3 H), 7.07 (t,J = 7.5 Hz, 1 H), 7.51-7.59 (m, 4 H),7.76 (d, J = 8.7 Hz, 2 H), 9.18 (s,1 H), 12.16 (brs, 1 H) 2-177 (DMSO-d6-300) (120C)1.64 (dd, J = 9.2, 5.1 Hz, 1 H),1.98 (dd, J = 8.8, 5.1 Hz, 1 H),2.04 (s, 3 H), 2.50-2.54 (m, 2 H),2.74 (t, J = 8.8 Hz, 1 H), 3.61-3.68 (m, 2 H), 4.10-4.15 (m, 2 H),6.23-6.29 (m, 1 H), 7.09 (d,J =1 H), 7.12-7.27 (m, 5 H),7.46 (d, J = 4.0 Hz, 1 H) 2-178 (DMSO-d6-300)1.87 (dd, J = 9.8, 5.7 Hz, 1 H),2.09 (dd, J = 8.9, 5.5 Hz, 1 H),2.66 (t, J = 8.7 Hz, 1 H), 7.17-7.27 (m, 3 H), 7.52-7.55 (m, 3 H),7.59 (s, 2 H), 7.76 (d, J = 8.7 Hz,2 H), 9.07 (brs, 1 H), 12.31 (brs,1 H) 2-179 (DMSO-d6-300)1.64 (dd, J = 9.8, 5.7 Hz, 1 H),2.07 (dd, J = 8.7, 5.3 Hz, 1 H), 2.47-2.53 (m, 2 H), 2.70 (t, J = 9.4 Hz,1 H), 2.83-2.85 (m, 1 H), 2.98-3.08 (m, 1 H), 7.05-7.14 (m, 4 H),7.53 (d, J = 8.3 Hz, 2 H), 7.57 (d,J = 4.1 Hz, 1 H), 7.60 (d, J = 4.1 Hz,1 H), 7.77 (d, J = 8.3 Hz, 2 H),12.16 (brs, 1 H) 2-180 (DMSO-d6-300)1.61 (dd, J = 5.1, 2.6 Hz, 1 H),2.02 (dd, J = 8.3, 5.7 Hz, 1 H), 2.46-2.50 (m, 2 H), 2.68-2.78 (m, 3 H),7.05-7.07 (m, 3 H), 7.15-7.17 (m,1 H), 7.53 (d, J = 8.7 Hz, 2 H),7.56 (d, J = 4.1 Hz, 1 H), 7.58 (d,J = 4.1 Hz, 1 H), 7.76 (d, J = 8.7 Hz,2 H), 9.19 (brs, 1 H), 12.17 (brs,1 H)

TABLE 2-37 Example Structural formula NMR 2-181 (DMSO-d6-300)1.66 (dd, J = 9.4, 3.8 Hz, 1 H), 1.78-1.90 (m, 1 H), 2.33 (t, J = 9.4 Hz,1 H), 3.07 (s, 2 H), 6.82 (d,J = 6.4 Hz, 1 H), 6.89-7.06 (m, 3 H),7.45-7.60 (m, 4 H), 7.74 (d,J = 8.3 Hz, 2 H) 2-182 (DMSO-d6-300)1.62 (q, J = 4.8 Hz, 1 H), 2.02 (dd,J = 8.5, 5.5 Hz, 1 H), 2.74 (t,J = 9.0 Hz, 1 H), 4.44 (s, 2 H),5.16 (brs, 1 H), 7.04-7.23 (m, 4 H),7.50-7.59 (m, 4 H), 7.76 (d,J = 8.3 Hz, 2 H), 9.21 (brs, 1 H),12.21 (brs, 1 H) 2-183 (DMSO-d6-300)1.55 (dd, J = 9.8, 5.7 Hz, 1 H),1.95 (dd, J = 8.7, 5.3 Hz, 1 H),2.66 (t, J = 9.1 Hz, 1 H), 2.94 (s,3 H), 4.54 (s, 2 H), 6.36-6.71 (m,2 H), 6.93-7.07 (m, 1 H), 7.21-7.89 (m, 9 H), 8.44 (s, 2 H),9.17 (brs, 1 H), 12.20 (brs, 1 H) 2-184 (DMSO-d6-300)1.71 (dd, J = 10.0, 5.5 Hz, 1 H),2.05 (dd, J = 6.8, 5.3 Hz, 1 H),2.81 (t, J = 6.4 Hz, 1 H), 3.84 (s,3 H), 7.38-7.59 (m, 6 H), 7.74-7.80 (m, 3 H), 7.86 (s, 1 H),9.25 (brs, 1 H), 12.32 (brs, 1 H) 2-185 (acetone-d6-400)1.76 (dd, J = 5.6, 9.0 Hz, 1 H), 2.12-2.16 (m, 1 H), 2.73-2.77 (m, 1 H),3.15 (d, J = 14.6 Hz, 1 H), 3.39-3.42 (m, 4 H), 3.82-3.85 (m, 4 H),4.30 (dd, J = 0.9, 14.6 Hz, 1 H),7.00 (d, J = 9.1 Hz, 1 H), 7.16-7.32 (m, 5 H), 7.80 (dd, J = 2.5,9.1 Hz, 1 H), 8.43 (s, 1 H)

TABLE 2-38 Example Structural formula NMR 2-186 (acetone-d6-400)1.78 (dd, J = 5.6, 9.0 Hz, 1 H),2.15 (dd, J = 6.5, 7.4 Hz, 1 H),2.77 (t, J = 8.4 Hz, 1 H), 3.19 (d,J = 14.7 Hz, 1 H), 3.45-3.48 (m, 4 H),3.65-3.67 (m, 4 H), 4.34 (d,J = 15.3 Hz, 1 H), 7.17-7.46 (m, 9 H) 2-187 (acetone-d6-400)1.87 (dd, J = 4.6, 7.2 Hz, 1 H),2.05 (td, J = 2.2, 4.4 Hz, 1 H), 2.54-2.58 (m, 1 H), 3.71 (d, J = 11.5 Hz,1 H), 4.02 (d, J = 11.5 Hz, 1 H), 7.14-7.29 (m, 5 H), 7.49-7.80 (m, 6 H) 2-188 (DMSO-d6-300)1.62 (dd, J = 5.0, 2.5 Hz, 1 H),2.00 (dd, J = 8.3, 6.0 Hz, 1 H),2.71 (t, J = 8.9 Hz, 1 H), 3.60 (s,5 H), 7.10 (t, J = 7.5 Hz, 3 H),7.20 (t, J = 7.3 Hz, 1 H), 7.46-7.60 (m, 4 H), 7.75 (d, J = 8.7 Hz,2 H), 9.17 (brs, 1 H), 12.24 (brs,1 H) 2-189 (DMSO-d6-300)1.62 (dd, J = 5.0, 2.5 Hz, 1 H),1.98 (dd, J = 8.3, 6.0 Hz, 1 H),2.69 (t, J = 9.4 Hz, 1 H), 2.81 (s,3 H), 2.93 (s, 3 H), 3.61 (s, 2 H),7.05 (t, J = 9.0 Hz, 3 H), 7.17 (t,J = 7.5 Hz, 1 H), 7.47-7.60 (m, 4 H),7.76 (d, J = 8.7 Hz, 2 H), 12.23 (brs,1 H) 2-190 (DMSO-d6-300)1.58-1.70 (m, 1 H), 1.87-1.99 (m,1 H), 2.54-2.67 (m, 1 H), 3.24-3.56 (m, 8 H), 3.63 (s, 2 H), 6.94-7.10 (m, 3 H), 7.15 (t, J = 7.0 Hz,1 H), 7.52 (d, J = 8.7 Hz, 2 H),7.56 (s, 2 H), 7.75 (d, J = 8.3 Hz, 2 H)

TABLE 2-39 Example Structural formula NMR 2-191 (DMSO-d6-300)1.63 (q, J = 4.6 Hz, 1 H), 1.92-2.02 (m, 1 H), 2.07-2.30 (m, 7 H),2.61-2.75 (m, 1 H), 3.20-3.56 (m,4 H), 3.63 (s, 2 H), 6.98-7.11 (m,3 H), 7.17 (t, J = 7.5 Hz, 1 H),7.52 (d, J = 8.7 Hz, 2 H), 7.57 (s,2 H), 7.76 (d, J = 8.3 Hz, 2 H) 2-192 (DMSO-d6-300)1.62 (dd, J = 9.8, 5.7 Hz, 1 H),2.03 (dd, J = 8.1, 5.5 Hz, 1 H),2.75 (dd, J = 9.2, 4.6 Hz, 1 H), 7.15-7.30 (m, 5 H), 7.53 (d, J = 8.7 Hz,2 H), 7.56 (d, J = 4.1 Hz, 1 H),7.58 (d, J = 4.1 Hz, 1 H), 7.76 (d,J = 8.7 Hz, 2 H), 9.21 (brs, 1 H),12.21 (brs, 1 H) 2-193 (DMSO-d6-300)1.89 (dd, J = 9.6, 5.8 Hz, 1 H),2.10 (dd, J = 8.7, 5.3 Hz, 1 H),2.66 (t, J = 11.3 Hz, 1 H), 7.17-7.27 (m, 3 H), 7.54 (d, J = 7.2 Hz,1 H), 7.72 (d, J = 4.1 Hz, 1 H),7.87 (d, J = 3.8 Hz, 1 H), 8.18 (s,1 H), 12.33 (brs, 1 H) 2-194 (DMSO-d6-300)1.71-1.76 (m, 1 H), 2.07-2.10 (m,1 H), 2.59-2.64 (m, 1 H), 3.43-3.59 (m, 4 H), 3.77 (d, J = 17.0 Hz,1 H), 3.84 (d, J = 16.6 Hz, 1 H), 6.98-7.00 (m, 1 H), 7.07-7.15 (m, 3 H),7.53 (d, J = 8.7 Hz, 2 H), 7.57 (d,J = 3.8 Hz, 1 H), 7.59 (d, J = 3.8 Hz,1 H), 7.76 (d, J = 8.7 Hz, 2 H),12.30 (d, J = 10.0 Hz, 1 H) 2-195 (DMSO-d6-300)1.71-1.76 (m, 1 H), 2.07-2.10 (m,1 H), 2.59-2.64 (m, 1 H), 3.43-3.59 (m, 4 H), 3.77 (d, J = 17.0 Hz,1 H), 3.84 (d, J = 16.6 Hz, 1 H), 6.98-7.00 (m, 1 H), 7.07-7.15 (m, 3 H),7.53 (d, J = 8.7 Hz, 2 H), 7.57 (d,J = 3.8 Hz, 1 H), 7.59 (d, J = 3.8 Hz,1 H), 7.76 (d, J = 8.7 Hz, 2 H),12.30 (d, J = 10.0 Hz, 1 H)

TABLE 2-40 Example Structural formula NMR 2-196 (DMSO-d6-300)1.68 (dd, J = 9.6, 5.8 Hz, 1 H),1.96 (dd, J = 8.9, 5.8 Hz, 1 H),3.09 (t, J = 8.9 Hz, 1 H), 7.24-7.34 (m, 2 H), 7.44-7.46 (m, 1 H),7.53 (d, J = 8.7 Hz, 2 H), 7.60 (d,J = 4.1 Hz, 1 H), 7.62 (d, J = 3.8 Hz,1 H), 7.74-7.78 (m, 4 H), 8.07 (brs,1 H) 2-197 (DMSO-d6-300)1.62-1.68 (m, 1 H), 1.89-1.92 (m,1 H), 2.44 (t, J = 4.5 Hz, 4 H),2.64 (t, J = 5.8 Hz, 2 H), 3.56 (t,J = 4.5 Hz, 4 H), 3.98 (t, J = 5.8 Hz,2 H), 6.71-6.76 (m, 3 H), 7.09 (t,J = 7.9 Hz, 1 H), 7.52 (d, J = 8.7 Hz,2 H), 7.55-7.58 (m, 2 H), 7.75 (d,J = 8.7 Hz, 2 H) 2-198 (DMSO-d6-300)1.63 (dd, J = 9.8, 5.7 Hz, 1 H),1.92 (dd, J = 8.1, 5.5 Hz, 1 H),2.13 (s, 3 H), 2.34-2.43 (m, 4 H),2.56-2.66 (m, 1 H), 2.64 (t,J = 5.7 Hz, 2 H), 3.97 (t, J = 5.7 Hz,2 H), 6.73-6.76 (m, 3 H), 7.11 (t,J = 7.9 Hz, 1 H), 7.52-7.56 (m, 4 H),7.75 (d, J = 8.7 Hz, 2 H) 2-199 (DMSO-d6-300)1.77 (dd, J = 9.8, 6.0 Hz, 1 H),2.15 (dd, J = 8.3, 6.0 Hz, 1 H),2.90 (t, J = 8.7 Hz, 1 H), 7.58 (t,J = 8.3 Hz, 1 H), 7.69 (d, J = 8.3 Hz,1 H), 7.73 (d, J = 4.1 Hz, 1 H),7.87 (d, J = 4.1 Hz, 1 H), 8.05-8.09 (m, 2 H), 8.18 (d, J = 0.8 Hz,1 H), 9.50 (brs, 1 H), 12.53 (brs,1 H) 2-200 (DMSO-d6-300)1.66 (q, J = 4.8 Hz, 1 H), 2.12 (dd,J = 7.0, 5.5 Hz, 1 H), 2.79 (s, 3 H),2.70-3.44 (m, 9 H), 7.23-7.32 (m,2 H), 7.38 (d, J = 4.1 Hz, 2 H),7.53 (d, J = 8.7 Hz, 2 H), 7.58 (d,J = 4.9 Hz, 1 H), 7.59 (d, J = 4.9 Hz,1 H), 7.76 (d, J = 8.3 Hz, 2 H),9.23 (s, 1 H), 10.44 (brs, 1 H),12.33 (brs, 1 H)

TABLE 2-41 Example Structural formula NMR 2-201 (DMSO-d6-300)1.55 (dd, J = 9.0, 5.3 Hz, 1 H),1.88 (dd, J = 8.9, 5.1 Hz, 1 H),2.55 (d, J = 5.1 Hz, 1 H), 4.94 (brs,2 H), 6.33-6.44 (m, 3 H), 6.86 (t,J = 7.5 Hz, 1 H), 7.69 (d, J = 3.8 Hz,1 H), 7.86 (d, J = 4.1 Hz, 1 H),8.18 (s, 1 H), 9.26 (brs, 1 H),12.18 (brs, 1 H) 2-202 (MeOH-d4-400)2.07 (dd, J = 6.0, 9.7 Hz, 1 H),2.27 (dd, J = 6.1, 7.9 Hz, 1 H), 2.74-2.78 (m, 1 H), 7.09 (d, J = 8.5 Hz,2 H), 7.37-7.49 (m, 6 H), 7.66 (d,J = 8.6 Hz, 2 H) 2-203 (MeOH-d4-400)1.94 (dd, J = 5.8, 9.8 Hz, 1 H),2.12 (dd, J = 5.9, 8.6 Hz, 1 H),2.79 (t, J = 9.7 Hz, 1 H), 7.18 (d,J = 8.3 Hz, 2 H), 7.36-7.44 (m, 5 H),7.57 (d, J = 4.0 Hz, 1 H), 7.65 (d,J = 8.6 Hz, 2 H) 2-204 (DMSO-d6-300)1.71 (dd, J = 9.8, 5.7 Hz, 1 H),2.11 (dd, J = 8.9, 5.5 Hz, 1 H),2.66 (t, J = 8.5 Hz, 1 H), 2.88 (s,3 H), 2.92 (s, 3 H), 3.74 (d,J = 16.2 Hz, 1 H), 3.82 (d, J = 17.0 Hz,1 H), 6.94-6.99 (m, 1 H), 7.08-7.15 (m, 3 H), 7.53 (d, J = 8.7 Hz,2 H), 7.57 (t, J = 1.9 Hz, 1 H),7.60 (d, J = 3.8 Hz, 1 H), 7.76 (d,J = 8.7 Hz, 2 H), 9.30 (brs, 1 H),12.26 (brs, 1 H) 2-205 (DMSO-d6-300)1.70-1.75 (m, 1 H), 1.891-1.98 (m,1 H), 3.05-3.08 (m, 1 H), 3.86 (s,3 H), 7.31-7.35 (m, 2 H), 7.45-7.48 (m, 1 H), 7.53 (d, J = 8.7 Hz,2 H), 7.61 (s, 2 H), 7.72-7.77 (m,3 H), 8.40 (brs, 1 H), 12.28 (brs,1 H)

TABLE 2-42 Example Structural formula NMR 2-206 (DMSO-d6-300)1.68 (dd, J = 5.1, 2.6 Hz, 1 H),2.09 (dd, J = 8.7, 5.3 Hz, 1 H),2.66 (t, J = 9.2 Hz, 1 H), 4.53 (d,J = 14.7 Hz, 1 H), 4.73 (d, J = 14.7 Hz,1 H), 5.09 (brs, 1 H), 7.02-7.23 (m,3 H), 7.37 (d, J = 7.2 Hz, 1 H),7.53 (d, J = 8.7 Hz, 2 H), 7.57 (d,J = 4.1 Hz, 1 H), 7.59 (d, J = 4.1 Hz,1 H), 7.76 (d, J = 8.3 Hz, 2 H),9.28 (brs, 1 H), 12.16 (brs, 1 H) 2-207 (MeOH-d4-300)2.00 (d, J = 6.0 Hz, 0.6 H), 2.18-2.23 (m, 0.4 H), 2.20, 2.23 (2s,3 H), 2.57 (d, J = 6.0 Hz, 0.4 H),2.58 (d, J = 6.0 Hz, 0.6 H), 3.64 (d,J = 12.0 Hz, 0.6 H), 3.95 (d,J = 12.0 Hz, 0.6 H), 4.12 (d,J = 12.0 Hz, 0.4 H), 4.33 (d,J = 15.0 Hz, 0.6 H), 4.56 (d,J = 15.0 Hz, 0.4 H), 4.67 (d,J = 15.0 Hz, 0.4 H), 4.91 (d,J = 15.0 Hz, 0.6 H), 7.10-7.24 (m,4 H), 7.36-7.49 (m, 3 H), 7.56-7.70 (m, 3 H) 2-208 (CDCl3-300)2.09-2.11 (m, 2 H), 2.54 (t,J = 7.5 Hz, 2 H), 2.82-2.92 (m, 3 H),3.60 (s, 3 H), 6.16 (brs, 1 H), 7.00-7.02 (m, 3 H), 7.12-7.17 (m, 2 H),7.39 (d, J = 8.3 Hz, 2 H), 7.51 (d,J = 8.3 Hz, 2 H), 7.57 (d, J = 3.8 Hz,1 H) 2-209 (DMSO-d6-400)1.60 (dd, J = 10.2, 5.6 Hz, 1 H),2.01 (dd, J = 8.8, 5.6 Hz, 1 H),2.54 (t, J = 8.3 Hz, 1 H), 2.66-2.77 (m, 3 H), 3.26-3.64 (m, 9 SH),7.00-7.09 (m, 3 H), 7.15 (t,J = 7.4 Hz, 1 H), 7.49-7.59 (m, 4 H),7.73-7.77 (m, 2 H), 9.19 (s, 1 H) 2-210 (DMSO-d6-400)1.61 (dd, J = 9.7, 5.6 Hz, 1 H),2.01 (dd, J = 8.8, 5.6 Hz, 1 H),2.51-3.01 (m, 13 H), 3.26-3.36 (m, 3 H),7.02-7.09 (m, 3 H), 7.16 (t,J = 7.4 Hz, 1 H), 7.50-7.59 (m, 4 H),7.73-7.79 (m, 2 H), 9.20 (s, 1 H),10.46 (brs, 1 H), 12.21 (brs, 1 H)

TABLE 2-43 Example Structural formula NMR 2-211 (DMSO-d6-300)1.61 (dd, J = 9.6, 5.5 Hz, 1 H),2.02 (dd, J = 8.7, 5.7 Hz, 1 H),2.55 (t, J = 8.3 Hz, 1 H), 2.67-2.79 (m, 4 H), 3.32-3.39 (m, 4 H),3.59-3.74 (m, 4 H), 7.01-7.10 (m,3 H), 7.12-7.19 (m, 1 H), 7.50-7.60 (m, 4 H), 7.73-7.78 (m, 2 H),9.20 (s, 1 H), 12.20 (brs, 1 H) 2-212 (DMSO-d6-300)1.63 (dd, J = 9.4, 5.7 Hz, 1 H),2.04 (dd, J = 8.5, 5.8 Hz, 1 H),2.75 (t, J = 9.0 Hz, 1 H), 3.50 (s,2 H), 7.07-7.24 (m, 4 H), 7.70 (d,J = 3.8 Hz, 1 H), 7.86 (d, J = 3.8 Hz,1 H), 8.18 (d, J = 0.8 Hz, 1 H),9.43 (s, 1 H), 12.28 (brs, 2 H) 2-213 (DMSO-d6-300)1.53 (dd, J = 9.4, 5.3 Hz, 1 H),1.92 (dd, J = 9.2, 5.5 Hz, 1 H),2.65 (t, J = 9.2 Hz, 1 H), 4.32 (brs,2 H), 4.45 (s, 2 H), 6.40-6.53 (m,3 H), 6.96 (t, J = 7.9 Hz, 1 H),7.68 (d, J = 3.8 Hz, 1 H), 7.87 (d,J = 3.8 Hz, 1 H), 7.98 (dd, J = 8.1,5.8 Hz, 1 H), 8.20 (s, 1 H), 8.46 (d,J = 8.3 Hz, 1 H), 8.79 (d, J = 5.3 Hz,1 H), 8.84 (d, J = 1.1 Hz, 1 H),9.38 (s, 1 H), 11.92 (brs, 1 H) 2-214 (DMSO-d6-400)1.55 (dd, J = 10.0, 5.8 Hz, 1 H),1.97 (dd, J = 8.8, 5.6 Hz, 1 H),2.69 (t, J = 9.3 Hz, 1 H), 2.99 (s,3 H), 4.26 (brs, 1 H), 4.70 (s, 2 H),6.56-6.60 (m, 2 H), 6.66 (s, 1 H),7.05 (t, J = 8.1 Hz, 1 H), 7.67 (d,J = 3.7 Hz, 1 H), 7.86 (d, J = 3.7 Hz,1 H), 7.90 (d, J = 7.4 Hz, 1 H),8.18 (d, J = 0.9 Hz, 1 H), 8.22 (t,J = 3.2 Hz, 1 H), 8.70 (s, 1 H),8.75 (d, J = 5.1 Hz, 1 H), 9.37 (s,1 H), 12.17 (brs, 1 H) 2-215 (DMSO-d6-300)1.61-1.65 (m, 1 H), 1.79-1.83 (m,1 H), 2.66-2.70 (m, 1 H), 2.73 (s,3 H), 3.00 (s, 3 H), 7.10-7.30 (m,4 H), 7.53 (d, J = 8.7 Hz, 2 H),7.57 (d, J = 3.8 Hz, 1 H), 7.59 (d,J = 3.8 Hz, 1 H), 7.76 (d, J = 9.0 Hz,2 H), 9.04 (brs, 1 H), 12.39 (brs,1 H)

TABLE 2-44 Example Structural formula NMR 2-216 (DMSO-d6-300)1.48-1.67 (m, 1 H), 1.73-1.81 (m,1 H), 2.04-2.44 (m, 4 H), 2.65-2.68 (m, 1 H), 3.17-3.67 (m, 7 H),7.12 (d, J = 7.2 Hz, 1 H), 7.26-7.35 (m, 3 H), 7.53 (d, J = 8.7 Hz,2 H), 7.58 (s, 2 H), 7.76 (d,J = 8.7 Hz, 2 H) 2-217 (MeOH-d4-300)1.52 (s, 9 H), 1.96 (dd, J = 9.8,5.7 Hz, 1 H), 2.11 (dd, J = 8.7,5.7 Hz, 1 H), 2.74 (t, J = 9.2 Hz, 1 H),7.00-7.07 (m, 1 H), 7.17-7.21 (m,2 H), 7.41-7.46 (m, 4 H), 7.63 (d,J = 4.1 Hz, 1 H), 7.68 (d, J = 8.7 Hz,2 H) 2-218 (DMSO-d6-300)0.92 (t, J = 5.7 Hz, 1 H), 1.74 (dd,J = 5.0, 2.5 Hz, 1 H), 2.89 (dd,J = 9.6, 6.2 Hz, 1 H), 6.84 (d,J = 7.2 Hz, 1 H), 6.95 (dd, J = 8.1,7.0 Hz, 1 H), 7.12-7.17 (m, 1 H),7.36-7.40 (m, 2 H), 7.51-7.55 (m,3 H), 7.70 (d, J = 8.7 Hz, 2 H),9.26 (brs, 1 H), 10.13 (brs, 1 H) 2-219 (DMSO-d6-300)1.64 (dd, J = 5.3, 2.6 Hz, 1 H), 1.97-2.06 (m, 1 H), 2.68-2.77 (m, 1 H),3.60 (s, 5 H), 7.10 (t, J = 7.3 Hz,3 H), 7.20 (t, J = 7.2 Hz, 1 H),7.70 (d, J = 3.8 Hz, 1 H), 7.86 (d,J = 3.8 Hz, 1 H), 8.17 (s, 1 H) 2-220 (DMSO-d6-300)1.63 (dd, J = 9.6, 5.5 Hz, 1 H),2.02 (dd, J = 8.7, 5.3 Hz, 1 H),2.76 (t, J = 9.0 Hz, 1 H), 3.35-3.54 (m, 8 H), 3.66 (s, 2 H), 7.07 (t,J = 7.9 Hz, 3 H), 7.20 (t, J = 7.7 Hz,1 H), 7.70 (d, J = 3.8 Hz, 1 H),7.86 (d, J = 3.8 Hz, 1 H), 8.18 (d,J = 1.1 Hz, 1 H), 9.42 (brs, 1 H),12.24 (brs, 1 H)

TABLE 2-45 Example Structural formula NMR 2-221 (DMSO-d6-300)1.63 (dd, J = 10.0, 5.8 Hz, 1 H),2.03 (dd, J = 8.3, 5.7 Hz, 1 H),2.77 (s, 3 H), 2.80-3.04 (m, 2 H),3.23-3.52 (m, 4 H), 3.71 (s, 2 H),3.98-4.19 (m, 1 H), 4.33-4.54 (m,1 H), 7.02-7.15 (m, 3 H), 7.22 (t,J = 7.3 Hz, 1 H), 7.70 (d, J = 4.1 Hz,1 H), 7.86 (d, J = 3.8 Hz, 1 H),8.18 (s, 1 H), 9.41 (s, 1 H),9.77 (brs, 1 H), 12.26 (brs, 1 H) 2-222 (DMSO-d6-300)1.01-1.31 (m, 2 H), 1.63 (q,J = 4.9 Hz, 1 H), 1.95-2.04 (m, 1 H),2.71 (t, J = 8.7 Hz, 1 H), 2.89-3.01 (m, 1 H), 3.03-3.14 (m, 1 H),3.54-3.70 (m, 4 H), 3.84-3.97 (m,1 H), 7.01-7.12 (m, 3 H), 7.18 (t,J = 7.3 Hz, 1 H), 7.70 (d, J = 3.8 Hz,1 H), 7.86 (d, J = 3.8 Hz, 1 H),8.18 (d, J = 0.8 Hz, 1 H) 2-223 (DMSO-d6-400)1.61 (dd, J = 9.7, 5.6 Hz, 1 H),1.94 (dd, J = 8.3, 5.6 Hz, 1 H), 2.46-2.53 (m, 2 H), 2.70-2.83 (m, 9 H),6.93 (d, J = 7.9 Hz, 1 H), 7.19 (t,J = 8.1 Hz, 1 H), 7.43-7.47 (m, 2 H),7.50-7.55 (m, 2 H), 7.57 (s, 2 H),7.72-7.78 (m, 2 H), 9.23 (s, 1 H),10.17 (s, 1 H), 12.22 (s, 1 H) 2-224 (DMSO-d6-300)1.16-1.30 (m, 2 H), 1.59-1.71 (m,3 H), 1.99-2.01 (m, 1 H), 2.51-2.54 (m, 2 H), 2.63-2.77 (m, 3 H),2.95-3.09 (m, 2 H), 3.60-3.67 (m,2 H), 3.84-3.95 (m, 1 H), 7.02-7.14 (m, 4 H), 7.49-7.59 (m, 4 H),7.75 (d, J = 8.3 Hz, 2 H), 8.32 (brs,1 H) 2-225 (MeOH-d4-400)1.89 (dd, J = 5.7, 9.8 Hz, 1 H),2.09 (dd, J = 5.8, 8.5 Hz, 1 H),2.76 (t, J = 9.2 Hz, 1 H), 5.01 (s,2 H), 6.85-7.67 (m, 15 H)

TABLE 2-46 Example Structural formula NMR 2-226 (MeOH-d4-400)1.82 (dd, J = 5.9, 9.8 Hz, 1 H),2.05 (dd, J = 5.8, 8.7 Hz, 1 H),2.77 (t, J = 9.3 Hz, 1 H), 4.50 (s,2 H), 7.16-7.65 (m, 7 H) 2-227 (DMSO-d6-300)1.18-1.24 (m, 3 H), 1.44 (d,J = 4.9 Hz, 1 H), 1.55-1.57 (m, 1 H),1.84-1.87 (m, 1 H), 1.98-2.01 (m,1 H), 3.24 (t, J = 6.2 Hz, 2 H), 7.11-7.24 (m, 5 H), 7.50-7.56 (m, 4 H),7.74 (d, J = 8.7 Hz, 2 H) 2-228 (DMSO-d6-300)1.58 (q, J = 5.1 Hz, 1 H), 1.99 (dd,J = 8.3, 5.7 Hz, 1 H), 2.71 (t,J = 9.8 Hz, 1 H), 2.85 (s, 6 H), 6.49-6.62 (m, 3 H), 7.04 (t, J = 7.7 Hz,1 H), 7.69 (d, J = 4.1 Hz, 1 H),7.86 (d, J = 3.8 Hz, 1 H), 8.18 (s,1 H), 9.38 (s, 1 H), 12.19 (brs, 1 H) 2-229 (MeOH-d4-400)1.84 (d, J = 4.5 Hz, 1 H), 2.07 (d,J = 5.3 Hz, 1 H), 3.76 (d, J = 11.3 Hz,1 H), 3.87 (d, J = 11.3 Hz, 1 H), 7.11-7.29 (m, 5 H), 7.38 (d, J = 3.0 Hz,1 H), 7.42 (d, J = 9.0 Hz, 2 H),7.58 (d, J = 3.0 Hz, 1 H), 7.65 (d,J = 9.0 Hz, 2 H) 2-230 (DMSO-d6-300)1.65 (dd, J = 9.4, 5.7 Hz, 1 H),2.12 (dd, J = 8.9, 5.8 Hz, 1 H), 2.49-2.58 (m, 2 H), 2.72-3.06 (m, 3 H),3.43-3.54 (m, 4 H), 7.00-7.16 (m,5 H), 7.71 (d, J = 3.8 Hz, 1 H),7.88 (d, J = 4.1 Hz, 1 H), 8.19 (s,1 H), 9.49 (brs, 1 H), 12.27 (brs,1 H)

TABLE 2-47 Example Structural formula NMR 2-231 (DMSO-d6-300)1.64 (dd, J = 9.2, 5.5 Hz, 1 H),2.11 (dd, J = 13.8, 4.7 Hz, 1 H),2.53-2.56 (m, 1 H), 2.74-2.88 (m,2 H), 2.84 (s, 3 H), 2.93 (s, 3 H),2.94-3.00 (m, 2 H), 7.01-7.16 (m,4 H), 7.71 (d, J = 3.8 Hz, 1 H),7.88 (d, J = 3.8 Hz, 1 H), 8.19 (s,1 H), 9.51 (brs, 1 H), 12.25 (brs,1 H) 2-232 (DMSO-d6-300)1.65-1.70 (m, 1 H), 2.14-2.16 (m,1 H), 2.59-2.61 (m, 1 H), 2.84-2.92 (m, 7 H), 3.27-3.53 (m, 4 H),3.99-4.10 (m, 2 H), 4.43-4.55 (m,2 H), 7.05-7.16 (m, 4 H), 7.72 (d,J = 3.8 Hz, 1 H), 7.89 (d, J = 4.1 Hz,1 H), 8.20 (s, 1 H), 9.52 (brs, 1 H),12.30 (brs, 1 H) 2-233 (DMSO-d6-300)1.16 (t, J = 9.6 Hz, 2 H), 1.35 (t,J = 11.5 Hz, 1 H), 1.45-1.88 (m, 5 H),1.92-2.06 (m, 2 H), 2.59-2.75 (m,1 H), 3.17-3.65 (m, 3 H), 4.85-4.99 (m, 1 H), 7.00-7.19 (m, 4 H),7.69 (d, J = 3.8 Hz, 1 H), 7.85 (d,J = 3.8 Hz, 1 H), 8.17 (s, 1 H),12.26 (brs, 1 H) 2-234 (DMSO-d6-300)1.62 (dd, J = 9.8, 5.7 Hz, 1 H),2.04 (dd, J = 8.5, 5.8 Hz, 1 H), 2.54-2.59 (m, 2 H), 2.69-2.79 (m, 3 H),3.34-3.61 (m, 8 H), 7.04-7.09 (m,3 H), 7.13-7.20 (m, 1 H), 7.70 (d,J = 4.1 Hz, 1 H), 7.86 (d, J = 3.8 Hz,1 H), 8.18 (s, 1 H), 9.40 (brs, 1 H),12.24 (brs, 1 H) 2-235 (DMSO-d6-300)1.63 (dd, J = 9.4, 5.7 Hz, 1 H),2.04 (dd, J = 8.7, 5.7 Hz, 1 H), 2.62-2.65 (m, 2 H), 2.71-2.97 (m, 10 H),3.28-3.37 (m, 2 H), 3.99-4.07 (m,1 H), 4.41-4.48 (m, 1 H), 7.05-7.09 (m, 3 H), 7.16-7.19 (m, 1 H),7.70 (d, J = 4.1 Hz, 1 H), 7.87 (d,J = 4.1 Hz, 1 H), 8.19 (s, 1 H),9.42 (brs, 1 H), 10.51 (brs, 1 H),12.23 (brs, 1 H)

TABLE 2-48 Example Structural formula NMR 2-236 (DMSO-d6-300)1.59-1.71 (m, 3 H), 2.03 (dd, J = 8.5,5.5 Hz, 1 H), 2.49-2.57 (m, 2 H),2.74 (t, J = 9.0 Hz, 1 H), 3.39 (t,J = 6.4 Hz, 2 H), 4.43 (brs, 1 H),6.99-7.07 (m, 3 H), 7.15 (t,J = 7.5 Hz, 1 H), 7.69 (d, J = 4.1 Hz,1 H), 7.86 (d, J = 4.1 Hz, 1 H),8.18 (d, J = 0.8 Hz, 1 H), 9.39 (brs,1 H), 12.22 (brs, 1 H) 2-237 (DMSO-d6-400)1.24 (d, J = 7.0 Hz, 3 H), 1.96 (dq,J = 10.7, 7.0 Hz, 1 H), 2.75 (d,J = 10.7 Hz, 1 H), 7.13-7.27 (m, 5 H),7.49-7.58 (m, 4 H), 7.71-7.76 (m,2 H) 2-238 (DMSO-d6-300)1.63 (q, J = 5.3 Hz, 1 H), 1.85 (t,J = 7.2 Hz, 2 H), 2.04 (dd, J = 8.7,5.7 Hz, 1 H), 2.60 (t, J = 7.5 Hz, 1 H),2.77 (t, J = 6.6 Hz, 4 H), 2.90-3.36(m, 7 H), 4.02 (t, J = 6.6 Hz, 4 H),7.02-7.09 (m, 3 H), 7.18 (t,J = 7.3 Hz, 1 H), 7.70 (d, J = 3.8 Hz,1 H), 7.87 (d, J = 4.1 Hz, 1 H),8.19 (d, J = 0.8 Hz, 1 H), 9.41 (s,1 H), 10.53 (brs, 1 H), 12.24 (brs, 1 H) 2-239 (CDCl3-300)1.25-1.29 (m, 2 H), 1.75-1.99 (m,2 H), 2.12 (dd, J = 8.7, 6.0 Hz, 1 H),2.25 (dd, J = 9.2, 6.6 Hz, 1 H), 2.60(q, J = 4.6 Hz, 1 H), 2.72 (dd,J = 13.0, 7.3 Hz, 1 H), 2.88 (t,J = 9.2 Hz, 1 H), 3.29-3.32 (m, 4 H),3.57 (t, J = 4.9 Hz, 4 H), 3.67-3.70(m, 1 H), 6.15 (brs, 1 H), 6.91 (s,1 H), 6.95 (s, 1 H), 7.01 (d,J = 7.5 Hz, 1 H), 7.10 (d, J = 7.5 Hz,1 H), 7.21 (t, J = 7.5 Hz, 1 H), 7.45 (d,J = 3.8 Hz, 1 H), 7.66 (d, J = 3.8 Hz,1 H) 2-240 (DMSO-d6-300)1.65-1.76 (m, 1 H), 2.04-2.16 (m,1 H), 2.62-2.82 (m, 2 H), 2.90-3.05 (m, 1 H), 3.53-3.67 (m, 2 H),4.52 (t, J = 5.8 Hz, 1 H), 6.96-7.22 (m, 4 H), 7.72 (d, J = 3.0 Hz,1 H), 7.87 (d, J = 3.8 Hz, 1 H),8.19 (s, 1 H), 9.41 (brs, 1 H),12.20 (brs, 1 H)

TABLE 2-49 Example Structural formula NMR 2-241 (MeOH-d4-300)1.94 (dd, J = 9.8, 5.7 Hz, 1 H), 2.12-2.14 (m, 4 H), 2.78 (t, J = 9.0 Hz,1 H), 7.09 (d, J = 4.1 Hz, 1 H), 7.16-7.28 (m, 5 H), 7.48 (d, J = 4.1 Hz,1 H), 7.52 (s, 1 H), 8.00 (s, 1 H) 2-242 (DMSO-d6-300)1.64-1.74 (m, 1 H), 2.05-2.17 (m,1 H), 2.65-2.79 (m, 1 H), 2.80-2.94 (m, 1 H), 3.06-3.19 (m, 1 H),3.26-3.38 (m, 4 H), 3.46-3.58 (m,4 H), 4.16-4.28 (m, 2 H), 7.04-7.18 (m, 4 H), 7.71 (d, J = 3.8 Hz,1 H), 7.87 (d, J = 3.8 Hz, 1 H),8.19 (s, 1 H), 9.46 (brs, 1 H),12.26 (brs, 1 H) 2-243 (DMSO-d6-300)1.73 (dd, J = 9.8, 5.7 Hz, 1 H),2.13 (dd, J = 7.9, 5.7 Hz, 1 H),2.69 (t, J = 9.2 Hz, 1 H), 3.23-3.62 (m, 8 H), 3.81 (dd, J = 21.7,16.4 Hz, 2 H), 6.95-7.03 (m, 1 H),7.05-7.21 (m, 3 H), 7.71 (d,J = 4.1 Hz, 1 H), 7.88 (d, J = 3.8 Hz,1 H), 8.19 (s, 1 H), 9.51 (brs, 1 H),12.32 (brs, 1 H) 2-244 (MeOH-d4-400)1.85-1.90 (m, 1 H), 2.11 (dd, J = 5.7,8.6 Hz, 1 H), 2.81-2.85 (m, 1 H),3.64 (brs, 2 H), 7.14-7.27 (m, 6 H),7.44 (dd, J = 2.2, 9.0 Hz, 1 H), 7.91-8.07 (m, 4 H) 2-245 (MeOH-d4-400)1.88 (dd, J = 6.1, 10.2 Hz, 1 H),2.08 (dd, J = 5.7, 8.6 Hz, 1 H),2.74 (t, J = 9.2 Hz, 1 H), 3.05-3.07 (m, 4 H), 3.77-3.80 (m, 4 H),6.83 (d, J = 8.7 Hz, 2 H), 7.14 (d,J = 8.6 Hz, 2 H), 7.37-7.48 (m, 3 H),7.57 (d, J = 4.0 Hz, 1 H), 7.65 (d,J = 8.6 Hz, 2 H)

TABLE 2-50 Example Structural formula NMR 2-246 (DMSO-d4-400)1.89 (dd, J = 5.7, 9.8 Hz, 1 H),2.08 (dd, J = 5.8, 8.6 Hz, 1 H),2.77 (t, J = 9.2 Hz, 1 H), 2.91-3.04 (m, 5 H), 3.20-3.31 (m, 2 H),3.56-3.58 (m, 2 H), 3.77-3.84 (m,2 H), 6.90 (d, J = 8.6 Hz, 2 H),7.20 (d, J = 8.4 Hz, 2 H), 7.39-7.45 (m, 3 H), 7.57 (d, J = 4.0 Hz,1 H), 7.66 (d, J = 8.6 Hz, 2 H) 2-247 (MeOH-d4-400)2.05 (dd, J = 5.9, 9.7 Hz, 1 H), 2.26-2.30 (m, 1 H), 2.69-2.73 (m, 1 H),2.88-3.05 (m, 5 H), 3.18-3.36 (m,2 H), 3.52-3.65 (m, 2 H), 3.74-3.87 (m, 2 H), 6.93 (d, J = 8.6 Hz,2 H), 7.12 (d, J = 8.6 Hz, 2 H), 7.39-7.50 (m, 4 H), 7.67 (d, J = 8.6 Hz, 2 H) 2-248 (MeOH-d4-300)1.04 (t, J = 7.2 Hz, 1 H), 1.31-1.47 (m, 2 H), 1.75-1.85 (m, 2 H),1.98-2.01 (m, 1 H), 2.22 (d,J = 6.0 Hz, 1 H), 3.46 (t, J = 6.6 Hz,2 H), 7.13-7.32 (m, 5 H), 7.63-7.68 (m, 3 H) 2-249 (MeOH-d4-300)1.44-1.47 (m, 2 H), 1.85-1.94 (m,3 H), 2.09 (d, J = 5.7 Hz, 1 H), 2.39-2.49 (m, 6 H), 3.68 (t, J = 4.7 Hz,4 H), 7.14-7.21 (m, 5 H), 7.38 (d,J = 4.1 Hz, 1 H), 7.44 (d, J = 8.7 Hz,2 H), 7.59 (d, J = 4.1 Hz, 1 H),7.67 (d, J = 8.7 Hz, 2 H) 2-250 (DMSO-d6-300)1.61 (dd, J = 9.8, 5.7 Hz, 1 H),1.97 (dd, J = 8.7, 5.7 Hz, 1 H),2.73 (t, J = 9.0 Hz, 1 H), 3.40 (t,J = 4.5 Hz, 4 H), 3.60 (t, J = 4.3 Hz,4 H), 6.81 (d, J = 7.9 Hz, 1 H),7.11 (t, J = 7.9 Hz,1 H), 7.30 (d,J = 7.9 Hz, 1 H), 7.38 (s, 1 H),7.71 (d, J = 4.1 Hz, 1 H), 7.86 (d,J = 4.1 Hz, 1 H), 8.18 (d, J = 0.8 Hz,1 H), 8.50 (s, 1 H), 9.43 (s, 1 H),12.23 (brs, 1 H)

TABLE 2-51 Example Structural formula NMR 2-251 (DMSO-d6-300)1.60 (q, J = 5.0 Hz, 1 H), 1.95 (t,J = 7.2 Hz, 1 H), 2.70 (t, J = 9.0 Hz,1 H), 3.40 (t, J = 4.7 Hz, 4 H),3.59 (t, J = 4.7 Hz, 4 H), 6.81 (d,J = 7.5 Hz, 1 H), 7.10 (t, J = 7.9 Hz,1 H), 7.29 (d, J = 9.0 Hz, 1 H),7.37 (s, 1 H), 7.53 (d, J = 8.7 Hz,2 H), 7.57 (s, 2 H), 7.76 (d,J = 8.7 Hz, 2 H), 8.50 (s, 1 H),9.22 (s, 1 H), 12.19 (brs, 1 H) 2-252 (DMSO-d6-300)1.65-1.76 (m, 3 H), 2.10-2.12 (m,1 H), 2.54-2.81 (m, 3 H), 3.49 (t,J = 6.4 Hz, 2 H), 7.04-7.12 (m, 4 H),7.71 (d, J = 3.8 Hz, 1 H), 7.87 (d,J = 4.1 Hz, 1 H), 8.18 (s, 1 H) 2-253 (DMSO-d6-300)1.70-1.74 (m, 1 H), 1.84-1.89 (m,2 H), 2.08-2.14 (m, 1 H), 2.60-2.68(m, 2 H), 2.76-2.90 (m, 1 H),3.31-3.38 (m, 4 H), 3.49-3.57 (m,4 H), 4.06-4.10 (m, 2 H), 7.06-7.16(m, 4 H), 7.71 (d, J = 4.1 Hz,1 H), 7.88 (d, J = 3.8 Hz, 1 H),8.19 (s, 1 H), 9.48 (brs, 1 H),12.21 (brs, 1 H) 2-254 (DMSO-d6-300)1.68-1.91 (m, 7 H), 2.08-2.15 (m,1 H), 2.62-2.69 (m, 1 H), 2.76-2.90(m, 2 H), 3.26-3.32 (m, 2 H),3.47-3.51 (m, 1 H), 3.70-3.74 (m,1 H), 4.02-4.07 (m, 2 H), 4.70-4.72(m, 1 H), 7.04-7.15 (m, 4 H),7.71 (d, J = 4.1 Hz, 1 H), 7.87 (d,J = 4.1 Hz, 1 H), 8.18 (s, 1 H),9.50 (brs, 1 H), 12.20 (brs, 1 H) 2-255 (DMSO-d6-300)1.70-1.92 (m, 5 H), 2.08-2.15 (m,1 H), 2.61-2.72 (m, 2 H), 2.80-2.83(m, 1 H), 3.16-3.21 (m, 1 H),3.31-3.39 (m, 3 H), 4.04-4.07 (m,1 H), 4.22-4.25 (m, 1 H), 4.91-4.92(m, 1 H), 7.05-7.15 (m, 4 H),7.71 (d, J = 3.8 Hz, 1 H), 7.87 (d,J = 4.1 Hz, 1 H), 8.19 (s, 1 H),9.51 (brs, 1 H), 12.20 (brs, 1 H)

TABLE 2-52 Example Structural formula NMR 2-256 (MeOH-d4-300)1.00 (d, J = 6.8 Hz, 3 H), 1.25-1.85(m, 6 H), 2.04 (dd, J = 9.0,5.7 Hz, 1 H), 2.66 (t, J = 9.0 Hz, 1 H),2.90 (t, J = 11.8 Hz, 2 H), 3.60 (d,J = 11.8 Hz, 2 H), 6.05 (d, J = 4.1 Hz,1 H), 7.13-7.33 (m, 6 H) 2-257 (DMSO-d6-300)1.60 (dd, J = 9.8, 5.5 Hz, 1 H),2.03 (dd, J = 8.7, 5.5 Hz, 1 H),2.74 (dd, J = 9.8, 8.7 Hz, 1 H), 3.03-3.12(m, 4 H), 3.70-3.78 (m, 4 H),6.72 (d, J = 7.2 Hz, 1 H), 6.79-6.88(m, 2 H), 7.12 (t, J = 7.9 Hz,1 H), 7.69 (d, J = 4.1 Hz, 1 H),7.87 (d, J = 4.1 Hz, 1 H), 8.18 (s,1 H), 9.38 (brs, 1 H) 2-258 (DMSO-d6-300)1.67 (dd, J = 9.7, 5.7 Hz, 1 H),2.11 (dd, J = 8.7, 5.7 Hz, 1 H),2.84 (dd, J = 9.7, 8.7 Hz, 1 H), 3.17-3.71(m, 8 H), 7.20-7.26 (m, 2 H),7.31-7.40 (m, 2 H), 7.71 (d,J = 4.1 Hz, 1 H), 7.87 (d, J = 4.1 Hz,1 H), 8.18 (s, 1 H), 9.41 (brs, 1 H),12.32 (brs, 1 H) 2-259 (DMSO-d6-300)1.63 (dd, J = 10.0, 5.8 Hz, 1 H),2.04 (dd, J = 8.3, 5.8 Hz, 1 H),2.65 (t, J = 7.9 Hz, 2 H), 2.75 (dd,J = 10.0, 8.3 Hz, 1 H), 3.13-3.27 (m,2 H), 3.23 (t, J = 4.7 Hz, 4 H),3.52 (t, J = 4.7 Hz, 4 H), 6.58-6.64(m, 1 H), 6.99-7.09 (m, 2 H),7.14-7.22 (m, 1 H), 7.70 (d,J = 4.1 Hz, 1 H), 7.86 (d, J = 4.1 Hz,1 H), 8.18 (s, 1 H), 9.42 (s, 1 H),12.24 (s, 1 H) 2-260 (DMSO-d6-300)1.64 (q, J = 4.9 Hz, 1 H), 1.98 (dd,J = 8.9, 5.1 Hz, 1 H), 2.81 (t,J = 9.6 Hz, 1 H), 3.18-4.24 (m, 11 H),7.00 (d, J = 7.2 Hz, 1 H), 7.25 (t,J = 8.3 Hz, 1 H), 7.47-7.51 (m, 2 H),7.72 (d, J = 4.1 Hz, 1 H), 7.87 (d,J = 3.8 Hz, 1 H), 8.19 (s, 1 H),9.45 (s, 1 H), 10.56 (brs, 1 H),12.28 (brs, 1 H)

TABLE 2-53 Example Structural formula NMR 2-261 (DMSO-d6-300)1.63 (dd, J = 10.0, 5.8 Hz, 1 H),1.97 (dd, J = 8.5, 6.2 Hz, 1 H),2.77 (t, J = 9.4 Hz, 1 H), 3.18-4.23(m, 10 H), 7.00 (d, J = 7.2 Hz,1 H), 7.24 (t, J = 8.1 Hz, 1 H), 7.46-7.59(m, 6 H), 7.76 (d, J = 8.7 Hz,2 H), 9.25 (s, 1 H), 10.70 (brs, 1 H),12.24 (brs, 1 H) 2-262 (DMSO-d6-300)1.25 (d, J = 6.8 Hz, 3 H), 1.97 (dd,J = 10.2, 6.4 Hz, 1 H), 2.76 (d,J = 10.2 Hz, 1 H), 7.12-7.29 (m, 5 H),7.52 (d, J = 8.7 Hz, 2 H), 7.56 (s,2 H), 7.74 (d, J = 8.7 Hz, 2 H) 2-263 (MeOH-d4-300)1.85 (d, J = 6.0 Hz, 1 H), 1.94-2.04(m, 1 H), 2.13-2.21 (m, 1 H),2.20 (d, J = 5.7 Hz, 1 H), 3.42 (t,J = 7.0 Hz, 2 H), 7.18-7.23 (m, 5 H),7.40 (d, J = 4.1 Hz, 1 H), 7.45 (d,J = 8.7 Hz, 2 H), 7.58 (d, J = 3.8 Hz,1 H), 7.67 (d, J = 8.7 Hz, 2 H) 2-264 (CDCl3-300)1.26 (s, 1 H), 1.50 (s, 2 H), 1.83-1.85(m, 1 H), 2.02 (s, 3 H), 2.21-2.23(m, 1 H), 3.97-3.99 (m, 2 H),6.09 (s, 1 H), 6.99 (s, 1 H), 7.08-7.09(m, 2 H), 7.23-7.25 (m, 3 H),7.44 (d, J = 4.0 Hz, 1 H), 7.63 (d,J = 4.0 Hz, 1 H) 2-265 (MeOH-d4-400)1.95 (dd, J = 5.8, 9.8 Hz, 1 H),2.14 (dd, J = 5.8, 8.6 Hz, 1 H),2.87 (t, J = 9.2 Hz, 1 H), 4.05 (s,2 H), 7.32-7.40 (m, 5 H), 7.44 (d,J = 8.6 Hz, 2 H), 7.58 (d, J = 4.0 Hz,1 H), 7.66 (d, J = 8.6 Hz, 2 H)

TABLE 2-54 Example Structural formula NMR 2-266 (MeOH-d4-400)1.97 (dd, J = 5.8, 9.8 Hz, 1 H),2.19 (dd, J = 5.9, 8.6 Hz, 1 H), 2.88-2.93(m, 1 H), 2.95 (s, 3 H), 3.07 (s,3 H), 7.31 (d, J8.3 Hz, 2 H), 7.37 (d,J = 8.1 Hz, 2 H), 7.65-7.68 (m, 3 H) 2-267 (DMSO-d6-300)1.64 (q, J = 5.0 Hz, 1 H), 1.92 (dd,J = 8.1, 5.8 Hz, 1 H), 2.67 (t,J = 7.9 Hz, 1 H), 3.03 (t, J = 4.3 Hz,4 H), 3.50 (t, J = 4.5 Hz, 4 H),6.91 (d, J = 7.9 Hz, 1 H), 7.00 (d,J = 8.7 Hz, 1 H), 7.12-7.19 (m, 2 H),7.70 (d, J = 3.8 Hz, 1 H), 7.85 (d,J = 4.1 Hz, 1 H), 8.17 (s, 1 H),9.87 (brs, 1 H), 12.27 (brs, 1 H) 2-268 (DMSO-d6-300)1.63 (q, J = 5.1 Hz, 1 H), 2.02 (dd,J = 8.7, 6.8 Hz, 1 H), 2.65 (t,J = 7.2 Hz, 1 H), 2.72 (t, J = 6.8 Hz,1 H), 3.54 (t, J = 7.3 Hz, 1 H),4.62 (brs, 1 H), 7.00-7.08 (m, 3 H),7.15 (t, J = 7.3 Hz, 1 H), 7.69 (d,J = 3.8 Hz, 1 H), 7.86 (d, J = 3.8 Hz,1 H), 8.17 (s, 1 H), 9.38 (brs, 1 H),12.24 (brs, 1 H) 2-269 (DMSO-d6-300)1.63 (q, J = 5.1 Hz, 1 H), 1.91 (dd,J = 7.7, 6.2 Hz, 1 H), 2.66 (t,J = 8.9 Hz, 1 H), 3.03 (t, J = 4.1 Hz,4 H), 3.50 (t, J = 4.5 Hz, 4 H),6.91 (d, J = 7.9 Hz, 1 H), 7.00 (d,J = 7.9 Hz, 1 H), 7.12-7.19 (m, 2 H),7.52 (d, J = 8.7 Hz, 2 H), 7.57 (s,2 H), 7.76 (d, J = 8.7 Hz, 2 H),9.91 (brs, 1 H), 12.28 (brs, 1 H) 2-270 (DMSO-d6-300)1.63 (dd, J = 9.6, 5.5 Hz, 1 H),2.05 (dd, J = 8.9, 5.5 Hz, 1 H),2.75 (t, J = 9.0 Hz, 1 H), 2.79 (t,J = 7.3 Hz, 1 H), 4.05 (t, J = 7.2 Hz,2 H), 6.45 (brs, 2 H), 7.06-7.12 (m,3 H), 7.17 (d, J = 6.8 Hz, 1 H),7.69 (d, J = 4.1 Hz, 1 H), 7.86 (d,J = 4.1 Hz, 1 H), 8.18 (d, J = 0.8 Hz,1 H), 9.41 (brs, 1 H), 12.12 (brs,1 H)

TABLE 2-55 Example Structural formula NMR 2-271 (MeOH-d4-400)1.95 (dd, J = 5.5, 9.6 Hz, 1 H),2.14 (dd, J = 6.0, 8.0 Hz, 1 H),2.78 (t, J = 9.1 Hz, 1 H), 2.94-3.72(complexm, 10 H), 7.28-7.38 (m,4 H), 7.65-7.70 (m, 3 H) 2-272 (MeOH-d4-300)1.30-1.38 (m, 3 H), 1.81 (d,J = 6.0 Hz, 1 H), 1.88 (s, 3 H), 1.93-2.03(m, 1 H), 2.19 (d, J = 6.0 Hz,1 H), 3.06-3.08 (m, 2 H), 7.16-7.23(m, 5 H), 7.40 (d, J = 4.1 Hz,1 H), 7.45 (dd, J = 6.6, 2.1 Hz, 2 H),7.57 (d, J = 4.1 Hz, 1 H), 7.67 (dd,J = 6.6, 2.1 Hz, 2 H) 2-273 (MeOH-d4-300)1.71-1.73 (m, 4 H), 2.19 (d,J = 6.0 Hz, 1 H), 4.03-4.05 (m, 2 H),6.21 (t, J = 2.3 Hz, 1 H), 7.16-7.23(m, 5 H), 7.41-7.46 (m, 4 H),7.53 (d, J = 4.1 Hz, 1 H), 7.67 (dd,J = 6.6, 2.1 Hz, 2 H) 2-274 (DMSO-d6-300)1.16 (s, 3 H), 1.34 (s, 3 H), 2.56 (s,1 H), 7.13-7.29 (m, 5 H), 7.51 (d,J = 8.7 Hz, 2 H), 7.55 (s, 2 H),7.73 (d, J = 8.7 Hz, 2 H), 9.03 (brs,1 H), 12.28 (brs, 1 H) 2-275 (DMSO-d6-300)1.17 (s, 3 H), 1.34 (s, 3 H), 2.57 (s,1 H), 7.13-7.31 (m, 5 H), 7.69 (d,J = 4.1 Hz, 1 H), 7.84 (d, J = 4.1 Hz,1 H), 8.15 (s, 1 H), 9.23 (brs, 1 H),12.31 (brs, 1 H)

TABLE 2-56 Example Structural formula NMR 2-276 (DMSO-d6-300)1.64 (dd, J = 9.7, 5.7 Hz, 1 H), 1.97-2.12(m, 3 H), 2.43-2.49 (m, 2 H),2.70-2.84 (m, 1 H), 3.71-3.85 (m,2 H), 6.98 (d, J = 7.5 Hz, 1 H),7.24 (dd, J = 7.9, 7.5 Hz, 1 H),7.50 (d, J = 7.9 Hz, 1 H), 7.53 (s,1 H), 7.71 (d, J = 4.1 Hz, 1 H),7.86 (d, J = 4.1 Hz, 1 H), 8.18 (s,1 H), 9.41 (brs, 1 H), 12.26 (brs,1 H) 2-277 (MeOH-d4-400)2.68 (t, J = 7.0 Hz, 1 H), 3.03 (d,J = 7.0 Hz, 1 H), 3.18 (dd, J = 7.0,17.5 Hz, 1 H), 3.50 (d, J = 17.3 Hz,1 H), 7.06 (s, 3 H), 7.24-7.28 (m,1 H), 7.65-7.67 (m, 3 H) 2-278 (DMSO-d6-400)1.60 (dd, J = 5.5, 9.6 Hz, 1 H),2.02 (dd, J = 5.8, 8.2 Hz, 1 H),2.31 (t, J = 7.7 Hz, 2 H), 2.70-2.75(m, 3 H), 6.74 (s, 1 H), 7.11 (q,J = 8.1 Hz, 4 H), 7.26 (s, 1 H),7.69 (d, J = 3.9 Hz, 1 H), 7.86 (d,J = 3.9 Hz, 1 H), 8.17 (s, 1 H),9.39 (s, 1 H) 2-279 (DMSO-d6-400)1.60 (dd, J = 5.6, 9.7 Hz, 1 H),2.02 (dd, J = 5.7, 8.4 Hz, 1 H), 2.55-2.59(m, 2 H), 2.70-2.77 (m, 3 H),3.37-3.43 (m, 4 H), 3.48-3.53 (m,4 H), 7.13 (s, 4 H), 7.69 (d,J = 3.9 Hz, 1 H), 7.86 (d, J = 3.9 Hz,1 H), 8.17 (s, 1 H), 9.39 (s, 1 H) 2-280 (DMSO-d6-400)1.61 (dd, J = 5.6, 9.8 Hz, 1 H),2.02 (dd, J = 5.7, 8.4 Hz, 1 H), 2.59-3.60(complexm, 16 H), 7.14 (s, 4 H),7.87 (d, J = 3.9 Hz, 1 H), 8.18 (s,1 H), 9.39 (s, 1 H)

TABLE 2-57 Example Structural formula NMR 2-281 (DMSO-d6-400)1.60 (dd, J = 5.6, 9.7 Hz, 1 H),2.02 (dd, J = 5.8, 8.4 Hz, 1 H), 2.29-2.33(m, 2 H), 2.54 (d, J = 4.5 Hz,3 H), 2.70-2.76 (m, 3 H), 7.10 (dd,J = 8.0, 19.3 Hz, 4 H), 7.69 (d,J = 3.9 Hz, 1 H), 7.71-7.73 (m, 1 H),7.86 (d, J = 3.9 Hz, 1 H), 8.17 (s,1 H), 9.38 (s, 1 H) 2-282 (DMSO-d6-400)1.60 (dd, J = 5.6, 9.8 Hz, 1 H),2.02 (dd, J = 5.7, 8.5 Hz, 1 H), 2.52-2.56(m, 2 H), 2.69-2.75 (m, 3 H),2.80 (s, 3 H), 2.90 (s, 3 H), 7.12 (s,4 H), 7.69 (d, J = 3.9 Hz, 1 H),7.86 (d, J = 3.9 Hz, 1 H), 8.18 (s,1 H), 9.39 (s, 1 H) 2-283 (DMSO-d6-300)1.66 (dd, J = 9.8, 5.7 Hz, 1 H),2.07 (dd, J = 8.7, 5.7 Hz, 1 H),2.80 (dd, J = 9.8, 8.7 Hz, 1 H),5.38 (s, 2 H), 7.23-7.36 (m, 4 H),7.70 (d, J = 3.8 Hz, 1 H), 7.86 (d,J = 3.8 Hz, 1 H), 8.18 (s, 1 H),9.43 (s, 1 H), 12.31 (s, 1 H) 2-284 (DMSO-d6-400)0.42-0.58 (m, 10 H), 0.98 (d,J = 5.6 Hz, 1 H), 1.07-1.21 (m, 1 H),1.35 (d, J = 5.6 Hz, 1 H), 2.12-2.14(m, 2 H), 6.33-6.40 (m, 5 H),6.57 (d, J = 4.2 Hz, 1 H), 6.62 (d,J = 8.8 Hz, 2 H), 6.75 (d, J = 4.2 Hz,1 H), 6.85 (d, J = 8.8 Hz, 2 H) 2-285 (MeOH-d4-300)1.54-1.57 (m, 2 H), 1.85-1.86 (m,1 H), 1.92 (d, J = 6.0 Hz, 1 H), 2.01-2.04(m, 1 H), 2.24 (d, J = 6.0 Hz,1 H), 2.77-2.88 (m, 2 H), 7.19-7.24(m, 5 H), 7.39 (d, J = 4.1 Hz,1 H), 7.43 (dd, J = 6.8, 1.9 Hz, 2 H),7.56 (d, J = 4.1 Hz, 1 H), 7.65 (dd,J = 6.8, 1.9 Hz, 2 H)

TABLE 2-58 Example Structural formula NMR 2-286 (MeOH-d4-300)1.33 (d, J = 6.8 Hz, 3 H), 2.14 (dd,J = 10.5, 6.8 Hz, 1 H), 2.84 (d,J = 10.5 Hz, 1 H), 4.01 (s, 2 H), 7.16-7.23(m, 5 H), 7.57 (dd, J = 8.3,1.9 Hz, 1 H), 7.79 (brs, 1 H),7.83 (d, J = 7.9 Hz, 1 H), 7.93-7.97(m, 2 H), 8.08 (brs, 1 H) 2-287 (MeOH-d4-400)1.37 (d, J = 6.5 Hz, 3 H), 2.14 (s,3 H), 2.16-2.24 (m, 1 H), 2.94 (d,J = 10.2 Hz, 1 H), 7.08 (d, J = 4.2 Hz,1 H), 7.16-7.30 (m, 5 H), 7.48 (dd,J = 4.2, 0.9 Hz, 1 H), 7.51 (s, 1 H),7.99 (brs, 1 H) 2-288 (DMSO-d6-300)1.27 (d, J = 6.4 Hz, 3 H), 2.01 (dd,J = 10.4, 7.0 Hz, 1 H), 2.80 (d,J = 10.2 Hz, 1 H), 7.11-7.34 (m, 5 H),7.70 (d, J = 3.8 Hz, 1 H), 7.85 (d,J = 3.8 Hz, 1 H), 8.17 (s, 1 H),9.28 (brs, 1 H), 12.35 (brs, 1 H) 2-289 (MeOH-d4-400)1.95 (dd, J = 5.8, 9.8 Hz, 1 H),2.15 (dd, J = 5.8, 8.6 Hz, 1 H),2.91 (t, J = 9.2 Hz, 1 H), 4.05 (s,2 H), 7.36 (dt, J = 8.2, 8.2 Hz, 4 H),7.65-7.68 (m, 3 H) 2-290 (DMSO-d6-400)1.61 (dd, J = 5.6, 9.6 Hz, 1 H),2.03 (dd, J = 5.8, 8.2 Hz, 1 H),2.74 (t, J = 9.2 Hz, 1 H), 2.81 (s,3 H), 2.96 (s, 3 H), 3.4-3.8 (s, 2 H),7.10 (d, J = 8.0 Hz, 2 H), 7.15 (d,J = 8.0 Hz, 2 H), 7.69 (d, J = 3.8 Hz,1 H), 7.86 (d, J = 3.8 Hz, 1 H),8.17 (s, 1 H), 9.40 (s, 1 H)

TABLE 2-59 Example Structural formula NMR 2-291 (DMSO-d6-400)1.59 (dd, J = 5.5, 9.4 Hz, 1 H),2.00 (dd, J = 5.9, 7.9 Hz, 1 H),2.71 (t, J = 9.1 Hz, 1 H), 3.41-3.48(m, 8 H), 3.62 (s, 2 H), 7.07 (d,J = 7.8 Hz, 2 H), 7.13 (d, J = 7.8 Hz,2 H), 7.66 (d, J = 3.7 Hz, 1 H),7.82 (d, J = 3.7 Hz, 1 H), 8.12 (s,1 H), 9.36 (s, 1 H) 2-292 (MeOH-d4-400)1.93 (dd, J = 5.8, 9.8 Hz, 1 H),2.14 (dd, J = 5.9, 8.5 Hz, 1 H),2.83 (t, J = 9.2 Hz, 1 H), 3.44 (s,2 H), 7.18-7.24 (m, 4 H), 7.65-7.68(m, 3 H) 2-293 (DMSO-d6-400)1.61 (dd, J = 5.5, 9.3 Hz, 1 H), 2.02-2.05(m, 1 H), 2.56 (s, 3 H), 2.74 (t,J = 9.1 Hz, 1 H), 3.33 (s, 2 H),7.15 (m, 4 H), 7.70 (d, J = 3.6 Hz,1 H), 7.86 (d, J = 3.6 Hz, 1 H),7.94 (s, 1 H), 8.17 (s. 1 H), 9.40 (s,1 H) 2-294 (MeOH-d4-400)1.91 (dd, J = 5.8, 9.7 Hz, 1 H),2.13 (dd, J = 5.9, 8.4 Hz, 1 H), 2.47-4.33(complexm, 14 H), 7.16 (d,J = 8.0 Hz, 2 H), 7.27 (d, J = 7.9 Hz,2 H), 7.65-7.69 (m, 3 H), 8.89 (s,2 H) 2-295 (DMSO-d6-300)1.58 (d, J = 5.7 Hz, 1 H), 1.77-1.87(m, 1 H), 2.03-2.20 (m, 2 H),3.56-3.70 (m, 2 H), 6.38 (brs, 2 H),7.11-7.26 (m, 5 H), 7.47-7.56 (m,4 H), 7.73 (d, J = 8.7 Hz, 2 H),9.19 (brs, 1 H), 12.19 (brs, 1 H)

TABLE 2-60 Example Structural formula NMR 2-296 (DMSO-d6-300)1.23 (d, J = 6.5 Hz, 3 H), 1.80 (dd,J = 10.4, 6.6 Hz, 1 H), 2.61 (d,J = 10.5 Hz, 1 H), 6.85 (brs, 1 H),7.04 (brs, 1 H), 7.12-7.28 (m, 5 H),7.74 (d, J = 3.8 Hz, 1 H), 7.87 (d,J = 3.8 Hz, 1 H), 8.17 (s, 1 H),9.11 (brs, 1 H) 2-297 (DMSO-d6-300)1.21 (d, J = 6.8 Hz, 3 H), 1.77 (dd,J = 10.7, 6.6 Hz, 1 H), 2.39 (d,J = 4.1 Hz, 3 H), 2.58 (d, J = 10.5 Hz,1 H), 7.09-7.27 (m, 5 H), 7.49 (d,J = 4.9 Hz, 1 H), 7.72 (d, J = 3.8 Hz,1 H), 7.87 (d, J = 3.8 Hz, 1 H),8.16 (s, 1 H), 9.01 (brs, 1 H) 2-298 (MeOH-d4-300)1.61-1.76 (m, 10 H), 2.17 (d,J = 5.7 Hz, 1 H), 2.96-2.99 (m, 1 H),4.95-4.98 (m, 1 H), 7.19 (t,J = 7.9 Hz, 5 H), 7.38 (d, J = 4.1 Hz,1 H), 7.43 (d, J = 8.7 Hz, 2 H),7.55 (d, J = 4.1 Hz, 1 H), 7.66 (d,J = 8.7 Hz, 2 H) 2-299 (MeOH-d4-400)1.07 (t, J = 7.3 Hz, 3 H), 1.70-1.80(m, 1 H), 1.82-1.93 (m, 1 H),2.03-2.10 (m, 1 H), 2.98 (d,J = 10.5 Hz, 1 H), 7.15-7.28 (m, 5 H),7.64-7.68 (m, 3 H) 2-300 (MeOH-d4-400)1.93 (dd, J = 6.0, 9.9 Hz, 1 H),2.12 (dd, J = 5.8, 8.5 Hz, 1 H),2.88 (dd, J = 8.0, 15.0 Hz, 1 H),3.13 (t, J = 7.8 Hz, 2 H), 3.18-3.24(m, 2 H), 7.17 (d, J = 7.9 Hz,2 H), 7.28 (d, J = 7.9 Hz, 2 H), 7.65-7.68(m, 3 H)

TABLE 2-61 Example Structural formula NMR 2-301 (MeOH-d4-400)1.91 (dd, J = 5.8, 9.7 Hz, 1 H),2.13 (dd, J = 6.1, 8.4 Hz, 1 H),2.75 (t, J = 7.0 Hz, 2 H), 2.81 (t,J = 9.2 Hz, 1 H), 3.69 (t, J = 7.0 Hz,2 H), 7.10 (d, J = 7.9 Hz, 2 H),7.19 (d, J = 7.8 Hz, 2 H), 7.64-7.67(m, 3 H) 2-302 (MeOH-d4-400)1.73-1.81 (m, 2 H), 1.91 (dd, J = 5.3,9.4 Hz, 1 H), 2.11-2.15 (m, 1 H),2.61 (t, J = 7.6 Hz, 2 H), 2.80 (t,J = 8.9 Hz, 1 H), 3.52 (t, J = 6.4 Hz,2 H), 7.08 (d, J = 7.7 Hz, 2 H),7.17 (d, J = 7.8 Hz, 2 H), 7.65-7.67(m, 3 H) 2-303 (DMSO-d6-300)1.48 (d, J = 6.0 Hz, 1 H), 1.83 (q,J = 7.4 Hz, 1 H), 2.11 (d, J = 5.3 Hz,1 H), 2.16-2.25 (m, 1 H), 2.65 (s,6 H), 3.62 (q, J = 8.3 Hz, 1 H),3.81 (q, J = 5.4 Hz, 1 H), 7.11-7.19(m, 3 H), 7.23 (d, J = 7.2 Hz,1 H), 7.27 (d, J = 4.1 Hz, 1 H), 7.48-7.57(m, 4 H), 7.74 (d, J = 8.3 Hz,2 H), 9.23 (s, 1 H), 12.19 (brs, 1 H) 2-304 (DMSO-d6-300)1.26 (d, J = 6.0 Hz, 6 H), 1.68 (dd,J = 8.7, 5.8 Hz, 1 H), 2.13 (dd,J = 8.5, 5.8 Hz, 1 H), 2.83 (dd,J = 8.7, 8.5 Hz, 1 H), 3.14-3.98 (m,3 H), 7.27-7.49 (m, 4 H), 7.72 (d,J = 3.8 Hz, 1 H), 7.88 (d, J = 3.8 Hz,1 H), 8.19 (s, 1 H), 9.45 (s, 1 H) 2-305 (DMSO-d6-400)1.41-1.91 (m, 5 H), 2.43-2.53 (m,1 H), 2.76 (d, J = 9.7 Hz, 1 H),2.99 (td, J = 13.0, 7.4 Hz, 1 H),7.04-7.18 (m, 4 H), 7.70 (d,J = 3.7 Hz, 1 H), 7.85 (d, J = 3.7 Hz,1 H), 8.17 (s, 1 H), 9.26 (brs, 1 H),12.43 (brs, 1 H)

TABLE 2-62 Example Structural formula NMR 2-306 (DMSO-d6-300)1.80 (d, J = 6.0 Hz, 1 H), 2.13 (d,J = 5.7 Hz, 1 H), 3.20-3.44 (m, 8 H),4.21 (d, J = 11.3 Hz, 1 H), 4.26 (d,J = 11.3 Hz, 1 H), 7.15-7.29 (m, 5 H),7.70 (d, J = 3.8 Hz, 1 H), 7.86 (d,J = 4.1 Hz, 1 H), 8.18 (s, 1 H),9.52 (brs, 1 H), 12.43 (brs, 1 H) 2-307 (DMSO-d6-300)1.63 (dd, J = 10.2, 6.0 Hz, 1 H),2.06 (dd, J = 8.7, 5.7 Hz, 1 H),2.79 (t, J = 9.4 Hz, 1 H), 7.15-7.31(m, 5 H), 7.62-7.73 (m, 4 H),7.89 (d, J = 8.7 Hz, 2 H), 9.49 (brs,1 H), 12.27 (brs, 1 H) 2-308 (DMSO-d6-300)1.02 (s, 3 H), 1.04 (s, 3 H), 1.75 (d,J = 5.7 Hz, 1 H), 2.14 (d, J = 5.3 Hz,1 H), 2.93-3.00 (m, 2 H), 3.20-3.29(m, 2 H), 3.43-3.50 (m, 1 H),4.15 (d, J = 11.7 Hz, 1 H), 4.26 (d,J = 10.9 Hz, 1 H), 6.92 (t, J = 5.7 Hz,1 H), 7.16-7.25 (m, 5 H), 7.70 (d,J = 3.8 Hz, 1 H), 7.86 (d, J = 4.1 Hz,1 H), 8.17 (s, 1 H), 9.38 (brs, 1 H),12.40 (brs, 1 H) 2-309 (DMSO-d6-300)1.68-1.79 (m, 5 H), 2.11-2.16 (m,1 H), 2.87-2.92 (m, 2 H), 3.54-3.72(m, 3 H), 4.15 (d, J = 11.3 Hz,1 H), 4.25 (d, J = 12.8 Hz, 1 H), 6.96-7.01(m, 1 H), 7.17-7.25 (m, 5 H),7.70 (d, J = 3.8 Hz, 1 H), 7.86 (d,J = 3.8 Hz, 1 H), 8.17 (s, 1 H),9.35 (brs, 1 H), 12.40 (brs, 1 H) 2-310 (DMSO-d6-300)1.21-1.37 (m, 4 H), 1.39-1.51 (m,2 H), 1.77 (d, J = 6.0 Hz, 1 H),2.15 (d, J = 6.0 Hz, 1 H), 3.13-3.24(m, 4 H), 4.16 (d, J = 12.0 Hz,1 H), 4.25 (d, J = 12.0 Hz, 1 H), 7.11-7.32(m, 5 H), 7.70 (d, J = 3.0 Hz,1 H), 7.87 (d, J = 3.0 Hz, 1 H),8.18 (s, 1 H), 9.49 (s, 1 H),12.40 (brs, 1 H)

TABLE 2-63 Example Structural formula NMR 2-311 (acetone-d6-400)2.14-2.19 (m, 5 H), 2.89 (t,J = 9.2 Hz, 1 H), 6.06 (s, 1 H), 7.73-7.74(m, 1 H), 7.81-7.82 (m, 2 H) 2-312 (CD3CN-400)2.95 (dd, J = 5.0, 9.0 Hz, 1 H),3.21 (d, J = 9.0 Hz, 1 H), 4.03 (d,J = 10.3 Hz, 1 H), 4.46 (dd, 5.0,10.3 Hz, 1 H), 7.28-7.41 (m, 5 H),7.47 (s, 1 H), 7.65 (d, J = 3.9 Hz,1 H), 7.75 (d, J = 3.9 Hz, 1 H) 2-313 (acetone-d6-400)2.05 (m, 1 H), 2.11-2.15 (m, 1 H),2.33 (s, 3 H), 2.77-2.82 (m, 1 H),6.00 (s, 1 H), 7.74-7.82 (m, 3 H) 2-314 (acetone-d6-400)2.16 (dd, J = 5.8, 9.7 Hz, 1 H), 2.27-2.31(m, 1 H), 2.37 (s, 3 H),2.80 (dd, J = 7.9, 9.6 Hz, 1 H),5.97 (s, 1 H), 7.68-7.83 (m, 3 H) 2-315 (acetone-d6-400)2.05-2.07 (m, 1 H), 2.12-2.15 (m,1 H), 2.81 (t, J = 9.3 Hz, 1 H),2.88 (t, J = 6.4 Hz, 2 H), 3.79 (t,J = 6.2 Hz, 2 H), 6.09 (s, 1 H), 7.74-7.81(m, 3 H)

TABLE 2-64 Example Structural formula NMR 2-316 (acetone-d6-400)2.17 (dd, J = 5.7, 9.6 Hz, 1 H), 2.25-2.31(m, 1 H), 2.82 (t, J = 8.8 Hz,1 H), 2.92 (t, J = 6.4 Hz, 2 H),3.82 (t, J = 6.5 Hz, 2 H), 6.05 (s,1 H), 7.68-7.82 (m, 3 H) 2-317 (acetone-d6-400)2.08-2.09 (m, 1 H), 2.15-2.18 (m,1 H), 2.84 (t, J = 9.7 Hz, 1 H),4.62 (s, 2 H), 6.20 (s, 1 H), 7.74-7.82(m, 3 H) 2-318 (acetone-d6-400)2.18-2.22 (m, 1 H), 2.33 (t,J = 6.7 Hz, 1 H), 2.85 (t, J = 8.7 Hz,1 H), 4.67 (s, 2 H), 6.19 (s, 1 H),7.69-7.82 (m, 3 H) 2-319 (CDCl3-300)0.87 (d, J = 7.2 Hz, 3 H), 0.94 (d,J = 6.4 Hz, 3 H), 1.26-1.29 (m, 1 H),1.89-1.93 (m, 2 H), 2.13 (d,J = 6.4 Hz, 1 H), 2.22-2.24 (m, 1 H),2.43 (d, J = 5.7 Hz, 1 H), 2.65-2.73(m, 1 H), 3.44-3.49 (m, 1 H),5.93 (brs, 1 H), 7.18-7.26 (m, 5 H),7.37 (d, J = 7.9 Hz, 2 H), 7.53-7.56(m, 3 H), 7.76 (d, J = 3.8 Hz, 1 H) 2-320 (DMSO-d6-300)1.77 (d, J = 6.0 Hz, 1 H), 2.14 (d,J = 6.0 Hz, 1 H), 2.67 (s, 3 H),2.70 (s, 3 H), 4.13 (d, J = 12.0 Hz,1 H), 4.23 (d, J = 12.0 Hz, 1 H), 7.16-7.28(m, 5 H), 7.70 (d, J = 3.0 Hz,1 H), 7.87 (d, J = 3.0 Hz, 1 H),8.18 (s, 1 H), 9.47 (s, 1 H),12.40 (brs, 1 H)

TABLE 2-65 Example Structural formula NMR 2-321 (DMSO-d6-300)0.91 (t, J = 7.5 Hz, 3 H), 1.75 (d,J = 6.0 Hz, 1 H), 2.16 (d, J = 6.0 Hz,1 H), 2.81-2.96 (m, 2 H), 4.13 (d,J = 12.0 Hz, 1 H), 4.28 (d, J = 12.0 Hz,1 H), 6.89-6.97 (m, 1 H), 7.13-7.28(m, 5 H), 7.70 (d, J = 3.0 Hz,1 H), 7.87 (d, J = 3.0 Hz, 1 H),8.18 (s, 1 H), 9.38 (s, 1 H),12.37 (brs, 1 H) 2-322 (DMSO-d6-300)2.10-2.23 (m, 1 H), 2.90-4.11 (m,10 H), 7.14-7.47 (m, 5 H), 7.69 (d,J = 4.1 Hz, 1 H), 7.86 (d, J = 4.1 Hz,1 H), 8.19 (s, 1 H), 9.53 (brs, 1 H),9.75 (brs, 1 H), 12.49 (brs, 1 H) 2-323 (DMSO-d6-300)1.20 (d, J = 6.4 Hz, 2 H), 1.73 (dt,J = 10.5, 6.5 Hz, 1 H), 2.56 (d,J = 10.5 Hz, 1 H), 7.11-7.27 (m, 5 H),7.74 (d, J = 3.8 Hz, 1 H), 7.86 (d,J = 3.8 Hz, 1 H), 8.15 (s, 1 H),8.62 (brs, 1 H), 8.92 (brs, 1 H),10.21 (brs, 1 H) 2-324 (DMSO-d6-300)1.21 (d, J = 6.8 Hz, 3 H), 1.82 (dd,J = 10.4, 6.6 Hz, 1 H), 2.62 (d,J = 9.8 Hz, 1 H), 5.21 (s, 2 H), 7.12-7.30(m, 7 H), 7.49 (dd, J = 8.5,1.7 Hz, 1 H), 7.63 (d, J = 8.3 Hz, 1 H),7.69-7.78 (m, 3 H), 8.60 (brs, 1 H),12.18 (brs, 1 H) 2-325 (DMSO-d6-300)1.14 (d, J = 6.4 Hz, 3 H), 1.53 (dd,J = 10.9, 6.4 Hz, 1 H), 2.38 (d,J = 10.5 Hz, 1 H), 5.21 (s, 2 H), 7.07-7.25(m, 7 H), 7.48 (d, J = 8.3 Hz,1 H), 7.62 (d, J = 8.3 Hz, 1 H),7.70 (s, 1 H), 7.78 (d, J = 8.3 Hz,2 H), 8.36 (brs, 1 H), 8.60 (brs,1 H), 10.13 (brs, 1 H)

TABLE 2-66 Example Structural formula NMR 2-326 (CDCl3-300)1.25 (d, J = 5.3 Hz, 3 H), 2.18-2.29(m, 1 H), 2.77-2.89 (m, 1 H),7.11-7.34 (m, 6 H), 7.37 (d,J = 8.3 Hz, 2 H), 7.48 (d, J = 8.3 Hz,2 H), 7.60 (d, J = 3.0 Hz, 1 H) 2-327 (MeOH-d4-400)1.07 (t, J = 7.3 Hz, 3 H), 1.68-1.80(m, 1 H), 1.83-1.93 (m, 1 H),2.07 (ddd, J = 5.8, 9.9, 10.1 Hz,1 H), 2.99 (d, J = 10.5 Hz, 1 H), 7.15-7.27(m, 5 H), 7.65-7.68 (m, 3 H) 2-328 (MeOH-d4-400)1.07 (t, J = 7.3 Hz, 3 H), 1.68-1.80(m, 1 H), 1.82-1.93 (m, 1 H),2.07 (ddd, J = 5.8, 9.9, 10.1 Hz,1 H), 2.99 (d, J = 10.5 Hz, 1 H), 7.15-7.27(m, 5 H), 7.64-7.68 (m, 3 H) 2-329 (DMSO-d6-300)1.62-1.94 (m, 4 H), 2.12 (d,J = 6.8 Hz, 1 H), 2.41 (d, J = 6.8 Hz,1 H), 2.53-2.68 (m, 2 H), 2.92-3.16(m, 2 H), 3.42-3.57 (m, 1 H),3.81-3.95 (m, 1 H), 7.21-7.43 (m,5 H), 7.71 (d, J = 4.1 Hz, 1 H),7.87 (d, J = 4.1 Hz, 1 H), 8.20 (s,1 H), 9.53 (brs, 1 H), 9.76 (brs,1 H), 12.50 (brs, 1 H) 2-330 (DMSO-d6-300)1.14-1.35 (m, 1 H), 1.47-1.76 (m,5 H), 2.12 (d, J = 6.8 Hz, 1 H), 2.70-2.97(m, 2 H), 3.07-3.44 (m, 3 H),3.77-3.91 (m, 1 H), 7.16-7.46 (m,5 H), 7.70 (d, J = 3.8 Hz, 1 H),7.87 (d, J = 3.8 Hz, 1 H), 8.20 (s,1 H), 9.16 (brs, 1 H), 9.52 (brs,1 H), 12.50 (brs, 1 H)

TABLE 2-67 Example Structural formula NMR 2-331 (DMSO-d6-300)0.25-0.30 (m, 1 H), 0.44-0.49 (m,1 H), 1.75-1.81 (m, 1 H), 2.09-2.14(m, 1 H), 2.29-2.36 (m, 1 H),4.12 (d, J = 11.3 Hz, 1 H), 4.29 (d,J = 10.2 Hz, 1 H), 7.12-7.23 (m, 6 H),7.69 (d, J = 3.8 Hz, 1 H), 7.86 (d,J = 3.8 Hz, 1 H), 8.17 (s, 1 H),12.43 (brs, 1 H) 2-332 (DMSO-d6-300)1.79 (d, J = 5.7 Hz, 1 H), 2.11 (d,J = 4.5 Hz, 1 H), 2.68-2.79 (m, 2 H),3.06-3.17 (m, 2 H), 3.36 (s, 3 H),4.13 (d, J = 8.7 Hz, 1 H), 4.22 (d,J = 11.3 Hz, 1 H), 7.18-7.25 (m, 5 H),7.69 (d, J = 4.1 Hz, 1 H), 7.86 (d,J = 3.8 Hz, 1 H), 8.17 (s, 1 H),12.43 (brs, 1 H) 2-333 (DMSO-d6-300)1.77 (d, J = 5.7 Hz, 1 H), 2.13 (d,J = 4.9 Hz, 1 H), 2.93 (dd, J = 6.3,3.1 Hz, 2 H), 3.30 (t, J = 6.0 Hz, 2 H),4.15 (d, J = 11.3 Hz, 1 H), 4.24 (d,J = 10.5 Hz, 1 H), 3.87 (t, J = 5.5 Hz,1 H), 7.16-7.24 (m, 5 H), 7.69 (d,J = 4.1 Hz, 1 H), 7.85 (d, J = 3.8 Hz,1 H), 8.17 (s, 1 H), 12.41 (brs, 0 H) 2-334 (DMSO-d6-300)1.04 (d, J = 6.0 Hz, 1 H), 1.78 (d,J = 5.7 Hz, 1 H), 2.07-2.17 (m, 4 H),2.12 (s, 3 H), 3.17-3.22 (m, 4 H),4.19 (d, J = 10.9 Hz, 1 H), 4.25 (d,J = 11.7 Hz, 1 H), 7.13-7.28 (m, 5 H),7.70 (d, J = 3.8 Hz, 1 H), 7.86 (d,J = 3.8 Hz, 1 H), 8.18 (s, 1 H) 2-335 (DMSO-d6-300)1.76 (d, J = 6.0 Hz, 1 H), 2.13 (d,J = 5.3 Hz, 1 H), 4.11 (d, J = 11.3 Hz,1 H), 4.25 (d, J = 11.7 Hz, 1 H),6.36 (brs, 2 H), 7.12-7.28 (m, 5 H),7.69 (d, J = 3.8 Hz, 1 H), 7.85 (d,J = 4.1 Hz, 1 H), 8.17 (s, 1 H),12.41 (brs, 1 H)

TABLE 2-68 Example Structural formula NMR 2-336 (DMSO-d6-300)2.08-2.13 (m, 1 H), 2.73-2.76 (m,1 H), 3.23-3.33 (m, 2 H), 3.28 (s,3 H), 3.35 (s, 3 H), 3.51-3.61 (m,2 H), 3.76-3.85 (m, 1 H), 4.14-4.18(m, 1 H), 7.33-7.37 (m, 5 H),7.70 (d, J = 3.8 Hz, 1 H), 7.88 (d,J = 3.8 Hz, 1 H), 8.21 (s, 1 H),9.50 (brs, 1 H), 12.51 (brs, 1 H) 2-337 (MeOH-d4-300)2.12 (d, J = 6.0 Hz, 1 H), 2.30 (d,J = 6.0 Hz, 1 H), 2.61-2.63 (m, 2 H),2.80 (brs, 6 H), 3.13-3.15 (m, 3 H),3.59-3.75 (m, 3 H), 7.31-7.40 (m,8 H), 7.57-7.67 (m, 3 H) 2-338 (DMSO-d6-300)1.28 (d, J = 6.8 Hz, 3 H), 2.02 (dd,J = 10.2, 6.8 Hz, 1 H), 2.81 (d,J = 10.2 Hz, 1 H), 7.19-7.30 (m, 5 H),7.71 (d, J = 3.8 Hz, 1 H), 7.81 (s,1 H), 7.85 (d, J = 3.8 Hz, 1 H) 2-339 (MeOH-d4-400)1.50 (s, 3 H), 1.75 (d, J = 5.8 Hz,1 H), 2.19 (d, J = 5.8 Hz, 1 H),6.93 (t, J = 8.8 Hz, 2 H), 7.23 (dd,J = 5.4, 8.7 Hz, 2 H), 7.62-7.66 (m,3 H) 2-340 (MeOH-d4-400)1.44 (s, 3 H), 1.82 (d, J = 6.1 Hz,1 H), 2.16 (d, J = 6.2 Hz, 1 H),7.00 (t, J = 8.8 Hz, 2 H), 7.21-7.25(m, 2 H), 7.44 (d, J = 3.9 Hz,1 H), 7.62-7.64 (m, 2 H)

TABLE 2-69 Example Structural formula NMR 2-341 (DMSO-d6-300)2.15 (d, J = 6.4 Hz, 1 H), 2.42-2.49(m, 1 H), 2.90-3.13 (m, 3 H),3.24-3.37 (m, 2 H), 3.60-3.97 (m,5 H), 7.21-7.42 (m, 5 H), 7.53 (d,J = 8.7 Hz, 2 H), 7.57 (d, J = 4.1 Hz,1 H), 7.58 (d, J = 4.1 Hz, 1 H),7.75 (d, J = 8.7 Hz, 2 H), 9.32 (brs,1 H), 10.17 (brs, 1 H), 12.48 (brs,1 H) 2-342 (DMSO-d6-300)1.73-1.93 (m, 1 H), 2.61-2.94 (m,6 H), 3.24-3.37 (m, 4 H), 3.82-4.01(m, 4 H), 7.17-7.29 (m, 5 H),7.70 (d, J = 4.1 Hz, 1 H), 7.88 (d,J = 3.8 Hz, 1 H), 8.21 (s, 1 H),9.42 (brs, 1 H) 2-343 (MeOH-d4-300)1.14-1.34 (m, 6 H), 2.37 (d,J = 7.2 Hz, 1 H), 2.66 (d, J = 6.0 Hz,1 H), 3.18-3.30 (m, 4 H), 3.52 (d,J = 13.9 Hz, 1 H), 3.99 (d, J = 14.3 Hz,1 H), 7.34-7.45 (m, 5 H), 7.70-7.71(m, 3 H) 2-344 (MeOH-d4-300)1.09 (d, J = 6.0 Hz, 3 H), 1.15-1.25(m, 3 H), 2.40 (d, J = 6.0 Hz,1 H), 2.59-2.80 (m, 3 H), 3.13 (d,J = 12.0 Hz, 1 H), 3.50 (d, J = 15.0 Hz,1 H), 3.57 (d, J = 12.0 Hz, 1 H), 3.69-3.83(m, 2 H), 4.02 (d, J = 12.0 Hz,1 H), 7.27-7.47 (m, 8 H), 7.58 (d,J = 3.0 Hz, 1 H), 7.65 (d, J = 9.0 Hz,2 H) 2-345 (MeOH-d4-300)1.93 (d, J = 6.0 Hz, 1 H), 2.23 (d,J = 6.0 Hz, 1 H), 2.30 (dd, J = 6.0,12.0 Hz, 1 H), 2.39 (dd, J = 6.0,12.0 Hz, 1 H), 2.99 (d, J = 12.0 Hz,1 H), 3.11 (d, J = 12.0 Hz, 1 H),3.46 (t, J = 6.0 Hz, 2 H), 7.12-7.29(m, 5 H), 7.38 (d, J = 3.0 Hz,1 H), 7.43 (d, J = 9.0 Hz, 2 H),7.57 (d, J = 3.0 Hz, 1 H), 7.66 (d,J = 9.0 Hz, 2 H)

TABLE 2-70 Example Structural formula NMR 2-346 (DMSO-d6-300)2.21-2.31 (m, 2 H), 4.36 (d,J = 14.3 Hz, 1 H), 4.77 (d, J = 14.3 Hz,1 H), 6.98-7.06 (m, 2 H), 7.15-7.23(m, 3 H), 7.48-7.56 (m, 4 H),7.60 (s, 2 H), 7.76 (d, J = 9.0 Hz,2 H), 8.78 (s, 1 H), 9.46 (brs, 1 H),12.56 (brs, 1 H) 2-347 (MeOH-d4-300)1.99 (d, J = 6.0 Hz, 1 H), 2.20 (d,J = 6.0 Hz, 1 H), 3.41-3.42 (m, 2 H),3.60-3.62 (m, 2 H), 3.74-3.79 (m,2 H), 7.17-7.33 (m, 5 H), 7.40 (d,J = 4.1 Hz, 1 H), 7.45 (d, J = 8.7 Hz,2 H), 7.59 (d, J = 4.1 Hz, 1 H),7.67 (d, J = 8.7 Hz, 2 H) 2-348 (MeOH-d4-300)1.03 (d, J = 6.8 Hz, 3 H), 1.15 (d,J = 6.8 Hz, 3 H), 2.36 (d, J = 7.2 Hz,1 H), 2.48-2.57 (m, 2 H), 3.40 (d,J = 14.7 Hz, 1 H), 3.91 (d, J = 14.7 Hz,1 H), 7.23-7.30 (m, 3 H), 7.35-7.46(m, 5 H), 7.60 (d, J = 3.8 Hz,1 H), 7.67 (d, J = 8.7 Hz, 2 H) 2-349 (MeOH-d4-300)1.06-1.07 (m, 6 H), 1.90 (d,J = 6.0 Hz, 1 H), 2.25 (d, J = 6.0 Hz,1 H), 2.53-2.55 (m, 1 H), 2.94 (d,J = 12.8 Hz, 1 H), 3.12 (d, J = 12.8 Hz,1 H), 7.18-7.27 (m, 5 H), 7.41 (d,J = 4.1 Hz, 1 H), 7.45 (d, J = 8.7 Hz,2 H), 7.59 (d, J = 4.1 Hz, 1 H),7.67 (d, J = 8.7 Hz, 2 H) 2-350 (CDCl3-300)1.98-2.11 (m, 1 H), 2.20-2.34 (m,1 H), 2.47-2.58 (m, 2 H), 2.68-2.86(m, 1 H), 2.98 (d, J = 9.8 Hz,1 H), 5.81 (s, 1 H), 7.01-7.16 (m,3 H), 7.19 (d, J = 3.8 Hz, 1 H), 7.29-7.35(m, 1 H), 7.39 (d, J = 8.7 Hz,2 H), 7.50 (d, J = 8.7 Hz, 2 H),7.61 (d, J = 3.8 Hz, 1 H)

TABLE 2-71 Example Structural formula NMR 2-351 (CDCl3-300)1.87-2.33 (m, 2 H), 2.44-2.58 (m,2 H), 2.69-2.85 (m, 1 H), 2.96 (d,J = 9.8 Hz, 1 H), 5.90 (s, 1 H),6.98 (s, 1 H), 7.01-7.07 (m, 1 H),7.09-7.19 (m, 2 H), 7.28-7.34 (m,1 H), 7.44 (d, J = 3.8 Hz, 1 H),7.65 (d, J = 3.8 Hz, 1 H) 2-352 (MeOH-d4-300)1.21 (t, J = 7.5 Hz, 3 H), 1.91 (d,J = 6.0 Hz, 1 H), 2.14 (d, J = 6.0 Hz,1 H), 2.86 (d, J = 15.0 Hz, 1 H),2.96 (d, J = 15.0 Hz, 1 H), 3.08 (d,J = 12.0 Hz, 1 H), 3.17 (d, J = 12.0 Hz,1 H), 4.07 (q, J = 7.0 Hz, 2 H), 7.10-7.28(m, 5 H), 7.36 (d, J = 3.0 Hz,1 H), 7.42 (d, J = 9.0 Hz, 2 H),7.58 (d, J = 3.0 Hz, 1 H), 7.66 (d,J = 9.0 Hz, 2 H) 2-353 (MeOH-d4-300)1.38 (d, J = 6.8 Hz, 3 H), 2.21 (dd,J = 10.5, 6.8 Hz, 1 H), 2.94 (d,J = 10.5 Hz, 1 H), 6.90-7.36 (m, 7 H),7.64-7.65 (m, 2 H) 2-354 (MeOH-d4-300)1.39 (d, J = 6.8 Hz, 3 H), 2.22 (dd,J = 10.5, 6.8 Hz, 1 H), 2.94 (d,J = 10.5 Hz, 1 H), 6.93-7.15 (m, 7 H),7.67-7.68 (m, 2 H) 2-355 (DMSO-d6-300)1.85-2.06 (m, 4 H), 2.25-2.64 (m,2 H), 5.23 (s, 2 H), 6.95-7.14 (m,4 H), 7.22 (d, J = 8.7 Hz, 2 H),7.49 (dd, J = 8.3, 2.3 Hz, 1 H),7.64 (d, J = 8.3 Hz, 1 H), 7.71 (d,J = 2.3 Hz, 1 H), 7.76 (d, J = 8.7 Hz,2 H), 8.54 (s, 1 H), 12.02 (brs, 1 H)

TABLE 2-72 Example Structural formula NMR 2-356 (CDCl3-300)1.87 (d, J = 6.0 Hz, 1 H), 2.10 (d,J = 6.0 Hz, 1 H), 3.56 (d, J = 9.8 Hz,1 H), 3.74 (d, J = 9.8 Hz, 1 H),4.35 (d, J = 12.1 Hz, 1 H), 4.46 (d,J = 12.1 Hz, 1 H), 6.10 (s, 1 H), 7.13-7.35(m, 11 H), 7.37-7.43 (m, 3 H),7.50 (d, J = 8.7 Hz, 2 H) 2-357 (MeOH-d4-300)1.93 (d, J = 6.0 Hz, 1 H), 2.24 (d,J = 6.0 Hz, 1 H), 2.82 (s, 3 H),2.88 (s, 3 H), 3.03-3.10 (m, 3 H),3.19 (d, J = 12.0 Hz, 1 H), 7.14-7.27(m, 5 H), 7.38 (d, J = 3.0 Hz,1 H), 7.43 (d, J = 9.0 Hz, 2 H),7.57 (d, J = 3.0 Hz, 1 H), 7.65 (d,J = 9.0 Hz, 2 H) 2-358 (MeOH-d4-300)1.89 (d, J = 6.0 Hz, 1 H), 2.20 (d,J = 6.0 Hz, 1 H), 2.89 (d, J = 15.0 Hz,1 H), 2.99 (d, J = 15.0 Hz, 1 H),3.07 (d, J = 12.0 Hz, 1 H), 3.20 (d,J = 12.0 Hz, 1 H), 7.11-7.30 (m, 5 H),7.38 (d, J = 3.0 Hz, 1 H), 7.42 (d,J = 9.0 Hz, 2 H), 7.57 (d, J = 3.0 Hz,1 H), 7.65 (d, J = 9.0 Hz, 2 H) 2-359 (MeOH-d4-300)1.73 (d, J = 6.0 Hz, 1 H), 2.15 (d,J = 6.0 Hz, 1 H), 2.98-3.14 (m, 4 H),3.35-3.58 (m, 8 H), 7.12-7.29 (m,5 H), 7.40 (d, J = 3.0 Hz, 1 H),7.44 (d, J = 9.0 Hz, 2 H), 7.60 (d,J = 3.0 Hz, 1 H), 7.68 (d, J = 9.0 Hz,2 H) 2-360 (DMSO-d6-300)1.64-1.79 (m, 2 H), 1.95-2.15 (m,2 H), 2.24-2.59 (m, 2 H), 5.26 (s,2 H), 6.90-7.07 (m, 4 H), 7.24 (d,J = 9.0 Hz, 2 H), 7.48 (dd, J = 8.3,2.3 Hz, 1 H), 7.65 (d, J = 8.3 Hz, 1 H),7.72 (d, J = 2.3 Hz, 1 H), 7.81 (d,J = 9.0 Hz, 2 H), 8.23 (brs, 1 H),8.64 (brs, 1 H), 9.75 (brs, 1 H)

TABLE 2-73 Example Structural formula NMR 2-361 (DMSO-d6-300)1.82 (d, J = 6.4 Hz, 1 H), 2.17 (d,J = 6.0 Hz, 1 H), 3.01 (d, J = 13.6 Hz,1 H), 7.26-7.32 (m, 6 H), 7.53 (d,J = 8.7 Hz, 2 H), 7.60 (d, J = 4.1 Hz,3 H), 7.76 (d, J = 8.3 Hz, 2 H) 2-362 (CDCl3-300)1.75 (d, J = 6.4 Hz, 1 H), 2.17 (d,J = 6.8 Hz, 1 H), 2.57-2.68 (m, 1 H),3.14-3.17 (m, 1 H), 3.34 (d,J = 14.7 Hz, 1 H), 3.78 (d, J = 15.1 Hz,1 H), 4.02 (dd, J = 8.3, 4.1 Hz, 1 H),4.14 (dd, J = 15.6, 8.9 Hz, 1 H),7.18-7.29 (m, 6 H), 7.39 (d,J = 8.7 Hz, 2 H), 7.53 (d, J = 8.3 Hz,2 H), 7.59 (d, J = 3.8 Hz, 1 H),7.97 (brs, 1 H) 2-363 (DMSO-d6-400)1.44-1.76 (m, 5 H), 2.37-2.58 (m,2 H), 2.88-2.99 (m, 1 H), 5.20 (s,2 H), 6.94-7.10 (m, 4 H), 7.17 (d,J = 8.8 Hz, 2 H), 7.47 (dd, J = 8.3,2.3 Hz, 1 H), 7.62 (d, J = 8.3 Hz, 1 H),7.69 (d, J = 2.3 Hz, 1 H), 7.75 (d,J = 8.8 Hz, 2 H) 2-364 (DMSO-d6-300)1.69-1.92 (m, 2 H), 2.08-2.59 (m,4 H), 6.91-6.98 (m, 1 H), 7.00-7.12(m, 3 H), 7.54 (d, J = 8.7 Hz,2 H), 7.62-7.67 (m, 2 H), 7.78 (d,J = 8.7 Hz, 2 H), 8.70 (brs, 1 H),9.78 (brs, 1 H) 2-365 (DMSO-d6-300)1.47-1.69 (m, 3 H), 1.71-1.90 (m,2 H), 2.43-2.51 (m, 1 H), 2.74 (d,J = 9.9 Hz, 1 H), 2.95-3.02 (m, 1 H),7.02-7.21 (m, 4 H), 7.59 (d,J = 4.0 Hz, 1 H), 7.84 (d, J = 4.0 Hz,1 H), 8.03 (dd, J = 8.1, 1.0 Hz, 1 H),8.08 (d, J = 8.1 Hz, 1 H), 8.63 (d,J = 1.0 Hz, 1 H), 12.38 (brs, 1 H)

TABLE 2-74 Example Structural formula NMR 2-366 (DMSO-d6-300)1.25 (d, J = 6.6 Hz, 3 H), 1.98 (dq,J = 10.6, 6.6 Hz, 1 H), 2.77 (d,J = 10.6 Hz, 1 H), 7.14-7.30 (m, 5 H),7.57 (d, J = 4.0 Hz, 1 H), 7.82 (d,J = 4.0 Hz, 1 H), 8.01-8.08 (m, 1 H),8.07 (d, J = 9.2 Hz, 1 H), 8.62 (d,J = 1.5 Hz, 1 H), 9.05 (s, 1 H),12.26 (s, 1 H) 2-367 (MeOH-d4-300)1.36 (d, J = 6.6 Hz, 3 H), 2.12-2.25(m, 4 H), 2.86 (d, J = 10.6 Hz,1 H), 7.17-7.21 (m, 7 H), 7.53 (d,J = 4.0 Hz, 1 H), 7.98 (d, J = 1.5 Hz,1 H) 2-368 (MeOH-d4-300)2.02 (d, J = 6.6 Hz, 1 H), 2.22 (d,J = 5.9 Hz, 1 H), 3.80 (dd, J = 14.3,4.4 Hz, 1 H), 3.94 (d, J = 13.9 Hz,1 H), 7.14-7.24 (m, 5 H), 7.39 (d,J = 4.0 Hz, 1 H), 7.43 (d, J = 8.4 Hz,2 H), 7.50-7.66 (m, 1 H), 7.60 (d,J = 4.0 Hz, 1 H), 7.66 (d, J = 8.4 Hz,2 H), 7.95-8.03 (m, 2 H), 8.56-8.60(m, 1 H) 2-369 (DMSO-d6-300)1.95-2.30 (m, 3 H), 2.78 (d,J = 9.9 Hz, 1 H), 3.99-4.18 (m, 2 H),6.81 (d, J = 7.7 Hz, 1 H), 6.96 (t,J = 6.8 Hz, 1 H), 7.11 (t, J = 6.8 Hz,1 H), 7.28 (d, J = 7.0 Hz, 1 H),7.52 (d, J = 8.8 Hz, 2 H), 7.57 (s,2 H), 7.75 (d, J = 8.4 Hz, 2 H),9.08 (brs, 1 H), 12.42 (brs, 1 H) 2-370 (DMSO-d6-300)1.95-2.29 (m, 3 H), 2.80 (d,J = 9.5 Hz, 1 H), 4.01-4.18 (m, 2 H),6.81 (dd, J = 7.9, 1.3 Hz, 1 H),6.97 (td, J = 7.4, 1.2 Hz, 1 H),7.12 (td, J = 7.8, 1.6 Hz, 1 H),7.28 (d, J = 7.3 Hz, 1 H), 7.70 (d,J = 3.7 Hz, 1 H), 7.86 (d, J = 4.0 Hz,1 H), 8.16 (s, 1 H), 9.30 (brs, 1 H),12.45 (brs, 1 H)

TABLE 2-75 Example Structural formula NMR 2-371 (DMSO-d6-300)1.63 (dd, J = 10.0, 5.5 Hz, 1 H),2.05 (dd, J = 10.4, 2.9 Hz, 1 H),2.84 (t, J = 9.2 Hz, 1 H), 7.14-7.27(m, 5 H), 7.31 (d, J = 3.8 Hz,1 H), 7.43 (d, J = 3.8 Hz, 1 H),7.97 (s, 1 H), 9.53 (s, 1 H),12.20 (s, 1 H) 2-372 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 2.01 (dt,J = 17.0, 6.8 Hz, 1 H), 2.88 (d,J = 17.0 Hz, 1 H), 7.15-7.29 (m, 5 H),7.31 (d, J = 4.1 Hz, 1 H), 7.43 (d,J = 3.8 Hz, 1 H), 7.95 (s, 1 H),9.39 (s, 1 H), 12.23 (s, 1 H) 2-373 (DMSO-d6-300)1.43-1.96 (m, 6 H), 2.84 (d,J = 9.8 Hz, 1 H), 2.94-3.10 (m, 1 H),7.03-7.22 (m, 5 H), 7.32 (d,J = 3.8 Hz, 1 H), 7.44 (d, J = 3.8 Hz,1 H), 7.97 (s, 1 H), 9.40 (s, 1 H),12.38 (s, 1 H) 2-374 (CDCl3-300)1.32 (d, J = 7.0 Hz, 3 H), 2.27-2.39(m, 1 H), 2.48 (s, 3 H), 3.05 (d,J = 10.3 Hz, 1 H), 6.26 (s, 1 H), 7.11-7.28(m, 6 H), 7.32 (d, J = 4.0 Hz,1 H), 7.59 (d, J = 4.0 Hz, 1 H) 2-375 (CDCl3-300)1.41-1.94 (m, 4 H), 2.09-2.29 (m,1 H), 2.33-2.72 (m, 4 H), 2.89-3.14(m, 2 H), 6.27 (s, 1 H), 6.94-7.69(m, 7 H)

TABLE 2-76 Example Structural formula NMR 2-376 (DMSO-d6-400)1.55 (d, J = 5.6 Hz, 1 H), 1.69 (s,3 H), 1.97 (d, J = 5.6 Hz, 1 H),3.20 (dd, J = 13.7, 4.4 Hz, 1 H),3.50 (dd, J = 13.9, 7.0 Hz, 1 H),7.08-7.31 (m, 5 H), 7.49-7.60 (m,4 H), 7.72-7.78 (m, 3 H), 9.21 (s,1 H), 12.34 (brs, 1 H) 2-377 (DMSO-d6-400)0.72 (t, J = 7.4 Hz, 3 H),1.37 (sextet, J = 7.4 Hz, 2 H),1.55 (d, J = 5.6 Hz, 1 H), 1.92 (t,J = 7.2 Hz, 2 H), 1.97 (d, J = 5.6 Hz,1 H), 3.23 (dd, J = 13.9, 4.6 Hz, 1 H),3.50 (dd, J = 13.9, 7.0 Hz, 1 H),7.07-7.22 (m, 5 H), 7.49-7.54 (m,2 H), 7.56-7.60 (m, 2 H), 7.68 (t,J = 6.3 Hz, 1 H), 7.73-7.78 (m, 2 H),9.23 (s, 1 H), 12.33 (brs, 1 H) 2-378 (DMSO-d6-400)1.37 (d, J = 5.1 Hz, 1 H), 1.94 (d,J = 5.1 Hz, 1 H), 2.69 (s, 6 H),3.17 (dd, J = 14.4, 5.1 Hz, 1 H),3.40 (dd, J = 14.4, 7.0 Hz, 1 H),6.17 (t, J = 5.8 Hz, 1 H), 7.05-7.10(m, 2 H), 7.13-7.25 (m, 3 H),7.49-7.54 (m, 2 H), 7.55-7.60 (m,2 H), 7.74-7.79 (m, 2 H), 9.73 (s,1 H), 12.25 (brs, 1 H) 2-379 (DMSO-d6-400)0.50-0.61 (m, 4 H), 1.38-1.46 (m,1 H), 1.53 (d, J = 6.0 Hz, 1 H),1.97 (d, J = 6.0 Hz, 1 H), 3.24 (dd,J = 14.4, 5.1 Hz, 1 H), 3.52 (dd,J = 14.4, 7.4 Hz, 1 H), 7.08-7.24 (m,5 H), 7.49-7.54 (m, 2 H), 7.56-7.59(m, 2 H), 7.73-7.78 (m, 2 H),7.95 (t, J = 6.0 Hz, 1 H), 9.25 (s,1 H), 12.31 (brs, 1 H) 2-380 (DMSO-d6-400)1.00-1.27 (m, 5 H), 1.44-1.66 (m,5 H), 1.54 (d, J = 6.0 Hz, 1 H), 1.90-1.99(m, 1 H), 1.96 (d, J = 5.6 Hz,1 H), 3.18 (dd, J = 14.4, 4.6 Hz, 1 H),3.51 (dd, J = 14.4, 7.4 Hz, 1 H),7.06-7.23 (m, 4 H), 7.49-7.64 (m,6 H), 7.73-7.78 (m, 2 H), 9.24 (s,1 H), 12.31 (brs, 1 H)

TABLE 2-77 Example Structural formula NMR 2-381 (DMSO-d6-400)1.46 (d, J = 5.6 Hz, 1 H), 1.96 (d,J = 5.6 Hz, 1 H), 3.10-3.56 (m, 10 H),6.36 (t, J = 5.8 Hz, 1 H), 7.06-7.24(m, 5 H), 7.52 (d, J = 8.8 Hz,2 H), 7.57-7.58 (m, 2 H), 7.76 (d,J = 8.3 Hz, 2 H), 9.43 (s, 1 H),12.28 (brs, 1 H) 2-382 (CDCl3-300)1.50 (s, 3 H), 1.83 (d, J = 5.9 Hz,1 H), 2.17 (d, J = 5.9 Hz, 1 H),6.12 (s, 1 H), 6.79 (t, J = 53.6 Hz,1 H), 6.90 (s, 1 H), 7.02-7.10 (m,2 H), 7.15-7.24 (m, 3 H), 7.41 (d,J = 4.0 Hz, 1 H), 7.58 (d, J = 4.0 Hz,1 H) 2-383 (CDCl3-300)1.42-1.97 (m, 4 H), 2.14-2.29 (m,1 H), 2.50-2.62 (m, 1 H), 2.94-3.10(m, 2 H), 5.96 (s, 1 H), 6.79 (t,J = 53.9 Hz, 1 H), 6.88 (s, 1 H), 7.03-7.21(m, 4 H), 7.44 (d, J = 4.0 Hz,1 H), 7.66 (d, J = 4.0 Hz, 1 H) 2-384 (MeOH-d4-300)1.13 (t, J = 7.0 Hz, 3 H), 1.92 (d,J = 5.9 Hz, 1 H), 2.14 (d, J = 6.2 Hz,1 H), 3.46 (d, J = 14.3 Hz, 1 H),3.57 (d, J = 14.7 Hz, 1 H), 3.94 (q,J = 7.2 Hz, 2 H), 7.15-7.19 (m, 5 H),7.38 (d, J = 4.0 Hz, 1 H), 7.43 (d,J = 8.4 Hz, 2 H), 7.57 (d, J = 4.0 Hz,1 H), 7.66 (d, J = 8.4 Hz, 2 H) 2-385 (DMSO-d6-300)1.46-2.04 (m, 6 H), 3.09-3.54 (m,2 H), 3.64-3.81 (m, 2 H), 3.96-4.10(m, 1 H), 7.06-7.26 (m, 5 H),7.52 (d, J = 8.4 Hz, 2 H), 7.57 (s,2 H), 7.76 (d, J = 8.4 Hz, 2 H),9.36 (brs, 1 H), 12.31 (brs, 1 H)

TABLE 2-78 Example Structural formula NMR 2-386 (DMSO-d6-300)1.68 (d, J = 5.7 Hz, 1 H), 2.06-2.15(m, 1 H), 3.07 (s, 3 H), 3.39 (d,J = 10.5 Hz, 1 H), 3.77 (d, J = 10.5 Hz,1 H), 7.10-7.26 (m, 5 H), 7.52 (d,J = 8.7 Hz, 2 H), 7.56 (d, J = 4.1 Hz,1 H), 7.58 (d, J = 4.1 Hz, 1 H),7.75 (d, J = 8.7 Hz, 2 H), 9.11 (brs,1 H), 12.29 (brs, 1 H) 2-387 (DMSO-d6-300)1.59 (q, J = 5.3 Hz, 1 H), 2.01 (dd,J = 8.3, 5.3 Hz, 1 H), 2.72 (t,J = 8.5 Hz, 1 H), 3.87 (s, 3 H), 7.16-7.29(m, 6 H), 7.48 (d, J = 3.8 Hz,1 H), 7.84 (s, 1 H), 8.19 (s, 1 H),9.07 (brs, 1 H), 12.19 (brs, 1 H) 2-388 (MeOH-d4-300)1.97 (dd, J = 9.8, 5.7 Hz, 1 H),2.18 (dd, J = 8.7, 6.0 Hz, 1 H),2.86 (t, J = 9.2 Hz, 1 H), 7.17-7.31(m, 5 H), 7.63 (d, J = 3.8 Hz,1 H), 7.66 (d, J = 3.8 Hz, 1 H),7.95 (d, J = 9.0 Hz, 2 H), 8.33 (d,J = 9.0 Hz, 2 H) 2-389 (MeOH-d4-400)1.98-2.08 (m, 1 H), 2.17-2.27 (m,1 H), 2.32-2.46 (m, 1 H), 2.90 (d,J = 10.2 Hz, 1 H), 3.16-3.28 (m, 2 H),6.65 (d, J = 8.3 Hz, 1 H), 6.73 (t,J = 7.4 Hz, 1 H), 6.95 (t, J = 7.7 Hz,1 H), 7.31 (d, J = 7.9 Hz, 1 H),7.38 (d, J = 4.2 Hz, 1 H), 7.47-7.41(m, 2 H), 7.58 (d, J = 4.2 Hz,1 H), 7.68-7.62 (m, 2 H) 2-390 (DMSO-d6-300)1.32-1.70 (m, 5 H), 2.32-2.56 (m,2 H), 2.75-2.88 (m, 1 H), 6.95-7.02(m, 1 H), 7.04-7.10 (m, 2 H),7.20-7.28 (m, 1 H), 7.21 (d,J = 9.0 Hz, 2 H), 7.46 (dd, J = 8.3,2.3 Hz, 1 H), 7.62 (d, J = 8.3 Hz, 1 H),7.70 (d, J = 2.3 Hz, 1 H), 7.79 (d,J = 9.0 Hz, 2 H), 8.25 (s, 1 H),8.58 (s, 1 H), 10.11 (s, 1 H)

TABLE 2-79 Example Structural formula NMR 2-391 (DMSO-d6-300)1.22-1.79 (m, 5 H), 2.36-2.59 (m,2 H), 2.82-2.98 (m, 1 H), 6.96-7.03(m, 1 H), 7.05-7.14 (m, 2 H),7.30-7.39 (m, 1 H), 7.52 (d,J = 8.7 Hz, 2 H), 7.59 (d, J = 3.8 Hz,1 H), 7.63 (d, J = 3.8 Hz, 1 H),7.75 (d, J = 8.7 Hz, 2 H), 8.63 (s,1 H), 8.70 (s, 1 H), 10.14 (s, 1 H) 2-392 (DMSO-d6-300)1.08 (t, J = 5.8 Hz, 6 H), 1.85 (d,J = 6.4 Hz, 1 H), 2.26 (d, J = 7.9 Hz,1 H), 3.01-3.10 (m, 1 H), 3.12-3.23(m, 1 H), 3.36-3.47 (m, 1 H),7.20-7.38 (m, 7 H), 7.54 (d,J = 9.0 Hz, 3 H), 7.58-7.63 (m, 2 H),7.76 (d, J = 9.0 Hz, 3 H), 8.23 (brs,1 H), 8.42 (brs, 1 H), 9.15 (s, 1 H),12.57 (s, 1 H) 2-393 (DMSO-d6-300)1.90 (d, J = 6.8 Hz, 1 H), 2.27 (d,J = 6.8 Hz, 1 H), 3.18-3.35 (m, 1 H),3.59-3.72 (m, 1 H), 4.44-4.53 (m,2 H), 7.21-7.37 (m, 5 H), 7.50-7.60(m, 4 H), 7.77-7.80 (m, 2 H),7.79-7.87 (m, 2 H), 9.15 (s, 1 H) 2-394 (DMSO-d6-300)1.74 (d, J = 6.0 Hz, 1 H), 2.06 (d,J = 6.0 Hz, 1 H), 3.50-3.60 (m, 1 H),3.73-3.82 (m, 1 H), 7.10-7.21 (m,5 H), 7.49-7.63 (m, 4 H), 7.77 (d,J = 8.7 Hz, 2 H), 8.02-8.09 (m, 1 H),8.44-8.52 (m, 1 H), 8.71 (dd, J = 4.9,1.5 Hz, 1 H), 8.81 (d, J = 2.3 Hz, 1 H),9.19 (s, 1 H) 2-395 (DMSO-d6-300)1.56 (d, J = 6.0 Hz, 1 H), 1.98 (d,J = 6.0 Hz, 1 H), 2.14 (t, J = 6.8 Hz,2 H), 3.16-3.26 (m, 1 H), 3.44-3.58(m, 3 H), 4.49 (t, J = 5.3 Hz,1 H), 7.09-7.25 (m, 5 H), 7.53 (d,J = 8.9 Hz, 2 H), 7.56-7.61 (m, 2 H),7.70-7.80 (m, 3 H), 9.24 (s, 1 H),12.32 (s, 1 H)

TABLE 2-80 Example Structural formula NMR 2-396 (DMSO-d6-300)0.94 (t, J = 6.8 Hz, 3 H), 1.36 (d,J = 6.4 Hz, 1 H), 1.95 (d, J = 6.4 Hz,1 H), 2.91-3.03 (m, 2 H), 3.21 (dd,J = 6.8, 3.4 Hz, 1 H), 3.36 (dd,J = 6.8, 3.4 Hz, 1 H), 5.76-5.91 (m,2 H), 7.09-7.28 (m, 2 H), 7.52 (d,J = 8.7 Hz, 1 H), 7.58 (dd, J = 4.5,3.8 Hz, 1 H), 7.77 (d, J = 8.3 Hz, 2 H),9.70 (s, 1 H), 12.24 (brs, 1 H) 2-397 (DMSO-d6-300)0.87 (d, J = 4.1 Hz, 3 H), 0.89 (d,J = 4.1 Hz, 3 H), 1.57 (d, J = 5.7 Hz,1 H), 1.99 (d, J = 6.0 Hz, 1 H), 2.19-2.28(m, 1 H), 3.25 (dd, J = 14.1,4.7 Hz, 1 H), 3.50 (dd, J = 13.6,6.8 Hz, 1 H), 7.09-7.26 (m, 5 H),7.51-7.69 (m, 4 H), 7.78 (d,J = 8.7 Hz, 2 H), 9.27 (brs, 1 H),12.34 (brs, 1 H) 2-398 (DMSO-d6-300)1.62 (d, J = 5.7 Hz, 1 H), 2.02 (d,J = 5.7 Hz, 1 H), 3.28 (dd, J = 12.8,3.4 Hz, 1 H), 3.62-3.69 (m, 6 H),7.13-7.34 (m, 5 H), 7.52-7.67 (m,4 H), 7.78 (d, J = 8.3 Hz, 2 H),9.35 (brs, 1 H), 12.36 (brs, 1 H) 2-399 (DMSO-d6-300)1.58 (d, J = 5.7 Hz, 1 H), 2.01 (d,J = 6.4 Hz, 1 H), 3.22 (dd, J = 13.8,4.3 Hz, 1 H), 3.66 (d, J = 5.7 Hz, 2 H),3.75 (dd, J = 13.9, 7.9 Hz, 1 H),5.42 (brs, 1 H), 7.11-7.26 (m, 5 H),7.54 (d, J = 8.7 Hz, 2 H), 7.59 (s,2 H), 7.69-7.81 (m, 3 H), 9.47 (brs,1 H), 12.33 (brs, 1 H) 2-400 (CDCl3-400)1.66 (d, J = 6.5 Hz, 1 H), 1.99-2.01(m, 1 H), 2.15 (d, J = 6.0 Hz,1 H), 2.97-3.01 (m, 1 H), 3.04 (d,J = 14.8 Hz, 1 H), 3.20-3.24 (m, 1 H),3.51-3.53 (m, 1 H), 4.07 (d,J = 17.2 Hz, 1 H), 4.11 (d, J = 14.8 Hz,1 H), 4.15 (d, J = 17.2 Hz, 1 H), 7.05-7.10(m, 2 H), 7.19 (d, J = 4.2 Hz,1 H), 7.24-7.26 (m, 3 H), 7.39 (d,J = 8.3 Hz, 2 H), 7.53 (d, J = 8.3 Hz,2 H), 7.56 (d, J = 3.7 Hz, 1 H),8.82 (brs, 1 H)

TABLE 2-81 Example Structural formula NMR 2-401 (DMSO-d6-300)1.25 (d, J = 6.4 Hz, 3 H), 1.92 (dd,J = 10.4, 6.6 Hz, 1 H), 2.70 (d,J = 10.2 Hz, 1 H), 7.17-7.29 (m, 5 H),7.45 (s, 1 H), 7.71 (s, 1 H), 7.95 (d,J = 8.7 Hz, 2 H), 8.15 (d, J = 8.7 Hz,2 H), 8.94 (brs, 1 H), 12.23 (brs,1 H) 2-402 (DMSO-d6-400)1.35-1.40 (m, 4 H), 2.02-2.07 (m,4 H), 7.11-7.24 (m, 5 H), 7.41 (d,J = 3.7 Hz, 1 H), 7.49 (d, J = 3.7 Hz,1 H), 7.64 (s, 2 H), 9.11 (brs, 1 H),10.11 (brs, 1 H), 12.10 (brs, 1 H) 2-403 (MeOH-d4-300)1.52 (s, 3 H), 1.76 (d, J = 6.0 Hz,1 H), 2.21 (d, J = 6.0 Hz, 1 H),3.44 (s, 3 H), 4.60 (s, 2 H), 6.85 (s,1 H), 7.18-7.21 (m, 5 H), 7.55 (d,J = 4.1 Hz, 1 H), 7.61 (d, J = 4.1 Hz,1 H) 2-404 (MeOH-d4-300)1.38 (d, J = 6.8 Hz, 3 H), 2.21 (dd,J = 10.5, 6.8 Hz, 1 H), 2.94 (d,J = 10.5 Hz, 1 H), 3.45 (s, 3 H),4.61 (s, 2 H), 6.86 (s, 1 H), 7.20-7.27 (m, 5 H), 7.56 (d, J = 4.1 Hz,1 H), 7.64 (d, J = 4.1 Hz, 1 H) 2-405 (DMSO-d6-300)1.58 (d, J = 5.7 Hz, 1 H), 2.10 (d,J = 5.7 Hz, 1 H), 3.65 (d, J = 10.2 Hz,1 H), 3.74 (d, J = 10.2 Hz, 1 H),3.80 (d, J = 17.3 Hz, 1 H), 3.86 (d,J = 17.3 Hz, 1 H), 7.20 (m, 5 H),7.53 (d, J = 8.7 Hz, 2 H), 7.57 (s,2 H), 7.75 (d, J = 8.7 Hz, 2 H)

TABLE 2-82 Example Structural formula NMR 2-406 (DMSO-d6-300)1.39 (s, 4 H), 2.09 (d, J = 5.7 Hz,1 H), 7.11-7.27 (m, 5 H), 7.42 (d,J = 8.3 Hz, 1 H), 7.56-7.69 (m, 3 H),7.92 (t, J = 8.5 Hz, 1 H), 9.25 (brs,1 H), 12.12 (brs, 1 H) 2-407 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 1.92-2.05 (m, 1 H), 2.78 (d, J = 10.5 Hz,1 H), 7.15-7.31 (m, 5 H), 7.42 (dd,J = 8.7, 1.9 Hz, 1 H), 7.58-7.69 (m,3 H), 7.92 (t, J = 8.5 Hz, 1 H),9.10 (brs, 1 H), 12.31 (brs, 1 H) 2-408 (MeOH-d4-300)1.28-1.40 (m, 9 H), 2.13-2.23 (m,1 H), 2.93 (d, J = 9.0 Hz, 1 H), 3.05-3.17 (m, 1 H), 6.57 (s, 1 H), 7.11-7.28 (m, 5 H), 7.51 (d, J = 3.0 Hz,1 H), 7.61 (d, J = 3.0 Hz, 1 H) 2-409 (MeOH-d4-300)1.22 (t, J = 7.5 Hz, 3 H), 1.98 (d,J = 6.0 Hz, 1 H), 2.29 (d, J = 6.0 Hz,1 H), 2.86 (d, J = 12.0 Hz, 1 H), 2.99-3.13 (m, 2 H), 3.24 (d, J = 12.0 Hz,1 H), 4.08 (q, J = 8.0 Hz, 2 H), 7.14-7.35 (m, 5 H), 7.61-7.68 (m, 3 H) 2-410 (MeOH-d4-300)1.97 (d, J = 6.0 Hz, 1 H), 2.28 (d,J = 6.0 Hz, 1 H), 2.83 (d, J = 15.0 Hz,1 H), 2.98 (d, J = 15.0 Hz, 1 H),3.07 (d, J = 12.0 Hz, 1 H), 3.24 (d,J = 12.0 Hz, 1 H), 7.13-7.31 (m, 5 H),7.61-7.68 (m, 3 H)

TABLE 2-83 Example Structural formula NMR 2-411 (DMSO-d6-400)1.58-1.67 (m, 2 H), 1.79-1.97 (m,3 H), 2.43-2.54 (m, 1 H), 2.76 (d,J = 9.7 Hz, 1 H), 4.65 (brs, 1 H),7.01-7.27 (m, 4 H), 7.51 (d,J = 8.3 Hz, 2 H), 7.54 (d, J = 3.7 Hz,1 H), 7.56 (d, J = 3.7 Hz, 1 H),7.73 (d, J = 8.3 Hz, 2 H) 2-412 (DMSO-d6-400)1.20-1.36 (m, 1 H), 1.41-1.68 (m,2 H), 1.82-1.91 (m, 1 H), 2.06-2.19 (m, 1 H), 2.43-2.55 (m, 1 H),2.64 (d, J = 9.7 Hz, 1 H), 4.99-5.04 (m, 1 H), 7.06-7.12 (m, 2 H),7.16-7.22 (m, 1 H), 7.38 (d,J = 7.4 Hz, 1 H), 7.51 (d, J = 8.3 Hz,2 H), 7.54-7.57 (m, 2 H), 7.73 (d,J = 8.3 Hz, 2 H) 2-413 (DMSO-d6-300)1.36-1.43 (m, 1 H), 1.39 (s, 3 H),2.08 (d, J = 5.3 Hz, 1 H), 7.11-7.27 (m, 5 H), 7.46-7.56 (m, 1 H),7.54 (d, J = 4.1 Hz, 1 H), 7.61 (d,J = 4.1 Hz, 1 H), 7.68-7.76 (m, 1 H),8.00 (dd, J = 6.8, 2.3 Hz, 1 H),9.22 (s, 1 H), 12.11 (s, 1 H) 2-414 (MeOH-d4-300)1.52 (d, J = 8.3 Hz, 3 H), 1.76 (d,J = 5.7 Hz, 1 H), 2.23 (d, J = 5.7 Hz,1 H), 7.11-7.25 (m, 5 H), 7.61 (d,J = 4.1 Hz, 1 H), 7.93 (d, J = 4.1 Hz,1 H), 8.89 (s, 2 H) 2-415 (DMSO-d6-300)0.81 (t, J = 6.2 Hz, 1 H), 1.55 (q,J = 5.3 Hz, 1 H), 2.63 (t, J = 8.9 Hz,1 H), 3.69 (q, J = 7.2 Hz, 1 H),4.92 (dd, J = 14.9, 5.1 Hz, 1 H),7.11-7.18 (m, 2 H), 7.24 (t,J = 7.0 Hz, 1 H), 7.35 (d, J = 7.5 Hz,1 H), 7.52 (d, J = 8.7 Hz, 2 H),7.57 (dd, J = 6.0, 4.1 Hz, 2 H),7.74 (d, J = 8.7 Hz, 2 H), 8.06 (t,J = 5.5 Hz, 1 H), 9.34 (brs, 1 H)

TABLE 2-84 Example Structural formula NMR 2-416 (DMSO-d6-300)1.38 (s, 3 H), 1.39 (d, J = 6.4 Hz,1 H), 2.08 (d, J = 5.7 Hz, 1 H), 7.12-7.26 (m, 5 H), 7.55 (d, J = 3.8 Hz,1 H), 7.78 (d, J = 3.8 Hz, 1 H),7.87 (td, J = 8.7, 3.0 Hz, 1 H),8.13 (dd, J = 4.4, 2.2 Hz, 1 H),8.60 (d, J = 3.0 Hz, 1 H), 9.19 (brs,1 H), 12.08 (brs, 1 H) 2-417 (CDCl3-400)1.44 (d, J = 7.0 Hz, 3 H), 2.35 (s,3 H), 2.49-2.51 (m, 1 H), 3.06 (d,J = 10.7 Hz, 1 H), 6.33 (brs, 1 H),6.79 (s, 1 H), 7.22-7.28 (m, 6 H),7.36 (d, J = 4.2 Hz, 1 H), 7.57 (d,J = 4.2 Hz, 1 H) 2-418 (CDCl3-400)2.07-2.10 (m, 1 H), 2.27-2.32 (m,4 H), 6.27 (brs, 1 H), 6.65 (s, 1 H),7.17-7.24 (m, 6 H), 7.53 (d,J = 4.2 Hz, 1 H) 2-419 (MeOH-d4-300)1.35 (d, J = 6.6 Hz, 3 H), 2.16 (dd,J = 10.5, 6.6 Hz, 1 H), 2.91 (d,J = 10.5 Hz, 1 H), 3.02 (s, 6 H), 7.17-7.23 (m, 6 H), 7.43 (d, J = 4.0 Hz,1 H), 7.59 (d, J = 4.0 Hz, 1 H) 2-420 (DMSO-d6-300)1.39 (s, 3 H), 1.40 (d, J = 3.4 Hz,1 H), 2.09 (d, J = 5.7 Hz, 1 H), 7.12-7.26 (m, 5 H), 7.59-7.63 (m, 3 H),8.11 (ddd, J = 8.9, 4.4, 2.2 Hz, 1 H),8.38 (dd, J = 6.0, 2.3 Hz, 1 H),9.25 (brs, 1 H), 12.12 (brs, 1 H)

TABLE 2-85 Example Structural formula NMR 2-421 (DMSO-d6-300)1.25 (d, J = 5.7 Hz, 1 H), 1.37 (s,3 H), 2.00 (d, J = 5.3 Hz, 1 H), 3.11-3.19 (m, 4 H), 3.69-3.75 (m, 4 H),6.16 (d, J = 4.5 Hz, 1 H), 7.14-7.23 (m, 6 H), 8.72 (brs, 1 H),12.03 (brs, 1 H) 2-422 (MeOH-d4-300)1.54 (s, 3 H), 1.79 (d, J = 5.7 Hz,1 H), 2.24 (d, J = 5.7 Hz, 1 H), 6.96-7.08 (m, 7 H), 7.64 (dd, J = 4.9,4.1 Hz, 2 H) 2-423 (MeOH-d4-300)1.50 (s, 3 H), 1.72 (d, J = 5.9 Hz,1 H), 2.19 (d, J = 5.9 Hz, 1 H),3.02 (s, 6 H), 5.47 (s, 1 H), 7.10-7.23 (m, 5 H), 7.42 (d, J = 4.0 Hz,1 H), 7.56 (d, J = 4.0 Hz, 1 H) 2-424 (CDCl3-400)1.32 (d, J = 6.7 Hz, 3 H), 2.23 (brs,1 H), 3.00 (d, J = 10.3 Hz, 1 H),3.48 (s, 1 H), 6.16 (brs, 1 H), 7.13-7.27 (m, 6 H), 7.46 (d, J = 3.9 Hz, 1 H) 2-425 (CDCl3-400)1.34 (d, J = 6.7 Hz, 3 H), 2.25-2.36 (m, 1 H), 2.58 (s, 3 H), 3.05 (d,J = 10.5 Hz, 1 H), 6.11 (s, 1 H), 7.16-7.29 (m, 5 H), 7.58 (dd, J = 3.9,18.4 Hz, 2 H)

TABLE 2-86 Example Structural formula NMR 2-426 (CDCl3-400)1.34 (d, J = 6.7 Hz, 3 H), 2.19-2.28 (m, 1 H), 3.11-3.20 (m, 5 H),3.36-3.43 (m, 4 H), 5.58 (s, 1 H),6.83 (d, J = 8.9 Hz, 2 H), 7.21-7.29 (m, 7 H) 2-427 (CDCl3-400)1.32-1.35 (m, 3 H), 2.17-2.28 (m,1 H), 3.01 (d, J = 10.3 Hz, 1 H),6.11 (brs, 1 H), 7.00 (d, J = 4.0 Hz,1 H), 7.18-7.32 (m, 5 H), 7.38 (d,J = 4.0 Hz, 1 H) 2-428 (CDCl3-400)1.33-1.36 (m, 3 H), 2.21-2.29 (m,1 H), 3.17 (d, J = 10.5 Hz, 1 H), 3.30-3.32 (m, 4 H), 3.40-3.42 (m, 4 H),5.59 (s, 1 H), 6.94 (d, J = 8.6 Hz,2 H), 7.14-7.29 (m, 5 H), 7.50 (d,J = 8.7 Hz, 2 H) 2-429 (CDCl3-300)1.93 (d, J = 5.9 Hz, 1 H), 2.14 (d,J = 5.9 Hz, 1 H), 3.35-3.67 (m, 5 H),3.38 (s, 3 H), 3.88 (d, J = 9.5 Hz,1 H), 7.11-7.25 (m, 5 H), 7.39 (d,J = 8.8 Hz, 2 H), 7.54 (d, J = 8.8 Hz,2 H), 7.57 (d, J = 3.7 Hz, 2 H) 2-430 (MeOH-d4-400)1.86-1.96 (m, 1 H), 2.08-2.21 (m,1 H), 2.62-2.68 (m, 1 H), 2.81 (d,J = 9.7 Hz, 1 H), 3.21-3.31 (m, 2 H),6.86-6.95 (m, 2 H), 7.17 (t,J = 7.7 Hz, 1 H), 7.23 (d, J = 7.4 Hz,1 H), 7.40 (d, J = 4.2 Hz, 1 H), 7.47-7.42 (m, 2 H), 7.60 (d, J = 3.7 Hz,1 H), 7.70-7.64 (m, 2 H)

TABLE 2-87 Example Structural formula NMR 2-431 (DMSO-d6-300)2.41 (dd, J = 6.8, 7.2 Hz, 1 H),2.95 (d, J = 6.8 Hz, 1 H), 3.11 (dd,J = 17.3, 7.2 Hz, 1 H), 3.24-3.40 (m,1 H), 7.04-7.10 (m, 3 H), 7.20-7.26 (m, 1 H), 7.53 (d, J = 8.7 Hz,2 H), 7.57 (d, J = 3.8 Hz, 1 H),7.60 (d, J = 3.8 Hz, 1 H), 7.76 (d,J = 8.7 Hz, 2 H), 9.07 (s, 1 H),12.10 (s, 1 H) 2-432 (MeOH-d4-300)1.77 (s, 3 H), 1.92 (d, J = 6.0 Hz,1 H), 2.25 (d, J = 6.0 Hz, 1 H),2.93 (d, J = 12.0 Hz, 1 H), 3.05 (d,J = 12.0 Hz, 1 H), 7.12-7.28 (m, 5 H),7.38 (d, J = 3.0 Hz, 1 H), 7.43 (d,J = 9.0 Hz, 2 H), 7.56 (d, J = 3.0 Hz,1 H), 7.65 (d, J = 9.0 Hz, 2 H) 2-433 (MeOH-d4-300)0.90-0.94 (m, 2 H), 1.05-1.12 (m,2 H), 1.32 (d, J = 6.6 Hz, 3 H), 2.09-2.15 (m, 2 H), 2.88 (d, J = 10.6 Hz,1 H), 6.44 (s, 1 H), 7.09-7.33 (m,5 H), 7.43 (d, J = 4.0 Hz, 1 H),7.56 (d, J = 4.0 Hz, 1 H), 2-434 (DMSO-d6-300)1.39 (s, 4 H), 2.08 (d, J = 5.7 Hz,1 H), 7.11-7.27 (m, 5 H), 7.53-7.71 (m, 4 H), 7.88 (dd, J = 10.5,2.3 Hz, 1 H), 9.24 (brs, 1 H),12.14 (brs, 1 H) 2-435 (DMSO-d6-300)1.27 (d, J = 6.4 Hz, 3 H), 1.92-2.06 (m, 1 H), 2.78 (d, J = 10.2 Hz,1 H), 7.13-7.31 (m, 5 H), 7.53-7.71 (m, 4 H), 7.87 (dd, J = 10.5,1.9 Hz, 1 H), 9.10 (brs, 1 H),12.31 (brs, 1 H)

TABLE 2-88 Example Structural formula NMR 2-436 (CDCl3-400)0.94-1.03 (m, 3 H), 1.08-1.13 (m,1 H), 1.39-2.11 (m, 13 H), 2.50-2.59 (m, 1 H), 5.94 (brs, 1 H),7.07 (d, J = 7.4 Hz, 2 H), 7.19-7.30 (m, 5 H), 7.77-7.78 (m, 2 H) 2-437 (DMSO-d6-400)1.55-1.67 (m, 2 H), 1.80-1.99 (m,3 H), 2.42-2.54 (m, 1 H), 2.77 (d,J = 10.2 Hz, 1 H), 4.66 (brs, 1 H),7.04 (d, J = 6.5 Hz, 1 H), 7.10 (dd,J = 7.0, 6.5 Hz, 1 H), 7.16 (dd,J = 7.0, 6.5 Hz, 1 H), 7.23 (d,J = 6.5 Hz, 1 H), 7.68 (d, J = 3.7 Hz,1 H), 7.85 (d, J = 3.7 Hz, 1 H),8.15 (s, 1 H) 2-438 (DDMSO-d6-400)1.55-1.67 (m, 2 H), 1.80-1.99 (m,3 H), 2.42-2.54 (m, 1 H), 2.77 (d,J = 10.2 Hz, 1 H), 4.66 (brs, 1 H),7.04 (d, J = 6.5 Hz, 1 H), 7.10 (dd,J = 7.0, 6.5 Hz, 1 H), 7.16 (dd,J = 7.0, 6.5 Hz, 1 H), 7.23 (d,J = 6.5 Hz, 1 H), 7.68 (d, J = 3.7 Hz,1 H), 7.85 (d, J = 3.7 Hz, 1 H),8.15 (s, 1 H) 2-439 (DMSO-d6-400)1.66-1.83 (m, 2 H), 1.88-2.00 (m,1 H), 2.49 (s, 3 H), 2.71 (d,J = 9.3 Hz, 1 H), 2.94 (ddd, J = 13.0,4.6, 2.8 Hz, 1 H), 4.39 (td, J = 12.5,5.6 Hz, 1 H), 7.15-7.21 (m, 1 H),7.25-7.37 (m, 3 H), 7.49-7.54 (m,2 H), 7.55-7.59 (m, 2 H), 7.71-7.76 (m, 2 H), 9.11 (brs, 1 H),12.59 (brs, 1 H) 2-440 (MeOH-d4-300)2.31 (d, J = 6.0 Hz, 1 H), 2.34 (s,3 H), 2.48 (d, J = 6.0 Hz, 1 H),3.42 (d, J = 15.0 Hz, 1 H), 3.95 (d,J = 15.0 Hz, 1 H), 7.13-7.46 (m, 8 H),7.58 (d, J = 3.0 Hz, 1 H), 7.65 (d,J = 9.0 Hz, 2 H)

TABLE 2-89 Example Structural formula NMR 2-441 (CDCl3-400)1.24-1.42 (m, 3 H), 2.19 (brs, 1 H),2.56 (s, 2 H), 3.13 (d, J = 11.3 Hz,1 H), 3.49 (s, 2 H), 3.93 (s, 2 H),5.64 (brs, 1 H), 6.01 (s, 1 H),7.24-7.31 (m, 9 H) 2-442 (CDCl3-400)0.90-0.94 (m, 3 H), 1.20-1.98 (m,9 H), 1.35 (d, J = 6.5 Hz, 3 H), 2.28-2.30 (m, 1 H), 2.95-3.07 (m, 4 H),3.34-3.62 (m, 4 H), 3.88-3.94 (m,2 H), 6.37 (brs, 1 H), 7.19-7.28 (m,5 H), 10.07 (brs, 1 H) 2-443 (DMSO-d6-300)1.19-1.39 (m, 9 H), 1.97-2.05 (m,1 H), 3.07-3.58 (m, 7 H), 3.65-3.80 (m, 2 H), 6.21-6.31 (m, 1 H),7.09-7.31 (m, 6 H), 8.80 (brs, 1 H),10.73 (brs, 1 H), 12.05 (brs, 1 H) 2-444 (DMSO-d6-300)1.26 (d, J = 6.6 Hz, 3 H), 2.00 (dq,J = 10.3, 6.6 Hz, 1 H), 2.78 (d,J = 10.3 Hz, 1 H), 7.14-7.30 (m, 5 H),7.35 (d, J = 4.0 Hz, 1 H), 7.50 (d,J = 4.0 Hz, 1 H), 7.93 (s, 1 H),8.87 (s, 1 H), 9.05 (brs, 1 H),12.20 (brs, 1 H) 2-445 (DMSO-d6-400)1.25 (d, J = 7.0 Hz, 3 H), 2.04 (dd,J = 10.4, 6.7 Hz, 1 H), 2.93 (d,J = 10.2 Hz, 1 H), 3.82 (t, J = 5.6 Hz,2 H), 4.31 (t, J = 5.6 Hz, 2 H),4.48 (brs, 1 H), 4.70 (s, 2 H), 7.16-7.32 (m, 5 H), 7.42 (dd, J = 8.8,1.9 Hz, 1 H), 7.71 (d, J = 8.3 Hz, 1 H),7.80 (d, J = 1.9 Hz, 1 H), 8.81 (s,1 H), 12.29 (brs, 1 H)

TABLE 2-90 Example Structural formula NMR 2-446 (DMSO-d6-300)2.20 (dd, J = 6.4, 7.2 Hz, 1 H),2.78 (d, J = 6.4 Hz, 1 H), 3.03 (dd,J = 17.3, 7.2 Hz, 1 H), 3.19-3.44 (m,1 H), 5.22 (s, 2 H), 7.01-7.09 (m,3 H), 7.16-7.22 (m, 1 H), 7.20 (d,J = 9.0 Hz, 2 H), 7.48 (dd, J = 8.3,2.3 Hz, 1 H), 7.63 (d, J = 8.3 Hz, 1 H),7.71 (d, J = 2.3 Hz, 1 H), 7.75 (d,J = 9.0 Hz, 2 H), 8.61 (brs, 1 H) 2-447 (DMSO-d6-300)2.23 (dd, J = 7.2, 7.3 Hz, 1 H),2.78 (d, J = 7.2 Hz, 1 H), 3.06 (dd,J = 17.9, 7.3 Hz, 1 H), 3.22-3.40 (m,1 H), 7.00-7.11 (m, 3 H), 7.19-7.26 (m, 1 H), 7.53 (d, J = 8.7 Hz,2 H), 7.62 (d, J = 4.1 Hz, 1 H),7.66 (d, J = 4.1 Hz, 1 H), 7.77 (d,J = 8.7 Hz, 2 H), 8.48 (s, 1 H),8.74 (brs, 1 H), 9.92 (s, 1 H) 2-448 (DMSO-d6-300)1.37-1.43 (m, 1 H), 1.40 (s, 3 H),2.10 (d, J = 5.7 Hz, 1 H), 7.12-7.27 (m, 5 H), 7.56 (d, J = 3.8 Hz,1 H), 7.65 (t, J = 1.9 Hz, 1 H),7.73 (d, J = 3.8 Hz, 1 H), 7.81 (d,J = 1.9 Hz, 2 H), 9.26 (s, 1 H),12.11 (brs, 1 H) 2-449 (DMSO-d6-400)1.36-1.38 (m, 1 H), 1.37 (s, 3 H),2.06 (d, J = 5.1 Hz, 1 H), 6.07 (s,2 H), 6.97 (d, J = 7.9 Hz, 1 H), 7.11-7.25 (m, 6 H), 7.32 (d, J = 1.9 Hz,1 H), 7.40 (d, J = 3.7 Hz, 1 H),7.47 (d, J = 3.7 Hz, 1 H), 9.11 (s,1 H), 12.10 (s, 1 H) 2-450 (DMSO-d6-400)1.23 (d, J = 6.5 Hz, 3 H), 1.93 (dd,J = 10.4, 6.7 Hz, 1 H), 2.73 (d,J = 10.2 Hz, 1 H), 3.70 (s, 3 H), 7.14-7.20 (m, 3 H), 7.22-7.27 (m, 3 H),7.47 (d, J = 3.7 Hz, 1 H), 7.77 (s,1 H), 7.97 (s, 1 H), 8.92 (s, 1 H),12.27 (brs, 1 H)

TABLE 2-91 Example Structural formula NMR 2-451 (DMSO-d6-400)1.25 (d, J = 7.0 Hz, 3 H), 1.99 (dd,J = 10.4, 6.7 Hz, 1 H), 2.65 (s, 3 H),2.78 (d, J = 10.7 Hz, 1 H), 7.14-7.20 (m, 3 H), 7.22-7.28 (m, 2 H),7.62 (t, J = 2.1 Hz, 1 H), 7.75 (q,J = 1.9 Hz, 1 H), 9.25 (brs, 1 H),12.31 (brs, 1 H) 2-452 (DMSO-d6-300)1.39 (s, 4 H), 2.07 (d, J = 5.3 Hz,1 H), 5.30 (brs, 2 H), 6.56-6.61 (m,1 H), 6.80-6.88 (m, 2 H), 7.04-7.27 (m, 6 H), 7.34 (d, J = 4.1 Hz,1 H), 7.50 (d, J = 3.8 Hz, 1 H),9.11 (brs, 1 H), 12.11 (brs, 1 H) 2-453 (DMSO-d6-400)1.40 (s, 4 H), 2.09 (d, J = 5.5 Hz,1 H), 3.05 (s, 3 H), 7.11-7.27 (m,6 H), 7.39-7.50 (m, 4 H), 7.54 (d,J = 4.0 Hz, 1 H), 9.18 (brs, 1 H),9.91 (brs, 1 H), 12.10 (brs, 1 H) 2-454 (DMSO-d6-300)1.19 (d, J = 6.0 Hz, 3 H), 1.78-1.94 (m, 3 H), 2.68 (d, J = 9.7 Hz,1 H), 3.06-3.19 (m, 2 H), 3.28-3.41 (m, 2 H), 3.53 (t, J = 5.8 Hz,2 H), 3.59 (t, J = 5.1 Hz, 2 H),6.71 (d, J = 9.3 Hz, 2 H), 7.10-7.19 (m, 5 H), 7.23 (d, J = 7.0 Hz,2 H), 8.10 (s, 1 H) 2-455 (DMSO-d6-400)1.27 (d, J = 5.1 Hz, 1 H), 1.36 (s,3 H), 2.00 (d, J = 5.6 Hz, 1 H), 2.03-2.13 (m, 4 H), 3.28-3.33 (m, 4 H),6.19 (d, J = 4.2 Hz, 1 H), 7.12-7.16 (m, 3 H), 7.20-7.23 (m, 3 H),8.71 (brs, 1 H), 12.01 (brs, 1 H)

TABLE 2-92 Example Structural formula NMR 2-456 (DMSO-d6-400)1.25 (d, J = 7.0 Hz, 3 H), 1.99 (dd,J = 10.4, 6.7 Hz, 1 H), 2.78 (d,J = 10.7 Hz, 1 H), 7.14-7.27 (m, 5 H),7.68 (d, J = 4.2 Hz, 1 H), 7.82-7.90 (m, 2 H), 8.09 (ddd, J = 11.6,7.7, 1.9 Hz, 2 H), 8.20 (d, J = 4.2 Hz,1 H), 9.18 (brs, 1 H), 9.62 (s, 1 H),12.32 (brs, 1 H) 2-457 (MeOH-d4-400)1.36 (d, J = 6.8 Hz, 3 H), 2.13-2.20 (m, 1 H), 3.03 (d, J = 10.5 Hz,1 H), 3.30-3.35 (m, 4 H), 3.58-3.61 (m, 4 H), 6.81-8.06 (m, 8 H) 2-458 (MeOH-d4-400)1.35-1.38 (m, 3 H), 2.12-2.20 (m,1 H), 3.03 (d, J = 10.4 Hz, 1 H), 3.20-3.23 (m, 4 H), 3.35-3.38 (m, 4 H),6.88-6.91 (m, 2 H), 7.16-7.34 (m,8 H) 2-459 (CDCl3-400)1.34 (d, J = 7.0 Hz, 3 H), 2.21-2.29 (m, 1 H), 3.15-3.21 (m, 5 H),3.37-3.40 (m, 4 H), 5.56 (s, 1 H),6.64 (ddd, J = 2.7, 10.4, 11.6 Hz,2 H), 7.20-7.30 (m, 6 H) 2-460 (MeOH-d4-400)1.36 (d, J = 7.0 Hz, 3 H), 2.14-2.22 (m, 1 H), 3.04 (d, J = 10.5 Hz,1 H), 3.10-3.12 (m, 4 H), 3.37-3.40 (m, 4 H), 6.99-7.33 (m, 8 H)

TABLE 2-93 Example Structural formula NMR 2-461 (CDCl3-400)1.20-1.32 (m, 2 H), 1.33 (d,J = 6.5 Hz, 3 H), 1.97-2.12 (m, 2 H),2.24-2.35 (m, 1 H), 2.99 (d,J = 10.2 Hz, 1 H), 3.29-3.92 (m, 6 H),6.04 (brs, 1 H), 6.83 (dd, J = 9.7,1.9 Hz, 1 H), 7.14-7.33 (m, 5 H),7.71 (dt, J = 9.7, 2.3 Hz, 1 H),7.92 (t, J = 2.3 Hz, 1 H) 2-462 (CDCl3-400)1.21-1.30 (m, 2 H), 1.33 (d,J = 6.5 Hz, 3 H), 1.97-2.11 (m, 2 H),2.25-2.35 (m, 1 H), 2.99 (d,J = 10.7 Hz, 1 H), 3.28-3.94 (m, 6 H),6.01 (brs, 1 H), 6.81-6.87 (m, 1 H),7.13-7.31 (m, 5 H), 7.62-7.69 (m,1 H), 7.87 (s, 1 H) 2-463 (CDCl3-400)1.31 (d, J = 7.0 Hz, 3 H), 2.25 (dq,J = 10.7, 7.0 Hz, 1 H), 3.10 (d,J = 10.7 Hz, 1 H), 3.47-3.59 (m, 4 H),3.77-3.89 (m, 4 H), 6.31 (brs, 1 H),7.13-7.33 (m, 6 H), 7.41-7.46 (m,1 H), 7.53-7.64 (m, 2 H) 2-464 (CDCl3-400)1.35 (d, J = 7.0 Hz, 3 H), 2.27 (dq,J = 10.2, 7.0 Hz, 1 H), 3.13 (d,J = 10.2 Hz, 1 H), 3.41-3.49 (m, 4 H),3.76-3.86 (m, 4 H), 6.18 (brs, 1 H),7.11-7.35 (m, 9 H) 2-465 (CDCl3-400)1.37 (d, J = 7.0 Hz, 3 H), 2.29-2.33 (m, 1 H), 2.59 (s, 3 H), 3.46 (t,J = 4.9 Hz, 4 H), 3.63 (t, J = 4.9 Hz,4 H), 5.98 (brs, 1 H), 7.21-7.32 (m,5 H)

TABLE 2-94 Example Structural formula NMR 2-466 (DMSO-d6-300)1.39 (s, 3 H), 1.40 (d, J = 4.9 Hz,1 H), 2.10 (d, J = 5.7 Hz, 1 H), 7.16-7.25 (m, 5 H), 7.60 (d, J = 4.1 Hz,1 H), 7.65-7.68 (m, 1 H), 8.13-8.19 (m, 1 H), 8.60 (d, J = 2.3 Hz,1 H), 9.27 (brs, 1 H), 12.10 (brs,1 H) 2-467 (DMSO-d6-300)1.24 (d, J = 5.3 Hz, 1 H), 1.37 (s,3 H), 2.00 (d, J = 5.3 Hz, 1 H), 2.59-2.61 (m, 1 H), 3.49 (t, J = 7.2 Hz,2 H), 3.73 (t, J = 12.8 Hz, 2 H),5.90 (d, J = 4.1 Hz, 1 H), 7.14-7.26 (m, 6 H), 8.69 (brs, 1 H),12.02 (brs, 1 H) 2-468 (DMSO-d6-300)1.26 (d, J = 6.4 Hz, 3 H), 1.98 (dd,J = 10.4, 6.6 Hz, 1 H), 2.78 (d,J = 10.5 Hz, 1 H), 7.14-7.30 (m, 6 H),7.45 (d, J = 3.8 Hz, 1 H), 7.54 (d,J = 3.8 Hz, 1 H), 7.61 (dd, J = 8.31.9 Hz, 1 H), 8.00 (d, J = 1.9 Hz, 1 H),9.01 (brs, 1 H), 12.22 (brs, 1 H) 2-469 (DMSO-d6-300)1.28 (d, J = 6.4 Hz, 3 H), 2.01 (dd,J = 10.2, 6.8 Hz, 1 H), 2.81 (d,J = 10.2 Hz, 1 H), 2.83 (s, 3 H), 7.16-7.31 (m, 5 H), 7.58 (d, J = 3.8 Hz,1 H), 7.65 (d, J = 4.1 Hz, 1 H),7.73 (dd, J = 8.5 1.7 Hz, 1 H),8.12 (d, J = 8.7 Hz, 1 H), 8.24 (d,J = 1.5 Hz, 1 H), 9.05 (s, 1 H),12.31 (brs, 1 H) 2-470 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 1.97 (dd,J = 10.5, 6.8 Hz, 1 H), 2.77 (d,J = 10.5 Hz, 1 H), 6.08 (s, 2 H),6.99 (d, J = 7.9 Hz, 1 H), 7.15-7.30 (m, 6 H), 7.33 (d, J = 1.5 Hz,1 H), 7.41 (d, J = 3.8 Hz, 1 H),7.50 (d, J = 3.8 Hz, 1 H), 8.98 (brs,1 H), 12.30 (brs, 1 H)

TABLE 2-95 Example Structural formula NMR 2-471 (DMSO-d6-300)1.21 (d, J = 6.0 Hz, 3 H), 1.80-2.01 (m, 3 H), 2.70 (d, J = 11.3 Hz,1 H), 3.10-3.21 (m, 2 H), 3.30-3.43 (m, 2 H), 3.51-3.66 (m, 4 H),6.53-6.78 (m, 3 H), 7.09-7.30 (m,6 H), 8.13 (s, 1 H) 2-472 (DMSO-d6-300)1.22 (d, J = 6.8 Hz, 3 H), 1.81-2.00 (m, 3 H), 2.71 (d, J = 10.9 Hz,1 H), 3.10-3.19 (m, 2 H), 3.32-3.43 (m, 2 H), 3.48-3.65 (m, 4 H),6.65-6.77 (m, 2 H), 6.92-7.02 (m,2 H), 7.12-7.30 (m, 5 H), 8.11 (s,1 H) 2-473 (DMSO-d6-300)1.39-1.52 (m, 1 H), 1.91-2.00 (m,1 H), 2.61-2.71 (m, 1 H), 7.11-7.28 (m, 5 H), 7.49-7.65 (m, 3 H),7.77 (d, J = 8.7 Hz, 2 H), 7.91-8.01 (m, 4 H), 8.78 (s, 1 H),10.58 (s, 1 H), 12.07 (s, 1 H) 2-474 (DMSO-d6-300)1.41-1.51 (m, 1 H), 1.92-2.01 (m,1 H), 2.64-2.74 (m, 2 H), 7.10-7.29 (m, 6 H), 7.37 (t, J = 8.1 Hz,2 H), 7.77 (d, J = 8.1 Hz, 2 H),7.93 (d, J = 8.3 Hz, 2 H), 8.11 (d,J = 8.3 Hz, 2 H), 9.05 (s, 1 H),10.42 (s, 2 H), 12.16 (s, 1 H) 2-475 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 1.93-2.07 (m, 1 H), 2.86 (d, J = 10.2 Hz,1 H), 3.11-3.19 (m, 2 H), 3.20-3.27 (m, 2 H), 3.28-3.34 (m, 4 H),6.05 (s, 1 H), 7.12-7.31 (m, 5 H),8.31 (s, 1 H), 12.37 (s, 1 H)

TABLE 2-96 Example Structural formula NMR 2-476 (DMSO-d6-300)1.26 (d, J = 7.5 Hz, 3 H), 1.98-2.11(m, 1 H), 2.91 (d, J = 9.8 Hz,1 H), 3.51-3.62 (m, 3 H), 3.82-3.93(m, 2 H), 3.96 (s, 2 H), 6.80 (s,1 H), 7.13-7.32 (m, 5 H), 8.66 (s,1 H), 12.47 (s, 1 H) 2-477 (DMSO-d6-300)1.39 (s, 3 H), 1.42 (d, J = 5.7 Hz,1 H), 2.08 (d, J = 4.9 Hz, 1 H), 7.12-7.25(m, 5 H), 7.58 (d, J = 4.1 Hz,1 H), 7.74 (d, J = 3.8 Hz, 1 H),7.84 (d, J = 8.7 Hz, 1 H), 8.03 (dd,J = 8.7, 2.3 Hz, 1 H), 8.44 (d,J = 2.3 Hz, 1 H), 9.29 (brs, 1 H),12.16 (brs, 1 H) 2-478 (DMSO-d6-300)1.34-1.42 (m, 1 H), 1.35 (t,J = 7.2 Hz, 3 H), 1.40 (s, 3 H),2.09 (d, J = 5.3 Hz, 1 H), 4.36 (q,J = 7.2 Hz, 2 H), 7.10-7.28 (m, 5 H),7.56 (d, J = 3.8 Hz, 1 H), 7.61-7.65(m, 1 H), 7.64 (d, J = 3.8 Hz,1 H), 7.94-8.04 (m, 2 H), 8.18 (brs,1 H), 9.25 (s, 1 H), 12.14 (s, 1 H) 2-479 (DMSO-d6-300)1.40 (s, 3 H), 1.42 (d, J = 5.7 Hz,1 H), 2.10 (d, J = 5.7 Hz, 1 H), 7.13-7.27(m, 5 H), 7.55-7.63 (m, 1 H),7.56 (d, J = 4.1 Hz, 1 H), 7.62 (d,J = 4.1 Hz, 1 H), 7.93-8.00 (m, 2 H),8.15-8.18 (m, 1 H), 9.22 (s, 1 H) 2-480 (DMSO-d6-300)1.37-1.41 (m, 4 H), 2.06 (s, 3 H),2.09 (d, J = 5.7 Hz, 1 H), 7.13-7.27(m, 5 H), 7.36-7.41 (m, 2 H),7.44 (d, J = 3.8 Hz, 1 H), 7.53-7.56(m, 1 H), 7.54 (d, J = 3.8 Hz,1 H), 7.97 (brs, 1 H), 9.18 (s, 1 H),10.08 (s, 1 H), 12.11 (brs, 1 H)

TABLE 2-97 Example Structural formula NMR 2-481 (DMSO-d6-400)1.64 (q, J = 5.1 Hz, 1 H), 1.97 (t,J = 7.2 Hz, 1 H), 2.10 (s, 3 H),2.69 (t, J = 8.6 Hz, 1 H), 7.11-7.24(m, 5 H), 7.72 (s, 1 H), 7.98 (d,J = 8.8 Hz, 1 H), 8.24 (dd, J = 8.8,2.3 Hz, 1 H), 8.44 (s, 1 H), 8.73 (d,J = 2.3 Hz, 1 H), 12.20 (brs, 1 H) 2-482 (CDCl3-300)1.67 (dd, J = 9.6, 5.5 Hz, 1 H),2.04 (dd, J = 8.5, 5.5 Hz, 1 H),2.79 (t, J = 9.4 Hz, 1 H), 3.80 (s,3 H), 7.15-7.29 (m, 5 H), 7.76 (s,1 H), 8.00 (d, J = 8.7 Hz, 1 H),8.25 (dd, J = 8.9, 2.4 Hz, 1 H),8.36 (s, 1 H), 8.73 (d, J = 2.3 Hz,1 H), 9.19 (s, 1 H), 12.30 (brs, 1 H) 2-483 (CDCl3-400)1.39 (d, J = 7.0 Hz, 4 H), 2.31 (dd,J = 10.0, 6.7 Hz, 1 H), 2.68 (s, 3 H),3.15 (d, J = 10.2 Hz, 1 H), 3.23-3.24(m, 4 H), 3.48-3.49 (m, 4 H),6.10 (brs, 1 H), 6.94 (dd, J = 8.8,2.3 Hz, 1 H), 7.19-7.31 (m, 5 H),7.53 (d, J = 2.3 Hz, 1 H), 7.59 (d,J = 8.8 Hz, 1 H) 2-484 (CDCl3-400)1.41 (d, J = 7.0 Hz, 3 H), 2.23 (d,J = 1.4 Hz, 3 H), 2.30-2.35 (m, 1 H),3.09 (d, J = 10.7 Hz, 1 H), 3.41-3.46(m, 8 H), 6.07 (brs, 1 H),6.62 (d, J = 0.9 Hz, 1 H), 7.26-7.30(m, 5 H) 2-485 (DMSO-d6-300)1.36 (s, 3 H), 1.43 (d, J = 4.9 Hz,1 H), 1.99 (d, J = 4.9 Hz, 1 H),4.28 (s, 4 H), 6.92 (d, J = 8.3 Hz,1 H), 7.07-7.24 (m, 7 H), 7.38 (d,J = 3.8 Hz, 1 H), 7.48 (d, J = 3.8 Hz,1 H)

TABLE 2-98 Example Structural formula NMR 2-486 (DMSO-d6-300)1.73-1.92 (m, 2 H), 2.08-2.55 (m,4 H), 6.91-6.99 (m, 1 H), 7.01-7.16(m, 3 H), 7.77 (d, J = 3.8 Hz,1 H), 7.91 (d, J = 3.8 Hz, 1 H),8.18 (s, 1 H), 8.70 (s, 1 H),8.90 (brs, 1 H), 9.80 (s, 1 H) 2-487 (DMSO-d6-300)1.37 (s, 3 H), 1.41 (d, J = 5.1 Hz,1 H), 2.07 (d, J = 5.6 Hz, 1 H), 7.07-7.22(m, 6 H), 7.34 (d, J = 10.2 Hz,1 H), 7.41-7.48 (m, 2 H), 7.58-7.63(m, 2 H), 9.10 (brs, 1 H),12.26 (brs, 1 H) 2-488 (DMSO-d6-300)1.38 (d, J = 5.3 Hz, 1 H), 1.39 (s,3 H), 2.09 (d, J = 5.3 Hz, 1 H),2.79 (s, 6 H), 7.14-7.27 (m, 5 H),7.30 (dd, J = 8.1, 2.1 Hz, 1 H),7.37 (d, J = 2.3 Hz, 1 H), 7.45 (d,J = 8.3 Hz, 1 H), 7.54 (d, J = 4.1 Hz,1 H), 7.58 (d, J = 3.8 Hz, 1 H),9.18 (s, 1 H), 12.10 (brs, 1 H) 2-489 (DMSO-d6-400)1.68 (dd, J = 10.2, 5.1 Hz, 1 H),1.95 (dd, J = 8.3, 5.1 Hz, 1 H),2.59 (t, J = 9.3 Hz, 1 H), 7.09-7.21(m, 5 H), 7.25-7.31 (m, 1 H),7.37-7.43 (m, 2 H), 7.81-7.86 (m,2 H), 8.23 (s, 1 H), 8.58 (s, 1 H) 2-490 (DMSO-d6-400)1.67 (dd, J = 9.7, 5.1 Hz, 1 H),1.96 (dd, J = 8.3, 5.1 Hz, 1 H),2.61 (t, J = 9.0 Hz, 1 H), 7.08-7.24(m, 5 H), 7.46 (d, J = 8.8 Hz,2 H), 7.86 (d, J = 8.8 Hz, 2 H),8.27 (s, 1 H), 8.60 (s, 1 H)

TABLE 2-99 Example Structural formula NMR 2-491 (DMSO-d6-400)1.69 (dd, J = 9.7, 5.6 Hz, 1 H),1.98 (dd, J = 8.6, 5.3 Hz, 1 H),2.64 (t, J = 9.0 Hz, 1 H), 7.11-7.27(m, 7 H), 7.84-7.91 (m, 2 H),8.21 (s, 1 H), 8.60 (s, 1 H) 2-492 (MeOH-d4-300)1.38 (d, J = 6.8 Hz, 3 H), 2.15-2.25(m, 1 H), 2.93 (d, J = 10.5 Hz,1 H), 3.81 (s, 3 H), 7.05 (d,J = 4.1 Hz, 1 H), 7.20-7.24 (m, 5 H),7.47-7.49 (m, 2 H), 7.97 (d,J = 0.8 Hz, 1 H) 2-493 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 1.99 (dd,J = 10.9, 6.8 Hz, 1 H), 2.79 (d,J = 10.9 Hz, 1 H), 6.86 (d, J = 1.5 Hz,1 H), 7.02 (t, J = 7.0 Hz, 1 H), 7.11-7.30(m, 6 H), 7.39 (d, J = 8.3 Hz,1 H), 7.48 (d, J = 3.8 Hz, 1 H), 7.51-7.58(m, 2 H), 9.03 (brs, 1 H),11.73 (brs, 1 H), 12.32 (brs, 1 H) 2-494 (MeOH-d4-300)1.36 (d, J = 9.0 Hz, 3 H), 2.14-2.26(m, 1 H), 2.93 (d, J = 9.0 Hz,1 H), 7.12-7.28 (m, 6 H), 7.49 (d,J = 3.0 Hz, 1 H), 7.69 (s, 1 H),8.41 (s, 1 H) 2-495 (DMSO-d6-300)2.26 (dd, J = 6.8, 7.3 Hz, 1 H),2.81 (d, J = 6.8 Hz, 1 H), 3.08 (dd,J = 17.5, 7.3 Hz, 1 H), 3.26-3.38 (m,1 H), 7.01-7.11 (m, 3 H), 7.20-7.29(m, 1 H), 7.76 (d, J = 3.8 Hz,1 H), 7.89 (d, J = 3.8 Hz, 1 H),8.17 (s, 1 H), 8.46 (s, 1 H),8.96 (brs, 1 H), 9.97 (s, 1 H)

TABLE 2-100 Example Structural formula NMR 2-496 (MeOH-d4-300)1.42 (d, J = 6.8 Hz, 3 H), 2.20 (dd,J = 10.0, 7.0 Hz, 1 H), 2.93 (d,J = 10.2 Hz, 1 H), 6.90 (dd, J = 8.3,1.9 Hz, 1 H), 7.10 (d, J = 1.9 Hz, 1 H),7.18-7.32 (m, 7 H), 7.56 (d,J = 4.1 Hz, 1 H) 2-497 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 2.01 (dd,J = 10.4, 6.6 Hz, 1 H), 2.80 (d,J = 10.5 Hz, 1 H), 7.15-7.29 (m, 5 H),7.62 (d, J = 4.1 Hz, 1 H), 7.83 (d,J = 3.8 Hz, 1 H), 8.09 (t, J = 4.7 Hz,1 H), 8.17 (d, J = 9.0 Hz, 1 H),8.45 (s, 1 H), 9.12 (brs, 1 H),12.31 (brs, 1 H) 2-498 (DMSO-d6-300)1.40 (s, 3 H), 1.42 (d, J = 5.7 Hz,1 H), 2.09 (d, J = 5.7 Hz, 1 H), 7.10-7.28(m, 5 H), 7.35 (d, J = 4.1 Hz,1 H), 7.49 (d, J = 4.1 Hz, 1 H),7.94 (s, 1 H), 8.88 (s, 1 H),9.20 (brs, 1 H), 12.08 (brs, 1 H) 2-499 (DMSO-d6-400)1.24 (d, J = 6.5 Hz, 3 H), 1.94 (dq,J = 10.4, 6.7 Hz, 1 H), 2.66 (d,J = 10.7 Hz, 1 H), 7.04-7.21 (m, 5 H),7.26-7.32 (m, 1 H), 7.38-7.43 (m,2 H), 7.82-7.86 (m, 2 H), 8.23 (s,1 H), 8.56 (s, 1 H) 2-500 (CDCl3-400)1.27-1.31 (m, 3 H), 2.16 (m, 3 H),3.11 (dd, J = 10.5, 16.6 Hz, 1 H),3.45-3.63 (m, 4 H), 4.85 (s, 1 H),5.71 (brs, 1 H), 6.71 (m, 2 H), 7.16-7.30(m, 7 H)

TABLE 2-101 Example Structural formula NMR 2-501 (CDCl3-400)1.29-1.34 (m, 3 H), 2.17 (m, 3 H),3.14 (dd, J = 11.1, 19.9 Hz, 1 H),3.49-3.74 (m, 4 H), 4.89 (s, 1 H),5.65 (brs, 1 H), 6.65-7.00 (m, 2 H),7.13-7.25 (m, 7 H) 2-502 (MeOH-d4-400)1.38 (d, J6.7 Hz, 3 H), 2.17-2.24 (m,1 H), 3.04 (d, J = 10.5 Hz, 1 H), 3.70-3.72(m, 2 H), 3.73-3.81 (m, 2 H),4.02-4.11 (m, 2 H), 7.17-7.33 (m,7 H), 7.41-7.45 (m, 2 H) 2-503 (MeOH-d4-400)1.36 (d, J6.7 Hz, 3 H), 2.10-2.16 (m,1 H), 2.93 (d, J = 10.4 Hz, 1 H), 3.37-3.39(m, 4), 3.71-3.74 (m, 4 H),7.14-7.47 (m, 7 H) 2-504 (MeOH-d4-400)1.39 (d, J = 6.67 Hz, 3 H), 2.21 (qd,J = 6.4, 12.9 Hz, 1 H), 3.05 (d,J = 10.5 Hz, 1 H), 3.72-3.74 (m, 2 H),3.86 (t, J = 5.2 Hz, 2 H), 4.05-4.14(m, 2 H), 7.17-7.30 (m, 5 H),7.55 (d, J = 8.4 Hz, 2 H), 7.73 (d,J = 8.4 Hz, 2 H) 2-505 (MeOH-d4-400)1.35-1.38 (m, 3 H), 2.07 (s, 1 H),2.84 (d, J = 10.4 Hz, 1 H), 4.57-4.73(m, 4 H), 7.12-7.45 (m, 8 H)

TABLE 2-102 Example Structural formula NMR 2-506 (MeOH-d4-400)1.51 (s, 3 H), 1.70 (d, J = 5.5 Hz,1 H), 2.17 (d, J = 5.5 Hz, 1 H), 7.17-7.21(m, 5 H), 8.01 (s, 4 H), 8.02 (s,1 H), 8.90 (s, 1 H) 2-507 (MeOH-d4-400)1.35 (d, J = 7.0 Hz, 3 H), 2.15 (qd,J = 6.7, 13.4 Hz, 1 H), 2.87 (d,J = 10.5 Hz, 1 H), 7.14-7.20 (m, 1 H),7.23 (d, J = 4.3 Hz, 4 H), 8.03 (s,5 H), 8.90 (s, 1 H) 2-508 (DMSO-d6-300)1.19 (d, J = 6.8 Hz, 3 H), 1.85 (dq,J = 10.2, 6.8 Hz, 1 H), 2.66 (d,J = 10.2 Hz, 1 H), 4.18 (s, 2 H),6.90 (d, J = 3.8 Hz, 1 H), 7.04-7.35(m, 10 H), 7.40 (d, J = 3.8 Hz,1 H) 2-509 (DMSO-d6-300)1.24 (d, J = 6.4 Hz, 3 H), 1.96 (dq,J = 10.2, 6.4 Hz, 1 H), 2.73 (d,J = 10.2 Hz, 1 H), 6.79 (d, J = 7.2 Hz,1 H), 6.90-7.29 (m, 8 H), 7.43 (d,J = 3.8 Hz, 1 H), 7.53 (d, J = 3.8 Hz,1 H) 2-510 (DMSO-d6-300)1.19 (d, J = 5.7 Hz, 6 H), 1.72 (dd,J = 9.6, 5.3 Hz, 1 H), 2.02 (dd,J = 9.4, 5.3 Hz, 1 H), 2.74 (t,J = 9.4 Hz, 1 H), 2.95-3.11 (m, 4 H),3.35-3.44 (m, 4 H), 4.74-4.82 (m,1 H), 7.12-7.30 (m, 5 H), 8.47 (s,1 H), 12.25 (s, 1 H)

TABLE 2-103 Example Structural formula NMR 2-511 (DMSO-d6-300)0.86 (d, J = 6.4 Hz, 6 H), 1.24-1.35(m, 2 H), 1.50-1.62 (m, 1 H),1.71 (dd, J = 5.5, 2.4 Hz, 1 H),2.01 (dd, J = 9.0, 5.5 Hz, 1 H), 2.24-2.32(m, 2 H), 2.34-2.44 (m, 4 H),2.73 (t, J = 9.0 Hz, 1 H), 2.95-3.11(m, 4 H), 7.10-7.31 (m, 5 H),8.34 (s, 1 H) 2-512 (DMSO-d6-300)1.00 (t, J = 7.2 Hz, 3 H), 1.72 (dd,J = 5.1, 8.5 Hz, 1 H), 2.01 (dd,J = 8.5, 5.1 Hz, 1 H), 2.72 (t,J = 8.5 Hz, 1 H), 2.92-3.11 (m, 6 H),3.24-3.38 (m, 4 H), 6.53 (t,J = 5.3 Hz, 1 H), 7.13-7.31 (m, 5 H),8.42 (s, 1 H), 12.28 (s, 1 H) 2-513 (DMSO-d6-300)0.89 (d, J = 6.8 Hz, 6 H), 1.71 (dd,J = 8.9, 5.7 Hz, 1 H), 1.92-2.06 (m,2 H), 2.20 (d, J = 6.8 Hz, 2 H),2.75 (t, J = 8.9 Hz, 1 H), 2.90-3.12(m, 4 H), 3.42-3.61 (m, 4 H),7.13-7.32 (m, 5 H), 12.27 (s, 1 H),12.27 (s, 1 H) 2-514 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 2.01 (dq,J = 10.2, 6.8 Hz, 1 H), 2.79 (d,J = 10.2 Hz, 1 H), 7.11-7.31 (m, 6 H),7.54 (d, J = 4.1 Hz, 1 H), 7.55 (d,J = 4.1 Hz, 1 H), 8.80 (s, 1 H),9.13 (brs, 1 H), 12.31 (brs, 1 H) 2-515 (DMSO-d6-300)1.31 (d, J = 5.3 Hz, 1 H), 1.37 (s,3 H), 2.02 (d, J = 5.3 Hz, 1 H),3.34 (s, 3 H), 6.21 (d, J = 4.1 Hz,1 H), 7.17-7.22 (m, 7 H), 7.33-7.42(m, 4 H), 8.71 (brs, 1 H),12.04 (brs, 1 H)

TABLE 2-104 Example Structural formula NMR 2-516 (DMSO-d6-300)1.39 (s, 3 H), 1.41 (d, J = 4.1 Hz,1 H), 2.08 (d, J = 6.0 Hz, 1 H),3.95 (s, 3 H), 7.13-7.24 (m, 5 H),7.28 (dd, J = 8.3, 1.9 Hz, 1 H),7.41 (d, J = 1.9 Hz, 1 H), 7.50 (d,J = 8.3 Hz, 1 H), 7.55 (d, J = 3.8 Hz,1 H), 7.63 (d, J = 3.8 Hz, 1 H),9.17 (brs, 1 H), 12.13 (brs, 1 H) 2-517 (DMSO-d6-300)1.28 (d, J = 6.8 Hz, 3 H), 2.02 (dd,J = 10.4, 6.6 Hz, 1 H), 2.81 (d,J = 10.5 Hz, 1 H), 7.14-7.30 (m, 5 H),7.65 (d, J = 4.1 Hz, 1 H), 7.89 (d,J = 4.1 Hz, 1 H), 8.02 (d, J = 10.2 Hz,1 H), 8.17 (d, J = 9.4 Hz, 1 H),8.45 (s, 1 H), 9.18 (s, 1 H),12.31 (brs, 1 H) 2-518 (DMSO-d6-400)1.42 (s, 3 H), 1.48 (d, J = 5.6 Hz,1 H), 2.13 (d, J = 5.6 Hz, 1 H), 7.13-7.30(m, 6 H), 7.40 (t, J = 7.7 Hz,2 H), 7.84 (d, J = 7.4 Hz, 2 H),8.23 (s, 1 H), 8.59 (s, 1 H),9.52 (brs, 1 H), 12.24 (brs, 1 H) 2-519 (DMSO-d6-400)1.41 (s, 3 H), 1.45 (d, J = 5.6 Hz,1 H), 2.12 (d, J = 6.0 Hz, 1 H),3.27 (s, 3 H), 4.36 (s, 2 H), 7.12-7.27(m, 5 H), 7.73 (s, 1 H), 8.53 (s,1 H), 9.49 (brs, 1 H), 12.24 (brs,1 H) 2-520 (DMSO-d6-400)1.18-1.27 (m, 4 H), 1.83-1.95 (m,1 H), 5.28 (s, 2 H), 7.18-7.04 (m,5 H), 7.51 (s, 1 H), 7.73 (s, 1 H),7.99 (s, 1 H), 8.48 (s, 1 H)

TABLE 2-105 Example Structural formula NMR 2-521 (CDCl3-300)1.34 (d, J = 6.7 Hz, 3 H), 1.37 (t,J = 7.1 Hz, 3 H), 2.36 (dq, J = 10.6,6.7 Hz, 1 H), 3.08 (d, J = 10.6 Hz,1 H), 4.34 (q, J = 7.1 Hz, 2 H),6.11 (brs, 1 H), 7.01 (d, J = 4.0 Hz,1 H), 7.12-7.31 (m, 5 H), 7.52 (d,J = 4.0 Hz, 1 H), 8.04 (s, 1 H),8.33 (s, 1 H) 2-522 (DMSO-d6-300)1.27 (d, J = 6.2 Hz, 3 H), 2.01 (dq,J = 10.3, 6.2 Hz, 1 H), 2.79 (d,J = 10.3 Hz, 1 H), 7.13-7.31 (m, 5 H),7.51 (d, J = 4.0 Hz, 1 H), 7.55 (d,J = 4.0 Hz, 1 H), 8.09 (s, 1 H),9.06 (brs, 1 H), 9.12 (s, 1 H) 2-523 (CDCl3-300)1.37 (d, J = 7.0 Hz, 3 H), 1.56 (s,3 H), 1.58 (s, 3 H), 2.45 (dq,J = 10.6, 7.0 Hz, 1 H), 3.06 (d,J = 10.6 Hz, 1 H), 6.16 (s, 1 H),6.85 (d, J = 4.0 Hz, 1 H), 7.09-7.30(m, 5 H), 7.46 (d, J = 4.0 Hz,1 H), 7.59 (s, 1 H), 7.78 (s, 1 H) 2-524 (MeOH-d4-300)1.36 (d, J = 6.0 Hz, 3 H), 2.12-2.22(m, 1 H), 2.91 (d, J = 9.0 Hz,1 H), 3.21 (s, 3 H), 7.14-7.28 (m,5 H), 7.35 (d, J = 3.0 Hz, 1 H),7.53 (d, J = 3.0 Hz, 1 H), 8.07 (s,1 H), 8.91 (s, 1 H) 2-525 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 1.98 (dq,J = 10.5, 6.8 Hz, 1 H), 2.78 (d,J = 10.5 Hz, 1 H), 4.55 (s, 2 H),5.28 (brs, 1 H), 7.14-7.45 (m, 7 H),7.48-7.65 (m, 2 H), 7.50 (d,J = 3.8 Hz, 1 H), 7.55 (d, J = 3.8 Hz,1 H), 9.00 (brs, 1 H), 12.29 (brs,1 H)

TABLE 2-106 Example Structural formula NMR 2-526 (DMSO-d6-300)1.40 (s, 3 H), 1.42 (d, J = 5.7 Hz,1 H), 2.12 (d, J = 5.7 Hz, 1 H), 7.12-7.28(m, 5 H), 7.67 (d, J = 4.1 Hz,1 H), 8.01 (d, J = 4.1 Hz, 1 H),8.06 (d, J = 6.8 Hz, 2 H), 8.78 (d,J = 6.8 Hz, 2 H), 9.39 (s, 1 H) 2-527 (DMSO-d6-300)1.35-1.46 (m, 4 H), 2.10 (d,J = 6.0 Hz, 1 H), 7.11-7.28 (m, 5 H),7.56-7.63 (m, 2 H), 7.71 (d,J = 3.8 Hz, 1 H), 8.24 (dt, J = 8.0,1.9 Hz, 1 H), 8.64 (dd, J = 4.9,1.9 Hz, 1 H), 9.02 (d, J = 1.9 Hz, 1 H),9.25 (s, 1 H) 2-528 (CDCl3-300)1.30 (d, J = 6.8 Hz, 3 H), 2.13-2.26(m, 1 H), 2.84 (t, J = 5.8 Hz,2 H), 3.13 (d, J = 10.5 Hz, 1 H),3.53 (t, J = 5.8 Hz, 2 H), 3.82 (s,3 H), 3.84 (s, 3 H), 4.36 (s, 2 H),5.62 (s, 1 H), 6.53 (s, 3 H), 6.59 (s,3 H), 7.15-7.28 (m, 5 H) 2-529 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 1.95-2.06(m, 1 H), 2.84 (d, J = 10.5 Hz,1 H), 2.98-3.07 (m, 4 H), 3.34-3.46(m, 4 H), 4.23 (d, J = 5.7 Hz,2 H), 7.09-7.36 (m, 11 H), 8.25 (s,1 H), 12.32 (s, 1 H) 2-530 (DMSO-d6-300)0.86 (d, J = 6.0 Hz, 6 H), 1.20-1.35(m, 5 H), 1.48-1.62 (m, 1 H),1.92-2.06 (m, 1 H), 2.22-2.31 (m,2 H), 2.33-2.44 (m, 4 H), 2.85 (d,J = 10.5 Hz, 1 H), 2.99-3.08 (m, 4 H),7.11-7.32 (m, 5 H), 8.14 (s, 1 H)

TABLE 2-107 Example Structural formula NMR 2-531 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 1.93-2.05(m, 1 H), 2.41-2.56 (m, 6 H),2.72 (t, J = 7.5 Hz, 2 H), 2.86 (d,J = 10.2 Hz, 1 H), 2.98-3.12 (m, 4 H),7.09-7.33 (m, 11 H), 8.16 (s, 1 H) 2-532 (DMSO-d6-300)1.26 (d, J = 7.2 Hz, 3 H), 1.94-2.06(m, 1 H), 2.84 (d, J = 10.9 Hz,1 H), 3.01-3.10 (m, 4 H), 3.39-3.51(m, 4 H), 5.09 (s, 2 H), 7.15-7.42(m, 10 H), 8.28 (s, 1 H),12.30 (s, 1 H) 2-533 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 1.96-2.09(m, 1 H), 2.87 (d, J = 10.2 Hz,1 H), 3.13-3.26 (m, 4 H), 3.73-3.81(m, 4 H), 7.15-7.31 (m, 7 H),8.28 (d, J = 7.5 Hz, 2 H), 8.42 (s,1 H), 12.37 (s, 1 H) 2-534 (DMSO-d6-300)1.28 (d, J = 6.2 Hz, 3 H), 1.95-2.07(m, 1 H), 2.86 (d, J = 10.6 Hz,1 H), 2.98-3.73 (m, 15 H), 7.12-7.31(m, 5 H), 8.50 (s, 1 H),10.26 (s, 1 H), 12.39 (s, 1 H) 2-535 (DMSO-d6-300)1.25 (d, J = 7.0 Hz, 3 H), 1.95-2.08(m, 1 H), 2.87 (t, J = 6.1 Hz,2 H), 3.40 (t, J = 6.1 Hz, 2 H),4.30 (s, 2 H), 7.11-7.29 (m, 9 H),8.32 (s, 1 H), 12.32 (s, 1 H)

TABLE 2-108 Example Structural formula NMR 2-536 (DMSO-d6-300)1.25 (d, J = 6.8 Hz, 3 H), 1.96 (dq,J = 6.8, 10.2 Hz, 1 H), 2.34-2.42 (m,4 H), 2.83 (d, J = 10.2 Hz, 1 H), 3.01-3.10(m, 4 H), 3.40 (s, 2 H), 3.73 (s,3 H), 6.87 (d, J = 9.0 Hz, 2 H), 7.14-7.29(m, 5 H), 7.19 (d, J = 9.0 Hz,2 H), 8.13 (brs, 1 H) 2-537 (DMSO-d6-300)1.25 (d, J = 6.8 Hz, 3 H), 1.97 (dq,J = 6.8, 10.5 Hz, 1 H), 2.41-2.54 (m,4 H), 2.85 (d, J = 10.5 Hz, 1 H), 3.02-3.15(m, 6 H), 6.22-6.32 (m, 1 H),6.54 (d, J = 16.2 Hz, 1 H), 7.14-7.36(m, 8 H), 7.39-7.46 (m, 2 H),8.16 (brs, 1 H) 2-538 (CD2Cl2-400)1.18-1.20 (m, 3 H), 1.96-2.00 (m,1 H), 2.92 (d, J = 10.4 Hz, 1 H),4.53 (s, 4 H), 7.05-7.24 (m, 8 H) 2-539 (MeOH-d4-400)1.74-1.81 (m, 1 H), 3.06 (d,J = 12.3 Hz, 1 H), 3.37 (s, 3 H), 3.77-3.91(m, 2 H), 7.15-7.30 (m, 5 H),7.63-7.73 (m, 3 H) 2-540 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 1.98 (dq,J = 10.2, 6.8 Hz, 1 H), 2.31-2.47 (m,2 H), 2.78 (d, J = 10.2 Hz, 1 H), 3.46-3.72(m, 6 H), 7.13-7.31 (m, 6 H),7.32-7.49 (m, 1 H), 7.50-7.71 (m,2 H), 7.52 (d, J = 3.8 Hz, 1 H),7.56 (d, J = 3.8 Hz, 1 H), 9.03 (s,1 H), 12.30 (brs, 1 H)

TABLE 2-109 Example Structural formula NMR 2-541 (DMSO-d6-300)1.21 (d, J = 6.4 Hz, 3 H), 1.82 (dq,J = 10.5, 6.4 Hz, 1 H), 2.64 (d,J = 10.5 Hz, 1 H), 2.91 (t, J = 7.5 Hz,2 H), 3.13 (t, J = 7.5 Hz, 2 H),6.84 (d, J = 3.4 Hz, 1 H), 7.07-7.30(m, 10 H), 7.36 (d, J = 3.4 Hz,1 H) 2-542 (MeOH-d4-400)1.38 (d, J = 6.5 Hz, 3 H), 2.19-2.23(m, 1 H), 2.95 (d, J = 10.2 Hz,1 H), 6.54 (t, J = 2.1 Hz, 1 H), 7.16-7.30(m, 6 H), 7.51 (d, J = 4.2 Hz,1 H), 7.70 (d, J = 2.1 Hz, 1 H),8.23 (d, J = 2.1 Hz, 1 H) 2-543 (DMSO-d6-300)1.26 (d, J = 6.6 Hz, 3 H), 1.91-2.06(m, 1 H), 2.78 (d, J = 10.6 Hz,1 H), 7.14-7.30 (m, 5 H), 7.35 (d,J = 4.0 Hz, 1 H), 7.48 (d, J = 4.0 Hz,1 H), 7.87 (s, 1 H), 8.79 (s, 1 H),9.03 (brs, 1 H), 12.27 (brs, 1 H) 2-544 (DMSO-d6-300)1.37-1.42 (m, 4 H), 2.09 (d,J = 5.7 Hz, 1 H), 7.11-7.27 (m, 5 H),7.49 (d, J = 8.3 Hz, 1 H), 7.52-7.59(m, 3 H), 7.88 (d, J = 1.5 Hz,1 H), 9.19 (brs, 1 H), 12.12 (brs,1 H) 2-545 (MeOH-d4-300)1.37 (d, J = 6.6 Hz, 3 H), 2.21 (dq,J = 10.6, 6.6 Hz, 1 H), 2.95 (d,J = 10.6 Hz, 1 H), 5.40 (d, J = 2.2 Hz,1 H), 5.84 (d, J = 2.2 Hz, 1 H), 7.11-7.30(m, 6 H), 7.50 (d, J = 4.0 Hz,1 H), 7.92 (s, 1 H), 8.44 (s, 1 H)

TABLE 2-110 Example Structural formula NMR 2-546 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 2.01 (dq,J = 10.2, 6.8 Hz, 1 H), 2.46 (s, 3 H),2.79 (d, J = 10.2 Hz, 1 H), 7.14-7.31(m, 5 H), 7.51 (d, J = 4.1 Hz,1 H), 7.54 (d, J = 4.1 Hz, 1 H),8.21 (s, 1 H), 9.10 (brs, 1 H),9.27 (s, 1 H), 12.30 (brs, 1 H) 2-547 (DMSO-d6-300)1.26 (d, J = 6.4 Hz, 3 H), 1.37 (d,J = 6.4 Hz, 3 H), 1.99 (dq, J = 10.5,6.4 Hz, 1 H), 2.78 (d, J = 10.5 Hz,1 H), 4.74 (dq, J = 4.9, 6.4 Hz, 1 H),5.14 (d, J = 4.9 Hz, 1 H), 7.14-7.28(m, 5 H), 7.30 (d, J = 4.1 Hz,1 H), 7.46 (d, J = 4.1 Hz, 1 H),7.68 (s, 1 H), 8.38 (s, 1 H),8.99 (brs, 1 H), 12.27 (brs, 1 H) 2-548 (MeOH-d4-400)1.29 (s, 3 H), 2.15 (m, 1 H), 2.93-2.96(d, J = 10.8 Hz, 1 H), 4.55-4.63(m, 4 H), 6.67-7.28 (m, 8 H) 2-549 (MeOH-d4-400)1.29 (t, J = 6.4 Hz, 3 H), 2.03-2.13(m, 3 H), 2.99 (t, J = 9.7 Hz,1 H), 3.40-3.50 (m, 4 H), 4.17-4.24(m, 1 H), 4.41-4.50 (m, 2 H),7.16-7.33 (m, 9 H) 2-550 (MeOH-d4-400)1.30 (t, J = 7.04 Hz, 3 H), 2.04-2.13(m, 3 H), 2.99 (dd, J = 10.5,13.1 Hz, 1 H), 3.41-3.48 (m, 4 H),4.19-4.22 (m, 1 H), 4.41-4.51 (m,2 H), 7.15-7.37 (m, 9 H)

TABLE 2-111 Example Structural formula NMR 2-551 (MeOH-d4-400)1.29 (t, J = 6.44 Hz, 3 H), 2.06-2.16 (m, 3 H), 3.00 (dd, J = 10.5,12.9 Hz, 1 H), 3.43-3.56 (m, 4 H),4.26-4.30 (m, 1 H), 4.44-4.58 (m,2 H), 7.13-7.52 (m, 8 H) 2-552 (MeOH-d4-400)1.19-1.38 (m, 9 H), 2.18-2.22 (m,1 H), 3.00 (d, J = 10.5 Hz, 1 H), 3.70-3.76 (m, 1 H), 4.72-4.85 (m, 4 H),7.16-7.44 (m, 8 H) 2-553 (MeOH-d4-400)1.29 (t, J = 6.3 Hz, 3 H), 2.06-2.17 (m, 3 H), 3.00 (dd, J = 4.9,10.4 Hz, 1 H), 3.39-3.54 (m, 4 H),4.24-4.28 (m, 1 H), 4.45-4.58 (m,2 H), 7.16-7.47 (m, 8 H) 2-554 (DMSO-d6-400)1.65 (dd, J = 10.0, 5.8 Hz, 1 H),2.02 (dd, J = 8.6, 5.8 Hz, 1 H),2.79 (t, J = 9.3 Hz, 1 H), 7.14-7.26 (m, 5 H), 8.03-8.07 (m, 2 H),8.32 (dd, J = 8.8, 2.3 Hz, 1 H),8.77 (d, J = 2.3 Hz, 1 H), 8.88 (d,J = 1.4 Hz, 1 H), 9.23 (s, 1 H),12.13 (brs, 1 H) 2-555 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 1.35 (t,J = 7.2 Hz, 3 H), 2.01 (dd, J = 10.5,6.8 Hz, 1 H), 2.80 (d, J = 10.5 Hz,1 H), 4.41 (q, J = 7.0 Hz, 2 H), 7.16-7.30 (m, 5 H), 7.66 (d, J = 3.8 Hz,1 H), 7.87 (d, J = 4.1 Hz, 1 H),7.99 (s, 1 H), 9.22 (s, 1 H),12.32 (brs, 1 H)

TABLE 2-112 Example Structural formula NMR 2-556 (DMSO-d6-300)1.27 (d, J = 6.4 Hz, 3 H), 2.05 (dq,J = 10.5, 6.4 Hz, 1 H), 2.83 (d,J = 10.5 Hz, 1 H), 7.13-7.32 (m, 5 H),8.17 (d, J = 8.7 Hz, 1 H), 8.39 (s,1 H), 8.39 (dd, J = 8.7, 1.9 Hz, 1 H),8.85 (d, J = 1.9 Hz, 1 H), 9.17 (s,1 H), 9.30 (s, 1 H), 12.24 (s, 1 H) 2-557 (DMSO-d6-400)1.25 (d, J = 7.0 Hz, 3 H), 2.02 (dq,J = 10.2, 7.0 Hz, 1 H), 2.80 (d,J = 10.2 Hz, 1 H), 7.13-7.28 (m, 5 H),8.05 (s, 1 H), 8.07 (d, J = 8.8 Hz,1 H), 8.32 (dd, J = 8.8, 2.3 Hz, 1 H),8.78 (d, J = 2.3 Hz, 1 H), 8.89 (s,1 H), 9.11 (s, 1 H), 12.24 (brs, 1 H) 2-558 (DMSO-d6-400)1.65 (dd, J = 9.3, 5.8 Hz, 1 H),2.02 (dd, J = 9.3, 5.8 Hz, 1 H),2.79 (t, J = 9.3 Hz, 1 H), 7.13-7.27 (m, 5 H), 8.13 (d, J = 8.8 Hz,1 H), 8.37 (dd, J = 8.8, 2.3 Hz, 1 H),8.37 (s, 1 H), 8.81 (d, J = 2.3 Hz,1 H), 9.27 (s, 2 H), 12.11 (brs, 1 H) 2-559 MeOH-d4-300)1.32-1.46 (m, 2 H), 1.68-1.85 (m,1 H), 1.73 (d, J = 6.0 Hz, 1 H), 1.91-2.06 (m, 1 H), 2.18 (d, J = 6.0 Hz,1 H), 3.19 (s, 3 H), 3.21-3.34 (m,2 H), 7.09-7.26 (m, 5 H), 7.37 (d,J = 3.0 Hz, 1 H), 7.43 (d, J = 9.0 Hz,2 H), 7.55 (d, J = 3.0 Hz, 1 H),7.65 (d, J = 9.0 Hz, 2 H) 2-560 (MeOH-d4-300)1.37-1.42 (m, 2 H), 1.73 (d,J = 5.9 Hz, 1 H), 1.74-1.80 (m, 1 H),1.96-1.98 (m, 1 H), 2.17 (d,J = 5.9 Hz, 1 H), 3.20 (s, 3 H), 7.14-7.19 (m, 6 H), 7.45 (d, J = 4.0 Hz,1 H), 7.66 (s, 1 H), 8.38 (s, 1 H)

TABLE 2-113 Example Structural formula NMR 2-561 (MeOH-d4-300)1.36 (d, J = 7.0 Hz, 3 H), 2.17-2.20 (m, 1 H), 2.92 (d, J = 10.3 Hz,1 H), 4.55 (s, 2 H), 7.12 (d,J = 4.0 Hz, 1 H), 7.23-7.24 (m, 5 H),7.49 (d, J = 4.4 Hz, 1 H), 7.66 (s,1 H), 8.15 (s, 1 H) 2-562 (DMSO-d6-300)1.37 (d, J = 7.5 Hz, 1 H), 1.38 (s,3 H), 2.08 (d, J = 5.3 Hz, 1 H), 6.69-6.77 (m, 1 H), 7.16-7.23 (m, 6 H),7.50-7.53 (m, 2 H), 9.27 (brs, 1 H),12.11 (brs, 1 H) 2-563 (DMSO-d6-300)1.34 (d, J = 5.7 Hz, 1 H), 1.38 (s,3 H), 2.09 (d, J = 5.7 Hz, 1 H), 6.10-6.14 (m, 1 H), 7.13-7.31 (m, 6 H),7.39 (d, J = 4.1 Hz, 1 H), 7.54 (d,J = 3.8 Hz, 1 H), 9.30 (brs, 1 H),12.12 (brs, 1 H) 2-564 (DMSO-d6-300)1.37-1.43 (m, 1 H), 1.40 (s, 3 H),2.10 (d, J = 5.3 Hz, 1 H), 4.59 (d,J = 5.3 Hz, 2 H), 5.53 (t, J = 5.3 Hz,1 H), 7.13-7.27 (m, 5 H), 7.49 (d,J = 8.3 Hz, 1 H), 7.53-7.55 (m, 2 H),7.65 (dd, J = 8.3, 2.3 Hz, 1 H),7.81 (d, J = 2.3 Hz, 1 H), 9.19 (s,1 H), 12.09 (s, 1 H) 2-565 (DMSO-d6-300)1.26 (d, J = 6.8 Hz, 3 H), 1.99 (dq,J = 10.2, 6.8 Hz, 1 H), 2.78 (d,J = 10.2 Hz, 1 H), 4.59 (d, J = 5.3 Hz,2 H), 5.52 (t, J = 5.3 Hz, 1 H), 7.17-7.30 (m, 5 H), 7.49 (d, J = 8.3 Hz,1 H), 7.53 (d, J = 3.8 Hz, 1 H),7.56 (d, J = 3.8 Hz, 1 H), 7.64 (dd,J = 8.3, 2.3 Hz, 1 H), 7.81 (d,J = 2.3 Hz, 1 H), 9.04 (s, 1 H),12.30 (s, 1 H)

TABLE 2-114 Example Structural formula NMR 2-566 (CDCl3-300)1.55 (s, 4 H), 1.98 (d, J = 5.7 Hz,1 H), 2.24 (d, J = 5.7 Hz, 1 H),5.87 (s, 1 H), 7.07-7.13 (m, 2 H),7.16-7.35 (m, 5 H), 7.39-7.45 (m,1 H), 7.49-7.58 (m, 2 H) 2-567 (CDCl3-300)1.56 (s, 3 H), 1.98 (d, J = 6.0 Hz,1 H), 2.26 (d, J = 6.0 Hz, 1 H),5.90 (s, 1 H), 7.07-7.14 (m, 2 H),7.19-7.28 (m, 3 H), 7.30-7.36 (m,1 H), 7.58-7.63 (m, 1 H), 7.65-7.74 (m, 4 H) 2-568 (DMSO-d6-300)1.28 (d, J = 5.3 Hz, 1 H), 1.35 (s,3 H), 2.03 (d, J = 5.3 Hz, 1 H),4.04 (s, 2 H), 7.08-7.26 (m, 5 H),7.50 (dd, J = 8.1, 2.1 Hz, 1 H),7.73 (d, J = 2.1 Hz, 1 H), 7.80 (dd,J = 8.1, 2.1 Hz, 1 H), 7.98 (d,J = 2.1 Hz, 1 H), 8.03 (d, J = 8.1 Hz,1 H), 8.09 (d, J = 8.1 Hz, 1 H),8.87 (s, 1 H) 2-569 (DMSO-d6-300)1.22 (d, J = 6.4 Hz, 3 H), 1.88 (d,J = 38.4 Hz, 1 H), 2.66 (d, J = 10.9 Hz,1 H), 4.04 (s, 2 H), 7.13-7.28 (m,5 H), 7.50 (dd, J = 8.3, 1.9 Hz, 1 H),7.72 (d, J = 1.9 Hz, 1 H), 7.84 (dd,J = 8.3, 1.9 Hz, 1 H), 8.00 (d,J = 1.9Hz, 1N), 8.02 (d, J = 8.3 Hz,1 H), 8.09 (d, J = 8.3 Hz, 1 H),8.72 (s, 1 H) 2-570 (DMSO-d6-300)1.27 (d, J = 6.4 Hz, 3 H), 1.99 (dd,J = 10.5, 6.0 Hz, 1 H), 2.79 (d,J = 9.8 Hz, 1 H), 7.02 (t, J = 7.0 Hz,1 H), 7.16-7.31 (m, 5 H), 7.39 (t,J = 7.9 Hz, 1 H), 7.56 (q, J = 3.9 Hz,2 H), 7.64 (d, J = 9.4 Hz, 1 H),8.50 (s, 1 H), 8.58 (d, J = 7.2 Hz,1 H), 9.02 (s, 1 H), 12.24 (brs, 1 H)

TABLE 2-115 Example Structural formula NMR 2-571 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 2.00 (dd,J = 9.8, 6.8 Hz, 1 H), 2.79 (d,J = 10.2 Hz, 1 H), 3.59 (brs, 2 H),7.11 (t, J = 5.5 Hz, 1 H), 7.16-7.30 (m, 4 H), 7.59 (dd, J = 9.4,3.8 Hz, 2 H), 8.42 (s, 1 H), 8.53-8.60 (m, 1 H), 8.93-9.03 (m, 2 H),12.25 (brs, 1 H) 2-572 (DMSO-d6-300)1.39-1.42 (m, 1 H), 1.40 (s, 3 H),2.10 (d, J = 5.7 Hz, 1 H), 7.11-7.28 (m, 5 H), 7.59 (d, J = 3.8 Hz,1 H), 7.70 (d, J = 3.8 Hz, 1 H),7.81 (d, J = 8.3 Hz, 2 H), 7.95 (d,J = 8.3 Hz, 2 H), 9.24 (brs, 1 H),12.12 (brs, 1 H) 2-573 (DMSO-d6-300)1.39-1.42 (m, 1 H), 1.40 (s, 3 H),2.10 (d, J = 5.3 Hz, 1 H), 2.60 (s,3 H), 7.10-7.28 (m, 5 H), 7.58 (d,J = 4.1 Hz, 1 H), 7.70 (d, J = 4.1 Hz,1 H), 7.87 (d, J = 8.3 Hz, 2 H),8.02 (d, J = 8.3 Hz, 2 H), 9.23 (brs,1 H), 12.11 (brs, 1 H) 2-574 (DMSO-d6-300)1.38-1.42 (m, 1 H), 1.39 (s, 3 H),2.08 (d, J = 4.1 Hz, 1 H), 4.53 (s,2 H), 7.10-7.27 (m, 5 H), 7.39 (d,J = 8.3 Hz, 2 H), 7.50 (d, J = 3.8 Hz,1 H), 7.53 (d, J = 3.8 Hz, 1 H),7.67 (d, J = 8.3 Hz, 2 H), 9.14 (brs,1 H), 12.09 (brs, 1 H) 2-575 (DMSO-d6-300)1.37-1.44 (m, 1 H), 1.40 (s, 3 H),2.09 (d, J = 5.7 Hz, 1 H), 3.73 (dt,J = 4.9, 5.5 Hz, 2 H), 4.06 (t,J = 4.9 Hz, 2 H), 4.86 (t, J = 5.5 Hz,1 H), 6.96-7.02 (m, 1 H), 7.13-7.29 (m, 7 H), 7.33-7.40 (m, 1 H),7.53 (d, J = 3.8 Hz, 1 H), 7.56 (d,J = 3.8 Hz, 1 H), 9.16 (s, 1 H),12.10 (s, 1 H)

TABLE 2-116 Example Structural formula NMR 2-576 (DMSO-d6-300)1.37-1.43 (m, 1 H), 1.39 (s, 3 H),1.88 (tt, J = 6.2, 6.4 Hz, 2 H),2.09 (d, J = 5.7 Hz, 1 H), 3.53-3.60 (m, 2 H), 4.10 (t, J = 6.4 Hz,2 H), 4.54 (brs, 1 H), 6.95-7.01 (m,1 H), 7.11-7.28 (m, 7 H), 7.32-7.39 (m, 1 H), 7.53 (d, J = 3.8 Hz,1 H), 7.56 (d, J = 3.8 Hz, 1 H),9.15 (s, 1 H), 12.10 (s, 1 H) 2-577 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 2.01 (dq,J = 10.2, 6.8 Hz, 1 H), 2.80 (d,J = 10.2 Hz, 1 H), 7.14-7.32 (m, 5 H),7.50 (d, J = 4.1 Hz, 1 H), 7.54 (d,J = 4.1 Hz, 1 H), 8.27 (s, 1 H),9.11 (brs, 1 H), 9.29 (s, 1 H),12.26 (brs, 1 H) 2-578 (MeOH-d4-300)1.39 (d, J = 6.8 Hz, 3 H), 2.23 (dq,J = 10.5, 6.8 Hz, 1 H), 2.97 (d,J = 10.5 Hz, 1 H), 7.18-7.30 (m, 5 H),7.40 (s, 1 H), 7.62-7.68 (m, 2 H) 2-579 (CDCl3-300)1.33 (d, J = 6.8 Hz, 3 H), 2.22-2.33 (m, 1 H), 3.03 (d, J = 10.9 Hz,1 H), 7.13-7.30 (m, 6 H), 7.44 (d,J = 3.8 Hz, 1 H), 7.65 (d, J = 3.8 Hz,1 H) 2-580 (CDCl3-300)1.33 (d, J = 6.0 Hz, 3 H), 2.27-2.39 (m, 1 H), 3.06 (d, J = 12.0 Hz,1 H), 5.98 (brs, 1 H), 7.09 (d,J = 6.0 Hz, 1 H), 7.11-7.29 (m, 5 H),7.55 (d, J = 6.0 Hz, 1 H), 7.96 (s,1 H), 8.30 (s, 1 H)

TABLE 2-117 Example Structural formula NMR 2-581 (DMSO-d6-300)1.35-1.43 (m, 4 H), 2.09 (d,J = 5.3 Hz, 1 H), 7.11 (s, 5 H), 7.11-7.29 (m, 5 H), 7.46-7.62 (m, 2 H),7.55 (d, J = 3.8 Hz, 1 H), 7.59 (d,J = 3.8 Hz, 1 H), 7.84-7.95 (m, 1 H),9.20 (s, 1 H), 12.10 (brs, 1 H) 2-582 (DMSO-d6-300)1.35-1.42 (m, 1 H), 1.39 (s, 3 H),2.06 (d, J = 6.0 Hz, 1 H), 6.83 (d,J = 8.7 Hz, 2 H), 7.10-7.27 (m, 5 H),7.32 (d, J = 3.8 Hz, 1 H), 7.47 (d,J = 3.8 Hz, 1 H), 7.53 (d, J = 8.7 Hz,2 H), 9.07 (brs, 1 H), 9.84 (brs,1 H), 12.08 (brs, 1 H) 2-583 (DMSO-d6-300)1.37-1.46 (m, 1 H), 1.41 (s, 3 H),2.09 (d, J = 5.7 Hz, 1 H), 5.16 (brs,2 H), 6.63 (dd, J = 8.3, 7.2 Hz, 1 H),6.81 (d, J = 8.3 Hz, 1 H), 7.06-7.27 (m, 8 H), 7.51 (d, J = 4.1 Hz,1 H), 9.08 (brs, 1 H) 2-584 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 2.01 (dq,J = 10.5, 6.8 Hz, 1 H), 2.80 (d,J = 10.5 Hz, 1 H), 7.15-7.31 (m, 7 H),7.53 (d, J = 7.2 Hz, 1 H), 7.61-7.68 (m, 1 H), 7.64 (d, J = 3.8 Hz,1 H), 7.77 (d, J = 3.8 Hz, 1 H),9.12 (brs, 1 H), 12.30 (brs, 1 H),13.20 (brs, 1 H) 2-585 (DMSO-d6-300)0.99 (d, J = 5.3 Hz, 1 H), 1.16 (s,3 H), 1.99 (d, J = 5.7 Hz, 1 H), 7.13-7.21 (m, 5 H), 7.42 (t, J = 7.3 Hz,1 H), 7.54 (t, J = 7.5 Hz, 2 H), 7.80-7.82 (m, 3 H), 8.18 (d, J = 8.7 Hz,1 H), 8.47 (d, J = 1.9 Hz, 1 H),8.51 (s, 1 H), 9.44 (brs, 1 H),12.07 (brs, 1 H)

TABLE 2-118 Example Structural formula NMR 2-586 (DMSO-d6-300)1.41 (s, 3 H), 1.42 (d, J = 7.5 Hz,1 H), 2.12 (d, J = 5.7 Hz, 1 H),4.15 (s, 3 H), 7.13-7.27 (m, 5 H),7.54 (d, J = 4.1 Hz, 1 H), 7.63 (d,J = 3.8 Hz, 1 H), 8.11 (s, 1 H),9.31 (brs, 1 H), 12.09 (brs, 1 H) 2-587 (DMSO-d6-300)1.38 (d, J = 4.1 Hz, 1 H), 1.39 (s,3 H), 2.09 (d, J = 5.7 Hz, 1 H),4.10 (s, 3 H), 7.12-7.26 (m, 5 H),7.41 (d, J = 4.1 Hz, 1 H), 7.54 (d,J = 3.8 Hz, 1 H), 8.59 (s, 1 H),9.16 (brs, 1 H) 2-588 (CDCl3-300)1.30-1.50 (m, 2 H), 1.69 (d,J = 6.0 Hz, 1 H), 1.82 (t, J = 7.5 Hz,2 H), 2.08 (d, J = 6.0 Hz, 1 H), 3.20-3.34 (m, 2 H), 3.24 (s, 3 H),6.73 (brs, 1 H), 6.99-7.10 (m, 3 H),7.14-7.22 (m, 3 H), 7.46 (d,J = 6.0 Hz, 1 H), 7.60 (d, J = 6.0 Hz,1 H) 2-589 (CDCl3-300)1.55 (s, 3 H), 1.98 (d, J = 6.0 Hz,1 H), 2.24 (d, J = 6.0 Hz, 1 H),5.84 (s, 1 H), 7.00-7.13 (m, 4 H),7.17-7.35 (m, 5 H), 7.53 (d,J = 4.1 Hz, 1 H) 2-590 (CDCl3-300)1.33 (d, J = 7.2 Hz, 3 H), 2.26-2.40 (m, 1 H), 3.09 (d, J = 10.9 Hz,1 H), 5.82 (s, 1 H), 7.14-7.31 (m,6 H), 7.62 (d, J = 4.1 Hz, 1 H), 7.67-7.70 (m, 4 H)

TABLE 2-119 Example Structural formula NMR 2-591 (CDCl3-300)1.37 (d, J = 6.4 Hz, 3 H), 2.32-2.45 (m, 1 H), 3.11 (d, J = 10.5 Hz,1 H), 6.19 (s, 1 H), 7.22 (d,J = 59.5 Hz, 4 H), 7.39-7.54 (m, 4 H),7.60 (d, J = 4.1 Hz, 1 H), 7.86 (d,J = 8.3 Hz, 1 H), 8.00 (d, J = 8.3 Hz,1 H) 2-592 (CDCl3-300)1.38 (s, 3 H), 1.99 (d, J = 6.4 Hz,2 H), 2.03 (d, J = 6.4 Hz, 2 H),3.88 (s, 3 H), 4.78 (d, J = 13.6 Hz,1 H), 4.91 (d, J = 13.6 Hz, 1 H), 6.63-6.70 (m, 3 H), 6.92-6.98 (m, 2 H),7.02-7.13 (m, 3 H), 7.40 (d,J = 3.8 Hz, 1 H), 7.54 (dd, J = 8.3,2.3 Hz, 1 H), 7.73 (d, J = 2.3 Hz, 1 H) 2-593 (CDCl3-300)1.50 (s, 3 H), 1.80 (d, J = 6.0 Hz,1 H), 2.16 (d, J = 6.0 Hz, 1 H),5.95 (s, 1 H), 7.01-7.08 (m, 2 H),7.18-7.24 (m, 3 H), 7.35 (d,J = 4.1 Hz, 1 H), 7.43-7.51 (m, 2 H),7.58 (d, J = 4.1 Hz, 1 H), 7.68 (dd,J = 8.5, 6.6 Hz, 1 H) 2-594 (CDCl3-300)1.53 (s, 3 H), 1.97 (d, J = 6.0 Hz,1 H), 2.19 (d, J = 6.0 Hz, 1 H),4.77 (s, 2 H), 5.79 (s, 1 H), 7.02-7.09 (m, 2 H), 7.15-7.30 (m, 5 H),7.37 (dd,J = 8.1, 1.7 Hz, 1 H),7.48 (d, J = 7.5 Hz, 1 H), 7.51 (d,J = 4.1 Hz, 1 H) 2-595 (DMSO-d6-300)1.36-1.43 (m, 4 H), 2.08 (d,J = 5.7 Hz, 1 H), 3.90 (s, 3 H), 7.10-7.27 (m, 6 H), 7.48-7.52 (m, 2 H),7.65 (dd, J = 8.7, 2.3 Hz, 1 H),7.82 (d, J = 2.3 Hz, 1 H), 9.15 (brs,1 H), 12.09 (brs, 1 H)

TABLE 2-120 Example Structural formula NMR 2-596 (DMSO-d6-400)1.21 (d, J = 6.7 Hz, 3 H), 1.84 (dq,J = 10.2, 6.7 Hz, 3 H), 2.62 (d,J = 10.2 Hz, 1 H), 7.12-7.27 (m, 5 H),7.48-7.81 (m, 5 H), 8.01 (brs, 1 H),8.18 (d, J = 6.5 Hz, 2 H), 8.64 (s,1 H), 12.10 (s, 1 H), 13.30 (s, 1 H) 2-597 (DMSO-d6-300)1.30 (s, 3 H), 1.45 (d, J = 6.8 Hz,3 H), 2.32 (q, J = 6.8 Hz, 1 H), 7.18-7.32 (m, 5 H), 7.34 (d, J = 3.8 Hz,1 H), 7.78 (d, J = 3.8 Hz, 1 H),8.15 (s, 1 H), 8.49 (brs, 1 H),12.50 (brs, 1 H) 2-598 (DMSO-d6-300)1.15 (d, J = 6.8 Hz, 3 H), 1.30 (s,3 H), 2.39 (q, J = 6.8 Hz, 1 H), 7.13-7.27 (m, 5 H), 7.68 (d, J = 4.1 Hz,1 H), 7.83 (d, J = 4.1 Hz, 1 H),8.16 (s, 1 H), 8.96 (s, 1 H),12.08 (brs, 1 H) 2-599 (DMSO-d6-300)1.40 (s, 3 H), 1.43 (d, J = 5.5 Hz,1 H), 2.10 (d, J = 5.5 Hz, 1 H), 7.11-7.28 (m, 5H), 7.51 (d, J = 4.0 Hz,1 H), 7.53 (d, J = 4.0 Hz, 1 H),8.26 (s, 1 H), 9.24 (brs, 1 H),9.30 (s, 1 H), 12.09 (brs, 1 H) 2-600 (DMSO-d6-300)1.36-1.44 (m, 1 H), 1.38 (s, 3 H),2.01-2.09 (m, 1 H), 7.08-7.26 (m,8 H), 7.38 (d, J = 3.8 Hz, 1 H),7.50 (d, J = 3.8 Hz, 1 H)

TABLE 2-121 Example Structural formula NMR 2-601 (DMSO-d6-300)1.37-1.43 (m, 1 H), 1.39 (s, 3 H),2.08 (d, J = 5.3 Hz, 1 H), 7.03-7.08 (m, 1 H), 7.13-7.27 (m, 6 H),7.44-7.48 (m, 1 H), 7.51 (d,J = 3.8 Hz, 1 H) 2-602 (CDCl3-300)1.51 (s, 3 H), 1.85 (d, J = 6.0 Hz,1 H), 2.21 (d, J = 6.0 Hz, 1 H),3.17 (s, 3 H), 6.24 (brs, 1 H), 6.99-7.11 (m, 3 H), 7.15-7.23 (m, 3 H),7.50 (d, J = 6.0 Hz, 1 H), 8.00 (s,1 H), 8.42 (s, 1 H) 2-603 (CDCl3-300)1.58 (s, 3 H), 2.04 (d, J = 6.0 Hz,1 H), 2.25 (d, J = 6.0 Hz, 1 H),4.62 (s, 2 H), 6.04 (brs, 1 H),6.84 (d, J = 6.0 Hz, 1 H), 7.09-7.28 (m, 5 H), 7.43 (d, J = 6.0 Hz,1 H), 7.63 (s, 1 H), 7.77 (s, 1 H) 2-604 (DMSO-d6-300)1.27 (d, J = 6.8 Hz, 3 H), 2.02 (dq,J = 10.5, 6.8 Hz, 1 H), 2.79 (d,J = 10.5 Hz, 1 H), 7.14-7.31 (m, 7 H),7.54-7.71 (m, 1 H), 7.65 (d,J = 3.8 Hz, 1 H), 7.80 (d, J = 3.8 Hz,1 H) 2-605 (MeOH-d4-300)2.08 (dd, J = 9.4, 5.7 Hz, 1 H),2.30 (dd, J = 8.3, 5.7 Hz, 1 H),2.75 (dd, J = 9.4, 8.3 Hz, 1 H), 7.18-7.30 (m, 6 H), 7.41 (d, J = 4.1 Hz,1 H), 7.72 (s, 1 H), 8.45 (s, 1 H)

TABLE 2-122 Example Structural formula NMR 2-606 (DMSO-d6-300)1.40 (s, 3 H), 1.41 (d, J = 5.7 Hz,1 H), 2.10 (d, J = 5.7 Hz, 1 H),3.92 (td, J = 13.9, 6.2 Hz, 2 H),5.64 (t, J = 6.2 Hz, 1 H), 7.11-7.27 (m, 5 H), 7.52-7.65 (m, 4 H),7.78-7.88 (m, 2 H), 9.20 (brs, 1 H),12.10 (brs, 1 H) 2-607 (DMSO-d6-300)1.28 (d, J = 6.8 Hz, 3 H), 2.01 (dq,J = 10.2, 6.8 Hz, 1 H), 2.80 (d,J = 10.2 Hz, 1 H), 3.81 (s, 3 H),6.87 (d, J = 8.7 Hz, 1 H), 7.07 (s,1 H), 7.15-7.32 (m, 5 H), 7.49 (d,J = 8.7 Hz, 1 H), 7.62 (d, J = 3.8 Hz,1 H), 7.71 (d, J = 3.8 Hz, 1 H),9.12 (s, 1 H), 12.30 (brs, 1 H) 2-608 (DMSO-d6-300)1.39 (s, 3 H), 1.45 (d, J = 5.5 Hz,1 H), 2.11 (d, J = 5.5 Hz, 1 H),7.19 (d, J = 8.4 Hz, 2 H), 7.30 (d,J = 8.4 Hz, 2 H), 7.68 (d, J = 4.0 Hz,1 H), 7.85 (d, J = 4.0 Hz, 1 H)8.15 (s, 1 H) 2-609 (DMSO-d6-300)1.16 (d, J = 6.6 Hz, 3 H), 1.91 (dd,J = 10.6, 6.6 Hz, 1 H), 2.12 (t,J = 19.8 Hz, 3 H), 2.57 (d, J = 10.6 Hz,1 H), 7.00-7.10 (m, 6 H), 7.67 (d,J = 4.0 Hz, 2 H), 7.79 (d, J = 4.0 Hz,1 H) 2-610 (DMSO-d6-300)1.37 (s, 3 H), 1.39 (d, J = 5.7 Hz,1 H), 2.08 (d, J = 5.7 Hz, 1 H),3.67 (s, 3 H), 6.68-6.77 (m, 3 H),7.10-7.18 (m, 1 H), 7.66 (d,J = 4.1 Hz, 1 H), 7.84 (d, J = 4.1 Hz,1 H), 8.15 (s, 1 H), 9.36 (brs, 1 H),12.13 (brs, 1 H)

TABLE 2-123 Example Structural formula NMR 2-611 (DMSO-d6-300)1.40 (s, 3 H), 1.45 (d, J = 5.7 Hz,1 H), 2.14 (d, J = 5.7 Hz, 1 H), 6.91-7.06 (m, 3 H), 7.21-7.35 (m, 1 H),7.68 (d, J = 4.1 Hz, 1 H), 7.86 (d,J = 4.1 Hz, 1 H), 8.17 (s, 1 H),12.26 (s, 1 H), 12.26 (s, 1 H) 2-612 (DMSO-d6-300)1.40 (s, 3 H), 1.45 (d, J = 5.7 Hz,1 H), 2.13 (d, J = 5.7 Hz, 1 H), 7.10-7.33 (m, 4 H), 7.69 (d, J = 4.1 Hz,1 H), 7.86 (d, J = 4.1 Hz, 1 H),8.17 (s, 1 H), 9.34 (s, 1 H),12.31 (s, 1 H) 2-613 (DMSO-d6-300)1.36 (s, 3 H), 1.59 (d, J = 5.5 Hz,1 H), 2.02 (d, J = 5.5 Hz, 1 H),3.72 (s, 3 H), 6.74-6.88 (m, 2 H),7.05-7.15 (m, 2 H), 7.63 (d,J = 3.7 Hz, 1 H), 7.76 (d, J = 3.7 Hz,1 H), 7.89 (s, 1 H), 8.52 (brs, 1 H). 2-614 (DMSO-d6-300)1.44 (s, 3 H), 1.54 (d, J = 5.7 Hz,3.13 (s, 3 H), 7.51-7.56 (m, 2 H),7.67-7.76 (m, 2 H), 7.69 (d,J = 3.8 Hz, 1 H), 7.86 (d, J = 3.8 Hz,1 H), 8.17 (s, 1 H), 9.43 (brs, 1 H),12.34 (brs, 1 H) 2-615 (MeOH-d4-300)1.51 (s, 3 H), 1.89 (d, J = 6.0 Hz,1 H), 2.18 (d, J = 6.0 Hz, 1 H), 6.96-7.05 (m, 2 H), 7.17-7.24 (m, 2 H),7.62-7.67 (m, 3 H)

TABLE 2-124 Example Structural formula NMR 2-616 (DMSO-d6-300)1.35 (d, J = 16.2 Hz, 3 H), 1.66 (dd,J = 13.9, 5.3 Hz, 1 H), 2.05 (t,J = 7.0 Hz, 1 H), 7.13-7.37 (m, 4 H),7.68 (d, J = 3.0 Hz, 1 H), 7.84 (d,J = 1.5 Hz, 1 H), 8.15 (s, 1 H),9.28 (brs, 1 H), 12.15 (brs, 1 H) 2-617 (MeOH-d4-300)1.54 (s, 3 H), 1.85 (d, J = 5.7 Hz,1 H), 2.22 (d, J = 6.0 Hz, 1 H),7.29 (dd, J = 7.7, 5.1 Hz, 1 H), 7.62-7.66 (m, 3 H), 7.70 (dt, J = 8.0,1.7 Hz, 1 H), 8.30 (dd, J = 4.9,1.5 Hz, 1 H), 8.41 (d, J = 1.9 Hz, 1 H) 2-618 (DMSO-d6-300)1.40 (s, 3 H), 1.44 (d, J = 5.7 Hz,1 H), 2.14 (d, J = 5.7 Hz, 1 H), 6.92-7.05 (m, 3 H), 7.23-7.34 (m, 1 H),7.69 (d, J = 4.1 Hz, 1 H), 7.86 (d,J = 4.1 Hz, 1 H), 8.17 (s, 1 H),9.38 (s, 1 H), 12.28 (s, 1 H) 2-619 (DMSO-d6-300)1.40 (s, 3 H), 1.45 (d, J = 5.7 Hz,1 H), 2.13 (d, J = 5.7 Hz, 1 H), 7.10-7.33 (m, 4 H), 7.69 (d, J = 4.1 Hz,1 H), 7.86 (d, J = 4.1 Hz, 1 H),8.17 (s, 1 H), 9.36 (s, 1 H),12.30 (s, 1 H) 2-620 (DMSO-d6-300)1.40 (s, 3 H), 1.44 (d, J = 5.7 Hz,1 H), 2.13 (d, J = 5.7 Hz, 1 H),7.19 (d, J = 8.3 Hz, 2 H), 7.32 (d,J = 8.7 Hz, 2 H), 7.69 (d, J = 4.1 Hz,1 H), 7.86 (d, J = 3.8 Hz, 1 H),8.17 (s, 1 H), 9.39 (brs, 1 H),12.22 (brs, 1 H)

TABLE 2-125 Example Structural formula NMR 2-621 (DMSO-d6-400)1.38 (s, 3 H), 1.42 (d, J = 5.6 Hz,1 H), 2.11 (d, J = 5.6 Hz, 1 H), 7.02-7.10 (m, 2 H), 7.15-7.23 (m, 2 H),7.67 (d, J = 3.7 Hz, 1 H), 7.85 (d,J = 3.7 Hz, 1 H), 8.16 (q, J = 0.9 Hz,1 H), 9.38 (brs, 1 H), 12.19 (brs,1 H) 2-622 (DMSO-d6-400)1.23 (d, J = 7.0 Hz, 3 H), 1.97 (dq,J = 10.2, 6.5 Hz, 1 H), 2.74 (d,J = 10.7 Hz, 1 H), 7.09-7.27 (m, 5 H),7.32-7.38 (m, 1 H), 7.43-7.49 (m,3 H), 7.71 (d, J = 9.7 Hz, 1 H), 7.93-7.97 (m, 2 H), 8.58 (s, 1 H), 9.12-9.09 (m, 1 H) 2-623 (DMSO-d6-400)1.31-1.39 (m, 6 H), 1.85 (q,J = 6.7 Hz, 1 H), 7.06-7.29 (m, 5 H),7.67 (d, J = 3.8 Hz, 1 H), 7.86 (d,J = 3.8 Hz, 1 H), 8.17 (s, 1 H),9.23 (brs, 1 H), 12.17 (brs, 1 H) 2-624 (DMSO-d6-300)1.35-1.37 (m, 6 H), 1.85 (q,J = 6.4 Hz, 1 H), 2.13 (t, J = 19.3 Hz,3 H), 7.08-7.28 (m, 5 H), 7.64 (d,J = 4.0 Hz, 1 H), 7.71 (s, 1 H),7.80 (d, J = 4.0 Hz, 1 H), 9.19 (s,1 H), 12.17 (s, 1 H) 2-625 (DMSO-d6-200)1.35-1.37 (m, 6 H), 1.85 (q,J = 6.4 Hz, 1 H), 2.13 (t, J = 19.3 Hz,3 H), 7.08-7.28 (m, 5 H), 7.64 (d,J = 4.0 Hz, 1 H), 7.71 (s, 1 H),7.80 (d, J = 4.0 Hz, 1 H), 9.19 (s,1 H), 12.17 (s, 1 H)

The following show the results of experiments performed with regard to the aggrecanase-1 inhibitory action, matrix metalloproteinase-1 (MMP-1) inhibitory action and matrix metalloproteinase-13 (MMP-13) inhibitory action of the compound of the present invention.

(Pharmacological Tests) EXPERIMENTAL EXAMPLE 1 Aggrecanase-1 Inhibitory Action

Particle Assay was used for determination of aggrecanase activity.

The enzyme and substrate were diluted with Tris-HCl buffer, and test compounds were diluted with dimethyl sulfoxide (DMSO).

Test compounds and the enzyme were added into 96-well plate, and polyacrylamide particles containing aggrecan were added as a substrate and the mixture was incubated at 37° C. for 15 hr.

After incubation, the supernatant was transferred to another plate, and mixed with 1,9-dimethylmethylene blue. The absorbence at 595 nm was measured to quantify the amount of glycosaminoglycan (GAG) released in the reaction supernatant. Whale chondroitin sulfate was used as the standard of GAG. The inhibitory activity of the compound in each well (%) was calculated based on the values of enzyme-free well and inhibitor-free well. The inhibitory activity of the compound was represented as TC₅₀(μM).

EXPERIMENTAL EXAMPLE 2 MMP-1 Inhibitory Action

For MMP-1 Assay, Type I collagen Activity Measurement kit (YAGAI YU-72013) modified to a 96-well plate format was used.

The principle of the kit is based on the property of collagen that becomes soluble in ethanol after being cleaved by MMP-1.

The enzyme and substrate were diluted with Tris-HCl buffer, and test compounds were diluted with dimethyl sulfoxide (DMSO).

The enzyme and test compounds were added into 96-well plate, and fluorescein isothiocianate (FITC)-labeled collagen type I was added as a substrate and the mixture was incubated at 37° C. for 3 hr.

The reaction was terminated by addition of Tris-HCl buffer containing ethanol. After centrifugation, the supernatant containing denatured substrate was transferred to another 96-well plate. The collagenase activity of MMP-1 was determined by measuring FITC fluorescence intensity (excitation wavelength 485 nm, emission wavelength 530 nm) of each well. The inhibitory activity of the compound in each well (%) was calculated based on the values of enzyme-free well and inhibitor-free well. The inhibitory activity of the compound was represented as IC₅₀(μM).

EXPERIMENTAL EXAMPLE 3

Inhibitory activity of tested compounds on MMP-13 was measured using MMP-13 specific fluorescent substrate with quencher.

The enzyme and substrate were diluted with Tris-HCl buffer, and test compounds were diluted with dimethyl sulfoxide (DMSO).

Test compounds and the enzyme (Recombinant Human MMP-13: R&D systems, 511-MM) were added into 96-well plate. The reaction was initiated by adding synthetic substrate (7-MCA-Pro-CHA-Gly-NVal-His-Ala-DPA: enzyme systems products, Met-06) into the plate. After incubation at 25° C. for 1 h, the reaction was terminated by addition of reaction terminating solution containing acetic acid. Fluorescence intensity of each well was measured (Ex: 325 nm, μm: 405 nm) and the MMP-13 inhibitory activity of the compound in each well (%) was calculated based on the values of enzyme-free well and inhibitor-free well. The inhibitory activity of the compound was represented as IC₅₀(μM).

The results of the aforementioned Experimental Examples 1 to 3 are shown in Tables 3-1 to 3-19. In the table, + means less than 1 μM, ++ means less than 0.1 μM, − means not less than 1 μM, −− means not less than 10 μM and blank column means “not tested”.

TABLE 3-1 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 1 + − 1-2 ++ − ++ 1-3 ++ − ++ 1-4 ++ − 1-7 + −− 1-10 + − + 1-11 + − + 1-12 + − ++ 1-13 + − 1-14 + −− 1-16 + − ++ 1-18 + − ++ 1-21 + − 1-26 + −− + 1-31 + −− 1-38 ++ −− ++ 1-40 + − ++ 1-41 + − ++ 1-42 + − 1-43 + − 1-44 + − 1-54 + − + 1-61 + − ++ 1-62 + − ++ 1-63 + − ++ 1-64 + − ++ 1-65 −− 1-66 + − ++ 1-68 + − ++ 1-69 ++ −− + 1-72 ++ − + 1-74 + − ++ 1-75 + − ++ 1-76 + −− ++ 1-80 ++ −− 1-83 + − ++ 1-84 + −− + 1-85 ++ − ++ 1-86 + − + 1-88 ++ −− + 1-90 + − ++

TABLE 3-2 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 1-91 ++ − ++ 1-94 ++ − ++ 1-98 + −− 1-100 + − 1-101 + −− 1-102 ++ − + 1-103 + −− + 1-104 + −− 1-105 + − 1-107 ++ − ++ 1-108 ++ − ++ 1-109 + −− + 1-110 + − 1-112 + − 1-113 ++ − + 1-114 + − 1-115 + − 1-116 + − 1-117 ++ − 1-118 ++ − 1-119 ++ − ++ 1-121 ++ − ++ 1-122 ++ − ++ 1-125 ++ −− 1-127 ++ − + 1-128 ++ − + 1-129 ++ − ++ 1-130 ++ − ++ 1-131 ++ − ++ 1-132 ++ − ++ 1-133 ++ − ++ 1-134 ++ − ++ 1-135 + − 1-136 ++ − ++ 1-137 + − 1-138 ++ − + 1-139 ++ −− + 1-145 + −− 1-146 ++ −− 1-147 + −−

TABLE 3-3 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2 − −− −− 2-2 −− −− −− 2-3 − −− − 2-4 ++ + ++ 2-5 + − ++ 2-6 ++ − + 2-7 ++ + ++ 2-8 ++ − ++ 2-9 ++ ++ ++ 2-10 ++ + ++ 2-11 − − − 2-12 ++ + ++ 2-13 ++ −− ++ 2-14 −− −− −− 2-15 −− −− − 2-16 −− −− + 2-17 − −− ++ 2-18 + − + 2-19 + −− + 2-20 + − ++ 2-21 + − + 2-22 ++ −− ++ 2-23 + −− + 2-24 + −− + 2-25 ++ −− + 2-26 + −− 2-27 + −− + 2-28 − −− 2-29 − ++ 2-30 − − 2-31 − − 2-32 ++ −− ++ 2-33 − + 2-34 − + 2-35 + −− + 2-36 + −− + 2-37 ++ −− ++ 2-38 − +

TABLE 3-4 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-39 + − ++ 2-40 + −− + 2-41 + −− + 2-42 ++ −− ++ 2-43 ++ + ++ 2-44 − −− − 2-45 − −− − 2-46 − −− − 2-47 − −− + 2-48 + −− − 2-49 − −− −− 2-50 − −− − 2-51 − −− − 2-52 + −− + 2-53 − −− − 2-54 − −− −− 2-55 − −− −− 2-56 ++ −− ++ 2-57 + −− ++ 2-58 + −− + 2-59 + −− + 2-60 −− −− − 2-61 + −− + 2-62 + −− + 2-63 ++ − ++ 2-64 −− −− − 2-65 + −− + 2-66 − −− − 2-67 −− −− + 2-68 − −− ++ 2-69 ++ − ++ 2-70 + −− 2-71 ++ −− + 2-72 ++ −− + 2-73 ++ −− + 2-74 + −− ++ 2-75 + −− + 2-76 ++ −− +

TABLE 3-5 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-77 ++ − + 2-78 ++ −− + 2-79 −− −− −− 2-80 −− −− −− 2-81 −− −− −− 2-82 −− −− −− 2-83 −− −− −− 2-84 ++ + ++ 2-85 + − ++ 2-86 ++ −− + 2-87 −− −− − 2-88 −− −− −− 2-89 − −− − 2-90 − − ++ 2-91 + −− + 2-92 ++ + ++ 2-93 −− −− − 2-94 −− −− −− 2-95 −− −− −− 2-96 −− −− + 2-97 −− −− −− 2-98 ++ − ++ 2-99 ++ + + 2-100 ++ + ++ 2-101 ++ − + 2-102 + + 2-103 −− −− −− 2-104 −− −− −− 2-105 −− −− −− 2-106 −− −− −− 2-107 ++ + ++ 2-108 ++ − ++ 2-109 ++ −− ++ 2-110 + − ++ 2-111 − −− + 2-112 + −− − 2-113 ++ + ++ 2-114 − + ++

TABLE 3-6 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-115 − + 2-116 −− −− −− 2-117 −− −− −− 2-118 − − 2-119 ++ + ++ 2-120 ++ + ++ 2-121 ++ + ++ 2-122 − + 2-123 + −− + 2-124 ++ − ++ 2-125 −− −− −− 2-126 −− −− −− 2-127 −− −− 2-128 −− −− −− 2-129 + −− + 2-130 − −− − 2-131 ++ − + 2-132 −− −− −− 2-133 −− −− + 2-134 −− −− + 2-135 − ++ 2-136 + − ++ 2-137 − + ++ 2-138 −− 2-139 − −− − 2-140 −− −− − 2-141 + − ++ 2-142 ++ − + 2-143 −− −− − 2-144 −− −− − 2-145 −− −− − 2-146 + −− + 2-147 − −− − 2-148 − −− + 2-149 − −− ++ 2-150 + − + 2-151 −− −− − 2-152 + −− ++

TABLE 3-7 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-153 −− −− − 2-154 − −− + 2-155 − −− + 2-156 − −− − 2-157 −− −− − 2-158 −− −− −− 2-159 −− −− −− 2-160 −− −− −− 2-161 −− −− − 2-162 −− −− −− 2-163 −− −− −− 2-164 −− −− −− 2-165 −− −− − 2-166 −− −− −− 2-167 + −− 2-168 + −− − 2-169 ++ − ++ 2-170 ++ −− ++ 2-171 + −− + 2-172 −− −− − 2-173 ++ − ++ 2-174 ++ − ++ 2-175 ++ − + 2-176 ++ −− ++ 2-177 − −− − 2-178 ++ −− + 2-179 ++ −− + 2-180 ++ −− ++ 2-181 ++ − ++ 2-182 ++ −− ++ 2-183 ++ − ++ 2-184 ++ − + 2-185 − −− + 2-186 − −− − 2-187 −− −− −− 2-188 ++ − ++ 2-189 ++ −− ++ 2-190 ++ − ++

TABLE 3-8 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-191 ++ −− ++ 2-192 + −− + 2-193 + −− + 2-194 + −− + 2-195 + −− + 2-196 ++ − ++ 2-197 + −− + 2-198 + −− + 2-199 + −− + 2-200 + −− + 2-201 + −− ++ 2-202 + −− + 2-203 + −− ++ 2-204 ++ −− + 2-205 ++ −− + 2-206 ++ − ++ 2-207 + −− + 2-208 ++ − ++ 2-209 ++ − ++ 2-210 + −− ++ 2-211 ++ −− ++ 2-212 ++ − + 2-213 ++ + ++ 2-214 ++ + ++ 2-215 ++ −− + 2-216 + −− + 2-217 + −− + 2-218 − −− 2-219 + − ++ 2-220 ++ − ++ 2-221 + − ++ 2-222 ++ − ++ 2-223 + −− + 2-224 ++ − ++ 2-225 − −− + 2-226 + −− + 2-227 ++ − + 2-228 + − +

TABLE 3-9 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-229 + −− + 2-230 + −− ++ 2-231 + − ++ 2-232 + − ++ 2-233 + − ++ 2-234 ++ − ++ 2-235 + − ++ 2-236 + − ++ 2-237 ++ − ++ 2-238 + − ++ 2-239 ++ − ++ 2-240 + − + 2-241 + − ++ 2-242 ++ − ++ 2-243 + − ++ 2-244 + −− + 2-245 − −− + 2-246 − −− + 2-247 −− −− −− 2-248 ++ − + 2-249 ++ −− + 2-250 + − ++ 2-251 + −− + 2-252 ++ − + 2-253 ++ − ++ 2-254 ++ − ++ 2-255 ++ − ++ 2-256 − −− −− 2-257 ++ − + 2-258 + − + 2-259 ++ − ++ 2-260 + − ++ 2-261 + −− + 2-262 ++ + ++ 2-263 ++ − + 2-264 ++ − ++ 2-265 + −− + 2-266 + − +

TABLE 3-10 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-267 ++ − ++ 2-268 ++ − ++ 2-269 ++ − ++ 2-270 ++ − ++ 2-271 − −− + 2-272 ++ −− ++ 2-273 ++ + ++ 2-274 ++ −− − 2-275 ++ − + 2-276 + − ++ 2-277 + − + 2-278 ++ + ++ 2-279 ++ + ++ 2-280 + −− ++ 2-281 ++ + ++ 2-282 ++ + ++ 2-283 + − ++ 2-284 ++ − ++ 2-285 + − − 2-286 ++ − ++ 2-287 ++ + ++ 2-288 ++ + ++ 2-289 + − + 2-290 ++ + ++ 2-291 ++ + ++ 2-292 ++ + ++ 2-293 ++ + ++ 2-294 ++ − ++ 2-295 ++ − ++ 2-296 − −− − 2-297 − −− − 2-298 ++ − ++ 2-299 ++ ++ ++ 2-300 + − ++ 2-301 ++ − ++ 2-302 ++ + ++ 2-303 ++ − ++ 2-304 + − +

TABLE 3-11 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-305 ++ − ++ 2-306 + − + 2-307 − −− − 2-308 + − + 2-309 + − + 2-310 + + ++ 2-311 + − + 2-312 − −− −− 2-313 + − + 2-314 − −− −− 2-315 + −− + 2-316 − −− −− 2-317 + − + 2-318 − −− −− 2-319 ++ − ++ 2-320 + − + 2-321 + − + 2-322 ++ − + 2-323 − − ++ 2-324 − −− − 2-325 − −− − 2-326 + − + 2-327 + + ++ 2-328 ++ ++ ++ 2-329 − −− − 2-330 − −− − 2-331 + − + 2-332 + − + 2-333 + − + 2-334 + − + 2-335 + − + 2-336 − −− − 2-337 + −− + 2-338 ++ − + 2-339 ++ − + 2-340 + −− − 2-341 ++ −− − 2-342 + − −

TABLE 3-12 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-343 − −− − 2-344 ++ −− + 2-345 ++ −− + 2-346 + −− + 2-347 ++ −− + 2-348 + −− + 2-349 ++ −− + 2-350 + − ++ 2-351 ++ + ++ 2-352 ++ − ++ 2-353 ++ + ++ 2-354 ++ − + 2-355 − − + 2-356 + + + 2-357 ++ − ++ 2-358 ++ − + 2-359 + − ++ 2-360 ++ −− + 2-361 − −− − 2-362 + −− ++ 2-363 − −− + 2-364 + + ++ 2-365 ++ + ++ 2-366 ++ + ++ 2-367 − −− − 2-368 + − + 2-369 ++ − ++ 2-370 ++ + ++ 2-371 − −− − 2-372 − −− − 2-373 − −− − 2-374 ++ + ++ 2-375 ++ + ++ 2-376 + −− + 2-377 + − + 2-378 + − + 2-379 + − + 2-380 + −− +

TABLE 3-13 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-381 + −− + 2-382 ++ + + 2-383 ++ + ++ 2-384 + −− ++ 2-385 + −− + 2-386 + − + 2-387 − −− + 2-388 + − + 2-389 ++ − ++ 2-390 + −− − 2-391 − −− + 2-392 − −− − 2-393 + − ++ 2-394 + − ++ 2-395 + −− + 2-396 + −− + 2-397 + −− + 2-398 + −− + 2-399 + − + 2-400 − − + 2-401 ++ + ++ 2-402 − −− 2-403 + + ++ 2-404 ++ + ++ 2-405 ++ −− + 2-406 ++ + ++ 2-407 ++ + ++ 2-408 ++ + ++ 2-409 + + ++ 2-410 ++ − − 2-411 ++ + ++ 2-412 ++ − ++ 2-413 ++ − + 2-414 + − + 2-415 − −− 2-416 + − + 2-417 + − 2-418 − −

TABLE 3-14 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-419 ++ + ++ 2-420 − −− − 2-421 − −− − 2-422 ++ + + 2-423 + + ++ 2-424 −− + + 2-425 −− −− − 2-426 + − ++ 2-427 −− + − 2-428 + − ++ 2-429 + − + 2-430 ++ − ++ 2-431 + − + 2-432 ++ − + 2-433 ++ + ++ 2-434 ++ − + 2-435 ++ + ++ 2-436 − −− − 2-437 ++ + ++ 2-438 ++ + ++ 2-439 ++ − ++ 2-440 + −− + 2-441 ++ − ++ 2-442 − −− − 2-443 − −− − 2-444 ++ + ++ 2-445 + −− + 2-446 − −− − 2-447 + + ++ 2-448 − −− − 2-449 ++ − ++ 2-450 + −− + 2-451 − −− − 2-452 + + ++ 2-453 − −− + 2-454 + −− − 2-455 − − 2-456 − −

TABLE 3-15 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-457 ++ − ++ 2-458 + −− ++ 2-459 + − ++ 2-460 + − ++ 2-461 + −− − 2-462 + − − 2-463 − −− − 2-464 − −− − 2-465 − −− −− 2-466 + − − 2-467 − −− −− 2-468 + − 2-469 − −− 2-470 ++ + ++ 2-471 − −− − 2-472 + − −− 2-473 − −− − 2-474 − −− − 2-475 − −− − 2-476 − −− −− 2-477 − −− − 2-478 − −− −− 2-479 − −− −− 2-480 + + ++ 2-481 − −− ++ 2-482 − −− ++ 2-483 − −− − 2-484 − −− + 2-485 + −− − 2-486 + + ++ 2-487 − −− − 2-488 − −− − 2-489 − −− ++ 2-490 − −− ++ 2-491 − −− ++ 2-492 ++ ++ ++ 2-493 ++ + ++ 2-494 ++ ++ ++

TABLE 3-16 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-495 ++ ++ ++ 2-496 ++ + ++ 2-497 ++ − ++ 2-498 ++ − + 2-499 + + ++ 2-500 − − + 2-501 − − − 2-502 − − − 2-503 + − + 2-504 − − + 2-505 − − + 2-506 − + ++ 2-507 − + ++ 2-508 − − − 2-509 + − ++ 2-510 − − − 2-511 − − − 2-512 − − − 2-513 − − − 2-514 + − + 2-515 − − − 2-516 + − + 2-517 ++ − + 2-518 + + ++ 2-519 − − − 2-520 − − − 2-521 + − ++ 2-522 − − ++ 2-523 + + ++ 2-524 ++ ++ ++ 2-525 ++ ++ ++ 2-526 − − − 2-527 − − − 2-528 − − − 2-529 − − − 2-530 − − − 2-531 − − − 2-532 − − −

TABLE 3-17 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-533 − − − 2-534 − − − 2-535 − − − 2-536 − − − 2-537 − − − 2-538 − − + 2-539 ++ + ++ 2-540 − − + 2-541 − − − 2-542 + − ++ 2-543 ++ ++ ++ 2-544 + − + 2-545 ++ ++ ++ 2-546 ++ ++ ++ 2-547 ++ ++ ++ 2-548 − − − 2-549 − − − 2-550 − − − 2-551 − − − 2-552 − − + 2-553 − − − 2-554 − − + 2-555 + − + 2-556 − − ++ 2-557 + − ++ 2-558 − − + 2-559 ++ − + 2-560 + − + 2-561 ++ ++ ++ 2-562 − − − 2-563 − − − 2-564 ++ − ++ 2-565 ++ + ++ 2-566 + − − 2-567 ++ − + 2-568 ++ + ++ 2-569 ++ + ++ 2-570 + − ++

TABLE 3-18 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-571 − − + 2-572 ++ − ++ 2-573 + − ++ 2-574 + + ++ 2-575 − 2-576 − 2-577 ++ + ++ 2-578 + − ++ 2-579 ++ + ++ 2-580 + − ++ 2-581 ++ − + 2-582 + − + 2-583 − − 2-584 + − ++ 2-585 − − 2-586 − −− 2-587 − − + 2-588 ++ + + 2-589 + − − 2-590 ++ − ++ 2-591 − − ++ 2-592 − 2-593 + − + 2-594 + − + 2-595 − − ++ 2-596 + − + 2-597 − − −− 2-598 ++ − + 2-599 ++ − + 2-600 + − + 2-601 + − − 2-602 ++ + + 2-603 + + + 2-604 + − 2-605 − −− − 2-606 − −− − 2-607 − − ++ 2-608 ++ + +

TABLE 3-19 Experimental Experimental Experimental Example 1 Example 2 Example 3 Example IC₅₀AG1 IC₅₀MMP1 IC₅₀MMP13 2-609 ++ ++ ++ 2-610 ++ + − 2-611 ++ + − 2-612 ++ + − 2-613 ++ + − 2-614 ++ + − 2-615 ++ ++ ++ 2-616 ++ + + 2-617 + − − 2-618 ++ + + 2-619 ++ + + 2-620 ++ + ++ 2-621 ++ + ++ 2-622 − − + 2-623 ++ + ++ 2-624 ++ 2-625 ++

The compound (1) of the present invention described in the results above has superior aggrecanase inhibitory activity and MMP-13 inhibitory activity, and high selectivity to aggrecanase as compared to the activity of MMP-1.

INDUSTRIAL APPLICABILITY

According to the present invention, a compound useful as a prophylactic or therapeutic agent for diseases mediated by aggrecanase, such as osteoarthritis (OA), rheumatoid arthritis (RA), joint injury, reactive arthritis, cancer, asthma, allergic reaction, chronic pulmonary emphysema, fibroid lung, acute respiratory distress (ARDS), lung infection, interstitial pneumonia, bone resorption disorder, etc. is provided.

Claims

1. A cyclopropane compound of formula (1): wherein or A2 and R27 may be taken together to form an optionally substituted fused ring group, or R2 and R3 may be taken together with a carbon atom bonded thereto to form the following ring wherein m13 is selected from an integer ranging from 1 to 6, provided that R2 and R3 are not hydrogen atoms at the same time; or A2, R30 and the cyclopropane ring may be taken together to form a optionally further substituted fused ring, or R9 of —CO2R9, R20 and the cyclopropane ring may be taken together to form an optionally further substituted fused ring, or R20 and R21 may be taken together with a carbon atom bonded thereto to form the following ring wherein m14 is selected from an integer ranging from 1 to 6; or a pharmaceutically acceptable salt thereof.

R1 is selected from

(1) a substituted C1-6 alkyl group

and

(2) —(CH2)m—X— (CH2)n-A1,

wherein m and n are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X is a linker selected from the following group A, group A:

(a) a single bond,

(b) a C3-6 alkylene group,

(c) a C2-6 alkenylene group,

(d) a C2-6 alkynylene group,

(e) —O—,

(f) —N(R5)—,

(g) —S(O)m1—,

(h) —CO—,

(i) —COO—,

(j) —OCO—,

(k) —CON(R5)—,

(l) —N(R5)CO—,

(m) —SO2N(R5)—,

(n) —N(R5) SO2—,

(o)—N(R5)CON(R6)—,

(p) —N(R5)SO2N(R6)—,

(q) —OCON(R5)—,

(r) —N(R5)COO—

and

(s) —S(O)m1—(CH2)n1—CO—; wherein R5 and R6 are the same or different and each is selected from a hydrogen atom, a C1-6 alkyl group optionally substituted by halogen atoms or hydroxyl groups, a C3-14 hydrocarbon ring group and a heterocyclic group, m1 is selected from 0 and an integer ranging from 1 to 2 and n1 is selected from an integer ranging from 1 to 2, and A1 is selected from a substituted C3-14 hydrocarbon ring group and a substituted heterocyclic group;

R2 and R3 are the same or different and each is selected from (1) —(CH2)p—X1—(CH2)q-A2,

wherein p and q are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X1 is a linker selected from the above-mentioned group A and A2 is selected from an optionally substituted C3-14 hydrocarbon ring group and an optionally substituted heterocyclic group,

and

(2) —(CH2)m8—X8—(CH2)n8—R27,

wherein m8 and n8 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X8 is a linker selected from the above-mentioned group A and R27 is a substituent selected from the following group B, group B:

(a) a hydrogen atom,

(b) a halogen atom,

(c) a hydroxyl group,

(d) a nitro group,

(e) a cyano group,

(f) a carboxyl group,

(g) an amino group,

(h) an amido group,

(i) a C2-6 acyl group,

(j) a halogenated C1-6 alkyl group,

(k) a C1-6 alkyl group optionally substituted by hydroxyl groups,

(l) a C2-6 alkenyl group optionally substituted by halogen atoms,

(m) a C2-6 alkynyl group,

(n) a C1-6 alkoxy group optionally substituted by hydroxyl groups,

(O) a C1-6 alkoxy-C1-6 alkyl group,

(p) a C1-6 alkoxy-carbonyl group,

(q) a C1-6 alkyl-aminocarbonyl group optionally substituted by halogen atoms,

(r) a mono(C1-6 alkyl)amino group,

(s) a di(C1-6 alkyl)amino group,

(t) a C1-6 alkyl-carbonylamino group optionally substituted by halogen atoms,

(u) a C1-6 alkylsulfonyl group

and

(v) a C1-6 alkylsulfonylamino group;

R4 is selected from

(1) —CO2R9,

(2) —C(O)NHOR9,

(3) —C(O)NH—SO2—R9,

(4) —C(O)NHR9,

(5) —SH,

(6) —CH2CO2R9,

(7) —C(O)R9,

(8) —N(OH)COR9,

(9) —SN2H2R9,

(10) —SONHR9,

(11) —CH2CO2H,

(12) —PO(OH)2,

(13) —PO(OH)NHR9,

(14) —CH2SH,

(15) —CH2OH,

(16) —(CH2)r1—PO(OH)—(CH2)r2—R9,

(17) —NHR9

(18) —NH—NHR9

and

(19) —(CH2)r1—R50

wherein r1 and r2 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, R9 is selected from (1) a hydrogen atom, (2) an optionally substituted C1-10 alkyl group, (3) an optionally substituted C6-14 aryl-C1-6 alkyl group and (4) —(CH2)m9—X9—(CH2)n9—R28 wherein m9 and n9 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X9 is a linker selected from the above-mentioned group A and R28 is a substituent selected from the following group C,

group C:

(a) a hydrogen atom,

(b) a halogen atom,

(c) a hydroxyl group,

(d) a nitro group,

(e) a cyano group,

(f) a carboxyl group,

(g) an amino group,

(h) an amido group,

(i) a C2-6 acyl group,

(j) a halogenated C1-6 alkyl group,

(k) a C1-6 alkyl group optionally substituted by hydroxyl groups,

(l) a C2-6 alkenyl group optionally substituted by halogen atoms,

(m) a C2-6 alkynyl group,

(n) a C1-6 alkoxy group optionally substituted by hydroxyl groups,

(o) a C1-6 alkoxy-C1-6 alkyl group,

(p) a C1-6 alkoxy-carbonyl group,

(q) a C1-6 alkyl-aminocarbonyl group optionally substituted by halogen atoms,

(r) a mono(C1-6 alkyl)amino group,

(s) a di(C1-6 alkyl)amino group,

(t) a C1-6 alkyl-carbonylamino group optionally substituted by halogen atoms,

(u) a C1-6 alkylsulfonyl group,

(v) a C1-6 alkylsulfonylamino group,

(w) a C3-14 hydrocarbon ring group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B and

(x) a heterocyclic group optionally substituted by 1 to 5 substituent(s) selected from the above-mentioned group B, and R50 is selected from an optionally substituted C3-14 hydrocarbon ring group and an optionally substituted heterocyclic group;

or R9 of —C(O)NHR9, A2 and the cyclopropane ring may be taken together to form an optionally further substituted fused ring;

R20 and R21 are the same or different and each is selected from —(CH2)m10—X10—(CH2)n10-A3, (1)

wherein m10 and n10 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X10 is a linker selected from the above-mentioned group A and A3 is selected from an optionally substituted C3-14 hydrocarbon ring group and an optionally substituted heterocyclic group,

and —(CH2)m12—X12—(CH2)n12—R30, (2)

wherein m12 and n12 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X12 is a linker selected from the above-mentioned group A and R30 is a substituent selected from the above-mentioned group B;

2. The compound of claim 1, wherein the substituted C3-14 hydrocarbon ring group or the substituted heterocyclic group in A1 is a group of the following formula: wherein or the ring A10 and the ring A11 may be taken together with a substituent thereof to form an optionally substituted fused ring group; the optionally substituted C3-14 hydrocarbon ring group or the optionally substituted heterocyclic group in A2 is a group of the following formula: wherein or R26 may be linked with R27, together with ring A12 to form an optionally substituted fused ring group, or R26 may be linked with R9 of —C(O)NHR9 or R30, together with the ring A12 and the cyclopropane ring to form an optionally further substituted fused ring; the optionally substituted C3-34 hydrocarbon ring group or the optionally substituted heterocyclic group in A3 is a group of the following formula: wherein or a pharmaceutically acceptable salt thereof.

ring A10 is selected from a C3-14 hydrocarbon ring group And a heterocyclic group,

r is selected from an integer ranging from 1 to 4,

R22 is —(CH2)m4—X4—(CH2)n4—R24, wherein m4 and n4 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X4 is a linker selected from the above-mentioned group A and R24 is a substituent selected from the above-mentioned group B,

wherein the substituents R22 are the same or different when r is an integer selected from the range of 2 to 4, and

R23 is

wherein m5 and n5 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X5 is a linker selected from the above-mentioned group A and ring A11 is selected from a C3-14 hydrocarbon ring group and a heterocyclic group, and the ring A11 is optionally substituted by 1 to 5 groups of the formula “—(CH2)m6—X6—(CH2)n6—R25”, which are the same or different, wherein m6 and n6 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X6 is a linker selected from the above-mentioned group A and R25 is a substituent selected from the above-mentioned group C;

ring A12 is selected from a C3-14 hydrocarbon ring group and a heterocyclic group, and the ring A12 is optionally substituted by 1 to 5 groups of the formula “—(CH2)m7—X7—(CH2)n7—R26”, which are the same or different,

wherein m7 and n7 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X7 is a linker selected from the above-mentioned group A and R26 is a substituent selected from the above-mentioned group C;

ring A13 is selected from a C3-14 hydrocarbon ring group and a heterocyclic group, and the ring A13 is optionally substituted by 1 to 5 groups of the formula “—(CH2)m11—X11—(CH2)n11—R29”, which are the same or different,

wherein m11 and n11 are the same or different and each is selected from 0 and an integer ranging from 1 to 6, X11 is a linker selected from the above-mentioned group A and R29 is a substituent selected from the above-mentioned group C;

3. The compound of claim 2, wherein R1 is —(CH2)m—X—(CH2)n-A1; or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3, wherein m and n are 0 and X is a single bond; or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4, wherein A1 is R23 is m5 and n5 are 0 and X5 is a single bond; or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5, wherein R4 is selected from —CO2R9 and —C(O)NHOR9; or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6, wherein R9 is a hydrogen atom; or a pharmaceutically acceptable salt thereof.

8. The compound of claim 7, wherein R2 is —(CH2)p—X1—(CH2)q-A2; or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8, wherein p and q are 0 and X1 is a single bond; or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, which is selected from the group consisting of 4-[5-((1S,2R)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester, (1S,2R)-2-Phenyl-1-[5-(1,2,3,6-tetrahydro-pyridin-4-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, 4-[5-((1S,2R)-1-carboxy-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid methyl ester, (1S,2R,3R)-1-[5-(4-Ethynyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1S,2R,3R)-1-{5-[5-(1,1-Difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,2R*,3R*)-2-Hydroxymethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-(4-phenylcarbamoyl-piperazine-1-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-Amino-4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,6aS*)-1-[4-(3,5-Dichloro-benzyloxy)-benzenesulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid hydroxyamide, (1R*,2S*)-1-[5-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[3-(4-Chloro-phenoxy)-azetidine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-[5-(4-trifluoromethoxy-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(3,4-Dichloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-[5-(4-trifluoromethyl-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(5-p-tolyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Fluoro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(pyridin-3-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(pyridin-2-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(pyridin-3-yloxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-hydroxy-2-methyl-propoxy)-phenyl]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Methyl-thiazol-2-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(6-Chloro-pyridin-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-[4-(3-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-[4-(4-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2s*)-1-[4-(4-Chloro-3-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(3-Chloro-phenyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-3-ylaminomethyl)-phenyl]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(6-Methoxy-pyridazin-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(5′-Cyano-[2,2′]bithiophenyl-5-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Hydroxy-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Benzyloxy-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(methyl-pyridin-3-ylmethyl-amino)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-Benzyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-(5′-Methyl-[2,2′]bithiophenyl-5-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(4′-methyl-biphenyl-2-yl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-cyclohexyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-2-methyl-propoxy)-phenyl]-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[5-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Pentafluoroethyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-vinyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-ylmethyl)-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-ethyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-dimethylamino-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(2-Methyl-thiazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Methyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenoxymethyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-[2-(2-tert-Butylamino-ethoxy)-phenyl]-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(2-Methyl-thiazol-5-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-(3-pyrazol-1-ylmethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-(3-methoxymethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-cyclobutyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-isopropyl-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[5-(4-trifluoromethyl-thiazol-2-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-cyclopentyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-tert-Butyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(4-Methoxy-phenyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-Acetyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(4-Fluoro-phenyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[(2-methoxy-ethyl)-methyl-carbamoyl]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-pyridin-3-yl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{2-[(2-methoxy-ethyl)-methyl-carbamoyl]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-hydroxy-ethylcarbamoyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(morpholine-4-carbonyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-1,1-dimethyl-ethylcarbamoyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-ethylcarbamoyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(morpholine-4-carbonyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-hydroxy-1,1-dimethyl-ethylcarbamoyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(2-Methyl-oxazol-5-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4-Acetyl-benzenesulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-Benzenesulfonyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-Chloro-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R)-1-{5-[5-(1,1-Difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Methyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(4-methyl-thiazol-2-yl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(2-Methyl-oxazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(5-Chloro-2-methyl-oxazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-phenyl)-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[5-(5-propyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-morpholin-4-ylmethyl-phenyl)-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Ethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(5-propylcarbamoyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-Isopropylcarbamoyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-Cyclopentylcarbamoyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(5-phenylcarbamoyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-[5-(3,3,3-trifluoro-propylcarbamoyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Fluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Difluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(7-Bromo-9H-fluorene-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(5′-Difluoromethyl-[2,2′]bithiophenyl-5-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, 5-((1R*,2S*)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-thiophene-2-carboxylic acid, (1R*,2S*)-1-(5-Ethylcarbamoyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-Cyclopropylcarbamoyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-[5-(2,2,2-trifluoro-ethylcarbamoyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-{5-[5-(1,1-Difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(2-Acetoxy-ethyl)-phenyl]-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-ethyl)-phenyl]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Methoxymethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Pentafluoroethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-1-[5-(5-pentafluoroethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(5-Benzo[b]thiophen-2-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[5-(5-phenyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Fluoromethyl-[1,2,4]thiadiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(5-propionyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-Butyryl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(5-Benzo[b]thiophen-3-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Difluoromethyl-isothiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Fluoromethyl-isothiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Fluoromethyl-isothiazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(5-Benzofuran-2-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-isopropyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-{5-[5-(1,1-Difluoro-ethyl)-isothiazol-3-yl]-thiophene-2-sulfonylamino}-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(1,3,4,9-tetrahydro-beta-carboline-2-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(3-phenyl-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine-7-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(2-phenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(4-Chloro-phenoxy)-piperidine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-ethyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-Hydroxy-3-methyl-but-1-ynyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3,3-Dimethyl-but-1-ynyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(5-Pent-1-ynyl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[5-(3-trifluoromethyl-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-(5-Indolizin-2-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-(3-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[4-(5-Fluoromethyl-isoxazol-3-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2S)-2-((R)-3-Benzyl-2-oxo-oxazolidin-5-yl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2S)-2-((S)-3-Benzyl-2-oxo-oxazolidin-5-yl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-((E)-2-phenyl-ethenesulfonylamino)-cyclopropanecarboxylic acid, (1S,2R)-1-(7-Fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(7-Chloro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4-Phenoxy-piperidine-1-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-[4-(4-trifluoromethyl-phenoxy)-piperidine-1-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(4-Fluoro-phenoxy)-piperidine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Ethyl-1-(7-fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, 1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2,2-dimethyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(4-phenyl-3,6-dihydro-2H-pyridine-1-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R,2s)-2-(3-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[(E)-2-(4-Chloro-phenyl)-ethenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[4-(5-Difluoromethyl-isoxazol-3-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[(E)-2-(3-Chloro-phenyl)-ethenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[5-(4,5,6,7-tetrahydro-benzo[d]isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(5-Bromo-pyrimidin-2-yl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(8-Chloro-3,4-dihydro-1H-pyrazino[1,2-a]indole-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4-Benzothiazol-2-yl-piperazine-1-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4-Benzyl-piperazine-1-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(4-Chloro-benzoyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(3-Chloro-benzoyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[(E)-2-(4-trifluoromethyl-phenyl)-ethenesulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[(E)-2-(3-trifluoromethyl-phenyl)-ethenesulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(2-Oxo-pyrrolidin-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(2-Oxo-piperidin-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-Amino-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(2-Cyclohexyl-2,3-dihydro-1H-isoindole-5-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(2-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R,2S)-2-(2-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-(3-Bromo-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-nitro-phenyl)-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[5-(3-trifluoromethyl-isoxazol-5-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(1-Methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[(pyridin-3-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1S,2R)-2-(3-amino-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, 3-{(1R,2S)-2-Carboxy-2-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid, (1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-dimethylamino-phenyl)-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(1-Acetyl-1,2,3,6-tetrahydro-pyridin-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-(2-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[2-(2-Carboxy-ethyl)-phenyl]-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(2-Carboxy-ethyl)-phenyl]-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Carboxymethyl-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid, (1S,2R)-1-[S-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(methyl-pyridin-3-ylmethyl-amino)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-3-{2-Carboxy-2-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid methyl ester, (1R*,2S*)-2-Phenyl-1-[4-(5-trifluoromethyl-pyridin-2-yl)-piperazine-1-sulfonylmethyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(4-Chloro-phenyl)-piperazine-1-sulfonylmethyl]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylmethyl]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methoxycarbonylmethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-dimethylcarbamoylmethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-morpholin-4-yl-2-oxo-ethyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-phenyl}-cyclopropanecarboxylic acid, (1R,2S)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-(2-Bromo-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-morpholin-4-yl-2-oxo-ethyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{2-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-2-[2-Carboxy-2-{5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Nitro-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(4-methyl-piperazine-1-carbonyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Amino-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-(4-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(4-Bromo-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-dimethylcarbamoylmethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-{2-Carboxy-2-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid methyl ester, (1S,2R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-Acetyl-1,2,3,4-tetrahydro-isoquinoline-4-spiro-2′-{1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-1′-cyclopropanecarboxylic acid}, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-methoxycarbonyl-ethyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(3-morpholin-4-yl-3-oxo-propyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(3-oxo-3-thiomorpholin-4-yl-propyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Carboxymethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-{3-[(Pyridin-3-ylmethyl)-amino]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(Methyl-pyridin-3-ylmethyl-amino)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-dimethylcarbamoyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(4-methyl-piperazine-1-carbonyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(2-tert-Butoxycarbonylamino-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1aR*,7bS*)-5-(4-Chloro-phenyl)-thiophene-2-sulfonic acid (2-oxo-1,2,3,7b-tetrahydro-3-aza-cyclopropa[a]naphthalen-1a-yl)-amide, (1R*,2S*)-2-(3-Methoxycarbonylmethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(2-Morpholin-4-yl-2-oxo-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-{3-[2-(4-Methyl-piperazin-1-yl)-2-oxo-ethyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-{3-[2-(4-Hydroxy-piperidin-1-yl)-2-oxo-ethyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(3-dimethylamino-propionylamino)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[3-(4-hydroxy-piperidin-1-yl)-3-oxo-propyl]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-2-(4-Benzyloxy-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(4-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-hydroxy-propyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Dimethylamino-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-hydroxymethyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-[2-(3-Morpholin-4-yl-3-oxo-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[2-(2-Dimethylcarbamoyl-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-{2-[3-(4-Methyl-piperazin-1-yl)-3-oxo-propyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-{3-[(4-trans-Hydroxy-cyclohexylcarbamoyl)-methyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(3-Morpholin-4-yl-3-oxo-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-{3-[3-(4-Methyl-piperazin-1-yl)-3-oxo-propyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(3-Hydroxy-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*,3S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-4-Methyl-piperazine-1-carboxylic acid 3-(3-{2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester, (1R*,2S*)-Morpholine-4-carboxylic acid 3-(3-{2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester, (1R*,2S*)-2-[2-(2-Hydroxy-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Methyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-Morpholine-4-carboxylic acid 2-(2-{2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-ethyl ester, (1R*,2S*)-2-[2-(2-Morpholin-4-yl-2-oxo-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R,2S)-1-(7-Fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(4-morpholin-4-yl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[4-(4-methyl-piperazin-1-yl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[4-(4-methyl-piperazin-1-yl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Hydroxy-propyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-morpholin-4-yl-propyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-{3-[(Morpholine-4-carbonyl)-amino]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[(morpholine-4-carbonyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-2-[2-(3-Hydroxy-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-Morpholine-4-carboxylic acid 3-(2-{2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester, (S)-2-Hydroxymethyl-pyrrolidine-1-carboxylic acid 3-(2-{(1R*,2S*)-2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester, (R)-3-Hydroxy-pyrrolidine-1-carboxylic acid 3-(2-{(1R*,2S*)-2-carboxy-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropyl}-phenyl)-propyl ester, (1S,2R)-1-[5-(4-Methyl-piperidin-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Morpholin-4-yl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(Morpholine-4-carbonyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-{2-[(Morpholine-4-carbonyl)-amino]-ethyl}-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(2-Morpholin-4-yl-acetylamino)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-morpholin-4-yl-acetylamino)-phenyl]-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxy-ethyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Acetoxy-propyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(4-Aminomethyl-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(4-Dimethylcarbamoyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2s*)-2-[3-(Morpholine-4-sulfonylamino)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(2-Hydroxy-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(morpholine-4-sulfonylamino)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(2-Carbamoyloxy-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Acetoxy-propyl)-2-{4-[(2-methoxy-ethyl)-methyl-carbamoyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Acetylamino-propyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-(3-pyrazol-1-yl-propyl)-cyclopropanecarboxylic acid, (1R*,3S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2,2-dimethyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,3S*)-2,2-Dimethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[3-(2-Oxo-pyrrolidin-1-yl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,1aS*,6aS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid, (1S,2R)-2-[4-(2-Carbamoyl-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-[4-(3-Morpholin-4-yl-3-oxo-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-3-cyclopropanecarboxylic acid, (1S,2R)-2-{4-[3-(4-Methyl-piperazin-1-yl)-3-oxo-propyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-[4-(2-Methylcarbamoyl-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-[4-(2-Dimethylcarbamoyl-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Hydroxymethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-tert-Butoxycarbonylamino-propyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Amino-propyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(7-Bromo-9H-fluorene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[5-(4-methyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1R,2S,3S)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R,2S)-2-(4-Aminomethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R,2S)-2-(4-Dimethylcarbamoylmethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R,2S)-2-[4-(2-Morpholin-4-yl-2-oxo-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R,2S)-2-(4-Carbamoylmethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R,2S)-2-(4-Methylcarbamoylmethyl-phenyl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R,2S)-2-{4-[2-(4-Methyl-piperazin-1-yl)-2-oxo-ethyl]-phenyl}-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-(2-Carbamoyloxy-ethyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid amide, (1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid methylamide, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-cyclopentyloxycarbonylamino-propyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*,3S*)-2-Ethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-[4-(2-Amino-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R,2S)-2-[4-(2-Hydroxy-ethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-[4-(3-Hydroxy-propyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-dimethylcarbamoyloxy-ethyl)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-[3-(4-Isopropyl-piperazin-1-ylmethyl)-phenyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,1aS*,8bS*)1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,2R*)-Morpholine-4-carboxylic acid 2-carboxy-1-phenyl-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropylmethyl ester, (1S,2R)-1-[5-(4-Chloro-benzoyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-2-(2-Isopropoxy-ethylcarbamoyloxymethyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-Phenyl-2-[(R)-1-(tetrahydro-furan-2-yl)methylcarbamoyloxymethyl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-Piperidine-1-carboxylic acid 2-carboxy-1-phenyl-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropylmethyl ester, (1R*,2R*)-2-(3-Methyl-isoxazol-5-yl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, 5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonic acid (1R*,2R*)-2-(5-Methyl-isoxazol-3-yl)-1-[′5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(5-Methyl-isoxazol-3-yl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-[5-(2-Hydroxy-ethyl)-isoxazol-3-yl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-[5-(2-Hydroxy-ethyl)-isoxazol-3-yl]-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-(5-Hydroxymethyl-isoxazol-3-yl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(5-Hydroxymethyl-isoxazol-3-yl)-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2s*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-isobutyrylamino-propyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-2-Dimethylcarbamoyloxymethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-Ethylcarbamoyloxymethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-Morpholin-4-ylmethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid hydroxyamide, (1S,2R,3R)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(2,4-Dichlor Q-benzyloxy)-benzenesulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid hydroxyamide, (1R*,2R*,3S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,2S*,3S*)-2-Ethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S*,2R*,3R*)-2-Ethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-2-pyrrolidin-1-ylmethyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2s*)-2-Phenyl-2-piperidin-1-ylmethyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-Cyclopropylcarbamoyloxymethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-{[(2-Hydroxy-ethyl)-methyl-carbamoyloxy]-methyl}-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-(2-Hydroxy-ethylcarbamoyloxymethyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-4-Methyl-piperazine-1-carboxylic acid 2-carboxy-1-phenyl-2-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropylmethyl ester, (1R*,2R*)-2-Carbamoyloxymethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-{[(2-Methoxy-ethyl)-methyl-amino]-methyl}-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-dimethylamino-ethylsulfanylmethyl)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(3-trifluoromethyl-isoxazol-5-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(4-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-(4-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-morpholin-4-ylmethyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(4-Methyl-piperazin-1-ylmethyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-Diethylaminomethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-((2R,6S)-2,6-dimethyl-morpholin-4-ylmethyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxy-ethylsulfanylmethyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-imidazol-1-ylmethyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxy-ethoxymethyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-(propane-2-sulfonylmethyl)-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-isopropylsulfanylmethyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,7bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid, (1R*,1aS*,7bS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-ethoxycarbonylmethylsulfanylmethyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(5-Difluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(3-Difluoromethyl-isoxazol-5-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,7bS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid, (1R*,2R*)-2-Benzyloxymethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-dimethylcarbamoylmethylsulfanylmethyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-2-Carboxymethylsulfanylmethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-morpholin-4-yl-2-oxo-ethylsulfanylmethyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,7bS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid hydroxyamide, (1R*,2S*)-2-Aminomethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-oxo-oxazolidin-3-ylmethyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,8bS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,1aS*,7bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid hydroxyamide, (1R*,1aS*,8bS*)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1S,2R,3R)-1-[5-(5-Chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[5-(4-methyl-imidazol-1-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-{[(pyridine-2-carbonyl)-amino]-methyl}-cyclopropanecarboxylic acid, (1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1a,2,3,8b-tetrahydro-1H-4-oxa-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,1aS*,8bS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1a,2,3,8b-tetrahydro-1H-4-oxa-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1S,2R)-2-Phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-furan-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-furan-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,1aS*,8bS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-furan-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1S,2R,3R)-2-Methyl-1-[5-(5-methyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,8bS*)-1-[5-(5-Methyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,2S*)-2-(Acetylamino-methyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(Butyrylamino-methyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3,3-dimethyl-ureidomethyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(cyclopropanecarbonyl-amino)-methyl]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(cyclohexanecarbonyl-amino)-methyl]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-{[(morpholine-4-carbonyl)-amino]-methyl}-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Difluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,8bS*)-1-[5-(5-Difluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(ethoxycarbonylamino-methyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-{[((S)-tetrahydro-furan-2-carbonyl)-amino]-methyl}-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methoxymethyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(1-Methyl-1H-pyrazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Nitro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-4-aza-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,1aS*,8bS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid hydroxyamide, (1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid hydroxyamide, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(isopropylamino-methyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-{[(thiazol-2-ylmethyl)-amino]-methyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-2-{[(pyridine-3-carbonyl)-amino]-methyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(3-hydroxy-propionylamino)-methyl]-3-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(3-ethyl-ureido)-methyl]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(isobutyrylamino-methyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2s*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(2-methoxy-acetylamino)-methyl]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2s*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-[(2-hydroxy-acetylamino)-methyl]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-oxo-morpholin-4-ylmethyl)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(5-Difluoromethyl-isoxazol-3-yl)-benzenesulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Acetylamino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Methoxymethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-methyl-1-[5-(5-Methoxymethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-2-Carboxymethoxymethyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-2-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Chloro-2-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(5-Isopropyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,2R*)-2-Ethoxycarbonylmethylsulfanylmethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-2-Carboxymethylsulfanylmethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,1aS*,4R*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-4-hydroxy-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,1aS*,4S*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-4-hydroxy-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1S,2R)-1-[5-(3-Chloro-4-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Bromo-pyrimidin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1aR*,8bS*)-5-(4-Chloro-phenyl)-thiophene-2-sulfonic acid (2-oxo-2,3,4,8b-tetrahydro-1H-3-aza-benzo[a]cyclopropan[c]cyclohepten-1a-yl)-amide, (1S,2R)-1-[5-(5-Fluoro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[5-(5-methyl-oxazol-2-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-1-[5-(5-methyl-oxazol-2-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(5-Dimethylamino-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-Cyano-4-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-1-(5-morpholin-4-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-Difluoromethyl-isoxazol-5-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-Dimethylamino-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Ethynyl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Acetyl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(4-Chloro-phenyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Bromo-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[4-(4-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-methoxy-ethoxymethyl)-2-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,8bS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-4-methyl-1,1a,2,3,4,8b-hexahydro-4-aza-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,1aS*,6aS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methylsulfanylmethyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(5-Cyclopropyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-3-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Chloro-3-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-1-[4-(4-methyl-cyclohexyl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,4R*,8bS*)-4-Hydroxy-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,1aS*,4S*,8bS*)-4-Hydroxy-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,1aS*,8bS*)-4-Acetyl-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,2,3,4,8b-hexahydro-4-aza-benzo[a]cyclopropan[c]cycloheptene-1-carboxylic acid, (1R*,2R*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-methanesulfonylmethyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[4-(4-methyl-cyclohexyl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Isopropyl-piperazin-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Chloro-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(8-Chloro-3,4-dihydro-1H-benzo[4,5]imidazol[1,2-a]pyrazine-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,6aS*)-1-[4-(2,4-Dichloro-benzyloxy)-benzenesulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid, (1R*,1aS*,6aS*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid hydroxyamide, (1S,2R)-1-[5-(3,5-Dichloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(5-Benzo[1,3]dioxol-5-yl-thiophene-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[5-(1-methyl-1H-imidazol-4-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[5-(5-methyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-Amino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-Methanesulfonylamino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(4-Chloro-phenyl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4,4-Difluoro-piperidin-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-(5-quinoxalin-2-yl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(5-Chloro-pyridin-2-yl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(4-Bromo-phenyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(4-Chloro-3-fluoro-phenyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(4-Chloro-2-fluoro-phenyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(5-Chloro-pyridin-2-yl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(5-Fluoro-pyridin-2-yl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(4-Benzothiazol-2-yl-piperazine-1-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(4-Benzoxazol-2-yl-piperazine-1-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[4-(5-methyl-[1,3,4]thiadiazol-2-yl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3,5-Difluoro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3,3-Difluoro-pyrrolidin-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[5-(2-oxo-2,3-dihydro-benzothiazol-6-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[5-(2-methyl-benzothiazol-5-yl)-thiophene-2-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Benzo[1,3]dioxol-5-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(3-Chloro-phenyl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(4-Fluoro-phenyl)-[1,4]diazepane-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(4-Benzoylamino-benzenesulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-(4-phenylcarbamoyl-benzenesulfonylamino)-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[4-(5-methyl-isoxazol-3-yl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[4-(5-methyl-isoxazol-3-yl)-3-oxo-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-3-nitro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-3-[5-((1S,2R)-1-Carboxy-2-methyl-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-benzoic acid ethyl ester, 3-[5-((1S,2R)-1-Carboxy-2-methyl-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-benzoic acid, (1S,2R)-1-[5-(3-Acetylamino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[6-(4-Methyl-pyrazol-1-yl)-pyridine-3-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[6-(4-Methoxy-pyrazol-1-yl)-pyridine-3-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[4-(2-methyl-benzothiazol-5-yl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[4-(5-methyl-thiazol-2-yl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,7bS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1a,2,3,7b-tetrahydro-1H-cyclopropa[a]naphthalene-1-carboxylic acid hydroxyamide, (1S,2R)-1-[5-(3-Hydroxy-3H-benzotriazol-5-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-3-dimethylamino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-Phenyl-1-(6-phenyl-imidazo[2,1-b]thiazole-2-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[6-(4-Chloro-phenyl)-imidazol[2,1-b]thiazole-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[6-(4-Fluoro-phenyl)-imidazol[2,1-b]thiazole-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Methoxy-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(1H-Indol-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Bromo-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,1aS*,6aS*)-1-[5-(5-Trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-1,1a,6,6a-tetrahydro-cyclopropa[a]indene-1-carboxylic acid hydroxyamide, (1S,2R,3R)-1-[5-(3-Amino-4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Benzo[2 μl, 3]thiadiazol-5-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-(6-phenyl-imidazo[2,1-b]thiazole-2-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[3-(4-Chloro-phenoxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[3-(3-Chloro-phenoxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(4-Chloro-phenyl)-3-oxo-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(6-Chloro-pyridazin-3-yl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[3-oxo-4-(4-trifluoromethyl-phenyl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Bromo-1,3-dihydro-isoindole-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-[4-(4-trifluoromethyl-pyrazol-1-yl)-benzenesulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[4-(4-trifluoromethyl-pyrazol-1-yl)-benzenesulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*,3S*)-1-(5-Benzyl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,2S*,3S*)-1-[5-(3-Hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, 4-((1S,2R)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-piperazine-1-carboxylic acid isopropyl ester, (1S,2R)-1-[4-(3-Methyl-butyl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(4-Ethylcarbamoyl-piperazine-1-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[4-(3-Methyl-butyryl)-piperazine-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(3-trifluoromethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-1-[5-(methyl-phenyl-amino)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-3-methoxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Benzo[2,1,3]oxadiazol-5-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-(6-phenyl-imidazo[2,1-b]thiazole-2-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R)-1-(6-Methoxymethyl-imidazo[2,1-b]thiazole-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[6-(4-Chloro-pyrazol-1-ylmethyl)-imidazol[2,1-b]thiazole-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, 1-[5-((1S,2R,3R)-1-Carboxy-2-methyl-3-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-1H-pyrazole-4-carboxylic acid ethyl ester, 1-[5-((1S,2R,3R)-1-Carboxy-2-methyl-3-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-1H-pyrazole-4-carboxylic acid, (1S,2R,3R)-1-{5-[4-(1-Hydroxy-1-methyl-ethyl)-pyrazol-1-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Methanesulfonyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,2S*,3S*)-1-[5-(3-Hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-(5-pyridin-4-yl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-(5-pyridin-3-yl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinoline-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(4-Benzylcarbamoyl-piperazine-1-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-[4-(3-methyl-butyl)-piperazine-1-sulfonylamino]-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-1-(4-phenethyl-piperazine-1-sulfonylamino)-3-phenyl-cyclopropanecarboxylic acid, 4-((1S,2R,3R)-1-Carboxy-2-methyl-3-phenyl-cyclopropylsulfamoyl)-piperazine-1-carboxylic acid benzyl ester, (1S,2R,3R)-2-Methyl-3-phenyl-1-(4-pyridin-4-yl-piperazine-1-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(2-Methoxy-ethyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(3,4-Dihydro-1H-isoquinoline-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[4-(4-Methoxy-benzyl)-piperazine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[4-((E)-3-phenyl-allyl)-piperazine-1-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Chloro-1,3-dihydro-isoindole-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,2R*,3R*)-2-Methoxymethyl-3-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*,3S*)-2-Methyl-1-[5-(3-morpholin-4-ylmethyl-phenyl)-thiophene-2-sulfonylmethyl]-3-phenyl-cyclopropanecarboxylic acid, (1R*,2S*,3S*)-2-Methyl-1-(5-phenethyl-thiophene-2-sulfonylamino)-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-(5-pyrazol-1-yl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Iodo-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-{5-[4-(1-Chloro-vinyl)-pyrazol-1-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Acetyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-{5-[4-(1-Hydroxy-ethyl)-pyrazol-1-yl]-thiophene-2-sulfonylamino}-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Hydroxy-1,3-dihydro-isoindole-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[3-(3-Chloro-benzyloxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[3-(4-Chloro-benzyloxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[3-(2,5-Dichloro-benzyloxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Isopropylamino-1,3-dihydro-isoindole-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[3-(2,4-Dichloro-benzyloxy)-pyrrolidine-1-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[6-(4-Chloro-pyrazol-1-yl)-pyridine-3-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, 3-[5-((1S,2R,3R)-1-Carboxy-2-methyl-3-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-isoxazole-5-carboxylic acid ethyl ester, (1S,2R,3R)-2-Methyl-3-phenyl-1-[6-(4-trifluoromethyl-pyrazol-1-yl)-pyridine-3-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[6-(4-Chloro-pyrazol-1-yl)-pyridine-3-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Phenyl-1-[6-(4-trifluoromethyl-pyrazol-1-yl)-pyridine-3-sulfonylamino]-cyclopropanecarboxylic acid (1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methoxy-propyl)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Hydroxymethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-[5-((E)-3,3,3-trifluoro-propenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-[5-((Z)-3,3,3-trifluoro-propenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Chloro-3-hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Chloro-3-hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(2,4-Dichloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Cyano-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(7-Chloro-9H-fluorene-2-sulfonylamino)-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(7-Chloro-9H-fluorene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Imidazo[1,2-a]pyridin-2-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Imidazo[1,2-a]pyrimidin-2-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-[5-(4-trifluoromethyl-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Acetyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-{5-[3-(2-Hydroxy-ethoxy)-phenyl]-thiophene-2-sulfonylamino}-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-{5-[3-(3-Hydroxy-propoxy)-phenyl]-thiophene-2-sulfonylamino}-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(4-trifluoromethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(5-Carbamoyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(5-Cyano-isoxazol-3-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(4-Cyano-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3,4-Difluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Amino-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(1H-Benzoimidazol-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-(5-phenyl-benzo[b]thiophene-3-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-1-[5-(3-methyl-3H-[1,2,3]triazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-1-[5-(1-methyl-1H-[1,2,3]triazol-4-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Methoxy-propyl)-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-Fluoro-4-hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-[5-(4-trifluoromethyl-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-1-(5-Benzothiazol-2-yl-thiophene-2-sulfonylamino)-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-Hydroxymethyl-4-methoxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Cyano-3-fluoro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-Fluoro-4-hydroxymethyl-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-chloro-4-methoxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-(2-phenyl-3H-benzoimidazole-5-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2R*,3S*)-2,3-Dimethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*,3R*)-2,3-Dimethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-Methyl-2-phenyl-1-[5-(4-trifluoromethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Fluoro-3-hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3,4-Difluoro-5-hydroxy-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Methanesulfonyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Hydroxymethyl-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(5-Chloro-1H-benzoimidazol-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-Bromo-pyrazol-1-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-{5-[3-(1,1-Difluoro-2-hydroxy-ethyl)-phenyl]-thiophene-2-sulfonylamino}-2-methyl-2-phenyl-cyclopropanecarboxylic acid, (1S,2R,3R)-1-[5-(5-Methoxy-1H-benzoimidazol-2-yl)-thiophene-2-sulfonylamino]-2-methyl-3-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(4-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Methoxy-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2s*)-2-(3-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(2-Methoxy-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-Methanesulfonyl-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(2-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(2-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-Methyl-2-pyridin-3-yl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-(3-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-(3-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-(4-Chloro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-(4-Fluoro-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R,3R)-2-Methyl-3-phenyl-1-(2-phenyl-imidazo[1,2-a]pyridine-6-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2R,3R)-2,3-Dimethyl-2-phenyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-2-(3-Methoxy-phenyl)-2-methyl-1-[5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, and (1S,2R,3R)-1-{5-[5-(1,1-Difluoro-ethyl)-isoxazol-3-yl]-thiophene-2-sulfonylamino}-2,3-dimethyl-2-phenyl-cyclopropanecarboxylic acid; or a pharmaceutically acceptable salt thereof.

((1S*,5S*,6S*)-2-oxo-6-phenyl-3-oxa-bicyclo[3.1.0]hex-1-yl)-amide,

(1R*,2S*)-1-[5-(4-Chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methoxy-propyl)-2-phenyl-cyclopropanecarboxylic acid,

11. The compound of claim 1, which is represented by the formula (1′): wherein or a pharmaceutically acceptable salt thereof.

R1 is selected from

(1) a substituted C1-6 alkyl group,

and

(2) —(CH2)m—X—(CH2)n-A1,

wherein

m and n are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X is selected from a single bond, a C1-6 alkylene group, a C2-6 alkenylene group, a C2-6 alkynylene group, —O—, —N(R5)—, —S(O)m1—, —CO—, —CON(R5)—, —N(R5)CO—, —SO2N(R5)—, —N(R5)SO2—, —N(R5)CON(R6)—, —N(R5)SO2N(R6)—, —OCON(R5)— and —N(R5)COO—,

wherein

R5 and R6 are the same or different and each is selected from a hydrogen atom and a C1-6 alkyl group,

m1 is selected from 0 and an integer ranging from 1 to 2,

A1 is selected from a substituted C3-14 hydrocarbon ring group and a substituted heterocyclic group;

R2 and R3 are the same or different and each is selected from (1) a hydrogen atom,

(2) a C1-6 alkyl group,

(3) a halogenated C1-6 alkyl group,

and

(4) —(CH2)p—X1—(CH2)q-A2,

provided that R2 and R3 are not hydrogen atoms at the same time,

wherein

p and q are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X1 is selected from a single bond, a C1-6 alkylene group, a C2-6 alkenylene group, a C2-6 alkynylene group, —O—, —N(R7)—, —S(O)m2, —CO—, —CON(R7)—, —N(R7)CO—, —SO2N(R7)—, —N(R7)SO2—, —N(R7)CON(R8)—, —N(R7)SO2N(R8)—, —OCON(R7)— and —N(R7)COO—,

wherein

R7 and R8 are the same or different and each is selected from a hydrogen atom and a C1-6 alkyl group,

m2 is selected from 0 and an integer ranging from 1 to 2,

r is selected from 0 and an integer ranging from 1 to 2, and

A2 is selected from an optionally substituted C3-14 hydrocarbon ring group and an optionally substituted heterocyclic group;

and

R4 is selected from

(1) —CO2R9,

(2) —C(O)NHOR9,

(3) —C(O)NH—SO2—R9,

(4) —C(O)NHR9,

(5) —SH,

(6) —CH2CO2R9,

(7) —C(O)R9,

(8) —N(OH)COR9,

(9) —SN2H2R9,

(10) —SONHR9,

(11) —CH2CO2H,

(12) —PO(OH)2;

(13) —PO(OH)NHR9,

(14) —CH2SH

and

(15) —CH2OH

wherein

R9 is selected from a hydrogen atom, an optionally substituted C1-10 alkyl group and an optionally substituted C6-14 aryl-C1-6 alkyl group;

12. The compound of claim 11, wherein R1 is —(CH2)m—X—(CH2)n-A1 and A1 is selected from or a pharmaceutically acceptable salt thereof.

(1) an optionally substituted fused C6-14 hydrocarbon ring group,

(2) an optionally substituted fused heterocyclic group,

and

(3) —V—W-Z,

wherein

V is selected from an optionally substituted C3-14 hydrocarbon ring group and an optionally substituted heterocyclic group;

W is —(CH2)t—X2—(CH2)u—;

wherein

t and u are the same or different and each is selected from 0 and an integer ranging from 1 to 6,

X2 is selected from a single bond, a C1-6 alkylene group, a C2-6 alkenylene group, a C2-6 alkynylene group, —O—, —N(R10)—, —S(O)m3, —CO—, —CON(R10)—, —N(R10)CO—, —SO2N(R10)—, —N(R10)SO2—, —N(R10)CON(R11)—, —N(R10)SO2N(R11)—, —OCON(R10)— and —N(R10)COO—, wherein

R10 and R11 are the same or different and each is selected from a hydrogen atom and a C1-6 alkyl group,

m3 is selected from 0 and an integer ranging from 1 to 2,

Z is selected from an optionally substituted C1-6 alkyl group, a halogen atom, a nitro group, a cyano group, a C1-6 alkoxy group, a hydroxyl group, a halogenated C1-6 alkyl group, a halogenated C1-6 alkoxy group, a carboxyl group, a C1-6 alkoxy-carbonyl group, an amino group, a mono(C1-6 alkyl)amino group, a di(C1-6 alkyl)amino group, an optionally substituted C3-14 hydrocarbon ring group and an optionally substituted heterocyclic group;

13. The compound of claim 12, wherein m and n are 0, and X is a single bond; or a pharmaceutically acceptable salt thereof.

14. The compound of claim 13, wherein t and u are 0; or a pharmaceutically acceptable salt thereof.

15. The compound of claim 14, wherein R4 is selected from —CO2R9 and —C(O)NHOR9; or a pharmaceutically acceptable salt thereof.

16. The compound of claim 15, wherein R9 is a hydrogen atom; or a pharmaceutically acceptable salt thereof.

17. The compound of claim 16, wherein R2 is —(CH2)p—X1—(CH2)q-A2; or a pharmaceutically acceptable salt thereof.

18. The compound of claim 11, which is selected from the group consisting of (1S,2R)-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(2,4-dichloro-benzyloxy)-benzenesulfonylamino]-3-2-phenyl-cyclopropanecarboxylic acid hydroxyamide, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(pyridin-3-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-methoxy-phenyl)-cyclopropanecarboxylic acid, (1S,2R)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R,2R)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R,2S)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R,2R)-2-benzyl-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1S,2S)-2-benzyl-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-phenoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(4-chloro-phenoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-methoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4-chloro-biphenyl-4-sulfonylamino)-2-(2-methoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(2-phenoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(4-methoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(4-phenoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-nitro-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-amino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-piperidine-4-yl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-isobutoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-dimethylamino-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-trifluoromethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-bromo-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3,5-diphenoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-biphenyl-3-yl-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-benzyloxycarbonylamino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-isobutoxycarbonylamino-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4-phenoxy-benzenesulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-bromo-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-2-phenyl-1-[5-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(2-methyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(2-ethyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-phenyl-1-[4-(2-propyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(2-isopropyl-2H-tetrazol-5-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(dibenzofurane-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-methanesulfonylamino-phenyl)-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-pentafluoroethyl-[1,2,4]oxadiazol-3-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-acetylamino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-methoxycarbonylamino-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-4-{3-[2-carboxy-2-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropyl]-phenylamino}-piperidine-1-carboxylic acid tert-butyl ester, (1R*,2S*)-2-(3-benzylamino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-hydroxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4-chloro-biphenyl-4-sulfonylamino)-2-cyclohexyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-phenyl-1-(4-thiophen-2-yl-benzenesulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-2-phenyl-1-(4-thiophen-3-yl-benzenesulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(4-methyl-thiophen-2-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, 5-[4-((1R*,2S*)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-phenyl]-thiophene-2-carboxylic acid, (1R*,2S*)-1-(9-oxo-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-4-[2-carboxy-2-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropyl]-piperidine-1-carboxylic acid tert-butyl ester, (1R*,2S*)-2-(3-benzenesulfonylamino-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-methoxy-biphenyl-4-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-phenyl-1-[4-(5-phenyl-[1,2,4]oxadiazol-3-yl)-benzenesulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-2-phenyl-1-(5-phenyl-thiophene-2-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(2-hydroxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-phenyl-1-[4-(5-phenyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-bromo-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(pyridin-2-ylamino)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(pyridin-2-carbonyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(pyridin-4-carbonyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(pyridin-3-carbonyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(2,4-dichloro-benzyloxy)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2s*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-hydroxy-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[(3-(2-dimethylamino-acetylamino)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(pyridin-3-yloxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-methoxy-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-dimethylamino-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(7-bromo-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-pyrazol-1-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(pyridin-3-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(2-isopropyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-(2-benzyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(7-fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S*,2S*)-1-(7-fluoro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2s*)-1-[4-(2-ethyl-thiazol-4-yl)-benzenesulfonylamino]2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-imidazol-1-yl-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(2-benzyloxy-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(2-hydroxy-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(2-benzyloxy-phenyl)-1-[5-(4-chloro-phenylethynyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-3-yloxy)-phenyl]-cyclopropanecarboxylic acid, (1S,2R)-2-phenyl-1-(1-phenyl-1H-pyrazole-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(3H-imidazol-4-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1S,2R)-1-(7-bromo-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(2-methyl-thiazol-4-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(1-hydroxy-ethyl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(7-chloro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[3-(6-chloro-pyridazin-3-yl)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S*,2S*)-1-(7-chloro-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[1-(4-chloro-phenyl)-1H-pyrazole-4-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-dimethylaminomethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(1-methyl-piperidine-4-ylamino)-phenyl]-cyclopropanecarboxylic acid, (1S,2R)-1-[2-(4-chloro-phenyl)-thiazole-5-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(1-methyl-1H-imidazol-2-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(2-hydroxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-{[methyl-(1-methyl-piperidine-4-yl)-amino]-methyl}-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(2-hydroxy-acetylamino)-phenyl]-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(4-chloro-phenyl)-4-methyl-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-3-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-2-ylmethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R,2S)-1-(7-bromo-9H-fluorene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(3-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-[3-(pyridine-3-sulfonylamino)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-{3-[(1H-imidazol-2-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-3-{2-carboxy-2-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropyl}-benzoic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-dimethylcarbamoylmethoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2s*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2s*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-hydroxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-carbamoylmethoxy-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(4′-chloro-biphenyl-4-sulfonylamino)-2-(3-methylcarbamoylmethoxy-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-carboxymethoxy-phenyl)-1-(4′-chloro-biphenyl-4-sulfonylamino)-cyclopropanecarboxylic acid, (1R*,2S*)-1-(5-isooxazol-3-yl-thiophene-2-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-phenyl-1-[5-(5-trifluoromethyl-isooxazol-3-yl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1S*,2R*)-1-(7-chloro-dibenzofurane-3-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S*,2S*)-1-(7-chloro-dibenzofurane-3-sulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(2-chloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(2,4-dichloro-phenyl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1S,2R)-1-(2-benzofuran-2-yl-ethansulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-nitro-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-amino-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-{3-[(pyridin-3-ylmethyl)-amino]-phenyl}-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-methanesulfonylamino-phenyl)-cyclopropanecarboxylic acid, (1S,2R)-1-[5-(5-chloro-pyridin-2-yl)-thiophene-2-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-trifluoromethanesulfonylamino-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-dimethylamino-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-hydroxymethyl-phenyl)-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-(3-ureido-phenyl)-cyclopropanecarboxylic acid, (1R*,2s*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridine-3-sulfonylamino)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(3-carbamoyl-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-hydroxy-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-2-(2-carboxymethoxy-phenyl)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-(3-phenoxy-benzenesulfonylamino)-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[3-(4-fluoro-phenoxy)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[3-(4-chloro-phenoxy)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[3-(3,4-dichloro-phenoxy)-benzenesulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-1-[4-(4-chloro-phenyl)-piperazin-1-sulfonylamino]-2-phenyl-cyclopropanecarboxylic acid, (1R*,2S*)-2-[2-(benzylcarbamoyl-methoxy)-phenyl]-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(2-morpholin-4-yl-2-oxo-ethoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[2-(isopropylcarbamoyl-methoxy)-phenyl]-cyclopropanecarboxylic acid, (1R*,2s*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-[3-(pyridin-3-ylaminomethyl)-phenyl]-cyclopropanecarboxylic acid, (1R*,2S*)-1-[5-(4-chloro-phenyl)-thiophene-2-sulfonylamino]-2-methyl-2-phenyl-cyclopropanecarboxylic acid; or a pharmaceutically acceptable salt thereof.

and

19. A pharmaceutical composition comprising a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

20. An aggrecanase inhibitor comprising a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof as an active ingredient.

21. An MMP inhibitor comprising a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof as an active ingredient.

22. The MMP inhibitor of claim 21, which is an MMP-13 inhibitor.

23. A prophylactic or therapeutic agent for osteoarthritis comprising a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof as an active ingredient.

24. A prophylactic or therapeutic agent for rheumatoid arthritis comprising a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof as an active ingredient.

25. A method for preventing or treating osteoarthritis, which comprises administering a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof to a mammal.

26. A method for preventing or treating rheumatoid arthritis, which comprises administering a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof to a mammal.

27. The agent of claim 23, which is used in combination with a different therapeutic agent for osteoarthritis.

28. The agent of claim 23, which is used in combination with a different therapeutic agent for rheumatoid arthritis.

29. The agent of claim 24, which is used in combination with a different therapeutic agent for osteoarthritis.

30. The agent of claim 24, which is used in combination with a different therapeutic agent for rheumatoid arthritis.

31. The method of claim 25, which is used in combination with a different therapeutic agent for osteoarthritis.

32. The method of claim 25, which is used in combination with a different therapeutic agent for rheumatoid arthritis.

33. The method of claim 26, which is used in combination with a different therapeutic agent for osteoarthritis.

34. The method of claim 26, which is used in combination with a different therapeutic agent for rheumatoid arthritis.